annual report gsk annual report global biopharma company purpose unite science technology talent get ahead disease together aim positively impact health billion people end bold ambitions patients reflected commitments growth stepchange performance company outstanding people thrive contents strategic report corporate governance investor information ahead together board gsk leadership team financial record performance key chairs governance statement product development pipeline performance indicators corporate governance architecture products competition chairs statement ahead together board oversight intellectual property ceos statement key decisions engagements principal risks uncertainties business model board committee reports share capital control culture people directors report dividends external environment financial calendar research development annual general meeting remuneration report commercial operations tax information shareholders chairs annual statement performance vaccines shareholder services contacts annual report remuneration performance specialty medicines us law regulation remuneration policy summary performance general medicines group companies responsible business glossary terms risk management financial statements principal risks summary directors statement climaterelated financial disclosures responsibilities naturerelated financial disclosure independent auditors report employees gender financial statements viability statement notes financial statements group financial review financial statements gsk plc prepared uk gaap cautionary statement see inside back cover document cautionary statement regarding forwardlooking statements nonifrs measures use number adjusted noninternational financial reporting standards ifrs measures report performance business total reported results represent groups overall performance ifrs adjusted results nonifrs measures may considered addition substitute superior information presented accordance ifrs adjusted results nonifrs measures defined pages reconciliations nearest ifrs measures pages gsk annual report strategic report governance remuneration financial statements investor information ahead together landmark year gsk following demerger consumer healthcare business form haleon july fully focused biopharma company prioritise innovation vaccines responsible business means getting specialty medicines maximising ahead disease together right way increasing opportunities prevent thats environmental social governance esg treat disease impacts embedded strategy support sustainable performance longterm growth help heart rd focus science us build trust stakeholders reduce risk immune system human genetics advanced operations deliver positive social impact technologies worldleading capabilities vaccines medicines development focus four therapeutic areas infectious diseases hiv culture gsk something immunologyrespiratory oncology powers purpose drives delivery strategy helps make gsk place people thrive confident future culture ambitious patients accountable impact right thing foundation bold ambitions patients reflected together well deliver patients shareholders commitments stepchange growth performance gsk people period means gsk vaccines medicines including innovative new products reach people ever beforegsk annual report performance key performance indicators financial delivered stepchange commercial execution growth across portfolio prioritised investment cost discipline supported strong growth operating profit earnings per share eps group turnover bn r turnover product area kpi bn aer vaccines bn cer aer cer specialty medicines bn aer cer general medicines bn aer cer growth excluding covid solutions aer cer total continuing operating profit bn kpi adjusted operating profit bn r bn bn aer aer cer cer growth excluding covid solutions aer cer total continuing earnings per share p adjusted earnings per share p p p aer aer cer cer p p p p p p growth excluding covid solutions aer cer cash generated operations attributable continuing free cash flow bn kpi r operations bn kpi bn bn use number adjusted nonifrs measures report performance business adjusted results nonifrs measures may considered addition substitute superior information presented accordance ifrs adjusted results nonifrs measures defined pages aer actual exchange rate cer constant exchange rate comparative results presented tables restated consistent basis previously published reflect demerger consumer healthcare business presentation continuing discontinued operations ifrs set kpi k ey performance indicator attributable continuing operations r l inked executive remuneration see pages details gsk annual report strategic report governance remuneration financial statements investor information performance summary key performance indicators continued research development continued strengthen latestage pipeline regulatory approvals positive data readouts strategic business development innovation sales bn kpi r innovative pipeline phase iii starts r bn sales products launched vaccines specialty medicines including depemokimab last five years including lifecycle based science eosinophilic disease cobolimab innovation immune system secondline nonsmall cell lung cancers new approvals since phase iiiregistration new collaborations acquisitions including affinivax sierra oncology spero therapeutics pipeline value progress kpi r reported externally commercial sensitivity responsible business continue recognised environmental sustainability leadership esg performance rating kpi track based performance metrics met exceeded metrics cover six new focus areas access healthcare global health health security environment r diversity equity inclusion r ethical standards product governance see pages st nd access medicine index pharmaceuticals industry reduction indirect scope th consecutive time sp global corporate sustainability carbon emissions assessment score february culture culture progress kpi ambitious patients accountable impact right thing measured employee surveys employee engagement score compared read based latest available data scope emissions gsk annual report chairs statement one important years gsks history strong operational financial performance successful demerger consumer healthcare said last year programme created two attractive increasing rd productivity change emma team competitive businesses building culture performance delivering designed compelling investment propositions take longer embed fundamentally reconstruct worldleading consumer healthcare critical levers longerterm value strengthen gsks operational business newly focused gsk creation gsk capability clear ambitious priorities strengthened balance sheet progress rd set sharpen commercial enable increased investment rd making good progress execution cost discipline improve future growth rd past five years pipeline rd productivity already seeing evidence new medicines vaccines tackle groups structure benefits simpler approved new capital allocation capacity shift focused business model medicines currently latestage gsks culture competitive clinical trial development performance focused operational performance gsk excellent strong good see clear progress seeing clear evidence growth sales vaccines pipeline reflected important success strategic specialty medicines doubledigit milestones transformation always growth operating profit eps respiratory syncytial virus rsv start new sustained vaccine candidate older adults delivered demerger period growth group achieved exceptional phase iii results separation gsks consumer sales operating profit forecast us food drug healthcare business form haleon grow administration fda approval separate company listed london cagr respectively period longacting hiv medicine july largest demerger board confident administered every two months europe years delivery targets underpinned reaffirms gsks leadership next culmination huge amount improvement seeing generation hiv treatment work several years groups commercial execution prevention competitiveness also remain ambitious support pipeline future growth business development acquisitions sierra oncology affinivax completed year delighted seamless transition tony wood chief scientific officer role august replacing hal barron tony outstanding highly respected scientist key architect rebuilding pipeline compound annual growth rate gsk annual report strategic report governance remuneration financial statements investor information chairs statement continued engaging shareholders disappointing board evolution board management company remains clear position delivery demerger obviously continue maintain significant matters namely resulted changes board engagement shareholders scientific consensus including departures vindi banga consistent reliable evidence vivienne cox haleon clear conversations zantac ranitidine increases risk retirement laurie glimcher would vast majority shareholders cancer decision december like thank support strategy company us federal court southern significant contributions gsk implementing nevertheless florida dismiss claims recent years despite progress cases relating ranitidine made board recognises committed using welcome gsk continue increase investor opportunity demerger defend vigorously claims confidence ability group deepen gsk boards biopharma brought state level sustain growth next experience credentials decade targets governance delighted welcome dr vishal sikka board adopt targets elizabeth mckee anderson important gsk sales operating profit growth board year vishal performed terms tsr share lightly commitments worldleading technologist price performance many years important demonstration elizabeth deep commercial board understands need confidence business expertise across large deliver determination held accountable specialty biopharma short term means delivery together continued consistent yearonyear delivery line introduced new involvement hal dietz hal targets sales operating remuneration policy linking barron believe scientific profit including successful launch executive remuneration reward credentials gsks board companys key new product outperformance among strongest industry opportunities rsv vaccine engaged extensively also look forward future shareholders develop appointment highly looking beyond successful proposals recognising new reward experienced julie brown new delivery strengthening system fundamental part cfo starting may would like latestage pipeline critical across architecture gsk postseparation thank outgoing cfo iain mackay vaccines specialty medicines ensure build performance outstanding work support including longacting hiv culture generate sustained last four years portfolio supported targeted delivery shareholder value business development would also like note pleased policy achieved appointments anne beal joined longer term board confident positive shareholder vote board may chair progress company recognise sizeable minority corporate responsibility committee making develop industryleading shareholders voted charles bancroft currently audit ai machine learning capabilities continue engage shareholders risk committee chair new application deep demonstrate believe senior independent director understanding genetics incentivising outperformance provide us edge able targets ultimately rewarded finally would like thank identify develop launch products shareholder value creation employees partners shareholders make difference patients customers support operating responsibly deliver value shareholders commitment last year operating responsibly foundation look forward promises zantac litigation stone gsk built exciting gsk groups share price performance committed ensuring second half year esg considerations properly impacted uncertainties embedded strategy associated zantac product liability litigation us supports longterm growth reduces risk helps us build trust sir jonathan symonds stakeholders board chair pleased see continued progress many esg areas including gsk topping independent access medicines indexgsk annual report ceos statement landmark year gsk enter strong momentum focused global biopharma company creating focused global reflecting huge progress strong operational performance biopharma company made improve competitiveness enabled us increase annual landmark year gsk commercial execution investment rd billion successfully delivered products exceeding billion demerger demerger haleon annual sales including shingrix also significantly strengthened gsks significant corporate change trelegy nucala benlysta dovato balance sheet creating additional company years began shingrix alone delivered record year flexibility invest growth new chapter competitive billion sales hiv sales innovation acquired profitable growth enter including dovato billion bostonbased vaccine company strong momentum focused cer affinivax gave us access global biopharma company disruptive maps technology vaccines specialty medicines ambition purpose unite higher valency broader coverage represent nearly twothirds science technology talent single vaccine phase ii sales compared get ahead disease together nextgeneration valent vaccine well track achieve pneumococcal disease also strong performance increases target revenues acquired sierra oncology including confidence delivering growth vaccines specialty medicines myelofibrosis treatment beyond evolving portfolio together momelotinib hope see group sales billion prioritised investment approved signed cer driven strong innovation good cost discipline exclusive licence agreement growth vaccines specialty reflected expansion spero therapeutics tebipenem medicines adjusted operating profit operating margin novel oral antibiotic latestage grew adjusted eps development complicated urinary cer tract infections cutis expect targeted business development addition generated billion free cash flow supporting investments dividend pence per share year strong momentum underpins confidence delivering ambitious sales profit outlooks set time continue build stronger portfolio pipeline based science immune system absorb loss revenues future patent expirations put us strong position deliver growth decade beyond gsk annual report strategic report governance remuneration financial statements investor information ceos statement continued innovation supports future growth bepirovirsen june introduced new pipeline undergoing final stage trials code sets culture vaccines specialty medicines assets pipeline aim well commitments gsk many potential first forefront new wave people make deliver bestinclass treatments ancient disease ambition purpose right way august tony wood took new hiv launched apretude esg focus access role gsks chief scientific officer first longacting injectable healthcare global health health succeeding hal barron hiv prevention alongside security environment diversity equity proven expertise science data cabenuva first complete inclusion ethical standards new technologies tony well placed longacting hiv treatment regimen product governance capture value opportunities means changing made excellent progress maintaining see rd approach landscape hiv patients also number one position made progress year access medicines index th focused across four core development nextgeneration consecutive time ranking nd therapeutic areas infectious diseases pipeline options including presenting sp corporate sustainability hiv immunologyrespiratory promising earlystage data nls assessment pharmaceutical oncology overall infectious diseases new broadly neutralising antibody industry hiv represent around twothirds look forward providing pipeline primary focus talked last year investors visibility pipeline rd stakeholders options demanding transparent reporting infectious diseases immunologyrespiratory performance esg matters developed potential bestinclass increased rd investment introducing new esg performance vaccine rsv older adults support phase iii programme rating track delivery pleased excited present depemokimab promising potential report performance phase iii results late new longacting medicine treat track details set demonstrated efficacy severe asthma area severe disease exceptional result gsk longstanding expertise world waiting jon made clear zantac proven commercial capability years rsv vaccine product liability litigation us oncology reported positive significant scientific achievement scientific consensus data jemperli potential submitted data consistent reliable evidence treatment patients primary regulators hope see approval zantac ranitidine increases risk advanced recurrent endometrial alongside existing cancer continue defend cancer following discussions inhouse capabilities vigorously state cases fda took decision withdraw adjuvants maps affinivax perspective important blenrep us market acquisition collaboration company november based previously curevac mrna get distracted main announced outcome broadest suite vaccine platform priority continuing deliver dreamm trial technologies company strategy patients shareholders sector building trust reducing risk people delivering positive social impact also made important advances looking ahead confidence committed running clinical development two enter believe gsk responsible business builds latestage assets gepotidacin new compelling prospects ever trust reduces risk deliver novel antibiotic uncomplicated people fuel confidence sustainable health impact scale urinary tract infections uutis want thank shareholder returns support bepirovirsen potential achieved strong people thrive provide firstinclass functional momentum delivering cure chronic hepatitis b set later report optimistic future remains significant unmet making good progress excited achieve medical need one three people strengthening culture key together around globe infected deliver ambition virus purpose committed making million living chronic hepatitis gsk place talented people b infection today current standard thrive culture care chronic hepatitis b achieves ambitious patients accountable emma walmsley functional cure patients impact right thing chief executive officer fewer vaccine efficacy versus gsk annual report business model ambition positively impact health billion people end aim developing transformational vaccines medicines making available responsible prices accessible patients sustainable business central success people experts science technology manufacturing regulation intellectual property commercialisation gsk people countries worldwide suppliers working directly gsk bn rd investment manufacturing sites global rd centres aer cer identifying researching developing testing groundbreaking discoveries manufacturing commercialising vaccines specialty medicines general medicines deliver one half million portfolio specialty medicines portfolio doses vaccines every day prevent treat diseases hiv products encompasses gsks around worlds children respiratory diseases immuno primary care medicines supplied receive gsk vaccine year inflammation diseases like lupus countries worldwide cancer many first bestinclass gsk annual report strategic report governance remuneration financial statements investor information business model continued products improve health millions people around world core therapeutic areas infectious diseases hiv immunologyrespiratory oncology world leader goal minimise unlocking science emerging portfolio infectious diseases like impact hiv immune system oncology potentially shingles meningitis peoples lives understand reacts bring new cancer including hiv treatment prevention diseases like lupus therapies patients account twothirds ultimately cure eosinophilic asthma need vaccines medicines inflammatory diseases pipeline steered longterm priorities innovation performance trust develop new medicines 've made commitments growth deliver strategy responsibly vaccines needed significant stepchange always considering esg impacts better faster smarter rd delivery everything lab patient helping build trust combining power confident ability stakeholders reduce risk genetic genomic insights sustain growth decade operations deliver positive causes disease beyond social impact speed scale artificial intelligence machine learning creating value patients shareholders society bn p bn packs medicines per share dividend corporate income tax paid doses vaccines delivered addition pay duties levies transactional employment taxes people people supported grow well work really matters reinvestment returns make enable us reinvest discovering developing new vaccines medicines continue getting ahead disease company directors required law promote success organisation benefit shareholders wider stakeholders including employees suppliers community information issues factors stakeholders board considers relevant complying section f companies act found ur business model supported esg strategy ur strategy supported robust framework described monitoring managing risk described pages gsk annual report culture people gsks purpose unite science technology talent get ahead disease together puts people heart success culture supporting people managers committed making gsk place people people managers play crucial role helping thrive culture ambitious teams thrive bring culture life expect people patients accountable impact right thing managers motivate focus care develop means support people things better teams last two years delivered first line faster focusing matters means setting leader training anchored four areas clear objectives accountability results giving population addition launched new everyone support space need succeed senior leader programme leading leaders build means everything responsibly care integrity leadership development senior levels people patients around world count us organisation dedicated significant leadership preparation brought people managers energy bringing life ahead together purpose together virtual event bring life biggest strategy culture across gsk also placed real priorities support managers setting focused emphasis individual ownership culture ambitious objectives teams aligned small changes need make reality innovation performance trust culture priorities change supported team conversation guides simple tools used globally support better faster focusing diversity equity inclusion decision making greater clarity accountabilities continuing focus building diverse ambitious focused objectives organisation equitable inclusive culture june introduced code sets culture everyone feels welcome valued included well commitments gsk people make delivering leadership representation aspirations deliver ambition right way gsk people implemented annual diversity equity inclusion sign code annually personally commit im dei training invested development tools build inclusive leaders support awardwinning see code gskcom leadership development programme accelerating difference support women ethnically diverse making gsk place people thrive leaders also continued evolve people core ahead together ambition make gsk policies processes practices support recruitment place people thrive although people thrive retention development diverse workforce individual also believe common themes details aspirational targets dei matter firstly belief purpose people business suppliers found desire live culture contribute delivering responsible business section ambition secondly feeling included able opportunities keep growing support driving performance choice feedback space needed succeed finally feeling performance choice approach hybrid working good positive mental physical financial social officebased roles quarter wellbeing requires gsk place people people continues allow us find right balance feel welcome valued environment including onsite remote working framework balanced policies workplaces ways working driving collective individual performance well wholeheartedly enables supports person supporting individual flexibility supporting personal deliver best wellbeing driving performance making us attractive employer year clear expectations spend enough time together person help us continue build sense community connectedness enable development better achieve ahead together ambition httpswwwgskcomengbcompanygovernancecompliancethecode gsk annual report strategic report governance remuneration financial statements investor information culture people continued developing outstanding people understanding people experience gsk committed developing outstanding people regularly measure people experience gsk giving people opportunities grow gsk people including progress culture focus areas place expected agreed development plan work includes annual survey employees regardless grade role underpinned robust featuring questions engagement confidence inclusivity conversation understand space support needed culture focus areas trust priorities also run succeed continue invest development series pulse surveys year statistically initiatives training accessed significant population get timely insights culture keep growing campus central platform progress well hot topics moment training knowledge sharing last year progress demonstrated increased engagement also redesigned talent framework confidence delivery ambitions positive focusing reviews people performance trends ambitions patients accountability impact living culture future potential gives us right thing measures inclusion simpler assessment process line culture support placing best people critical roles measure effectiveness global manager strong diverse succession plans allows us population teams provide feedback via annual spend time development action planning one survey managers receive anonymised aggregate less process feedback effectiveness motivating team focusing people matters leading care health wellbeing improvements inclusive leadership supporting performance development managers rated announced improvements health highly effective reports wellbeing benefits better support people different life stages make sure offerings fair inclusive include new global minimum recognising rewarding people standard weeks parental leave primary sharing success recognising rewarding secondary carers forms family new global people progress made minimum standard care family member end made continues important part life serious health emergencies insured benefits culture addition bonus scheme rewards include sex partners wherever possible new performance across company year award financial wellbeing service mental health training population extra ahead together awards available everyone delivering exceptional performance line culture people identified missed november gave onetime discretionary payment performance deliver people feeling greatest impact objectives live culture year addition rising costofliving challenges payment given annual bonus longterm incentive structure almost half global workforce also gave special thank people countries using consistent criteria determine eligible excluding gsk leadership team glt allowing us countries recognise real time achieved together preparation separation unprecedented transformation gsk everyone received oneoff weeks salary march separate bonus payout remain energised continually live evolve culture line internal external environment part everyone 's objectives starting top leadership team members ambitious goals embed grow culture shows act every daygsk annual report external environment set five major themes influenced environment work governments regulators industry partners keep providing medicines vaccines patients worldwide life sciences continue shaped new technology rapid advances science underscored potential new infrastructure responsible access technology changing life sciences technologies approaches public datasets aiml advances rd particularly evident improve patient outcomes growth different regulatory approaches expansion artificial intelligence areas include nextgeneration use ai medicines emerging machine learning aiml vaccines collaboration also needed create potential transform outcomes substantial increase assets common models standards ai patients making rd precise development driven regulation support innovation productive research advancement mrna dna benefit patients identified nearly companies vaccine technology r ead focus data working aidriven drug discovery greater use new technologies platform technologies pages industry 're investing building digital tools well growth aiml capabilities forging decentralised trials accelerating partnerships strengthen drive towards modernisation position biopharma companies clinical trial regulatory processes also collaborating ai governments regulators organisations partnerships continuing build lessons learned companies working struck compared covid expand aidriven drug discovery industry pivotal role innovation international collaboration complex managing covid pandemic trials develop policies geopolitical tensions prompt countries shift priorities focus scientific technological advances governments recognise us europe uk march offer significant promise patients importance minimising trade us enacted new federal geopolitical tensions putting friction domestic interests remain agency advanced research pressure systems needed priority governments projects agency health deliver innovation rising encouraging companies localise improve governments ability nationalism friction shorten value chains prioritising speed biomedical health research countries due conflict strategic resilience efficiency life sciences earmarked key ukraine tensions policies restrict trade secure strength uk governments new us china bring potential risk access essential items including growth plan given potential disruption face medical goods persisted bolster economic productivity tensions governments taking example governments protect lives healthcare life interventionist actions protect introduced harmful policy sciences likely subject domestic economic competitiveness interventions affecting trade muscular industrial policy strengthen national security create pharmaceutical goods interventions additional domestic jobs improve public support rd well state environment defined tensions health scrutiny supply chain resilience trade disruption economic notable examples uncertainty health life sciences solidarity year constructive continue viewed sectors world trade organization discussions strategic importance governments reducing tariffs demonstrated across advanced markets including governments ai biopharma research time focus scale mckinsey october introduced harmful deep pharma intelligence artificial intelligence drug discovery landscape overview q policy interventions affecting kpmg singapore six key trends impacting global supply chains trade pharmaceutical goods global trade alert hm treasury growth plan september gsk annual report strategic report governance remuneration financial statements investor information external environment continued economic slowdown energy crisis inflation bite lockdowns height vaccination programmes concerns negotiation provisions pandemic weighed economies spending estimated fallen allowing federal health secretary worldwide outlook continued real terms failed negotiate prices certain weaken global growth keep pace inflation medicines expensive drugs year forecast slow spending expected return medicare could potentially amid surging inflation heightened prepandemic growth rates limit investment innovation geopolitical uncertainty albeit pricing value well cost containment tightening financial conditions energy increasing scrutiny next also seeing examples prices soared across europe due years due economic pressures innovative contracting support increased demand restricted geopolitical disruption prudent stewardship healthcare supply contributing rising inflation governments meet economic spending companies payers immediate headwinds cost containment continuing explore innovative challenging consequences measures rise pricing models facilitate individuals businesses healthcare budgets facing significant patient access support payer energy prices climbing pressures uk eu confidence value medicine governments staged significant advanced markets august vaccine time launch costly interventions protect us president signed law r ead pricing access households seek alternative energy inflation reduction act includes sources invest renewable provisions drive us national energy infrastructure government debt higher taxes lowering interventions scale risk growing energy costs lowering drug fiscal deficits put pressure prices parts act focus areas public spending patients welcome including healthcare bring benefits people would global growth forecast pandemic healthcare spending otherwise face challenges accessing slow increased governments rolled important vaccines green transition disrupted longterm momentum remains energy crisis investor sentiment particularly despite disruption seen weakened economies also us seen similar shifts getting ahead climate disrupted green transition amid esg agenda becomes increasingly change remains longterm concerns reliability supply polarised politicised investor societal expectation affordability policymakers face year florida texas implemented government priority conflicting priorities energy measures banning pension funds reinforced billion clean transition necessary mitigate investing asset energy investment us inflation climate change immediate energy managers policies reduction act setback needs driving renewed investment excluding fossil fuels taking esg energy transition likely time traditional fossil fuel energy sources factors account limited companies must continue european countries announced plans demonstrate leadership fractured backdrop revert higher coal usage issue remain committed cutting corporate net zero efforts remain produce electricity us climate impact spotlight stakeholder taken steps reopening oil expectations credibility r ead climate nature gas leasing public lands transparency net zero continuing pages rise voluntary commitments coalitions tested example unbacked race bn zero dropping explicit bar support new coal projects allocated climate clean energy programmes us inflation reduction act imf world economic outlook october economist intelligence unit healthcare outlook eiucom iqvia global use medicines gsk annual report external environment continued access focus covid shines light health inequity covid demonstrated value industry sought encourage treatment pandemic life sciences sector holistic approach realising could adverse effect potential delivering innovative equitable timely access survival years come health interventions speed future pandemics recognises systems continue manage pandemic also raised questions multiple factors enable access longterm repercussions pace medicines sustainable funding pandemic opportunity vaccines could rolled shining free trade international move towards new models care light inequalities access pharmaceutical industry along enable earlier action prevent healthcare outcomes within biotechs vaccine manufacturers diagnose treat disease investing countries around based developing countries united prevention get ahead disease people lowincome countries behind vision access future clear return improves health partially fully vaccinated pandemics known berlin outcomes costeffective covid compared declaration outlined industrys contributes healthier lives societies highincome countries willingness reserve allocation economies realtime production distribution scrutiny covid vaccine ee pages pricing priority populations future rollout reignited debate access global health pandemics success health security around intersection approach rely strong intellectual property ip rights innovation ecosystem removal access medicines vaccines regulatory trade barriers evidenced trips export procurement mechanisms waiver agreed june low middleincome countries temporarily removes developing robust health systems people lowincome country obligations patent countries partially fully protections covid vaccines resilient health systems vaccinated covid step n't address needed counter inequitable access instead increasing threat infectious disease undermines industrys ability emergencies also manage partner invest risk respond growing burden noncommunicable quickly future pandemics diseases delays cancer diagnosis position challenging economic advocating appropriate ip risk uncertainty also political landscape 's protections balanced regulatory recognising full health social important ever invest framework supports discovery economic value innovative pipeline vaccines specialty delivery vaccines medicines vaccines also medicines meet changing medicines developed continue collaborate global unmet healthcare needs emerging technologies health partners increase reach time work reinforcing importance global patients lower income countries governments regulators industry diversified supply chains support delivery innovative partners make sure medicines pricing environment becomes medicines vaccines continue vaccines reach patients tougher well placed offer advocate investment resilient bringing value people differentiated highvalue pipeline healthcare systems around world need payers across prevention treatment robust infrastructure needed scientific innovation improving disease built using new support example routine health remain critical pathway technology techniques make lifecourse immunisation getting sustainable economic growth rd faster smarter demand ahead future pandemics therefore continue work data realworld evidence managing effectively peers governments make support continued reimbursement happen starts investing sure policy regulatory new products likely increase health systems improving environment stimulates sustains continue work payers design public health innovation includes example innovative solutions manage financial times covid vaccine tracker global race vaccinate december gsk annual report research development science technology never opened many possibilities new vaccines medicines patients weve continued harness science immune system alongside genetics genomics advanced technology continue strengthen pipeline ssstttrrraaattteeegggiiiccc rrreeepppooorrrttt governance remuneration financial statements investor information gsk annual report research development highlights rds vaccines medicines new approvals pipeline comes pipeline since infectious diseases hiv potential bestinclass rsv older adults expansion depemokimab phase iii candidate vaccine filed us eu japan programme trials longacting il shingrix interim year data presented inhibitor three additional eosinophildriven id week diseases continued progress development long business development including acquisition acting hiv treatments positive phase ii data affinivax giving access disruptive maps nls broadlyneutralising antibody technology phase ii nextgeneration presented hiv glasgow vaccine pneumococcal disease acquisition sierra oncology adding pivotal phase iii trials gepotidacin momelotinib myelofibrosis patients antibiotic uutis stopped early efficacy anaemia regulatory submission eu us positive phase iib data bepirovirsen exclusive licence spero therapeutics investigational treatment chronic giving access tebipenem hbr latestage hepatitis b started phase iii study antibiotic cutis early rd approach research team takes approach follows science identify opportunities greatest rd central purpose get ahead disease probability success lead differentiated vaccines together combining science immune system medicines including opportunities outside four areas genetics genomics advanced technologies outstanding scientists prioritise genetically identified targets talent discover develop vaccines medicines least twice likely succeed clinic also make transformational impact peoples lives prioritise infectious disease targets immunemodulators rd expenditure million greater lifecycle opportunities aer cer strengthened pipeline platform capabilities strategic prioritising execution technology business development means vaccines priorities medicines development see many potential firstinclass flawless execution latestage pipeline acceleration organically derived pipeline latestage rd aligns four therapeutic areas doubling technology deliver innovation infectious diseases see faster hiv see finding new ways help patients lifecycle immunologyrespiratory see innovation oncology see targeted business development push towards new discoveries gsk annual report strategic report governance remuneration financial statements investor information research development continued flawless execution acceleration finding new ways help patients pipeline lifecycle innovation pipeline across phases potential vaccines look innovate throughout lifecycle vaccines medicines modulating medicines exploring new ways treat immune system human genetic patients examples include validation started phase programmes approval us boostrix immunisation moved nine candidates phase ii started five phase pregnancy prevent whooping cough newborn babies iii programmes fda approval new convenient presentation also achieved industryleading milestones including rotarix vaccine prevent gastroenteritis caused approval launch first longacting hiv medicines rotavirus fda priority review exceptional rsv older approval priorix vaccine measles mumps adult vaccine candidate potential bestinclass rubella us children months profile also presented new data idweek showing shingrix provide least years approval twodose regimen cervarix human protection shingles completed papillomavirus vaccine girls aged china acquisition affininax approval china benlysta treat adults active lupus nephritis ln fda approval benlysta made significant progress improving key paediatric patients active ln measures productivity reduced overall cycle times start new drug discovery projects continue develop new monoclonal antibody end phase compared depemokimab development high affinity phase portfolio includes many longacting suppression il function potential firstinclass medicines pushing towards new discoveries strategic business development doubling technology deliver work commercial organisations academic innovation faster institutions find new research discovery believe combination science technology opportunities access new technology platforms holds key fundamentally transforming medical progress development pipeline remain agile discovery improving success rates shaping ambitious looking opportunities address high treat prevent even challenging diseases unmet medical needs complement rd strategy technology plays growing role progressing rd towards vaccines medicines previously look grow pipeline acquisitions thought possible covers included affinivax adding novel class next generation pneumococcal vaccine candidates data technology helps us understand innovative maps technology see sierra patient human biology choose targets design oncology adding momelotinib treatment clinical trials access large rich datasets mylefibrosis see thanks datafocused collaborations including recent collaboration tempus see well also announced five new collaborations giving established partnerships example andme us access exciting new vaccines medicines uk biobank laboratory genomic research technologies deepening understanding university california see prevent treat disease partnered precision platform technology efficient design medicine company tempus oncology first development new vaccines medicines area focus added pipeline new access broad set platform technologies including partnerships mersana therapeutics option unrivalled suite within vaccines like mrna maps codevelop commercialise xmt adjuvant science growing investment immunosynthen antibodydrug conjugate oncology oligonucleotides see wuxi progress bispecific tcell engaging antibodies oncology zheming progress phase tlr agonist hepatitis b virus hbv announced new partnership wave life sciences drive discovery development oligonucleotide therapeutics including programme alphaantitrypsin deficiency novel rnaediting mechanism action also announced exclusive licence agreement spero therapeutics tebipenem hbr latestage antibiotic may treat cutisgsk annual report research development continued genetics genomics advanced technologies get ahead disease use innovative tools several collaborations functional genomics providing maximise chances success accelerate insight improve target selection work pace discovery genomics predictive power range institutions innovating fastmoving field aiml changing find right medicines crispr pioneers startups us includes right patients dedicated genomics research centres altius institute seattle broad institute affiliated advanced technologies realworld data bringing mit harvard university boston continue patients discovery development process partner adrestia british biotech open earlier turn improves researchers integrate targets uk consortium 're founding member data decision making diseases like cancer neurological conditions 're investigating tools like advances complement progress 're making genetic validation wearables genomics aiml genomics lab founded crispr pioneers provide important insights make us better choosing university california san francisco drug targets specific groups patients laboratory genomic research advancing study portfolio active technology biology projects automating advancing crispr scientists work data produced using tools helps us side side academic researchers uncover new select novel targets genetically validated knowledge disease mechanisms immunology likely become approved medicines vaccines oncology neurology scientists creating new design clinical trials include patients likely technologies stem crispr benefit potential medicines vaccines identifying additional applications technologies find better starting points new medicines recruit patients faster accelerate pace clinical trials crispr tools contribute data understand underlying causes disease improving drug discovery power information sources range tissue blood samples genomics partnerships human behaviour wearable technology today projects pipeline proprietary aiml capabilities help researchers supported human genetic evidence informed interpret volume data also make connections large genetic datasets ongoing collaborations predictions help identify targets uk biobank andme finngen likely succeed assets move pipeline founding member creation future aiml functional genomics continue play role health ambitious uk effort aiming recruit five including optimising clinical trial design example million people capture wide range medical happening bepivorisen genetic information 're also working genes health discover south africa expand building inhouse aiml teams expanding work ensure diverse robust genetic collaborations representation diseases aiml enables us generate deeper insights collaboration consumer genetics research data collaborations work applied research company andme approximately aiml primarily focuses two areas rd early active joint drug discovery programmes genetically discovery stage find genetically validated targets validated targets extended collaboration clinical stage match patients right fifth year identify validate additional new drug medicines targets july year also took sole weve built one largest inhouse functions dedicated development responsibility phase collaboration aiml work partners lead way programme consisting investigational antibody fields aiml team includes targeting cd novel immunooncology agent experts based key gsk rd sites including london san investigational antibody currently francisco tel aviv philadelphia boston combining evaluated cancer alongside gsk medicines team resources expertise partners helps us collect data find patterns genetic data faster could ultimately helps us increase success rates making lifechanging medicines continue expand partnerships world leader data aggregation companies tempus complement internally generated data gsk annual report strategic report governance remuneration financial statements investor information research development continued models becoming advanced develop technologies every iteration 've created new imaging tool using external collaborations key areas new medicine aiml using inform target selection vaccine technologies 're actively investing include potential business development opportunities maps multiple antigen presenting system novel challenging complex disease area nonalcoholic highly efficient vaccine technology platform steatohepatitis nash potentially enables broader coverage generating higher also partnership kings college london antibody responses maps mainly directed 're using tumour models alongside digital pathology preventing pneumococcal disease also shown ai develop personalised immunooncology treatments promise addressing infectious disease pathogens several solid cancers including lung gastrointestinal including cause hospitalacquired infections womens cancers mrna validated launch covid vaccines could potentially oxfordgsk institute molecular computational applied across number diseases 're progressing medicine imcm established partnership development mrna technology inhouse oxford university december combines human parallel curevac collaboration 're currently genetics functional genomics ml focus evaluating second generation mrna backbone neurological diseases like als alzheimers parkinsons developed curevac phase trial featuring collaborations data technology complement modified mrna vaccine candidates targeting covid existing capabilities resources include ongoing flu based promising preliminary analysis work cerebras pioneer high performance ai studies evaluating safety reactogenicity computer systems nvidia global leader ai hard immunogenicity preparing move software started two data candidates latestage clinical testing collaborations rnai oligonucleotides including arohsd phase pathai global leader aipowered pathology aimed ii programme nash inlicensed arrowhead accelerating rd oncology nash well consisting rna interference rnai molecule combine predictive datadriven approach genetically validated target bepirovirsen drug discovery trials pathais models build antisense oligonucleotide designed recognise algorithms uncover new insights 'll integrate hbv dna phase iii inlicensed ionis trials help us predict patients also announced collaboration impacted wave life sciences allows us advance eight preclinical programmes using wave 's prism tempus enables access library de oligonucelotide platform includes inlicensing identified patient data tempus dataset draws novel rnaediting oligonucleotide treat liver work oncologists us academic lung disease caused alphaantitrypsin deficiency medical centres community hospitals work tempus improve clinical trial design speed monoclonal antibodies mabs xevudy enrolment identify drug targets initial focus covid codeveloped vir biotechnology oncology well research programmes new ways understand biology pharmacology platform technology across vaccines genetically validated targets best medicines intervene disease processes chemical work use technology drive drug discovery also biology group developed several methods includes expanding platform capabilities including chemogenomic libraries encoded libraries technologies allow us broaden range options reactive fragments part collaboration future medicines vaccines going beyond existing francis crick institute novel technologies help modalities like small molecules antibodies adjuvants find critical starting points drug discovery projects help immune responses vaccines importantly also natural products derived biosphere ensure remain highly competitive faster collaboration started lifemine therapeutics confident identifying new medicines gives us access platform genetically validated targets proprietary evolutionaryderived genomic drug discovery bispecific antibodies multiple autoimmune diseases advancing preclinical phases digitisation optimise phase vaccine development production working siemens atos two worlds leading digital transformation technology companies 've developed digital twin complete realtime simulation vaccine manufacturing processgsk annual report research development continued infectious diseases twothirds vaccines medicines pipeline vaccine generally well tolerated favourable address global public health burden infectious safety profile data presented part diseases caused hiv rsv meningococci infectious disease society americas idweek hepatitis b rotavirus antibiotic resistant bacteria annual meeting washington dc october also diseases cause significant morbidity mortality shared positive data coadministration rsv put strain global healthcare systems older adult vaccine candidate flu vaccine key finding practical immunisation generated pivotal data rsv candidate vaccine older adults positive interim analysis readout based data vaccine candidate granted gepotidacin antibiotic treat uutis gonorrhoea priority review fda also accepted potential first bestinclass accelerated assessment european medicines agency ema review japanese ministry also sought opportunities boost pipeline health labour welfare mhlw business development completed acquisition clinicalstage biopharmaceutical committed finding solutions people high risk company affinivax pioneered novel class serious consequences rsv infection nextgeneration pneumococcal vaccine candidates started clinical trial exploring effect rsv older include valent vaccine candidate adults adult vaccine candidate people aged including completed phase ii paediatric version increased risk rsvlrtd compared people currently phase ii plus valent pneumococcal also began two flu coadministration vaccine programme preclinical development trials aresvi trial also continue evaluate vaccines incorporate maps technology see annual revaccination schedule longerterm protection multiple seasons new partnership spero therapeutics inc gave us exclusive licence agreement tebipenem hbr shingles latestage antibiotic developed spero first oral carbapenem antibiotic potential approximately one three adults develop shingles treat cutis clear fda regulatory path potential painful potentially serious illness shingrix first approval tebipenem hbr address unmet medical approved shingles vaccine combine nonlive antigen need novel oral antibiotic alternative one adjuvants may help overcome natural intravenous hospital therapy drugresistant cutis agerelated decline immunity contributes challenge protecting people aged disease rsv rsv major cause acute respiratory illness older shingrix available countries weve adults currently one major infectious diseases continued broaden access japan without vaccine rsv worsen underlying conditions shingrix already approved people weve also cause pneumonia leads approximately submitted application extend indications hospitalisations deaths year adults include yearolds risk immune industrialised countries around people hospitalised suppression immune deficiency us cancer rsv underlying comorbidities network recommended shingrix cancer survivors vaccine preferential recommendation became first company announce positive brazilian immunization society phase iii efficacy data rsv older adult vaccine candidate interim results aresvi phase iii presented new data idweek showing pivotal trial showed vaccine efficacy observed shingrix provide least years protection rsv lower respiratory tract disease rsvlrtd shingles primary endpoint analysis adults least one comorbidity interest interim data showed overall efficacy severe disease overall vaccine efficacy followup period approximately six ten years rsvlrtd meeting trial 's primary endpoint initial vaccination new safety concerns consistent high vaccine efficacy observed across identified followup period data range prespecified secondary endpoints including significantly add realworld evidence demonstrating severe disease adults aged across longterm benefit shingrix rsv b strains versus versus versus cases fu years versus cases fu years cases placebo group estimated zoe placebo groups assess vaccine efficacy zoeltfu study fu follow confidence interval ci gsk annual report strategic report governance remuneration financial statements investor information research development continued meningitis providing solutions new covid vaccines around million people develop invasive meningococcal pandemic adjuvant technology part several disease imd year fatal proteinbased covid vaccines weve developed survivors longterm disabilities brain sanofi sk bioscience licensed damage deafness nervous system problems loss markets vaccines important new options limbs bacterial meningitis also particular concern one help protect covid people diagnosed bacterial meningitis end dying left severe complications chronic hepatitis b chronic hepatitis b chb major global health issue bexsero meningitis b vaccine menveo approximately million people infected meningitis acwy vaccine registered approximately people dying annually due countries together protect forms imd liver complications including cirrhosis liver cancer since launch million doses vaccines mainstay therapy includes nucleosidenucleotide distributed received fda approval analogues na often taken life us anvisa approval brazil fully liquid suppress rarely clear virus readytouse single vial presentation menveo gives healthcare providers convenient option removing bepirovirsen drug development need reconstitute vaccine monotherapy chb works reduce virus replication suppress surface antigen stimulate immune system investigational first generation menabcwy candidate november phase ii fullstudy data published pentavalent vaccine combines technologies new england journal medicine demonstrated used bexsero menveo vaccines goal treatment bepirovirsen resulted sustained clearance introducing meningitis vaccine protect people hepatitis b surface antigen hbsag hbv dna five serotypes cause disease subgroup patients followed six months one vaccine two meningitis vaccine discontinuation bepirovirsen levels hbsag potential help improve vaccination rates providing hbv dna together key efficacy measures convenient way prevent imd hbsag hbv dna remain undetectable menabcwy currently phase iii development trial six months without medications patients considered spanning five countries participants aged functional cure outcome associated expect results early new multivalent vaccines significant decreased risk developing cirrhosis like potential support global strategy hepatocellular carcinoma death currently standard defeat meningitis set world health care treatment na rarely achieves functional organizations global road map cure new therapies needed patients diagnosed chronic hbv phase iii study secondgeneration meningitis vaccine currently started early build understanding phase ii aimed improving protection b bepirovirsen works aim bepirovirsen strains allowing broader age indications globally become potential monotherapy backbone future therapy hepatitis b patients exploring potential covid sequential treatment trials expect share data later end million cases covid reported around world million deaths disease continues infectious diseases challenge healthcare systems innovation diptheria tetanus pertussis partners part response developing treatments vaccines since cases pertussis whooping cough us year infants treating covid xevudy likely experience complications disease xevudy sotrovimab sarscov monoclonal boostrix tetanus diphtheria pertussis vaccine antibody treatment developed vir biotechnology tdap received approval fda october works preventing virus entering infecting immunisation third trimester pregnancy healthy cells body important part prevention whooping cough newborn infants early treatment prevent highrisk patients makes first vaccine us approved developing severe disease vir developed specifically use pregnancy vaccine sotrovimab discovery approval less years approved countries including eu canada delivered two million doses xevudy australia new zealand countries including government purchases meet current future needgsk annual report research development continued rotavirus antibiotics antimicrobial resistance november fda approved new fully according world health organization liquid presentation rotarix vaccine prevent antimicrobial resistance amr one top global gastroenteritis caused rotavirus new presentation health threats undermining effectiveness makes convenient healthcare providers antibiotics contributes around million worldwide prepare rotarix removing need reconstitute deaths year dose point use expect commercially 're using expertise developing prevention available early treatment options focus pathogens varicella highest probability developing amr identified february started phase ii study us centers disease control cdc children aged months compare safety progressing towards new treatment urinary tract immunogenicity varicella chickenpox new infections gonorrhoea strain candidate vaccine vaccine currently developing gepotidacin novel mechanism available aim develop vaccine fits topoisomerase inhibitor uncomplicated utis advisory committee immunization practices ' acip gonorrhoea partnership biomedical advanced recommended us immunisation schedule offers research development authority barda us healthcare professionals parents alternative early november received positive results eagle current vaccine varicella new strain vaccine could also eagle phase iii trials evaluating gepotidacin used component measlesmumpsrubella female adults adolescents uutis following varicella vaccine us recommendation independent data monitoring herpes simplex virus committee idmc stopped trials early efficacy started phase study investigate potential plan submit new drug application fda gsk immunotherapeutic herpes also studying gepotidacin potential simplex virus hsv aim offer better solution treatment urogenital gonorrhoea gc eagle people virus current standard care phase iii trial potential read second half study gathering safety immunogenicity data gsk healthy people phase ii development november started phase iii study focus safety immunogenicity well proofof evaluate safety efficacy new vaccine concept efficacy candidate gonorrhoea prevention vaccine human papillomavirus candidate based proprietary gmma generalised human papillomavirus hpv common sexually modules membrane antigens aims protecting transmitted infection around million people year adolescents adults gonorrhoea infections become infected us alone often symptoms also started phase ib study firstin cause genital warts cancer weve begun class fimh antagonist novel molecule blocks phase iii study nextgeneration adjuvanted binding e coli bacteria bladder epithelium vaccine developed collaboration innovax treatment recurrent urinary tract infection protect nine types hpv study evaluating reactogenicity safety immunogenicity investigating salmonella vaccine adjuvanted vaccine candidate girls women aged july started phase study university aim identify effective vaccine oxford investigate candidate vaccine invasive formulation take phase iii trials nontyphoidal salmonellosis ints vaccine uses generalised modules membrane antigens gmma also received approval china cervarix human technology explore potential partnering papillomavirus vaccine girls aged nine vaccints consortium partners eight countries twodose regimen including ints endemic pneumococcal disease pneumococcal disease term illness caused bacterium streptococcus pneumoniae leading cause acute bacterial disease worldwide acquisition affinivax adds novel class nextgeneration pneumococcal vaccine candidates incorporate maps technology see pages gsk annual report strategic report governance remuneration financial statements investor information research development continued hiv recent years weve made breakthroughs treating offering range options people living preventing hiv transform patients lives hiv building achievements new products offer different medicines meet varying needs including longacting injectables many means people living hiv significantly reducing therapy times year portfolio antiretrovirals also includes tivicay hiv one worlds biggest health threats triumeq contain dolutegravir triumeq us million new cases including approximately approval dispersible oncedaily tablet formulation us around million people living hiv children weighing kg committee worldwide half subsaharan africa medicinal products human use chmp ema hiv work viiv healthcare worlds issued positive opinion recommending marketing specialist hiv pharmaceutical company majority authorisation triumeq pd children kg pfizer shionogi shareholders goal end million children living virus treat prevent eventually cure hiv important medicine first fixeddose tablet regimen children available form thats easier transforming experience patients take fda also lowered minimum weight child prescribed triumeq living hiv tablet kg kg portfolio antiretroviral medicines transforming experience people living hiv commitment leave person hiv behind instead taking medicine orally every day cabenuva includes working develop medicines heavily treatment cabotegravir rilpivirine longacting injectable regimen experienced adults treatment options allows patients treatment six times safety concerns intolerance resistance year treatment established viiv healthcare announced fiveyear data rukobia industry leader longacting hiv medicines fostemsavir firstinclass attachment inhibitor ongoing brighte study week data shows cabenuva approved dosing every two months patients take fostemsavir part antiretroviral us europe combination vocabria regimen keep virus suppressed long term cabotegravir rekambys rilpivirine combination received marketing approval japan exploring ways improve lives dosage every two months fda also approved label update cabenuva means patients longer people living hiv take cabotegravir rilpivirine tablets month exploring new types longacting therapy based starting cabenuva injections cabotegravir could give people living hiv option take medicine home involve combining viivs dolutegravir worlds widely prescribed cabotegravir assets earlystage pipeline integrase inhibitor hiv taken around million create medicines patients administer people three four currently hiv medications foundation dovato juluca 're also investigating ultralongacting medicines twodrug regimen oral therapies effective dosing every three months longer based studies threedrug regimens allow people take fewer choose partners cabotegravir drugs still maintaining viral suppression begin phase iib phase iii studies combinations working prevent hiv october announced positive phase iia data preventing hiv central part viiv healthcares work nls novel broadly neutralising antibody bnab late received fda approval apretude study showed strong antiviral efficacy two dosing levels cabotegravir first longacting injectable bnabs recognise different strains hiv stop preexposure prophylaxis prep option reduce risk entering healthy cells block virus sexually acquired hiv approval based results replicating offer potentially new approach two pivotal phase iii studies hiv prevention trials treatment may help us combat treatment resistance network hptn demonstrating superiority efforts end hiv epidemic established standard care european study vocabria cabotegravir injection august announced data showing rekambys rilpivirine longacting injectable suspension continued superior efficacy cabotegravir longacting showed treatment well received people living prep daily tablets unblinded portion hptn hiv clinic staff carisel study trial women subsaharan africa showed participants said injectable treatment less substantially lower rate hiv acquisition stigmatising daily tablets combination showed high clinical effectiveness low rate viral failuregsk annual report research development continued immunologyrespiratory years leaders medicines eosinophildriven diseases associated poor advance management asthma chronic symptom control worsening asthma cause obstructive pulmonary disease copd 've sold breathing difficulties interfere taste smell products respiratory problems since sleep draw expertise science immune system firstinclass monoclonal antibody nucala develop medicines immunemediated conditions mepolizumab targets interleukin il reduce including lupus eosinophilicdriven diseases number eosinophils treatment us severe eosinophilic asthma inflammatory europe indications across four eosinophilic diseases diseases innovative medicines help millions including severe eosinophilic asthma sea chronic people immune respiratory conditions rhinosinusitis nasal polyps crswnp eosinophilic granulomatosis polyangiitis egpa widening access benlysta beyond systemic hypereosinophilic syndrome hes lupus erythematosus sle include lupus nucala approved us japan europe nephritis ln mg prefilled syringe yearolds sea sle chronic autoimmune disease immune prefilled syringe allows healthcare professionals system mistakenly attacks healthy tissue many parts caregivers administer nucala home previously body causes symptoms like swollen joints fever hair children could receive medicine hospitals loss facial rash along potential longterm physicians offices prefilled syringes available complications including irreversible damage vital organs adult strength like heart kidneys sle affects around five million people worldwide ln kidney inflammation caused also continue develop new monoclonal antibody lupus progress kidney failure left untreated depemokimab development high affinity approximately patients sle develop ln longacting suppression il function current il inhibitors dosed every four weeks every eight weeks innovative research role b cells depemokimab designed administered every six autoimmune conditions led development benlysta months means potential first belimumab biologic approved sle biologic deliver ultralongacting treatment patients ln benlysta monoclonal antibody targets sea began phase iii trials blymphocyte stimulator blys underlying cause sle depemokimab crswnp egpa hes following ln reducing autoantibody levels help treat initiation trials sea shortterm symptoms inflammation prevent irreversible damage vital organs received otilimab approval china benlysta treat adults active data contrast programme examining otilimab ln also received fda approval benlysta potential treatment rheumatoid arthritis showed paediatric patients active ln followed earlier limited efficacy support suitable benefitrisk approvals adult treatment markets including eu profile result decided progress member states japan brazil regulatory submissions ambition improve outcomes lupus patients treat target approach aims remission clinical advances reduced disease activity moved two antibodies phase phase ii anti ccl novel anticytokine antibody pain innovating treat eosinophildriven diseases osteoarthritis diabetic peripheral neuropathy eosinophildriven diseases associated heightened representing novel nonopioid nonnsaid analgesic levels eosinophils type white blood cell increased therapy antiil novel anticytokine antibody levels eosinophils blood tissue cause atopic dermatitis identified use range symptoms across variety conditions human genetics human translational studies eosinophils infiltrate certain tissues cause inflammation organ damage time affect patients daytoday life gsk annual report strategic report governance remuneration financial statements investor information research development continued oncology cancer remains leading cause death unmet late phase ii perla study comparing jemperli patient need emerging portfolio oncology plus chemotherapy pembrolizumab plus chemotherapy develop programmes using science metastatic nonsquamous nonsmallcell lung cancer immune system human genetics new technology returned positive data results support ambition jemperli backbone immunooncology oncology take balanced pragmatic approach programme either alone combined standard investment research areas immunooncology care novel cancer therapies especially patients tumour celltargeting therapies synthetic lethality limited treatment options investigational medicines oncology pipeline potential make meaningful difference phase iii costar trial studying jemperli patients cancer combination cobolimab investigational selective antitim monoclonal antibody chemotherapy also grow oncology pipeline targeted patients advanced nonsmallcell lung cancer business development acquisitions collaborations progressed antipdl therapy acquired sierra oncology biopharmaceutical chemotherapy combination potential company focused therapies rare forms blood first kind cancer myelofibrosis also entered exclusive global licence option agreement mersana cd axis range herexpressing tumours breast gastric nonsmallcell lung cancers expanded work focused immunooncology aims help global nonexclusive licence collaboration agreement immune system recognise kill cancer cells springworks therapeutics multiple myeloma effectively investigating jemperli also expanded existing collaboration combination novel assets targeting cd precision medicine partner tempus initial focus axis support antitumour activity oncology see company access antibodies targeting three checkpoints cd axis including positive readouts jemperli pvrig tigit cd executing comprehensive colorectal cancer third common form cancer development plan combine investigational million new cases exploring antibodies jemperli doublet triplet immunotherapy treatment curative intent using therapies addition several early phase trials jemperli dostarlimab subset rectal cancer asco underway phase ii platform study firstline non breakthrough findings presented published smallcell lung cancer began dosing patients initial new england journal medicine researchers combination jemperli tigit antibody partnered memorial sloan kettering cancer center msk confirming iteos therapeutics clinical complete response patients received treatment jemperli neoadjuvant treatment gynaecologic breast cancers mismatch repairdeficient locally advanced rectal cancer nearly million women around world february fda oncologic drugs advisory diagnosed gynaecologic cancer committee odac voted two proposed singlearm trials would sufficient characterise continue explore potential existing benefits risks jemperli curativeintent setting treatments advance standard care hardto patients mismatch repairdeficientmicrosatellite treat gynaecologic cancers alone combination instabilityhigh locally advanced rectal cancer agents secondline endometrial cancer fda granted full approval jemperli february treatment adult patients mismatch repairdeficient dmmr recurrent advanced endometrial cancer determined fdaapproved test progressed following prior platinumcontaining regimen setting candidates curative surgery radiationgsk annual report research development continued december announced positive headline results multiple myeloma worlds third common blood planned interim analysis part ruby cancer people developing every phase iii trial investigating jemperli combination year blenrep belantamab mafodotin patients chemotherapy frontline treatment advanced relapsed refractory multiple myeloma received recurrent endometrial cancer showed statistically least four therapies significant clinically meaningful progressionfree blenrep approved europe hong kong survival pfs benefit prespecified dmmrmsih dreamm trials investigating potential earlier lines patient subgroup overall population part treatment together standard novel therapies ruby study assess jemperli combination well exploring dosing scheduling modifications zejula setting initial results anticipated second half first trial evaluating november announced would withdraw combination potential new firstline maintenance blenrep us market following request therapy ovarian cancer results expected fda request based outcome second half dreamm confirmatory trial meet requirements fda accelerated approval regulations phase iii trial zest exploring efficacy safety trials dreamm clinical trial programme zejula niraparib earlystage treatment breast continue designed demonstrate benefit cancer trial uses circulating tumour dna technology blenrep combination novel therapies standard first time pivotal breast cancer study offers ofcare treatments earlier lines therapy dosing potential detect tumour cells earlier molecular optimisation maintain efficacy reducing corneal level identify women higher risk recurrence events anticipate data dreamm means therapy zejula could start burden dreamm phase iii trials second half disease still low may create opportunity slow stop cancers progress effectively early science collaborations announced exclusive global licence option investigating zejula lung cancer agreement codevelop commercialise mersana 're evaluating zejula phase iii zeal lung cancer therapeutics xmt immunosynthen antibodydrug trial investigating zejula firstline maintenance conjugate targets novel epitope therapy patients advanced nonsmallcell lung designed activate innate immune system cancer squamous nonsquamous histologies sting signalling immune cells tumours tumour received platinumbased chemotherapy trial cells mersana initiated phase clinical studying efficacy safety zejula combination trial xmt investigate potential range standard care treatment herexpressing tumours breast gastric colorectal nonsmallcell lung cancers fda blood cancers granted orphan drug designation xmt myelofibrosis rare blood cancer affects around treatment gastric cancer patients us either additionally enhance tumourcell targeting anaemia theyre diagnosed develop eventually portfolio entered agreement wuxi patients often need transfusions around stop biologics exclusive licences four bi treatment anaemia multispecific tcell engaging tce antibodies developed momelotinib may address significant medical needs using wuxi biologics proprietary technology platforms myelofibrosis patients anaemia reducing deal allows us access potential bestinclass tce dependence transfusions still treating antibodies optimised effective tumor symptoms disease enlarged spleen killing desirable safety profile new drug application marketing authorisation application momelotinib currently review fda ema respectively momelotinib currently approved market anticipate us launch request fda late restricted secondline ovarian cancer maintenance indication zejula us patient population deleterious suspected deleterious germline brca mutations gbrcamut gsk annual report strategic report governance remuneration financial statements investor information research development continued opportunity driven well portfolio across therapy areas pursue progressing towards new treatment opportunities emerging science indicates cholestatic pruritus primary biliary cholangitis potential important new opportunities linerixibat ileal bile acid transporter ibat inhibitor major impact addressing unmet need potentially treat cholestatic pruritus patients primary biliary cholangitis pbc rare autoimmune transforming treatment anaemia liver disease affecting approximately per daprodustat people significant numbers pbc patients suffer million people suffer chronic kidney disease cholestatic pruritus debilitating itch ckd worldwide estimated one seven new pharmacologic therapy area years anaemia many treatment options limited development programme demonstrates left untreated undertreated anaemia ckd using digital technology modernise drug development associated poor clinical outcomes leads using novel platforms run studies potential substantial burden patients healthcare systems increase trial diversity example new daprodustat oral treatment class medicines decentralised clinical trial dct design potential called oral hypoxiainducible factor prolyl hydroxylase improve patient recruitment retention glisten inhibitors hifphis 's based human genetics phase iii trial linerixibat cholestatic pruritus nobel prizewinning science showing cells sense patients pbc emerging trial model adapt oxygen availability daprodustat offers assessment patients occur patients home potentially easier oral treatment current injection improving accessibility patients may live near based standard care still managing haemoglobin specialist first expect innovation levels effectively 's approved duvroq japan continue october reported fda cardiovascular linerixibat received orphan drug designation renal drugs advisory committee crdac supported europe us benefit treatment daprodustat outweighs risks adult dialysis patients anaemia ckd vote adult nondialysis patients anaemia ckd crdac support benefit treatment daprodustat outweighs risks vote february fda approved daprodustat name jesduvroq treatment anaemia chronic kidney disease adults dialysis march ema validated marketing authorisation application daprodustat currently regulatory review decision anticipated midgsk annual report research development continued pipeline overview assets development latestage phase iiiregistration phase bexsero infants us recombinant protein menb recombinant protein c difficile skycovione sk bioscience covid bioconjugated recombinant protein k pneumoniae conjugated recombinant protein menabcwy st gen recombinant subunit cmv recombinant protein rsv older adults mrna flu gepotidacin bti inhibitor uuti gc mrna covid bepirovirsen hbv aso hbv bivalent gmma ints typhimurium enteritidis tebipenem pivoxil antibacterial carbapenem cuti recombinant protein therapeutic hsv gmma gonorrhoea xevudy sotrovimabvir monoclonal antibody covid bivalent conjugate salmonella typhoid paratyphoid blenrep antibcma adc multiple myeloma mtb inhibitor tuberculosis jemperli antipd l endometrial cancer crk inhibitor visceral leishmaniasis zejula parp inhibitor ovarian lung breast cancer proteasome inhibitor visceral leishmaniasis momelotinib jak jak acvr inhibitor myelofibrosis p falciparum whole cell inhibitor malaria cobolimab antitim nsclc fimh antagonist uuti latozinemab al antisortilin frontotemporal pik inhibitor viral copd exacerbations dementia vir monoclonal antibody covid depemokimab la anti il asthma papd inhibitor hbv nucala antiil copd tlr agonist hbv maturation inhibitor hiv daprodustat hifphi anaemia chronic kidney disease cabotegravir mgml formulation hiv linerixibat ibat inhibitor cholestatic pruritus primary capsid protein inhibitor hiv biliary cholangitis capsid protein inhibitor hiv phase ii integrase inhibitor hiv recombinant protein malaria fractional dose sting agonist cancer live attenuated mmrv new strain antilag cancer gmma shigella anticd cancer viral vector recombinant protein antipvrig cancer therapeutic hbv xmt sting agonist adc cancer wholly owned conjugated recombinant protein menabcwy mersana therapeutics nd gen al antisortilin neurodegenerative diseases live attenuated varicella new strain anticcl osteoarthritis pain maps pneumococcal valent paediatric antiil atopic dermatitis maps pneumococcal valent adults antiil multiple sclerosis proteinadiuvant hpv dnmt inhibitor sickle cell disease leucyl trna inhibitor tuberculosis advanced indications shown asset sanfetrinem cilexetil serine beta lactamase inhibitor inlicence alliance relationship third party tuberculosis additional indications candidates also investigation bvlgsk ethionamide booster tuberculosis adjuvanted gsk contributing pandemic adjuvant vir neutralising monoclonal antibody influenza gsk exclusive option codevelop post phase ii maturation inhibitor hiv phase iii study transition activities underway enable progression partner broadly neutralising antibody hiv imminent study start phase iii trial patients progranulin gene mutation antitigit cancer phase ii iii study start expected benlysta antiblys systemic sclerosis associated gsk exclusive global license option codevelop commercialise candidate interstitial lung disease fda approved february hsdb sirna nonalcoholic steatohepatitis progress phase iii menb meningitis b rsv respiratory syncytial virus uuti uncomplicated urinary tract infection gc urogenital gonorrhoea hbv hepatitis b virus cuti complicated urinary tract infection adc antibody drug conjugate nsclc nonsmall cell lung cancer la longacting copd chronic obstructive pulmonary disease mmrv measles mumps rubella varicella hsv herpes simplex virus sirna small interfering rna hpv human papillomavirus maps multiple antigen presenting system cmv cytomegalovirus gmma generalised modules membrane antigens ints invasive nontyphoidal salmonella aso antisense oligonucleotide gsk annual report commercial operations performance vaccines broad vaccines portfolio targets infectious diseases every stage life helping protect people meningitis shingles flu polio many herpes zoster virus shingles strategic report governance remuneration financial statements investor information gsk annual report performance vaccines turnover key products bn product disease total revenue key information shingrix herpes zoster aer record sales year launched shingles cer markets aer cer bexsero meningitis aer approved france national group b cer immunisation programme available markets fluarix flulaval seasonal aer joint first market sanofi us influenza cer enabling vaccinations begin july boostrix diphtheria aer us approval maternal immunisation tetanus acellular cer indication pertussis booster infanrix pediarix diphtheria aer pediarix leads us market share tetanus pertussis cer volume polio hepatitis b haemophilus influenza type b engerix twinrix hepatitis aer travel routine immunisation hepatitis established havrix cer recovering expected shingles rotarix rotavirus aer rotarix fully liquid us approved meningitis cer france national immunisation programme influenza menveo meningitis aer menveo fully liquid us brazil pandemic group c w cer synflorix invasive disease aer affinivax acquisition nextgeneration pneumonia acute cer pcv valents greater otitis media priorix priorix measles mumps aer us approval priorix supporting tetra varilrix rubella cer continued expansion established chickenpox portfolio cervarix human papilloma aer china approval twodose schedule virus cer sales performance meningitis vaccines sales grew aer cer million mainly driven bexsero aer achieved strong growth vaccines driven cer million resulting higher cdc demand record sales shingles vaccine continued increased share us menveo sales also geographic expansion meningitis vaccine aer cer million primarily driven vaccines turnover million aer postpandemic vaccination catchup higher public cer total aer cer excluding demand international together favourable pricing pandemic adjuvant sales performance reflected mix share gain us favourable comparator impacted covid fluarixflulaval sales grew aer decreased related disruptions several markets primarily h cer million primarily driven lower post strong commercial execution shingrix particularly pandemic demand europe us partly offset us europe lower expected returns us shingrix sales grew aer cer established vaccines grew aer stable cer million regions grew significantly reflecting post million mainly resulting supply constraints pandemic rebound strong uptake new market mmrv vaccines lower tender demand international launches half growth contributed synflorix offset hepatitis vaccines demand outside us us shingrix grew aer rebound us europe boostrix postpandemic cer million due higher nonretail demand recovery increased share us retail demand strong commercial execution germany china contributed strongly shingrix growth shingrix launched nine markets available countries gsk annual report strategic report governance remuneration financial statements investor information performance vaccines continued pandemic vaccines decreased aer cer primarily established platform technologies new reflecting comparison pandemic adjuvant sales platforms building maps mrna us canadian governments partly offset gsks technologies key part vaccines growth strategy share contracted european volumes related enabling us tackle complex diseases covid booster vaccine developed birth throughout adulthood see collaboration sanofi pasteur sanofi drivers growth across portfolio record annual sales shingrix driven strong strategy growth demand existing markets geographic expansion vaccines play critical role growth aim shingrix continues recommended adults reach billion people vaccines significant atrisk groups countries around world driving contribution overall ambition positively impact uptake aim launched markets health billion people achieve make vaccine market value growth existing adult paediatric vaccines new launches focus accelerating vaccines continue strengthen leadership position pipeline particularly rsv menabcwy ensuring meningitis vaccines aim double sales manufacturing capability capacity rsv shingrix continued market share growth geographic established portfolio entering new markets expansion bexsero anticipated launch also prioritise targeted business development pentavalent vaccine year france approved complements existing vaccine portfolio gives us bexsero national immunisation programme access new patients also launched bexsero taiwan received marketing authorisation south korea making bexsero available vaccines complex highly technical develop total countries manufacture established generic industry therefore generally face remain committed growing established portfolio socalled 'patent cliff ' longer lifecycle means represents half total vaccines business vaccines remain use decades initial continue seek expand availability authorisation example boostrix infanrix priorix vaccines markets around world lifecycle engerix beyond patents remain important management strategy strengthened presence parts portfolio terms contribution us example priorix measles mumps performance importantly vaccines rubella vaccine protecting people worldwide strong efficacy profile portfolio sales years launch us year underscores efficacy level helping protect remains important part established portfolio portfolio potential disruption new also us received fda approval fully liquid technologies formulations rotarix rotavirus vaccine menveo meningitis acwy vaccine also first receive portfolio marketed vaccines one fda approval vaccine given pregnancy boostrix industrys broadest helping protect people maternal administered third trimester throughout lives diseases including meningitis help prevent whooping cough young babies see shingles flu polio measles many deliver one half million doses vaccines every day around worlds children receive gsk vaccine year full benefits vaccination go beyond health individuals vaccination programmes help minimise health inequity reduce costs healthcare system potentially promoting economic growth societal wellbeing acquisition affinivax get approval future launch rsv vaccine older adults well positioned adult vaccination segment key growth driver global vaccines marketgsk annual report performance vaccines continued meeting needs healthcare professionals strengthening manufacturing network patients hcps support vaccines growth age immune system starts manufacturing sites nine countries decline becomes less effective leading increased produced delivered million vaccine doses vulnerability infectious diseases given despite supply challenges incoming materials focusing efforts helping keep older adults healthy shipping impacts caused covid global want improve physicianpatient dialogue economic environment conflict ukraine vaccination raise awareness adults vaccine sites routinely inspected multiple regulatory preventable diseases increase access vaccination agencies inspections health beyond physician 's office authorities across manufacturing sites vaccine study report explored attitudes preparing manufacturing supply beliefs hcps years vaccination capabilities support inline product growth study showed hcps patient 's number one source pipeline products pending approval includes information vaccines hcps ca n't always meet rsv vaccine older adults rsv production patients needs lack time want avoid facility wavre belgium produced first doses conflict dont enough information training market success rate ready demand ease pressure hcps 've started announced million investment second digital channel partnership nextdoor us manufacturing facility rsv antigen production providing vaccination information directly patients belgium also belgium invested capacity 've also launched consumer campaign lyophilised products well building internal mrna importance vaccination 're working directly capabilities following acquisition affinivax hcps series vaccinology master classes adding maps production technology platforms helping better equip conversations using capabilities singapore site well new patients vaccines investments gsk binney street cambridge boston us research company iqvia also launched overall 're focused increasing control vaccine track data platform help improve adult robustness supply chain good example vaccination nationwide platform gives hcps manufacturing key adjuvants 've information uptake recommended adult brought production mpl qs components immunisations data hcps target efforts inhouse hamilton 've also formulated increase discussion vaccination improve batches adjuvant belgium since current coverage areas showing relative decline future key assets shingrix mosquirix rsv immunisation candidate vaccine older adults 're working expert groups adult vaccination throughout year invested modernising digitising calendars show hcps patients automating manufacturing network example vaccines 're eligible quality control laboratories sites went completely paperless 'll transition launched firstever shingles awareness week production lines sites electronic batch records international federation ageing reaching build digital capability better million people globally campaigns remain operational efficiency compliance yield shorter important way increasing awareness vaccine lead times preventable diseases prompting patients seek hcp guidance next steps including preventative options globally governments policymakers healthcare providers recognising potential advantages increased access vaccination additional channels vaccination centres well retail pharmacies 're working pharmacy chains provide information patients consider vaccination options gsk annual report continue global leaders hiv medicines focus pioneering treatments immunemediated conditions respiratory diseases emerging portfolio cancer medicines hiv virus strategic report governance remuneration financial statements investor information commercial operations performance specialty medicines gsk annual report performance specialty medicines turnover key marketed products bn product disease total revenue key information xevudy covid monoclonal antibody treatment delivered aer cer treatment aer cer two million doses countries since approval triumeq hiv treatment aer dolutegravirbased fixed dose combination cer tablets marketed countries nucala respiratory aer treatment indicated us eosinophildriven cer europe use across four eosinophil diseases driven diseases see tivicay hiv treatment flat aer dolutegravir tablet use combination cer antiretroviral agents marketed countries dovato hiv treatment aer dolutegravir based twodrug regimen cer launched markets benlysta lupus lupus aer biologic approved treat sle nephritis cer ln us europe elsewhere hiv juluca hiv treatment aer dolutegravir based twodrug regimen mmunoinflammation cer marketed countries respiratory zejula ovarian cancer aer parp inhibitor commercially available l cer maintenance markets l pandemic maintenance markets oncology cabenuva hiv treatment aer first complete longacting vocabria cer injectable regimen cabotegravir rilpivirine rekambys launched countries europe japan blenrep blood cancer aer antibodydrug conjugate commercially multiple myeloma cer available countries patients relapsed refractory multiple myeloma rukobia hiv treatment aer extendedrelease tablets people living cer multidrug resistant hiv use combination antiretrovirals approved us canada europe apretude hiv prevention first longacting injectable cabotegravir hiv prevention launched us jemperli endometrial aer pdblocking antibody available cancer cer countries continuing investigated future monotherapy combination regimens multiple tumour types sales performance new hiv products delivered sales two billion million aer cer representing specialty medicines sales million total hiv portfolio compared last year aer cer driven consistent doubledigit growth growth primarily driven sales dovato therapy areas specialty medicines excluding sales cabenuva dovato recorded sales million xevudy million aer cer aer cer cabenuva recorded sales hiv sales million growth aer million apretude delivered sales million cer performance benefited strong immunoinflammation respiratory sales patient demand new hiv medicines dovato million aer cer strong cabenuva juluca rukobia apretude performance benlysta nucala benlysta sales contributed approximately three quarters growth million aer cer representing us pricing favourability yearend inventory build strong underlying demand us worldwide nucala together contributed one third growth sales million aer cer partially offset international tender decline reflecting continued strong patient demand launch additional indications gsk annual report strategic report governance remuneration financial statements investor information performance specialty medicines continued oncology sales million aer immunologyrespiratory continue see strong cer zejula sales million aer demand benlysta nucala cer driven firstline indication diagnosis benlysta systemic lupus erythematosus lupus treatment rates continuing impacted nephritis adults children continues perform pandemic especially us sales blenrep strongly around us patients initiating therapy million grew aer cer included also became chinas biologic medicine impact withdrawal us market q kind helping around patients sales xevudy million compared focused supporting earlier identification greater million sales sales delivered regions urgency treat patients lupus progresses comprising million us million europe organ damage occurs see million international nucala targeted biologic therapy approved use across four eosinophilic diseases continues strategy growth driver growth expanded access nucala portfolio specialty medicines focused four approvals europe japan us mg therapeutic areas infectious diseases hiv immunology syringe use home children follows earlier respiratory oncology 're leaders infectious approvals athome use adults evidence diseases hiv innovation also building behind nucala continues grow shared positions immunology oncology next five twoyear data realitia realworld study years expect specialty medicines hiv part nucala patients severe eosinophilic asthma specialty continue important part growth demonstrating il inhibition everyday practice increasing convergence disease prevention help achieve treatment goals pioneering treatment expertise vaccines medicines work il inhibition continues research mean uniquely placed focus connections depemokimab monoclonal antibody specifically treatment prevention engineered increased affinity il longer duration action allow longer periods time accelerating pipeline well injections see prioritising strategic business development oncology zejula monotherapy parp inhibitor complements existing portfolio acquisition approved firstline therapy newly diagnosed patients sierra oncology global licence agreement advanced ovarian cancer regardless biomarker mersana therapeutics group patients represents significant area drivers growth across portfolio growth healthcare providers using parps hiv strategy growth future firstline setting since covid seen number built innovative portfolio medicines patients presenting doctors ovarian cancer transforming hiv treatment prevention landscape symptoms decline volume newly diagnosed ovarian cancer patients precovid launched dolutegravirbased twodrug monthly averages expect numbers increase regimen dovato continues build positive momentum patients return normal health practices benefiting people living hiv globally working develop combination therapies delivering million revenue zejula see longacting therapies also central growth delivering results launch across daprodustat treatment anaemia chronic kidney markets disease marketleading preferred hifphi japan available duvroq february launched longacting treatment daprodustat approved jesduvroq us regimen cabenuva known vocabria rekambys adults dialysis seeking approval eu europe markets noninferior daily antiviral expect decision mid see therapy dosed every two months cabenuva addresses challenges associated daily oral covid treatment xevudy developed vir therapy stigma adherence daily pill fatigue biotechnology continued play important role january launched apretude us 's pandemic response vulnerable patients date longacting medicine hiv prevention offering delivered two million doses superior efficacy daily oral prevention ftctdf countries generating billion sales tablets twomonthly dosing launch supported directtoconsumer campaign well innovative communitydriven interventions focused reaching key populations could benefit preventative option estimate longacting regimens cabenuva apretude generate around billion sales representing around third hiv net salesgsk annual report performance specialty medicines continued building commercial capabilities use digital data analytics extends driving medical affairs effectiveness advanced analytics delivering growth across portfolio continuing text mining produced medical insights allow focus disciplined commercial medical execution highquality scientific engagement experts capability enhancement competitive resourcing improve patient outcomes well continue prioritise use customerfacing activity rigorous investment omnichannel communication platforms medical affairs allocation engage hcps latest scientific advances attaining keeping leading positions markets means attracting retaining best people managing global supply chain industry weve focused developing leaders internally supply chain global network enabled us recruit specific marketing commercial experts produce deliver billion packs 've outside business streamlined network make smaller agile last year senior commercial leadership resilient capacity capability bring appointments specialty medicines internal next generation medicines patients globe recruited senior people externally drive growth amid geopolitical uncertainties 're focused oncology supplement specialty global marketing availability energy commodities managing capability top markets constraints around freight resources needed weve also focused strengthening sales execution supply medicines patients despite challenges capability markets appointed general programme productivity efficiency improvements managers bringing fresh leadership remains track year delivered million positions savings programme taking cumulative total million target programme maintaining strong links healthcare deliver million savings savings professionals patients support improvements gross margin connecting hcps patients helps us meet sites manufacturing medicines gsk needs also helps us keep informed clinical network overall site productivity increased data products pipeline upcoming launches year year last three years effectively interact better understand science behind products benefits best strengthening manufacturing base use modern manufacturing facilities help us launch specialty scaled use dataled omnichannel medicines quickly build strengthen communication platforms reach patients faceto market positions performance face digitally date 've digitally enabled june opened new manufacturing facility brands campaigns across markets doubling barnard castle uk sustainably designed efforts compared last year resulting paperless fully automated using robotic aseptic incremental growth market share filling technology increase efficiency facility manufacture many existing new biopharmaceutical assets pipeline gsk annual report strategic report governance remuneration financial statements investor information performance specialty medicines continued also opened expanded facility upper merion supporting innovation ambition pennsylvania one advanced specialty medicines supply chain continues support singleuse facilities manufacture bulk drug innovation strategy delivering launch products across substances able manufacture wide range therapy areas regions worldwide making biopharmaceutical pipeline assets including monoclonal internal external network flexible enough enable antibodies expanded facility rockville maryland ontime launches upcoming medicines 're also target start manufacturing facility working rd investing rapid knowledge transfer combines singleuse systems largescale stainless steel chemistry manufacturing control project teams manufacturing automation produce lupus manufacturing sites treatment benlysta investment million increase capacity rockville around following successfully managed rapid launch covid therapeutic xevudy sotrovimab end 're also investing million new oral solid two million doses xevudy supplied dose facility ware uk help us deliver new globally also preparing successful launch products pace partnership rd product supply latestage assets like daprodustat performance qualification first set batches momelotinib approved specialty medicines confirm commercial manufacturing process performs supply chain support multiple latestage clinical expected due start second half programmes upcoming launches second streamlining supply chain helps us control costs half allocate capital developing launching f details general medicines supply chain see marketing medicines includes investing aiml helps us optimise yield inventory ontime infull otif delivery maintaining consistent reliable supply reliable highquality supply products essential us meet patients needs maintain performance routinely update quality management system qms keep pace evolving regulatory environment new scientific understanding products processes 've also made policies procedures simpler understand implement 've improved deviation rates reliability supply remains strong otif measure across full supply chain specialty medicines f information product governance data recalls regulatory inspections audits see pages gsk annual report commercial operations performance general medicines antibiotics inhaled medicines asthma copd general medicine products many leaders class making life better millions people worldwide escherichia coli e coli bacteria gsk annual report strategic report governance remuneration financial statements investor information performance general medicines turnover key marketed products bn product disease total revenue key information trelegy ellipta copd asthma aer prescribed single inhaler triple therapy aer cer cer worldwide reaching estimated million patients since launch seretideadvair asthma copd aer one marketleading icslaba cer treatments worldwide relvarbreo asthma copd aer one leading icslaba treatments ellipta cer worldwide powered hour sustained efficacy convenience ellipta inhaler device ventolin asthma copd aer global marketleading saba reliever cer augmentin common bacterial aer global leader oral antibiotics available infections cer countries lamictal epilepsy bipolar aer brand sales value global disorder cer lamotrigine market respiratory anoro ellipta copd aer global market leader lamalaba general medicines cer class approved countries avodart benign prostatic aer market leaders sales value global duodart hyperplasia bph cer dutasteride dutasteridetamsulosin fdc market respectively approved countries avamys allergic rhinitis aer global leader inhaled corticosteroids veramyst cer prescription class dermovate inflammatory aer global leader topical corticosteroids across betnovate skin conditions cer markets globally cutivate eumovate labalama longacting beta agonistslongacting muscarinic antagonists icslaba inhaled corticosteroidlongacting beta agonists saba shortacting beta agonist fdc fixed dose combination key information source iqvia sales performance partially offsets ongoing adverse impact generic competition approximately two percentage general medicines sales year million points impact aer cer divestment aer cer impact generic cephalosporin products q competition us europe japan offset trelegy growth respiratory postpandemic rebound antibiotic market since h general strategy impact medicines general medicines portfolio encompasses primary care medicines prelaunch rd assets growth respiratory sales million aer established products general medicines cer performance driven trelegy sales contributed one third gsk 's sales helping fuel million aer cer including strong growth investment rd growth across regions advairseretide sales million decreased aer cer predominantly combination products several reflecting adverse impact generic competition market leaders expected impact lives growth certain international markets due targeted millions patients next years products promotion offsetting decrease supplied countries worldwide delivering total medicines supply volume general medicines sales million every day medicines improve health make life decreasing aer cer augmentin sales better millions people world million aer cer reflecting postpandemic rebound antibiotic market since h international europe regionsgsk annual report performance general medicines continued expected growth trelegy anoro established maximising commercial capabilities products portfolio emerging markets successful targeted investment strategy deliver returns gepotidacin tebipenem committed backing largest opportunities branded positively impacting lives every day geographic maximise launches new medicines continue focus maximising investment indications parallel target investments growth brands new opportunities managing appropriately optimise returns mature brands expected decline products mature markets broader range opportunity risk lose exclusivity decline established continue invest omnichannel digital customer products well managed targeted investments engagement digital plays important role towards growth opportunities reflects continued strong connect customers especially important demand core products general medicines given expansive global footprint datadriven customer experience ddcx programme drivers growth across portfolio trelegy recognised externally international main sources growth general medicines customer experience awards icxa across sectors trelegy anoro augmentin among companies initiatives entered trelegy single inhaler tripletherapy asthma three silver awards trelegy competing across copd continued accelerate strongly growth industries following categories regions including us third biggest growth best businesstobusiness customer experience strategy driver excluding xevudy across gsks portfolio year trelegy prescribed countries business change transformation dual indications key markets several new approvals customer experience team year received expanding trelegys availability asthma patients argentina taiwan new zealand maintaining efficient supply chain oman bahrain south korea kuwait copd demand many products general medicines patients kuwait indonesia portfolio increased significantly covid lockdowns lifted global markets recovered effects trelegy leads market share two largest markets us pandemic increased packs supplied billion japan market shares significantly exceeding billion growth demonstrated next largest competitor competitive market resilience general medicines brands anticipate position trelegy strengthened network increasing billion metaanalysis triple therapy class demonstrating differentiation among copd singleinhaler triple keep supply chain lean continue simplify therapies continue expect trelegy key driver portfolio standardising packaging formats growth general medicines coming years discontinuing products end general medicines reduced number brands anoro approved approximately countries portfolio plan treatment symptomatic copd anoro remains global discontinue nonpriority brands market leader lamalaba class continued growth global sales exus anoro robust clinical also taken key decisions part focus data profile includes headtohead data within productivity efficiency example outsource lamalaba class versus common initial manufacture amoxicillin maintenance therapy options lama rigorously benchmark performance general augmentin global leader oral antibiotics medicines supply chain competition make available countries reached billion thoughtful choices optimise cost patients since launching years ago continues cash footprint portfolio grow strongly emerging markets augmentin grew aer cer million recovery key emerging f global supply chain also covers specialty medicines see pages markets europe recovering stronger competitor postpandemic today augmentin still recognised impact recently bronze best pharmaceutical product category prix galien golden jubilee awards october two important products latestage pipeline anticipated future growth drivers general medicines include gepotidacin uutis urogenital gonorrhoea tebipenem hbr latestage antibiotic licensed exclusively spero therapeutics may treat cutis see pages gsk annual report responsible business approach esg integral part strategy investment case helps us build trust create value shareholders society get ahead disease together ssstttrrraaattteeegggiiiccc rrreeepppooorrrttt governance remuneration financial statements investor informationgsk annual report responsible business responsible business means getting ahead metrics developed stakeholder input disease together right way therefore need understanding key issues industry consider esg impacts across everything company committed ensuring esg lab patient 's esg embedded performance rating responds stakeholder expectations strategy supports sustainable performance continue review metrics business longterm growth helps us build trust deliver external expectations change returns stakeholders reduce risk operations create esg performance rating management deliver positive social impact sought metrics six esg focus areas well defined ensure standardised approach deliver purpose embed esg everything identified six esg focus used consistently future years areas address material business ambitious achievable issues matter stakeholders focus externally assured areas core strategy areas meaningful stakeholders greatest positive impact societys urgent challenges focus areas assess performance access healthcare glt accountable delivering progress global health health security metrics regularly reviews performance along environment boards corporate responsibility committee crc individual metric assessed either track metric met diversity equity inclusion exceeded track work least ethical standards metric achieved track metric missed product governance approach guided extensive stakeholder addition order calculate overall esg engagement key issues relevant industry performance rating performance across metrics company results recent materiality aggregated single score illustrate whether assessment reaffirmed material issues track track work track rating business well aligned six esg focus areas defined aware however responsible business static requirement operating environment track metrics track continues change pace continue adapt track work metrics respond proactively change approach ensure either track track work gsk continues deliver strong esg performance track metrics track esg performance rating esg performance rating support integration esg strategy delivery esg performance rating track based make esg performance measurable verifiable performance metrics met exceeded introduced new esg performance rating rating one corporate kpis measures progress assessment performance annual targets key metrics aligned six focus areas reviewed overall esg performance included metrics cover rating score externally assured performance section report external benchmarking detailed perform key esg ratings ftsegood member ftsegood index since frequently asked investors cdp climate change b water security access medicines ranked st access forests palm oil b forests timber medicines index industry leader sustainalytics low risk rating antimicrobial resistance benchmark msci aa rating sp corporate sustainability assessment ranked nd moody 's esg solutions ranked nd pharmaceuticals industry score pharmaceuticals sector february included djsi world europe indices iss corporate rating b rating f full details progress six focus areas latest materiality assessment esg performance rating metrics please see esg performance report gsk annual report strategic report governance remuneration financial statements investor information responsible business continued access ambition positively impact health billion vaccines people end achieve partner gavi since foundation developing vaccines medicines making reserve lowest vaccine prices gavi available responsible pricing strategic access similar organisations passed milestone programmes partnerships supplying gavi one billion vaccines since commitment partnership includes supplying cervarix critical make products available valuebased prices vaccine lower income countries addressing cervical sustainable business implement access cancer supplied around million doses strategies increase use medicines pneumococcal vaccine synflorix eight gavieligible vaccines treat protect underserved people countries lowest price rotarix vaccine rotavirus reaches children across gavieligible countries assess performance four former gavi countries since march well develop externally publish pricing access synflorix also offered rotarix principles humanitarian mechanism civil society organisations progress towards goal reaching billion serving refugees working emergency situations people lower income countries products also longstanding supplier oral polio vaccines opv unicef alone supplied around progress million doses help eradicate polio putting right value innovation neglected tropical diseases follow set pricing access principles published donated million doses albendazole first time help us get balance medicine used help eliminate lymphatic filariasis right responsible pricing sustainable treat soiltransmitted helminths also extended profitable business allows us reinvest financial soiltransmitted helminths commitment include pre returns future innovation ensuring people school children made additional commitment access medicines vaccines donate albendazole treatment echinococcosis us gsk viiv healthcares patient hiv assistance programs foundation provided prescribed viiv healthcare medicines patent pool medicines vaccines lowincome mpp signed new voluntary licensing agreement allow uninsured underinsured medicare part patients generic manufacturers develop manufacture supply us year combined average net cabotegravir longacting hiv preexposure prophylaxis price discounts rebates allowances viiv healthcare also voluntary licensing agreements pharmaceutical vaccines portfolio increased generic manufacturers produce sell lowcost average list price increased compared single fixeddose combination products containing list industry demonstrates hiv medicine dolutegravir adults low middle responsible pricing decisions past five income countries one direct licence others via years average net price products decreased mpp similar agreements generic annually average list price rose manufacturers children covering countries compared list industry result voluntary licence agreements around reaching patients lower income countries million people living hiv across countries goal reach billion people lower income access generic product containing dolutegravir countries products end end least people living hiv access initiatives voluntary licensing donations antiretrovirals low middleincome countries work gavi vaccine alliance viiv healthcare donated around packs reached million people products supplied antiretroviral medicines ngo partners national hiv additional million doses albendazole aids programmes support people living hiv ranked first access medicines index eighth impacted conflict ukraine viiv consecutive time also provided positive action programme support communitybased organisations industry averages sourced drug channels annual brandname humanitarian response activities within ukraine drug list change report surrounding countries hosting refugees million figure includes people reached synflorix rotarix cervarix opv mosquirix vaccines people access generic dolutegravir product voluntary licensing agreements however include people reached albendazole assessment made gskgsk annual report responsible business continued positive action viiv healthcare 's community grantgiving prerequisite un agencies procure programme celebrated th anniversary vaccine important step rolling countries yearlong campaign showcase people heart moderate high p falciparum malaria transmission programme partners implementation gsk path bharat biotech agreed product progress made collaboration invested transfer help ensure longterm supply rtss million reaching approximately malaria vaccine committed supply people providing grants across countries million doses next three years addition malaria donation million doses whocoordinated working partners million children malaria vaccine implementation programme ghana africa received least one dose malaria kenya malawi vaccine mosquirix rtssas e september f full details progress six focus areas please awarded prequalification vaccine see esg performance report global health health security use expertise address biggest health march australian regulator therapeutic challenges underserved people around world goods administration approved use singledose medicine tafenoquine children aged two commitment combination chloroquine radical cure p vivax malaria develop novel products technologies treat prevent priority diseases including pandemic threats fda approved triumeq pd first dispersible single tablet formulation containing dolutegravir children assess performance weighing kg increases age progress three global health pipeline assets address appropriate treatment options children living hiv priority diseases end chmp ema also issued positive opinion recommending marketing authorisation progress triumeq pd children kg global health rd invasive nontyphoidal salmonella disease life june gsk including viiv healthcare announced threatening children africa key driver billion investment rd help us get ahead amr 're using innovative vaccine technology infectious diseases lower income countries year partnership university oxford vaccints investment support rd new medicines vaccines develop potential candidate vaccine using prevent treat tuberculosis tb malaria hiv enteric generalised modules membrane antigens technology diseases neglected tropical diseases reduce help support global rd december amr progressed global health pipeline announced fourth call proposals part assets address priority diseases including malaria africa open lab call proposals aimed african tb exceeding target three earlycareer scientists based subsaharan want discover shorter simpler safer treatments africa focus infectious diseases tb alongside partners public disproportionately affect subsaharan populations private research consortiums continued progress malaria tb neglected tropical diseases pipeline novel tb medicines announced getting ahead antimicrobial resistance positive phase iia study results gsk new rd projects across medicines firstinclass candidate medicine patients tb vaccines relevant amr ranging early results study demonstrated potential latestage development include gepotidacin candidate become component simpler treatment could first novel oral antibiotic treatment regimens future uncomplicated urinary tract infections years partnership bioversys university lille announced exclusive licence agreement innovative medicines initiative imi project trictb spero therapeutics tebipenem hbr latestage also successfully completed phase trials bvlgsk antibiotic may treat complicated urinary tract potential help tackle drug resistance infections projects target pathogens deemed boosting activity existing antibiotic 'critical ' 'urgent ' us cdc see rd pipeline partners weve brought two products prevention treatment malaria market worlds first vaccine malaria singledose radical cure p vivax malaria gsk annual report strategic report governance remuneration financial statements investor information responsible business continued surveillance central tackling amr shared declaration stated sectors willingness reserve data longrunning survey antibiotic resistance allocation realtime production medicines soar study tracks communityacquired respiratory vaccines distribution priority populations infections new amr register developed vivli determined health authorities future pandemics also worked amr industry alliance gsk concluded series contracts publish new antibiotic manufacturing standard would provide least million doses pandemic provides clear guidance manufacturers global influenza vaccine governments around world antibiotic supply chain help ensure antibiotics made responsibly compliance scientifically february extended pandemic influenza robust discharge limits vaccine stockpile contract united states government followed renewed agreement f full details progress six focus areas please see esg performance report june supply pandemic influenza vaccines july contract government future pandemic preparedness canada seasonal pandemic influenza vaccines july gsk along major biopharmaceutical signed agreement europe reservation companies signed berlin declaration sets future production supply pandemic influenza industrys vision equitable access future vaccines also continuing partner barda pandemics manufacture assess safety immunogenicity pandemic influenza vaccine candidates environment continue work hard protect waste materials environment often partnership others weve set operational waste material reduction sites clear measurable targets help achieve goals biodiversity number highrisk materials implementing commitment sustainable sourcing roadmaps commit net zero nature positive healthier planet ambitious goals set progress climate assess performance set clear pathway net zero impact following metrics included esg performance climate ambitious goals rating support delivery carbon nature updated climate targets line new ambitions science based targets initiative sbti netzero standard climate aim reduce carbon emissions across operational emissions reduction scope scopes baseline marketbased emissions remaining offset investment highquality naturebased solutions also set longer industrialisation green ventolin initiated clinical term target reduce carbon emissions least nonclinical data available support regulatory remainder tackled highquality offsets submissions additional context changes see pages percentage carbon offset volume project pipeline esg performance report water targets average percentage gsk sites suppliers reduction carbon emissions investment compliant wastewater active pharmaceutical naturebased solutions remaining ingredient limits percentage suppliers footprint scopes compliant amr industry alliance common antibiotic manufacturing framework discharge renewable electricity scope limits net zero emissions across full value chain scopes targets measured baseline previously stated net zero new longerterm target aligned sbti netzero standard definition net zerogsk annual report responsible business continued performance environmental impact reduction products reduced scope carbon emissions packaging compared primarily waste reduction supply chain increasing use renewable electricity continued positive impact biodiversity sites delivery energy efficiency across sites agricultural forestry marinederived materials installation new solar panels upgraded lighting sustainably sourced deforestation free replacing chillers reduce use ozone depleting refrigerant member committed performance source renewable electricity reduced overall water use operations reached increase since since sites high water stress regions since decrease overall water use sites high water stress regions baseline following demerger consumer healthcare achieved overall water use reduction target business restating value chain carbon footprint review sites good baseline year latest available water stewards line alliance water data scope emissions reduced compared stewardships definition reductions reflect evolution product portfolio initially identified three water basins water stressed areas algeria india pakistan approximately total emissions footprint comes manufacturing sites aim water neutral goods services buy september manufacturing facility nashik india built launched sustainable procurement programme plants rainwater harvesting require suppliers among things disclose emissions set carbon reduction targets aligned sites suppliers oc switch renewable power heat manufacture antibiotics complied amr alliance industry standards safe discharges also working peers energize programme encourage use renewable energy continued reduce waste sites throughout pharmaceutical sectors supply chain increase amount materials recovered nine suppliers formed first energize buyers cohort circular routes like reuse recycling also targeting together purchase two terawatthours materials across existing product portfolio renewable electricity progressing plans net positive biodiversity see pages disclosure climate risk sites investing individual site action plans resilience line task force climaterelated improve habitats protect species improve soil financial disclosures tcfd framework water quality completed baseline biodiversity assessments sites commenced nature biodiversity uplift projects three largest rd facilities committed working towards goal also completed full assessment net positive impact nature reducing biodiversity impact across entire value chain environmental impacts across water waste materials taking targeted actions address highly biodiversity investing protecting stressed areas restoring nature leadup un convention biological diversity targets critical cop conference canada end achieve good water stewardship sites worked partners call mandatory disclosure businesses financial institutions impacts dependencies nature reduce overall water use operations part leaf coalition lowering emissions water neutral operations key accelerating forest finance privatepublic effort suppliers waterstressed regions protect tropical forests also testing framework voluntary carbon credits voluntary carbon market zero impact active pharmaceutical ingredient api levels integrity initiative working establish globally sites key suppliers standardised benchmark guide use carbon credits zero operational waste including eliminating singleuse companies plastics see pages plan disclose impacts dependencies nature line emerging taskforce naturerelated financial targets measured baseline disclosures tnfd framework see environment basis reporting definition zero impact predicted effect concentrations f full details progress six focus areas please see esg performance report regulatory obligations allow excluding plastics critical product discovery development health safety gsk annual report strategic report governance remuneration financial statements investor information responsible business continued diversity equity inclusion diversity equity inclusion dei central gsk science summer initiative offers free purpose getting ahead disease together handson stem learning students traditionally inclusive diverse business business underrepresented groups stem careers inclusively makes us successful making resourced communities us reached peoples potential increasing positive impact students nationwide nurturing people commitment women held vpandabove roles globally create diverse equitable inclusive workplace compared women made enhance recruitment diverse patient populations employees management roles clinical trials support diverse communities published sixth uk gender pay gap report gender pay gap permanent ukbased gsk assess performance employees mean compared national phase iii trials initiated proactive average published first uk ethnicity pay plans place designed enrol appropriately diverse gap report using approach trial participants consistent disease epidemiology gender pay gap ethnicity pay gap permanent performance towards aspirations fair ukbased gsk employees mean time equitable opportunities national average comparator women hold least vpandabove roles countries meet criteria data globally end confidentiality anonymity disclose race least ethnically diverse leaders roles ethnicity people level set aspirational vp us increase targets currently us uk meet criteria percentage black african american hispanic us ethnically diverse leaders latinx vpandabove leaders year year vp level reaching aspirational least ethnically diverse leaders target least increasing percentage roles vp uk increase black african american hispanic latinx people percentage black vpandabove leaders year roles year year uk year ethnically diverse leaders vp continuing improve yearonyear spend certified usbased make progress towards aspirational target diverseowned suppliers reaching least black representation vp remains flat focused efforts progress achieve aspiration yearonyear growth building inclusive business members uk governments disability committed improving diversity clinical trial confident scheme active member enrolment already using disease insights set valuable pledge grouping global companies diversity enrolment goals end gsk 's committed placing disability inclusion leadership phase iii trials diversity plan place enrol agenda delivering scheme 's objectives groups affected disease studied based longterm measurable disability confidence epidemiology data example hepatitis b trials plan includes educating people issue disease disproportionately affects people african introduced new global minimum standard asian descent participants asian origin weeks ' parental leave primary secondary carers actively working improve representation forms family new global minimum standard participants african descent care family member end life serious health supplier diversity programme well established emergencies insured benefits include sex partners us expansion plan developed uk wherever possible new financial wellbeing service target increase spend annually certified mental health training available everyone usbased diverseowned suppliers significantly year recognised gold employer within exceeded combination spend stonewalls top global employers index allyship increases selected suppliers marketing sales programme received award recognising tangible technology well identification new global diverse impact campaign lives lgbt suppliers strong multiyear strategy engagement employees also achieved human rights campaign key advocacy groups foundation 's best places work lgbt equality standard f full details progress six focus areas please see esg performance reportgsk annual report responsible business continued ethical standards culture guides people right thing upholding commitment human rights speak concerns important signatories un global compact people live expect human rights position statement lays commitment suppliers un guiding principles business human rights year established human rights commitment steering group formal reporting mechanism promote ethical behaviour across business boards corporate responsibility committee supporting employees right thing working developed guidance enhance supplier visits suppliers share standards operate help employees better understand labour human responsible way rights noncompliances support guidance also developed delivered labour rights training assess performance environment health safety ehs procurement employees complementary workers employees better equip spot human rights complete gsks mandatory training issues visiting suppliers percentage employees believe committed application fair equitable speak things dont feel right general pay practices includes ensuring employees industry benchmark globally receive pay competitive local number employees leaving gsk 's employment markets sufficient support sustainable standard misconduct last months versus threeyear living completed first global living wage rolling average review partnership fair wage foundation direct highrisk suppliers achieve gsks minimum assessed pay employees people ecovadis score improvement plan place countries differences detected fewer cases countries necessary adjustments progress made end first quarter factoring living wage data standard supporting gsk people right thing compensation processes ensure continue launched new code conduct offer fair wage built annual living wage reflects purpose unite science technology talent review standard cycle get ahead disease together new code sets commitments make company working third parties deliver purpose ambitions expect third parties meet abac labour employees complementary workers rights standards comply standards completed accompanying global mandatory learning quality health safety environment see pages curriculum due year end information certain highrisk roles geographic regions updated thirdparty risk management tprm also complete additional antibribery corruption programme evaluates mitigates risks introduced abac training employees third parties engaged gsk provide goods complementary workers completed training due services year end approach managing abac risk highrisk third parties determined risks relating ethical standards forms part location highrisk markets size spend well embedded risk management framework performed assessments across risk areas described detail pages assessments presented risks one reporting investigating concerns areas third parties goods services year updated report breakdown providers distributors wholesalers contract types policy violations provide granularity manufacturers suppliers direct material case class saw overall decrease suppliers also use tools assess suppliers disciplinary cases attributed part revision manage risks including ecovadis desktop assessments procedures discipline regarding late completion mandatory training reported employee conduct category general industry benchmark according research kornferry gsk annual report strategic report governance remuneration financial statements investor information responsible business continued visit sites person virtually help suppliers better privacy ethical use data part global understand control risks relaxation travel mandatory learning curriculum living code restrictions allowed us increase inperson visits people complete ensure key privacy identify reduce risk enabling us conduct physical personnel certifications sufficient training visits across priority suppliers year completed experience carry roles effectively warehouse safety surveys priority suppliers investing aiml capability example contract manufacturing suppliers large warehouses help analyse patients genetic data mindful hold stock year surveys generated ai machine learning raise ethical issues corrective preventative action plans subject evolving decisions policymakers expect complete best promote trust systems avoid conducted supplier audits compared unintended outcomes harmful impacts following industry standard pharmaceutical rd oversight boards new advisory supply chain initiative guidelines corrective panel oversees controls manage use preventative actions tracked completion also reuse data respond bioethical questions trained supplier employees ehs esg research activities fundamentals revised ehs contractual obligations tracked management actions completion political engagement helped suppliers improve ecovadis scores see major multinational company seek contribute information public policy debate especially relation life sciences healthcare political engagements data engagement committed ensuring adhere highest created new digital privacy information ethical standards legislative requirements security team within legal compliance streamline make corporate political contributions sponsor support provide expertise around gsks digital party political meetings anywhere around world data strategy f full details progress six focus areas please see esg performance report product governance ensuring quality safety reliable supply total number class iii external product recalls across products critical protecting patients delivering markets health impact register disclose human subject research gsk products specifically register protocol summaries commitment studies initiated disclose results summaries commit maintaining robust quality safety studies results due processes using data new technologies responsibly progress focus quality management assess performance gsk quality management system detailed average number critical major findings specific framework describes comply fdamhraema regulators regulatory requirements standards across percentage inspections regulators markets addresses global local regulations critical findings official action indicated across manufacturing distribution processes based principles defined international council number fda warning letters harmonisation technical requirements pharmaceuticals human use ehs priority suppliers api suppliers medically rd revenuecritical gsk high spend suppliers supplier employees trained includes data previous consumer healthcare business consider observations fda majorgsk annual report responsible business continued inspections recalls audit maintaining pharmacovigilance regulatory inspections pharmacovigilance aims protect use manufacturing sites local operating companies medicines vaccines support public health compared remain prepared programmes reliable comprehensive information inspections regulators received warning letters overall benefitrisk balance products us fda critical findings medicines well established rigorous worldwide system monitor healthcare products regulatory agency mhra ema review safety products throughout clinical regulators however received one critical finding development regulatory approval chinese regulator continue learn vigilance falsified medicines vaccines respond inspection findings taking necessary robust approach handling falsified product action address incidents ensuring cases confirmed counterfeit throughout class product recalls products reported relevant fewer class ii iii recalls regulatory authorities actively participate legal hesitate voluntarily recall products protect patients proceedings illegal actors provide regular training customs local authorities monitor online working suppliers quality marketplaces social media request takedowns expect contract manufacturers suppliers sites illicitly selling prescriptiononly medicines comply gsk standards regularly conduct audits verify conducted quality committed transparency audits suppliers increased focus api suppliers part commitment made protocol summaries summaries results available since comprehensive quality oversight model setup gsk trial register also aligned quality management system uses listed studies data sharing via wwwvivliorg riskbased approach assess qualify manage wwwclinicalstudydatarequestcom monitor thirdparty suppliers driving continuous performance f full details progress six focus areas please see esg performance report critical finding one inspection chinese regulator thirdparty manufacturing facility used gsk class recalls triggered reasonable probability use exposure violative product cause serious adverse health consequences death class ii recalls address use exposure violative product may cause temporary medically reversible adverse health consequences probability serious adverse health consequences remote class iii recalls relate use exposure violative product likely cause adverse health consequences gsk annual report strategic report governance remuneration financial statements investor information risk management board continuously reviews oversees risk management internal control framework reflects responsible biopharma company bold ambitions patients managing risks line longterm assessing emerging current risks priorities risk assessment process considers likelihood well embedded risk management internal control impact risks timescale risk could framework gives board ability evaluate occur well considering current risks evaluate oversee company manages principal emerging risks could affect ability achieve emerging risks line strategy longterm longterm priorities risks threeyear horizon priorities fullyfocused biopharma company following line viability statement also define risks year 's demerger haleon companywide policy emerging need know likely sets requirements roles responsibilities materialise impact would management governance risks controls well 'll evaluate whether investigate supporting guidance essential elements classifying principal risks internal control framework routinely evaluate risk management compliance boards levels framework improvements organisation identify emerging risks ongoing basis rocc discusses emerging risks meeting board oversight risk appetite time scan risk horizon throughout management systems year identify external trends may opportunities board oversees risk management system andor emerging risks monitor business activities establishes risk appetite supported audit risk internal environment committee arc corporate responsibility committee rocc conducts annual risk review assess principal crc science committee assess emerging risks company review effectiveness risk management strategies fall within supported extensive analysis external trends defined remits risk oversight compliance insights seniorlevel interviews recommendations council rocc helps arc crc science risk management compliance boards risk owners committee oversee risks strategies used rocc shares annual review arc board address alongside risk management assessment forming basis following years compliance boards across group promote tone risk management focus top establish risk culture oversee effectiveness risk management activities also enabling effective risk management line communicating information internal controls culture management held accountable delivering objectives line established risk appetite define enterprise risk plans include description pertaining principal risks enterprise risk owner risk context assessment risk appetite responsible principal risk overseen glt treat risk actions businesses need take member risk owners report risk mitigation rocc line internal control framework mitigate risk appropriate board committee quarter legal plans enable board committees assess compliance support efforts advising effectiveness risk management strategies business strategies activities risks controls audit report risks rocc board committees every assurance provides assessments adequacy quarter drive dynamic datadriven discussions effectiveness framework agile risk management strategies oversight report existing control measures implementation emerging risks external insights key risk indicators risk reporting thresholds aligned risk appetite include risks mitigations associated relevant events around us covid geopolitical tensionsgsk annual report risk management continued code sets overarching expectations covid pandemic employees complementary workers risk potential impact covid pandemic gsks management framework complements culture trading performance principal risks continually speak processes making sure identify assessed appropriate mitigation plans put place mitigate risks effectively monitor important asneeded basis gsk encouraged risks take action address issues annual uptake vaccines medicines company confirmation exercise checks key risks well remains confident underlying demand vaccines managed actions place address gaps medicines especially given significant number principal risks include controls responding problems covid vaccinations boosters administered within risk plans also business continuity worldwide however pandemic remains dynamic planning embedded framework critical ongoing risk continuing monitor processes continue business operations emergence new variants current rate infection event crisis predominantly driven circulation ba subvariant descendent lineages still current risks dominant subvariants omicron globally covid table starting shows current principal vaccines updated omicron variants risks respective trends assessments mitigation provide broader immunity circulating emerging activities year order significance variants subvariants potential future variants full risk definitions potential impact context concern could potentially impact gsks trading results mitigating activities see principal risks uncertainties clinical trials supply continuity employees materially pages separation principal risk removed july following successful demerger changes risks analysis residual risk december annual risk review arc agreed risks level principal risks roccs recommendation principal risks opportunities related esg including environmental remain largely unchanged identified new sustainability climate change managed principal risk legal matters brings greater six focus areas described esg performance focus range legal risks result antibribery report additional information climaterelated risk corruption longer standalone principal risk management climaterelated financial disclosures additionally expanded information security see pages principal risk explicitly include cyber risks also identified data management new emerging risk evaluate year emerging risks geopolitical tensions healthcare reform embedded risk management activities throughout year reported separately v iability statement see rc report see nternal control framework see l egal proceedings see e nvironment see c limaterelated financial disclosures report see gsk annual report strategic report governance remuneration financial statements investor information principal risks summary trend versus risk prior year assessment mitigation activities patient external risk environment remains stable regulatory environment remains safety external challenging recent examples evolving regulatory requirements related safety reporting clinical trials also risk external parties including regulatory agencies technology companies may reach conclusions communicate information safety products based realworld evidence available us could inhibit ability make timely decisions take appropriate action relation safety products confirm refute conclusions asserted external parties risk exposure remains stable continue balance resources change programmes maintaining routine activities 've allocated resources gsk optimise pharmacovigilance operations advance innovative solutions safety case management simplify key safety processes change initiatives shortterm potential distract focus key business priorities however changes reduce overall risk exposure increasing workload capacity organisational capability product external risk environment stabilising remains high following covid quality external regulators resuming multiple onsite inspections check product quality expectations met continues focus data governance data integrity requirements evaluation products presence nitrosamines regulatory environment evolving respect continued use titanium dioxide medicines ema due make decision potential discontinuation risk exposure stabilised return prepandemic levels health authority inspections continue inspection readiness programmes ensure full preparedness gsk 've continued invest technology digital platforms strengthen controls around good data management practices 've completed nitrosamine product assessments line regulatory expectations financial external risk environment remains challenging due political uncertainty proposed controls external increases obligations directors auditors increasing threats cyber attacks reporting fraud increasing esg disclosure requirements risk exposure remains stable due ongoing focus resilience personnel gsk testing internal control framework implement optimal risk mitigation transformational programmes technology centralised processes risk control assessments maintain effective tax treasury strategies continually strengthen control frameworks collaborate external bodies setting standards antibribery external risk environment remains stable enforcement anticorruption laws corruption external regulations remains priority many countries particular us uk abac continued focus investigating use third parties bribe foreign public officials result rigorous antibribery corruption controls expected disruption global supply chains commercial pressures caused higherthanusual inflation rates may increase risks bribery corruption certain contexts coming years risk exposure remains stable continuously improve abac programme make sure controls match evolving emerging risks 've enhanced gsk mandatory abac training employees provide role risktailored abac training ongoing basis also impose stringent abac training requirements certain third parties provide services behalf commercial external risk environment stabilised macroeconomic factors energy price practices external increases inflationary pressure ongoing effects covid pandemic contribute challenging environment stakeholders competitive pressure remains intense across therapy areas market segments governments remain focused initiatives drive medicine vaccine costs consumers risk exposure remains stable mature robust control environment gsk evolved match competitive enhancements commercial practices including higher volumes engagement healthcare professionals strengthened sales force incentive schemesgsk annual report principal risks summary continued trend versus risk prior year assessment mitigation activities scientific external risk environment remains stable continues characterised complex patient external dynamic disease areas treatments increased patientcentric focus engagement phases product lifecycle increasing diversity engagement platforms virtual engagements risk exposure remains stable continue mitigate risk modernising adjusting engagement practices internal controls rapidly evolving environment gsk internal networks foster collaboration best practice sharing well identification emerging risks associated scientific patient engagement activities data ethics external risk environment continues increase global landscape data privacy external protection privacy cyber laws develops given current pace technology focused innovation expected continue companies need mindful relevant potential legislation regulations increasing trend data sovereignty initially affecting tech companies could affect healthcare companies ability drive medical innovation effectively operate internationally risk exposure increasing context unstable privacy regulatory environment gsk multinational footprint realign digital transformation focus datadriven science laws key markets us eu uk china india continue evolve including relating international data transfer mechanisms research external risk environment remains stable research remains critical development practices external safe effective products advances technology use data societal expectations ethical considerations new entrants sector continue influence environment global regulations quality standards continue evolve particularly impactful expectations change countryspecific requirements risk exposure remains stable laws regulations continually evolving gsk continue perform robust risk scanning assessments inform evolution control framework response regulatory changes ensuring clear accountabilities actions environment external risk environment remains stable manufacturing sites operating full health external staffing levels work location arrangements made maintain safety safety wellbeing employees affected ukraine conflict ehs risk exposure remains stable 've continued focus safety leadership training embedding life saving rules adhering ehs standards 're introducing gsk safety leadership experience across global supply chain rd operations programme trains leaders take ehs accountability make sure people understand importance adhering ehs standards information external risk environment continues rise digital footprints increase threats security external hackers become sophisticated growing geopolitical conflicts significantly increased cyber risk large corporations governments tightening regulatory frameworks regards data information seeing rise enforcement risk exposure continues increase operate increasingly digital healthcare gsk ecosystem continue expand digital footprint response cyber security maturity programme continues improve controls governance identify protect detect respond recover cyber incidents supply external risk environment increasing due unpredictable external forces put continuity external pressure resilience supply chains include geopolitical tensions growing nationalistic approaches including uschina decoupling risk exposure remains stable across medicines vaccines supply chains continue focus strategic materials planning parameters adapting changes gsk external environment including inventory strategies safety stocks hedging 're making concerted effort stabilise accelerate newly acquired assets 're focusing making sure recruit right people support future portfolio gsk annual report strategic report governance remuneration financial statements investor information risk management continued climaterelated financial disclosures gsk climaterelated financial disclosures consistent metrics include climaterelated metrics recommendations recommended disclosures reduction scope emissions reaching key task force climaterelated financial disclosures milestones rd programme reduce greenhouse tcfd including tcfd allsector guidance gas emissions ghg metered dose inhalers asthma compliance requirements lr r chronic obstructive pulmonary disease see uk listing rules gsk leadership team glt gsk reporting climaterelated financial glt meets regularly opportunity members disclosures accordance tcfd recommendations discuss strategic financial reputational matters since purpose building trust regis simard president global supply chain glt connecting strategic financial disclosures member management responsibility environmental climate change year updated climate sustainability includes climate change scenarios used model transition physical risks responsible governance oversight risks enabled us extend timeframe model risks opportunities ensures effective framework data available broaden scope place manage risks opportunities across include gsks supply chain continue monitor business units along delivering emerging risks new data include future commitments made net zero nature positive healthier assessments planet ambitious goals set across entire value chain governance board regis supported gsks vice president vp sustainability regularly reviews progress board considers climaterelated matters throughout cochairs quarterly gsk sustainability council year assessing risk management processes place challenging endorsing business plan glt reviewed discussed midyear budgets including overseeing major capital expenditures performance key environmental metrics including acquisitions divestments committee climaterelated ones part reviewing gsks esg exercises oversight provides guidance reviews performance rating esg performance including climaterelated risks opportunities environmental performance gsk sustainability council targets crc sustainability council held quarterly attended senior leaders across business play key role committee supported glt rocc delivering commitment net zero nature positive receive quarterly updates environmental sustainability healthier planet ambitious goals set including climate regular attendees include ceo across entire value chain members include president global supply chain see crc report leaders procurement finance hr compliance rd details board architecture manufacturing council cochaired crc met four times key areas focus president global supply chain vp sustainability supported global sustainability team discussed climaterelated issues three separate provides specialist expertise advice business occasions management including progress delivering climate ambitions implications council geopolitical landscape key milestones decisions received monthly performance dashboards covering key required achieve net zero targets performance metrics escalations potential reviewed midyear performance key environmental concerns issues metrics including climaterelated metrics part held quarterly performance reviews across areas reviewing gsks esg performance rating programme delivery focused reviews aspects approved gsks tcfd statement public programme implementation sustainable environmental reporting disclosures sourcing strategy recommendations refreshing remuneration committee support gsks science based target commitments council crc introduced measure gsks longterm reviews include decisions interventions support incentive plan opportunity senior leaders based key required maintain progress towards targets metrics related gsks esg performance reviewed insights esg trends regulations approved proposed sustainability data strategygsk annual report risk management continued order address key priorities climate impact supply chain emissions shared challenge across gsks metered dose inhaler specific council sector working peers collaborative established attended senior leaders initiatives across commercial supply chain regulatory rd activate programme help active pharmaceutical businesses aligned gsks respiratory business ingredients api suppliers accelerate decarbonisation council chaired president global supply chain initiatives decisionmaking body energize programme encourage use programme reduce climate impact metered renewable energy throughout pharmaceutical dose inhalers contribute approximately sectors supply chain gsks total ghg emissions clinical manufacture initiative encourage suppliers trials successful measure manage reduce emissions advocacy engagement regulators september launched sustainable policymakers procurement programme require suppliers industrialisation strategy progress disclose emissions set carbon reduction targets aligned business support c sustainability programme steering team use metered dose inhalers patients coordinates sustainability programme asthma chronic obstructive pulmonary disease associated workstreams oversight monitoring makes around total climate impact performance progress enablers required investing rd programme reduce greenhouse gas deliver sustainability programme emissions vital medicine could potentially business unit sustainability councils meet quarterly reduce climate impact clinical review business unit performance delivery studies confirm new propellant could company sustainability ambition appropriate replacement gsk work securing capital allocations board cab includes approval regulators markets new product cfo group financial controller reviews climate could made available patients process take related capital expenditure part annual planning time gsk focused meeting commitment capital allocation process made considerable investments towards achieving goal finance sustainability network includes leaders across finance sustainability procurement science based targets initiative sbti accredited focuses key financial enablers deliver climate targets set prior demerger aligned sustainability programme c pathway reduction pathway significantly ambitious currently seeking strategy reaccreditation sbti targets fully gsk 's commitment net zero nature positive healthier focused biopharma company planet embedded gsks strategic longterm priorities recognise global energy crisis described always considering social environmental disrupting delaying green governance impacts everything laboratory transition across world may impact pace patient decarbonisation short term setback many teams across gsk involved process energy transition expected timelimited ensure make sound strategic decisions developed threeyear plan embed process identifying assessing climaterelated risks climate risk analysis across material areas business opportunities set risk management focused risks impacting direct operations part tcfd section achieve climate ambition updated climate scenarios used model active holistic management climaterelated risk transition physical risks enabled us extend components important addition risk also timeframe model climate risks data continue identify opportunities gsk risks available broaden scope include gsks opportunities described table pages sites suppliers across geographies strategic revenue dependency aligned supply chain risk order achieve reductions emissions across management processes operations part transition plans focusing maximising energy efficiency sites transitioning renewable electricity increasing use electric vehicles sales fleet gsk annual report strategic report governance remuneration financial statements investor information risk management continued continue monitor emerging risks new current trajectory scenario ssp rcp data include future assessments using external parties scenario sets show extent announced provide horizon scanning insights esg trends ambitions targets path deliver regulations emissions reductions required achieve net zero emissions temperature rise exceed c gsk prioritised scenario modelling following risks noticeable shift happen latter half century net zero pledge emissions within changes regulations governing supply high scenario necessarily mean co emissions global warming potential gwp substances eu energy sector need reach net zero uk us governments could restrict gsks ability allocation carbon offsetting within pledges manufacture metered dose inhalers breach planetary boundaries scenarios future regulatory policy responses address climate ssp rcp change could lead imposition carbon taxes scenario aligned pledges laid countries gsk manufactures sources goods within paris agreement one countries third parties unable meet united nations sustainable increasing levels water stress could lead development goals scenario severe interruptions supply water gsk thirdparty physical consequences planet temperature rise supply sites exceed c leading high loss biodiversity increasing frequency impact extreme weather species extinction events could cause disruption gsk thirdparty risk opportunity analysed including supplier sites managed gsk metrics targets climate scenarios place potential impact profit using low reviewed updated climate scenarios million medium million million high developing four climate scenarios used three million threshold scenarios modelling transition risks net zero low due inherent uncertainty nature carbon current trajectory three scenarios risks across gsk strategy business model climate modelling physical risks low carbon current trajectory related issues monitored within time horizons breach planetary boundaries short term less years medium term years net zero scenario ssp rcp long term years scenario sets narrow achievable pathway comparison disclosure extended global energy sector achieve net zero co emissions timeframe climate risk assessments rely emissions reduction data available able differentiate outside energy sector achieve goal scenario potential longterm outcomes different climate scenarios consistent limiting global temperature rise c without temperature overshoot net zero means based different climate scenarios analysis huge declines use coal oil gas shift performed taking consideration climate risk renewable energy sources opportunities identified across geographies described table tested resilience low carbon scenario ssp rcp gsk 's business strategy identify material scenario current net zero pledges achieved impact business resilience full extensive efforts realise nearterm emissions reductions advanced economies reach net zero emissions china around countries latest scenario consistent limiting global temperature rise c level net negative emissions temperature rise could reduced c iea net zero emissions scenario httpswwwieaorgreportsglobal energyandclimatemodelnetzeroemissionsbyscenarionze last accessed november iea world energy outlook chapter p download report httpswwwieaorgreportsworldenergyoutlookoverview last accessed november iea announced pledges httpswwwieaorgreportsglobalenergy andclimatemodelannouncedpledgesscenarioaps last accessed november gsk annual report risk management continued potential physical risk financial impact description gsk response scenario timeframe metrics targets risk identified three water basins current medium sites achieve increasing levels waterstressed areas algeria india trajectory good water water stress leading pakistan manufacturing sites achieved stewardship interruptions aim water neutral long term water supply water years stewardship sites manufacturing facility nashik india gsk sites built plants rainwater harvesting total thirdparty supply supplied reduce sites climate scenario analysis identified breach low water overall water number sites supplier sites located planetary gsk third use water basins could become water boundaries long term party suppliers use operations stressed added years freshwater watch list monitor changes risk main source water levels update site water risk manufacture assessments appropriately medicines vaccines water availability restricted factory production operations would interrupted increasing frequency climate scenario modelling indicated low business extreme weather seven physical perils flood rainfall carbon continuity climate events causing presents highest likelihood acute scenario plans related risks disruption gsk interruption however risk flooding reviewed business thirdparty supplier rainfall extreme weather annually continuity sites events expected remain low identified extreme weather performed risk assessments current low events one manufacturing operations trajectory taken action precipitation business continuity plans place scenario long term h em ri si kgate rainfall flood reviewed annually respond years precipitation tidal impacts extreme weather events including flood extreme wind adopting appropriate mitigation plans wildfire extreme heat gsk well established loss prevention breach extreme cold risk engineering programme identify planetary result shortterm range risks could impact sites boundaries interruptions flood risks exist taken action scenario manufacturing mitigate risk gsk supplier sites regulations investing rd programme current high onoff track governing use reduce greenhouse gas emissions trajectory high global warming metered dose inhalers used treat asthma scenario medium delivery reduction potential gwp copd made good progress years key carbon substances towards reformulating alternative gas milestones emissions updated eu could potentially reduce climate impact rd scopes uk clinical trials programme updated recently successful plan us respectively already portfolio dry powder could lead inhaler products use propellants increasing costs impacted risk restrict ability manufacture metered dose inhaler mdi products use high gwp propellant hfaa gsk annual report strategic report governance remuneration financial statements investor information risk management continued potential transitional risk financial impact description gsk response scenario timeframe metrics targets future regulatory gsk managing risk reducing scope net zero medium scope policy responses emissions following scenario carbon address climate gsks energy efficiency programme emissions reduction change could lead transitioning renewable electricity medium scope carbon imposition years carbon emissions carbon taxes long term scopes investigating options renewable heat emissions countries gsk years technology manufactures transitioning sales fleet electric vehicles source goods respectively using shadow carbon pricing capital low medium third parties investments us per tonne ghg carbon emissions scenario medium gsk managing risk reducing scope year emissions following term falling rd programmes reduce greenhouse gas low emissions metered dose inhalers long term new supply chain programme requiring years suppliers take action carbon set targets aligned c switch renewable power heat current low collaborating sector peers energize trajectory medium activate programmes manufacture scenario years initiative long term joining sustainable markets initiative health years systems task force reduce healthcare supply chain emissions potential profit impact opportunities gsk response scenario timeframe metrics targets cop reducing scope carbon net zero scope november emissions turn reduces scope scenario footprint customers suppliers carbon reduction countries around example site irvine scotland closed emissions carbon world committed loop heat system helped drive reductions emissions total provide low carbon operating costs onsite renewables low waste scopes healthcare systems biogas provide energy carbon low materials could lead ecodesign programme reduce scenario respectively increasing demand impacts products packaging long low carbon investing rd programme reduce years zero medicines operational greenhouse gas emissions metered dose vaccines inhalers used treat asthma copd current waste made good progress towards reformulating trajectory alternative gas could potentially reduce scenario climate impact clinical trials successful portfolio dry powder inhaler products low carbon footprints september gsk microsoft announced current long several reports innovative collaboration centre trajectory years applicable applicable exploring impact health disease studies chds nepal scenario climate change pilot project leverage microsofts health showing premonition systems gsks expertise health climate change disease investigate ai robotics affects water support local community response vector vectorborne diseases borne diseases climate change could lead july gsks annual palio conference increasing demand explored role vaccines finding solutions new medicines global healthcare protect people planet vaccinesgsk annual report risk management continued risk management physical risks typically identified asset project level managed depending level risk described risk management section assessed increasing levels water stress physical risk gsks risk management policies designed address could reduce availability water types risks including group principal risks operations affected locations important risk uncertainties climate risk assessment follows gsk uses freshwater main source water policy framework manufacture medicines vaccines water availability nature risks opportunities climate restricted factory production operations change depends physical aspects could interrupted perform water stewardship risk climate change also regulatory commercial assessments manufacturing sites update changes markets gsk operates including every three years pressures reduce climate impact gsks metered transition risks typically identified enterprise level dose inhaler medicines market level currently transitions risks terms gsk climate risk management policies priority gsk regulatory commercial risks specific dedicated environmental sustainability risk manage investment decisions management plan put place risk sustainability transformation programme legal management plan covers expectations gsk point view consider risks may arise addressing impact environment product claims based environmental performance environment increasing impacts operational manage risk use external accreditation processes resilience access energy water natural organisations review evidence used support resources used products along anticipated cost environmental claims products criteria increases regulatory changes environmental taxes technological point view gsk developed tools policy developments global national level incorporate ecodesign principles design monitored potential impact example development new products identify opportunities result un montreal protocol kigali amendment reduce environmental impacts existing products mandates global phase use high communications governance affairs team global warming potential hydrofluoroalkane gases manages corporate reputation identification governments introducing proposing introduce monitoring climaterelated issues undertake quota restrictions hfaa used gsk proactive reactive engagement relevant manufacture metered dose inhalers used treat asthma stakeholder groups communicate gsks position copd gsk part industry consultation annual basis crossfunctional team gsks uk department environment food rural business units sustainability team finance perform affairs uk government develops uk specific review risks climate change identify new regulations control fgases emerging risks determine updated risk gsk policies procedures place identify risks assessment required existing risks climaterelated climate change things change example risks considered strategic operational assess climate impact merger acquisition perspective ensure maintain comprehensive view activity construction new buildings major different types climate risks face different capital expenditure furthermore internal control time horizons may affect gsk review framework established environmental approved vp sustainability finance vps sustainability including appointment dedicated gsks business units senior leaders environmental sustainability ensure identified risks assessed climate risk working governance processes place effective group consider likelihood financial impact purposes tcfd disclosures made risk gsk different climate scenarios use tcfd distinction physical impact assessments approved president global transition climaterelated risk supply chain company level responsibility environmental sustainability vp sustainability risks may identified include potential effects finance vps gsks business units results operations asset level performance business level shared business unit risk management control developments regional level extreme weather boards rmcb finance rmcb ensure risks transition lower carbon economy contextualised business risks managed appropriately allows management take holistic view optimise risk mitigation responses ensure responses climaterelated risks properly integrated relevant businesses ' functions ' activities gsk annual report strategic report governance remuneration financial statements investor information risk management continued metrics targets gsk commits net zero nature positive healthier planet water waste annually esg performance report ambitious goals set across entire detailed performance data environmental kpi value chain gsk reports progress reducing scope public responses cdp climate water carbon emissions scope carbon emissions energy use forest questionnaires disclose gsk considered key metrics following guidance tables well metrics metrics used consistent crossindustry climaterelated metrics described tcfd based strategic organisation metrics assess climate risks scope emissions marketbased locationbased approach described table opportunities scope emissions described table line renewably sourced electricity described table strategy risk total supplied water described table management total waste materials described table process esg composite metric part senior leaders remuneration policy see sites achieved water stewardship described table esg performance report includes additional metrics used support strategic metrics listed b isclose scope energy carbon emissions see table applicable scope emissions energy scope ghg scope sources emissions scope emissions marketbased related risks scope emissions locationbased scope emissions metrics scope emissions intensity metrics prioritised physical transition risks included strategy section c describe targets targets measured baseline applicable used reduction carbon emissions investment naturebased solutions remaining organisation footprint scopes manage climate renewable electricity scope related risks net zero emissions across full value chain scopes opportunities achieve good water stewardship sites performance reduce overall water use operations targets zero operational waste water neutral operations key suppliers waterstressed regions performance targets found pages see basis reporting esg resources section gskcom httpswwwgskcomengbresponsibilityesgresources detailed methodologies measuring reporting gsk environmental kpisgsk annual report risk management continued metrics data carbon emissions carbon emissions tonnes coe scope emissions energy scope emissions scope emissions marketbased scope emissions locationbased scope emissions uk scope emissions metrics scope emissions energysales revenue tonnes coem scope emissions energyfte tonnes coefte total energy used gwh uk energy used gwh renewably sourced electricity total supplied water million total waste materials metric tonne sites achieved water stewardship data reported excludes previous consumer healthcare business unless otherwise specified carbon emissions calculated according greenhouse gas protocol corporate accounting reporting standard revised edition gsk uses marketbased scope emissions reporting purposes reports scope emissions across categories esg performance report ask external assurance providers deloitte provide limited assurance isae energy scope selected scope carbon emission data water wastewater data methodologies reporting measurements provided basis reporting esg resources section gskcom httpswwwgskcomengbresponsibilityesgresources refers emissions sales force vehicles propellant emissions released manufacture inhalers majority propellant emissions released patient use included scope carbon emissions onsite waste wastewater treatment refrigerant gas losses collect publish scope data across categories recent scope data available process compiling data yet complete except scope emissions patient use inhalers disclosed esg performance report publish data becomes available included esg performance report naturerelated financial disclosure gsk committed playing part minimise strategy impact dependencies nature well helping committed net positive impact protect restore nature performed full nature reducing environmental impacts assessment impacts nature across value chain across water waste materials biodiversity setting targets reduce pressures line investing nature protection restoration evolving guidance science based targets conducted assessment gsks naturerelated risks nature sbtn line commitment nature opportunities line latest tnfd guidance building achievements climaterelated november following latest tnfd leap financial disclosures gsk currently piloting locate evaluate assess prepare methodology recommendations taskforce naturerelated able better understand magnitude financial disclosures tnfd ahead launch gsks physical transitional risks across nature tnfd 's final framework expected september pressure continue refine assessment part pilot working understand following methodology tnfd look utilise tnfd guidelines report risks report final version available impacts dependencies nature present additionally gsk one first companies conduct business making initial disclosure materiality assessment full value chain line particular focus strategy metrics targets sbtn methodology better understand impacts early findings results inprogress analysis dependencies included gsk annual report strategic report governance remuneration financial statements investor information risk management continued process clearly indicated achieve net targets continue evolve incorporate nature positive requires us build portfolio findings materiality assessment progress pressurespecific initiatives drive action targeted towards achieving net nature positive support landscapes regions impact part progress actively engage external partners commitment acknowledge collaboration across including sbtn world business council different stakeholders continue imperative sustainable development ensure targets metrics multiyear journey ultimately direction provided meaningful robust sbtn technical guidance help shape addressing impacts natural world strategy ensure minimise impacts understanding impacts changing state nature dependencies nature globally globally gsk small undertaking proud pioneering use naturerelated financial metrics targets disclosures industry ultimately delivering positive address gsks pressures nature existing outcomes environment fundamental delivering targets across water waste materials biodiversity positive outcomes human health gsk excited see continue path uniting science technology talent get ahead disease together nonfinancial information statement following aligns nonfinancial reporting requirements contained sections ca cb companies act description business model human rights policy due diligence outcomes business model human rights risk management working third parties principal risks uncertainties social matters data engagement viability statement access audit risk committee report global health health security antibribery corruption ethical standards nonfinancial key performance employees reporting investigating indicators culture people concerns performance key employee engagement performance indicators diversity equity inclusion environmental matters wellbeing development environment policies gender pay gap climaterelated financial public policies codes ethical standards disclosures standards available gskcom board diversity naturerelated financial disclosure employees gender male female total board management employees senior managers defined companies act strategic report directors report regulations gsk annual report risk management continued viability statement accordance provision revision downside scenarios consider gsks cash flows code gsk assessed prospects group sustainability dividends funding strategy insurance longer period months required going provision recovery well key financial ratios concern provision directors confirm period metrics subject reasonable expectation gsk continue operate sensitivity analysis involves flexing number meet liabilities fall due next three main assumptions underlying forecasts individually years directors assessment made combination along mitigating actions reference gsks current position prospects could realistically taken avoid reduce impact strategy boards risk appetite gsks principal risks occurrence underlying risk managed detailed pages following hypothetical downside scenarios strategic report evaluated board reviews internal controls risk scenario business performance risks include key management policies approves governance performance risks including lower sales new products structure code conduct also appraises greater adverse impact generic competition approves major financing investment licensing competitive launches gsk products well decisions evaluates monitors performance possible supply manufacturing challenges prospects gsk whole focus largely improving longterm financial performance scenario external macroeconomic risks scenario delivery companys business strategies aligned reflects incremental risks business driven outside priorities factors intense competition increased pricing pressure us europe well potential board reviews gsks strategy makes significant impact material negative changes macro capital investment decisions longterm time horizon economic healthcare environment based multiyear assessment return capital performance company market opportunities scenario principal risks scenario includes severe medicines vaccines approach aligned assessment potential loss impact principal gsks model achieving balanced growth investing risks related patient safety product quality supply chain high quality innovative products patients continuity environmental harm well antibribery healthcare providers however since many internal corruption consequent regulatory actions external parameters become increasingly unpredictable fines significant litigation could longer time horizons gsk focuses detailed bottom fundamentally threaten operations risks plan threeyear cycle plan reviewed least managed mitigating activities described pages annually directors approve business forecasts showing expected financial impact directors believe scenario put option exercise scenario evaluates threeyear assessment period viability additional funding requirements assuming earliest statement appropriate aligns groups potential exercise outstanding put option held well established business planning processes balance partner hiv business longterm nature investments medicines vaccines assessment period threeyear review also makes certain assumptions analysis nearterm business performance realistically normal level capital recycling likely occur visible considers whether additional financing facilities required respective level funding flexibility plan stress tested series robust headroom operational principal risk downside scenarios part boards review risk plan assumes next results stress testing show certain several years challenging healthcare industry combinations hypothetical scenarios could continued pressure pricing pharmaceuticals gsk increase funding demands gsk require mitigating assumes premature loss exclusivity key products changes groups funding strategy however light period anticipated launches proceed liquidity available group based planned despite ongoing recovery healthcare analysis directors reasonable expectation systems impact covid pandemic even severe stress tests group uncertain economic conditions prevail across many markets able continue operation meet liabilities gsk operates fall due threeyear period assessment gsk annual report group financial review section summary full year results financial performance reporting framework adjusting items cash generation conversion financial position resources approach tax treasury policies critical accounting policies gsk annual report group financial review summary full year results full year growth growth full year full year aer cer turnover total continuing operating profit total eps p p p total continuing eps p p p total discontinued eps p p p adjusted operating profit adjusted eps p p p cash generated operations attributable continuing operations free cash flow amounts presented continuing operations adjusted results excludes consumer healthcare business discontinued operation amounts presented discontinued eps demerger consumer healthcare business presentation continuing discontinued operations ifrs set comparative results restated consistent basis previously published reflect demerger consumer healthcare business see impact share consolidation implemented july see total turnover total continuing operating profit total turnover million aer total operating profit continuing operations cer reflecting strong performance three product million compared million groups commercial operations turnover excluding covid included billion upfront income received solution sales grew aer cer specialty settlement gilead sciences inc gilead increased profits medicines included million sales xevudy turnover growth cer fair value gains doubledigit growth across therapy areas vaccines growth investments partly offset higher remeasurement charges reflected strong shingrix meningitis performance partially contingent consideration liabilities offset pandemic adjuvant sales general medicines reflected recovery antibiotics market strong total continuing adjusted operating profit performance trelegy respiratory across regions adjusted operating profit million higher aer cer adjusted operating margin specialty medicines percentage points higher aer specialty medicines sales million aer percentage points higher cer compared cer driven consistent doubledigit growth primarily reflected impact low margin covid therapy areas specialty medicines excluding sales xevudy solutions sales xevudy offset operating leverage million aer cer strong sales growth mix benefit lower inventory adjustments writeoffs higher royalty income vaccines vaccines turnover million aer total earnings per share cer total aer cer excluding total eps p compared p pandemic adjuvant sales performance reflected increase primarily reflected profit taxation favourable comparator impacted covid discontinued operations recognised consumer related disruptions several markets primarily h healthcare business demerger upfront income received strong commercial execution shingrix particularly settlement gilead increased profits fair value us europe gains investments partly offset higher remeasurement general medicines charges contingent consideration liabilities general medicines sales year million unfavourable comparison due credit million aer cer impact generic competition taxation us europe japan offset trelegy growth respiratory postpandemic rebound antibiotic market since h general medicines strategic report governance remuneration financial statements investor information gsk annual report group financial review continued total continuing earnings per share cash generated operations attributable total eps continuing operations p compared continuing operations p primarily reflected upfront income cash generated operations attributable continuing received settlement gilead increased profits operations year million million turnover growth fair value gains investments increase primarily reflected significant increase partly offset higher remeasurement charges contingent operating profit favourable exchange impact favourable consideration liabilities unfavourable comparison due timing collections partly offset unfavourable timing credit million taxation profit share payments xevudy sales increased cash contributions uk defined benefit pension schemes total discontinued earnings per share increased contingent consideration payments higher eps discontinued operations p compared increase inventory p increase primarily reflected gain arising demerger consumer healthcare recognised profit free cash flow taxation discontinued operations free cash inflow continuing operations million million increase primarily reflected adjusted earnings per share significant increase operating profit favourable exchange adjusted eps p compared p reduced purchases intangible assets favourable timing operating leverage strong sales growth beneficial mix collections partly offset unfavourable timing lower inventory adjustments writeoffs higher royalty profit share payments xevudy sales increased cash income lower effective tax rate partly offset contributions pensions increased contingent consideration increased investment behind launches higher supply chain payments higher tax payments lower proceeds freight distribution costs higher noncontrolling disposals higher capital expenditure higher increase interests inventorygsk annual report group financial review continued financial performance total results group set growth turnover turnover cer turnover cost sales gross profit selling general administration research development royalty income operating expensesincome operating profit net finance costs loss disposal interest associates share aftertax lossesprofits associates joint ventures profit taxation taxation profit taxation continuing operations year profit taxation discontinued operations gains demerger remeasurement discontinued operations distributed shareholders demerger profit taxation discontinued operations total profit taxation year profit attributable noncontrolling interests continuing operations profit attributable shareholders continuing operations profit attributable noncontrolling interests discontinued operations profit attributable shareholders discontinued operations total profit attributable noncontrolling interests total profit attributable shareholders earnings per share continuing operations p p p earnings per share discontinued operations p p p total earnings per share p p p earnings per ads continuing operations us earnings per ads discontinued operations us total earnings per ads us adjusted results group set reconciliations total results adjusted results set pages growth turnover turnover cer turnover cost sales selling general administration research development royalty income adjusted operating profit adjusted profit attributable shareholders adjusted profit attributable noncontrolling interest adjusted profit tax adjusted earnings per share p p p comparative results restated consistent basis previously published reflect demerger consumer healthcare business see impact share consolidation implemented july see strategic report governance remuneration financial statements investor information gsk annual report group financial review continued reporting framework total adjusted results costs ordinary course smaller scale restructuring legal charges expenses retained within total group financial review discusses operating adjusted results financial performance group cash flows financial position resources results year adjusted results include benefits major restructuring compared primarily results preceding year programmes exclude significant costs amortisation intangible assets except computer software total results capitalised development costs significant legal major total reported results represent groups overall restructuring transaction items performance regarded complete picture groups financial gsk also uses number adjusted nonifrs measures performance presented total results report performance business adjusted results exclusion adjusting items may result adjusted nonifrs measures may considered addition earnings materially higher lower total earnings substitute superior information presented particular significant impairments restructuring accordance ifrs adjusted results defined charges legal costs excluded adjusted earnings nonifrs measures defined higher total earnings gsk believes adjusted results considered together gsk undertaking number major restructuring total results provide investors analysts programmes response significant changes groups stakeholders helpful complementary information trading environment overall strategy following material understand better financial performance position acquisitions costs cash noncash group period period allow groups programmes provided individual elements performance easily compared majority approved meet accounting recognition criteria peer companies measures also used result charges may incurred number years management planning reporting purposes may following initiation major restructuring programme directly comparable similarly described measures significant legal charges expenses arising used companies settlement litigation government investigations gsk encourages investors analysts rely normal course materially larger single financial measure review gsks annual reports regularly occurring individual matters also include including financial statements notes entirety certain major legacy matters reconciliations total adjusted results providing adjusted results information key adjusting items adjusted results exclude profits discontinued set pages operations consumer healthcare business see gsk provides earnings guidance investor community details following items relation basis adjusted results line peer companies continuing operations total results together tax expectations investor community supporting easier effects items comparison groups performance peers gsk amortisation intangible assets excluding computer software able give guidance total results reliably capitalised development costs forecast certain material elements total results impairment intangible assets excluding computer particularly future fair value movements contingent software goodwill consideration put options given rise significant adjustments driven external factors major restructuring costs include impairments currency movements capital markets tangible assets computer software specific board approved programmes structural significant scale costs individual related projects exceed million including integration costs following material acquisitions transactionrelated accounting adjustments related significant acquisitions proceeds costs disposals associates products businesses significant settlement income significant legal charges net insurance recoveries expenses settlement litigation government investigations operating income royalty income itemsgsk annual report group financial review continued reporting framework continued historical record adjusting items reconciliations total adjusted operating profit continuing operations last three years summarised follows total operating profit continuing operations intangible amortisation intangible impairment major restructuring transactionrelated items divestments significant legal items adjusted results analysis impact transactionrelated items operating profit last three years follows contingent consideration former shionogiviiv healthcare jv including shionogi preferential dividends viiv healthcare put options pfizer preferential dividends contingent consideration former novartis vaccines business contingent consideration acquisition affinivax adjustments transactionrelated items hree year financial data presented reflecting restated results following demerger consumer healthcare business financial results restated presented comparative results restated consistent basis previously published reflect demerger consumer healthcare business see full reconciliations total adjusted results including continuing discontinued operations set pages explanations adjusting items reported pages nonifrs measures return capital employed return capital employed calculated total profit free cash flow taxation percentage average net assets year free cash flow defined net cash inflowoutflow continuing operating activities less capital expenditure total net debt property plant equipment intangible assets net debt defined total borrowings less cash cash contingent consideration payments net finance costs equivalents liquid investments shortterm loans third dividends paid noncontrolling interests plus proceeds parties subject insignificant risk change value sale property plant equipment intangible please see note net debt calculation net debt assets dividends received joint ventures associates used management planning total operating margin reporting purposes discussions presentations total operating margin operating profit dividend turnover investment analysts rating agencies free cash flow growth calculated reported basis reconciliation compound annual growth rate cagr net cash inflow continuing operating activities free cash flow set cagr defined compound annual growth rate shows annualised average rate revenue growth working capital number given years assuming growth takes place exponentially compounded rate working capital represents inventory trade receivables less trade payables cer aer growth order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used comparative period cer represents growth constant exchange rates aer represents growth actual exchange rates strategic report governance remuneration financial statements investor information gsk annual report group financial review continued reporting framework continued noncontrolling interests viiv healthcare cash payments reflected cash flow statement partly operating cash flows partly within investing trading profit allocations activities tax relief payments reflected viiv healthcare subsidiary group groups adjusting items part tax charge part operating results turnover operating profit profit payment relating original estimate fair value tax included within group income statement contingent consideration acquisition portion earnings allocated noncontrolling shionogiviiv healthcare joint venture million interests owned shareholders line reported within investing activities cash flow statement respective equity shareholdings pfizer inc pfizer part payment relating increase shionogi co ltd shionogi shareholders liability since acquisition reported within operating cash including gsk also entitled preferential dividends flows determined performance certain products movements contingent consideration payable shionogi shareholder contributed relative performance follows products changes time proportion overall earnings allocated shareholder also changes particular increasing proportion sales dolutegravir contingent consideration beginning year cabotegravircontaining products favourable remeasurement income statement impact proportion preferential dividends movements allocated gsk adjusting items allocated cash payments operating cash flows shareholders based equity interests gsk entitled cash payments investing activities approximately total earnings contingent consideration end year adjusted earnings viiv healthcare remeasurements liabilities preferential dividends contingent consideration payable posttax basis allocated pfizer shionogi included within shionogi december million december operating incomeexpense million expected paid within one year acquisitionrelated arrangements exit rights consideration acquisition shionogis interest pfizer may request ipo viiv healthcare time former shionogiviiv healthcare joint venture shionogi either gsk consent ipo offering received equity stake viiv healthcare viiv completed within nine months pfizer could require gsk healthcare also agreed pay additional future cash acquire shareholding original agreements gsk consideration shionogi contingent future sales unconditional right long made subsequent performance products developed joint distribution shareholders withhold consent venture dolutegravir cabotegravir ifrs business exercise pfizer put option result accordance combinations gsk required provide estimated ifrs gsk recognise liability put option fair value contingent consideration time balance sheet however q gsk notified pfizer acquisition required update liability latest irrevocably given right accordingly estimate fair value subsequent period end recognised liability put option groups liability contingent consideration recognised balance sheet q initial value balance sheet date acquisition million million consistent revised treatment end q subsequent remeasurements reflected within gsk also recognised liabilities future preferential operating incomeexpense within adjusting items dividends anticipated become payable pfizer income statement period shionogi groups balance sheet cash payments settle contingent consideration pfizer right require gsk acquire shareholding made shionogi viiv healthcare quarter based viiv healthcare certain circumstances time put actual sales performance income relevant option liability therefore recorded groups balance products previous quarter payments reduce sheet current liability measured gross balance sheet liability hence recorded income redemption basis derived internal valuation viiv statement cash payments made shionogi viiv healthcare business healthcare million closing balances liabilities related pfizers liability required recorded fair value shareholding follows estimated future payments significant timing difference charges recorded total income statement reflect movements fair value pfizer put option liability actual cash payments made settle liabilitygsk annual report group financial review continued reporting framework continued original agreements shionogi could also reporting definitions requested gsk acquire shareholding viiv healthcare sixmonth windows commencing gsk covid solutions unconditional right long made subsequent covid solutions include sales pandemic adjuvant distribution shareholders withhold consent covid solutions including vaccine exercise shionogi put option result gsk manufacturing xevudy associated costs recognise liability put option balance sheet include reinvestment rd categorisation used however q gsk notified shionogi management believe helpful investors irrevocably given right accordingly recognised providing clarity results group showing liability put option groups balance sheet contribution growth covid solutions q initial value million q shionogi irrevocably agreed waive put option result gsk general medicines derecognised liability put option groups general medicines usually prescribed primary balance sheet directly equity value liability care community settings general healthcare million derecognised practitioners gsk includes medicines inhaled respiratory dermatology antibiotics diseases gsk also call option shionogis shareholding viiv healthcare original agreements specialty medicines exercisable sixmonth windows commencing gsk irrevocably agreed waive first specialty medicines typically prescription medicines used two exercise windows last sixmonth window treat complex rare chronic conditions gsk remains call option fair value value comprises medicines infectious diseases hiv oncology accounting purposes immunology respiratory settlement gilead share consolidation february viiv healthcare reached agreement shareholders received new ordinary shares nominal gilead settle global patent infringement litigation value pence every existing ordinary shares relating commercialisation gileads biktarvy nominal value pence earnings per terms global settlement licensing agreement share diluted earnings per share adjusted earnings per share gilead made upfront payment billion viiv dividends per share retrospectively adjusted healthcare february addition gilead also pay reflect share consolidation periods presented royalty future us sales biktarvy respect bictegravir component future bictegravir earnings per share containing products sold us royalties earnings per share retrospectively adjusted payable gilead viiv healthcare february share consolidation july applying ratio new expiry viiv healthcares us patent ordinary shares every existing ordinary shares october gileads obligation pay royalties extend period regulatory paediatric exclusivity total earnings per share awarded unless otherwise stated total earnings per share refers impact settlement gilead contingent total basic earnings per share principle applies consideration liability ccl increase million continuing discontinued earnings per share posttax basis q due obligation viiv healthcare pay future cash consideration shionogi share upfront future us sales performance biktarvy products containing bictegravir liability discounted million december posttax basis impact settlement pfizer put option liability increase million included remeasurement december strategic report governance remuneration financial statements investor information gsk annual report financial performance group turnover specialty medicines group turnover business turnover bn specialty medicines bn aer growth cer growth bn aer growth cer growth group turnover vaccines bn aer growth cer growth general medicines bn aer growth cer growth specialty medicines turnover group turnover geographic region pecialty turnover excluding covid solutions us bn bn aer growth cer growth aer growth cer growth europe pandemic turnover bn bn aer growth cer growth aer growth cer growth international bn revised growth growth aer growth cer growth cer hiv group turnover oncology gsk revised operating segments year immunoinflammation respiratory previously gsk reported results four segments pharmaceuticals pharmaceuticals rd vaccines consumer healthcare gsk reports results two pandemic segments namely commercial operations total rd see specialty medicines note consolidated financial statements revised reflect changes product groups previously reported details established pharmaceuticals commercial operations segment three product groups hiv specialty medicines vaccines general medicines hiv sales million growth aer specialty medicines products includes gsks marketed cer performance benefited strong patient products hiv oncology immunoinflammation demand new hiv medicines dovato cabenuva juluca respiratory specialty medicines including nucala rukobia apretude contributed approximately three pandemic solution xevudy quarters growth us pricing favourability yearend v accines products including sales gsks adjuvant inventory build together contributed one third growth part pandemic solutions partially offset international tender decline general medicines products include products new hiv products delivered sales two billion previously reported established pharmaceuticals million aer cer representing sales trelegy ellipta anoro ellipta previously reported total hiv portfolio compared last year growth within respiratory category specialty products primarily driven sales dovato cabenuva dovato products typically accessed patients recorded sales million aer cer primary care settings cabenuva first long acting injectable treatment hiv infection recorded sales million apretude group turnover million year aer first long acting injectable prevention hiv delivered cer sales grew aer cer excluding sales million covid solutionsgsk annual report group financial review continued financial performance continued oncology vaccines oncology sales million aer cer zejula sales million aer cer turnover bn driven first line indication diagnosis treatment rates continuing impacted pandemic bn aer growth cer growth especially us sales blenrep million grew aer cer included impact withdrawal group turnover us market q immunoinflammation respiratory immunoinflammation respiratory sales million aer cer strong performance benlysta nucala benlysta sales million aer cer representing strong vaccines turnover underlying demand us worldwide nucala sales million aer cer reflecting continued v accines turnover excluding strong patient demand launch additional covid solutions indications bn pandemic aer growth cer growth sales xevudy million compared million pandemic turnover sales sales delivered regions comprising million us million europe million million international aer decline cer decline growth growth cer meningitis influenza shingles established vaccines pandemic vaccines vaccines meningitis meningitis vaccines sales grew aer cer million mainly driven bexsero aer cer million resulting higher cdc center disease control demand increased share us menveo sales also aer cer million primarily driven postpandemic vaccination catchup higher public demand international together favourable pricing mix share gain us influenza fluarixflulaval sales grew aer decreased cer million primarily driven lower postpandemic demand europe us partly offset lower expected returns us strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued shingles general medicines shingrix sales grew aer cer million regions grew significantly reflecting postpandemic turnover bn rebound strong uptake new market launches half growth contributed outside us aer growth cer growth bn us shingrix grew aer cer million due higher nonretail retail demand strong commercial execution germany china contributed group turnover strongly shingrix growth shingrix launched markets available countries established vaccines established vaccines grew aer stable cer million mainly resulting supply constraints mmrv vaccines lower tender demand international general medicines turnover synflorix offset hepatitis vaccines demand rebound us europe boostrix postpandemic demand recovery increased share us revised growth growth cer respiratory pandemic vaccines general medicines pandemic vaccines decreased aer cer primarily general medicines reflecting comparison pandemic adjuvant sales us canadian governments partly offset gsks share revised reflect changes product groups previously reported contracted european volumes related covid established pharmaceuticals booster vaccine developed collaboration sanofi pasteur sanofi respiratory respiratory sales million aer cer performance driven trelegy sales million aer cer including strong growth across regions advairseretide sales million decreased aer cer predominantly reflecting adverse impact generic competition growth certain international markets due targeted promotion offsetting decrease general medicines general medicines sales million decreasing aer cer augmentin sales million aer cer reflecting post pandemic rebound antibiotic market since h international europe regions partially offsets ongoing adverse impact generic competition approximately two percentage points impact aer cer divestment cephalosporin products q gsk annual report group financial review continued financial performance continued turnover regions general medicines sales million decreased aer cer reflecting ongoing impact generic us competitive pressures seretide divestment q us sales million aer cephalosporin products caused one percentage cer sales adjusted covid solutions aer point drag growth aer cer partly cer sales xevudy million offset however strong demand trelegy growth specialty hiv sales million aer augmentin following postpandemic rebound cer growth benefited strong patient demand antibiotic market since h new hiv products pricing favourability yearend international inventory build new hiv medicines dovato cabenuva international sales million aer juluca rukobia apretude sales million cer including xevudy sales million sales grew aer cer nucala respiratory benlysta aer cer excluding sales covid solutions immunology continued grow doubledigit reflected ongoing strong patient demand oncology sales specialty hiv sales million stable aer increased aer cer diagnosis decreased cer primarily driven tender decline treatment rates continuing impacted pandemic excluding tenders international grew driven strong dovato zejula withdrawal blenrep us market growth combined tivicay triumeq sales q million aer cer nucala sales million grew aer cer reflecting vaccine sales million aer cer strong market growth patient uptake benlysta sales excluding impact pandemic adjuvant sales sales million grew aer cer reflecting growth increased aer cer performance biological market japan inclusion chinas primarily driven shingrix sales million national reimbursement drug list aer cer mostly due higher nonretail retail demand strong commercial execution demand recovery vaccine sales million aer cer established vaccines share gains meningitis vaccines reflecting percentage points drag aer cer also contributed growth covid vaccine adjuvant sales growth excluding covid solutions driven strong shingrix takeup general medicines sales million aer china canada japan offsetting impact cer trelegy aer cer supply constraints mmrv vaccines lower synflorix reflecting increased patient demand growth single tender demand across several markets inhaler triple therapy market flovent grew launch authorised generics year overall three general medicines sales million aer percentage point reduction growth us general medicines cer respiratory sales million increased aer due prior period returns rebates rar adjustments cer trelegy sales aer cer year reflecting strong demand inclusion chinas national reimbursement drug list sales advairseretide europe aer cer adverse impact generic europe sales million aer competition offset growth certain markets due cer including covid solution sales million targeted promotion general medicines sales contributing percentage points growth aer cer million increased aer cer reflected growth specialty medicines hiv sales million augmentin following postpandemic rebound aer cer primarily driven strong patient demand antibiotic market since h partially offset generic dovato cabenuva juluca dovato delivered sales competition price reductions certain markets million juluca million cabenuva million benlysta immunology nucala respiratory oncology medicines zejula blenrep jemperli continued show strong doubledigit growth vaccine sales million aer cer performance driven shingrix sales million aer cer particularly germany pandemic adjuvant sales million contributed four percentage points growth aer cer strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued cost sales research development growth growth growth growth cer cer total cost sales total research development adjusted cost sales adjusted research development comparative results restated consistent basis previously published reflect demerger consumer comparative results restated consistent basis healthcare business see previously published reflect demerger consumer healthcare business see total cost sales percentage turnover total rd expenditure million aer percentage points lower aer percentage points cer included amortisation impairments higher cer terms adjusted rd expenditure fullyear increased adjusted cost sales percentage turnover aer cer million reflected continued percentage points higher aer percentage points increased investment across vaccines clinical development higher cer compared primarily reflected including investments mrna technology platforms higher sales lower margin xevudy compared continued investment latestage portfolio several included higher margin pandemic adjuvant sales increasing early discovery programmes well expenditure related cost sales margin percentage points aer cer recent acquisition affinivax inc affinivax well impact increased commodity prices freight costs partially offset favourable mix addition specialty medicines level rd investment primarily increased sales shingrix us increased support phase iii respiratory programme europe increased sales hiv medicines us depemokimab potential new medicine treat severe lower inventory adjustments write offs vaccines asthma bepirovirsen study chronic hepatitis b continued contribution restructuring savings preparation start phase iii trial oncology investment increased earlystage immunooncology selling general administration assets momelotinib mmb potential new treatment myelofibrosis patients anaemia acquired part growth growth cer recent sierra oncology acquisition increases total selling general investment offset decreases related completion administration several latestage clinical development programmes adjusted selling general reduced rd investment covid pandemic solutions administration versus comparative results restated consistent basis previously published reflect demerger consumer royalty income healthcare business see royalty income million million total sga costs percentage turnover aer cer increase primarily reflecting royalty percentage points lower aer stable cer compared income gilead settlement licensing included reduction restructuring charges agreement gilead announced february gardasil royalty income increasing million due adjusted sga costs percentage turnover higher sales percentage points higher aer percentage points higher cer adjusted sga costs increased aer cer primarily reflected increased level launch investment specialty medicines particularly hiv vaccines including shingrix drive postpandemic recovery demand support market expansion growth adjusted sga also reflected unfavourable comparison beneficial legal settlement well impairment provisions relating russia ukraine growth partly offset continuing benefit restructuring tight control ongoing costsgsk annual report group financial review continued financial performance continued operating incomeexpense adjusted operating profit business net operating expense million commercial operations operating profit million million reflecting accounting charges million aer cer turnover increase million arising remeasurement contingent cer operating margin percentage consideration liabilities liabilities pfizer put points lower aer percentage points lower cer option pfizer shionogi preferential dividends viiv primarily reflected strong sales lower margin healthcare included remeasurement charge xevudy increased investment behind launches specialty million million contingent consideration medicines including hiv vaccines plus higher commodity liability due shionogi including unwinding freight distribution costs well adverse comparison discount million charge million favourable legal settlement partly offset primarily changes exchange rates well leverage strong sales growth mix lower inventory adjustments sales forecasts partly offset adjustments writeoffs continued tight control ongoing million upfront income received settlement costs benefits continued restructuring increased gilead fair value gain investments including million royalty income biktarvy gardasil sales retained stake haleon plc haleon reflecting rd segment operating expenses million increase share price since listing milestone income aer cer primarily reflecting increased investment disposals vaccines including priority investments mrna late stage portfolio expenditure acquisition affinivax operating profit specialty medicines early stage hiv depemokimab total operating profit continuing operations partly offset decreases related completion million compared million several latestage clinical development programmes included million upfront income received reduced rd investment covid pandemic solutions settlement gilead increased profits turnover versus growth aer cer fair value gains investments including million retained stake haleon partly offset higher remeasurement charges contingent consideration liabilities adjusted operating profit million higher aer cer turnover increase cer adjusted operating margin percentage points higher aer percentage points higher cer compared primarily reflected impact low margin covid solutions sales xevudy reduced adjusted operating profit growth aer cer reduced adjusted operating margin approximately percentage points aer approximately percentage points cer offset operating leverage strong sales growth mix benefit lower inventory adjustments write offs higher royalty income contingent consideration cash payments made shionogi companies reduce balance sheet liability hence recorded income statement total contingent consideration cash payments amounted million million included cash payments made shionogi million million strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued net finance costs charge million represented effective tax rate total results reflected different finance income tax effects various adjusting items included interest income credit million resulting remeasurement deferred tax assets following enactment proposed fair value movements change uk corporate income tax rates tax adjusted profit amounted million represented effective adjusted tax rate finance expense interest expense unwinding discounts provisions issues related taxation described note financial statements taxation group continues believe remeasurements fair value movements made adequate provision liabilities likely arise finance expense lease liabilities periods open yet agreed tax finance expense authorities ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities comparative results restated consistent basis previously published reflect demerger consumer healthcare business see noncontrolling interests total net finance costs million compared allocation total profit continuing operations million adjusted net finance costs million noncontrolling interests amounted million compared million increase mainly million increase primarily due increased allocation driven costs associated sterling notes repurchase viiv healthcare profits million million q higher interest tax offset increased including gilead upfront settlement income partly offset interest income due higher interest rates larger cash increased credits remeasurement contingent consideration balances result consumer healthcare demerger liabilities well higher net profits groups entities noncontrolling interests share tax profits associates joint allocation adjusted earnings continuing operations ventures noncontrolling interests amounted million share tax loss associates joint ventures million increase allocation primarily reflected increased million million share profit allocation viiv healthcare profits million million well higher net profits groups loss disposal interest associates entities noncontrolling interests group also reported net loss disposal earnings per share continuing operations interests associates million primarily driven loss disposal interest associate innoviva inc total eps continuing operations p compared p primarily reflected million profit tax upfront income received settlement gilead increased profits turnover growth cer fair taking account net finance costs share profits value gains investments including retained stake associates loss disposal interest associates profit haleon partly offset higher remeasurement charges taxation million compared contingent consideration liabilities unfavourable million comparison due credit million taxation resulting remeasurement deferred tax assets taxation adjusted eps p compared p aer cer cer turnover increase operating uk current year charge leverage growth sales specialty medicines including hiv vaccines beneficial mix lower inventory rest world current year charge adjustments writeoffs higher royalty income lower chargecredit respect prior periods effective tax rate partly offset increased investment total current taxation behind launches specialty medicines including hiv total deferred taxation vaccines plus higher supply chain costs freight taxation total profits distribution costs higher noncontrolling interests growth lower margin covid solutions sales reduced adjusted comparative results restated consistent basis eps growth aer cer previously published reflect demerger consumer healthcare business see gsk annual report group financial review continued financial performance continued profit earnings per share discontinued guidance outlook operations gsk expects turnover increase per cent discontinued operations include consumer healthcare adjusted operating profit increase per cent business certain corporate costs directly attributable adjusted earnings per share increase per consumer healthcare business profit taxation cent guidance provided cer excludes discontinued operations amounted million contributions covid solutions million includes million gain arising outlining guidance group made certain demerger consumer healthcare split amount assumptions healthcare sector different markets distributed shareholders demerger million profit group operates delivery revenues taxation discontinued operations retained stake financial benefits current portfolio pipeline million addition profit taxation restructuring programmes due phasing quarterly results discontinued operations consumer healthcare business resulting comparators gsk expects turnover million million adjusted operating profit growth slightly lower first half eps discontinued operations p compared including challenging comparator q p increase primarily reflected gain arising somewhat higher second half relative fullyear demerger consumer healthcare business expectations despite ongoing recovery healthcare systems details see impact covid pandemic uncertain economic conditions prevail across many markets gsk operates total earnings per share continue expect see variability performance quarters total eps p compared p increase primarily reflected profit taxation discontinued expect sales specialty medicines increase mid high operations recognised consumer healthcare business singledigit per cent sales vaccines increase midteens per demerger upfront income received settlement cent sales general medicines decrease slightly gilead increased profits fair value gains investments partly offset higher remeasurement charges contingent covid solutions consideration liabilities unfavourable comparison due based known binding agreements governments gsk credit million taxation anticipate significant covid pandemicrelated sales operating profit sales covid solutions dividends billion therefore expect reduction turnover board declared four interim dividends resulting total growth approximately reduction adjusted dividend year p per share retrospectively adjusted operating profit growth however company share consolidation dividend per share p continues discuss future opportunities support governments retrospectively adjusted share consolidation see note healthcare systems patients whereby covid solutions financial statements dividends address emergence new covid variant concern dividend policy june new gsk investor update gsk set progressive dividend policy implemented guided percent payout ratio investment cycle dividend policy total expected cash distribution respective dividend payout ratios gsk remain unchanged gsk previously stated expected declare p per share dividend first half p per share dividend second half p per share dividend share consolidation targeted dividends per share would increase step share consolidation maintain aggregate dividend payout absolute sterling terms accordingly using consolidation ratio gsks expected dividend fourth quarter converts p per new ordinary share results expected total dividend second half p per new ordinary share expected dividend converts p per new ordinary share line original expectation converted share consolidation rounded strategic report governance remuneration financial statements investor information gsk annual report group financial review continued adjusting items profit divestments adjusted results reconciliation discon intangible intangible significant december total tinued asset asset major transaction legal adjusted results operations amortisation impairment restructuring related items results turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax losses associates joint ventures profit taxation taxation tax rate profit taxation continuing operations profit taxation discontinued operations gainslosses demerger remeasurement discontinued operations distributed shareholders demerger profit taxation discontinued operations total profit taxation year profit attributable noncontrolling interests continuing operations profit attributable shareholders continuing operations profit attributable noncontrolling interest discontinued operations profit attributable shareholders discontinued operations total profit attributable noncontrolling interests total profit attributable shareholders earnings per share continuing operations p p p p p p p earnings per share discontinued operations p p total earnings per share p p p p p p p p weighted average number shares millions gsk annual report group financial review continued financial performance continued profit divestments adjusted results reconciliation discon intangible intangible significant december total tinued asset asset major transaction legal adjusted results operations amortisation impairment restructuring related items results turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs loss disposal interest associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation continuing operations profit taxation discontinued operations gainslosses demerger profit taxation discontinued operations total profit taxation year profit attributable noncontrolling interests continuing operations profit attributable shareholders continuing operations profit attributable noncontrolling interest discontinued operations profit attributable shareholders discontinued operations total profit attributable noncontrolling interests total profit attributable shareholders earnings per share continuing operations p p p p p p p earnings per share discontinued operations p p total earnings per share p p p p p p p p weighted average number shares millions comparative results restated consistent basis previously published reflect demerger consumer healthcare business see impact share consolidation implemented july see strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued profit divestments adjusted results reconciliation discon intangible intangible significant december total tinued asset asset major transaction legal adjusted results operations amortisation impairment restructuring related items results turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation continuing operations profit taxation discontinued operations gainslosses demerger profit taxation discontinued operations total profit taxation year profit attributable noncontrolling interests continuing operations profit attributable shareholders continuing operations profit attributable noncontrolling interest discontinued operations profit attributable shareholders discontinued operations total profit attributable noncontrolling interests total profit attributable shareholders earnings per share continuing operations p p p p p p p earnings per share discontinued operations p p total earnings per share p p p p p p p p weighted average number shares millions comparative results restated consistent basis previously published reflect demerger consumer healthcare business see impact share consolidation implemented july see gsk annual report group financial review continued adjusting items continued profit discontinued operations cash charges million separation preparation programme primarily arose restructuring discontinued operations include consumer healthcare administrative functions well global supply chain rd business certain corporate costs directly attributable functions commercial noncash charges consumer healthcare business profit taxation million primarily reflected writedown assets discontinued operations amounted million administrative manufacturing locations impairment million includes million gain arising assets demerger consumer healthcare split amount distributed shareholders demerger total cash payments made million million profit taxation discontinued operations million million million relating retained stake million addition profit separation preparation restructuring programme million taxation discontinued operations consumer relating significant acquisitions nil million healthcare business million million million relating legacy programmes including settlement certain charges accrued previous intangible asset amortisation quarters see description information intangible analysis major restructuring charges income asset amortisation statement line follows intangible asset impairment see description information intangible cost sales asset impairment individual intangible asset accounted selling general administration material impairment research development total major restructuring costs continuing major restructuring integration operations within pharmaceuticals sector highly regulated comparative results restated consistent basis manufacturing operations supply chains long life previously published reflect demerger consumer cycle business mean restructuring programmes healthcare business see particularly involve rationalisation closure benefit restructuring programmes manufacturing rd sites likely take several years billion primarily relating separation preparation complete restructuring programme major restructuring costs related specific group initiated q separation preparation boardapproved major restructuring programmes programme prepare separation gsk two excluded adjusted results major restructuring companies programme aims programmes including integration costs following material acquisitions structural drive common approach rd improved capital significant scale costs individual related allocation projects exceed million ordinary course smaller align improve capabilities efficiency global scale restructuring costs retained within total adjusted support functions support gsk results optimise supply chain product portfolio total major restructuring charges incurred including divestment noncore assets million million analysed follows prepare consumer healthcare operate standalone company non non cash cash total cash cash total programme delivered billion annual savings targets deliver billion total costs separation estimated billion billion expected preparation cash costs proceeds divestments largely covered restructuring cash costs programme programme significant acquisitions legacy programmes comparative results restated consistent basis previously published reflect demerger consumer healthcare business see strategic report governance remuneration financial statements investor information gsk annual report group financial review continued adjusting items continued transactionrelated adjustments viiv healthcare contingent consideration liability fair valued ifrs explanation accounting transactionrelated adjustments continuing operations noncontrolling interests viiv healthcare set resulted net charge million million included net million accounting charge remeasurement contingent consideration liabilities divestments significant legal charges liabilities pfizer put option pfizer shionogi preferential dividends viiv healthcare items divestments significant legal charges items chargecredit primarily included million upfront settlement income contingent consideration former shionogiviiv received gilead fair value gain investments healthcare joint venture including shionogi including million retained stake haleon well preferential dividends milestone income gains number asset viiv healthcare put options pfizer disposals partly offset certain adjusting items preferential dividends contingent consideration former novartis discontinued operations vaccines business q group started report additional costs contingent consideration acquisition prepare establishment consumer healthcare affinivax business independent entity separation costs adjustments presented part discontinued operations total total transactionrelated charges separation costs incurred million comparative results restated consistent basis million includes million relating transaction costs previously published reflect demerger consumer incurred connection demerger preparatory healthcare business see admission costs related listing haleon million charge relating contingent total separation costs date million including consideration former shionogiviiv healthcare joint million relating transaction costs venture represented increase valuation contingent consideration due shionogi result unwind discount million charge million primarily adjustments sales forecasts settlement gilead well updated exchange rate assumptions million charge relating viiv healthcare put option pfizer preferential dividends represented increase valuation put option result settlement gilead offset lower cash updated exchange rate assumptionsgsk annual report group financial review continued cash generation conversion summary consolidated cash flow statement set capital expenditure financial investment cash payments tangible intangible fixed assets amounted million million disposals realised million million cash payments total net cash inflow operating activities acquire equity investments amounted million total net cash outflow investing million sales equity investments realised activities million million total net cash inflowoutflow financing activities decrease cash bank overdrafts free cash flow free cash flow amount cash generated group cash bank overdrafts beginning year meeting obligations contingent consideration exchange adjustments interest tax dividends paid noncontrolling interests decrease cash bank overdrafts capital expenditure property plant cash bank overdrafts end year equipment intangible assets cash bank overdrafts end year comprise cash cash equivalents free cash inflow overdrafts comparative results restated consistent basis previously published reflect demerger consumer healthcare business see reconciliation net cash inflow continuing total cash payments shionogi relation viiv operating activities free cash inflow healthcare contingent consideration liability year million million million reconciliation net cash inflow operating activities recognised cash flows operating activities closest equivalent ifrs measure free cash flow million recognised contingent consideration paid within shown investing cash flows payments deductible tax purposes net cash inflow continuing operating activities future cash flow purchase property plant equipment long term expect future cash generated purchase intangible assets operations sufficient fund operating debt proceeds sale property plant servicing costs normal levels capital expenditure obligations equipment existing licensing agreements expenditure arising proceeds sale intangible assets restructuring programmes routine outflows including net finance costs tax pension contributions dividends subject dividends joint ventures associates principal risks uncertainties discussed pages contingent consideration paid reported may time time additional demands investing activities finance acquisitions access multiple contribution noncontrolling interests sources liquidity short longterm capital markets distributions noncontrolling interests financial institutions needs addition cash free cash inflow flow operations comparative results restated consistent basis previously published reflect demerger consumer healthcare business investment appraisal capital allocation see strong framework capital allocation including board govern allocation capital businesses utilise consistent cash return invested capital croic methodology prioritise investment across group whole effectively compare returns businesses allocate capital also consider impact eps credit profile relevant strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial position resources property plant equipment business sciencebased technologyintensive highly assets regulated governmental authorities allocate significant noncurrent assets financial resources renewal maintenance property plant equipment property plant equipment vehicles minimise risks right use assets interruption production ensure compliance goodwill regulatory standards number processes use intangible assets hazardous materials investments associates joint ventures total cost property plant equipment investments december million net book value deferred tax assets million land buildings represented derivative financial instruments million plant equipment vehicles million assets noncurrent assets construction million invested total noncurrent assets million new property plant equipment mainly current assets related large number projects renewal inventories improvement expansion facilities various worldwide current tax recoverable sites support new product development launches trade receivables well improve efficiency existing supply chains derivative financial instruments property mainly held freehold new investment financed current equity investments liquid resources december liquid investments contractual commitments future capital expenditure million believe property plant facilities cash cash equivalents adequate current requirements assets held sale total current assets right use assets total assets right use assets amounted million december liabilities compared million december current liabilities decrease year reflected impact depreciation shortterm borrowings transfer assets held saledistribution million contingent consideration liabilities million respectively disposals impairments trade payables amounting million partly offset additions derivative financial instruments business combinations million additions current tax payable million shortterm provisions total current liabilities goodwill noncurrent liabilities goodwill decreased million december million primarily result transfer assets longterm borrowings held saledistribution million consumer corporation tax payable healthcare demerger partially offset increase deferred tax liabilities million acquisitions sierra oncology affinivax pensions postemployment benefits provisions intangible assets derivative financial instruments contingent consideration liabilities intangible assets include cost intangibles noncurrent liabilities acquired third parties computer software net book value intangible assets december total noncurrent liabilities million million decrease total liabilities primarily reflected transfer assets held saledistribution net assets million impairment losses net reversals total equity amortisation million offset additions net disposals writeoffs million exchange rate gains milliongsk annual report group financial review continued financial position resources continued investments associates joint ventures trade payables held investments associates joint ventures december trade payables carrying value december million million compared million december million see note financial statements investments see note financial statements trade associates joint ventures details payables decrease mainly driven consumer healthcare demerger profit share collaborations offset current equity investments increase promotional activity regions current equity investments amounted million december nil current equity investments comprise provisions equity investments group holds intention sell carried deferred tax provisions shortterm may sell short term acquired noncurrent provisions million december intention measured fair value profit million provisions yearend included loss fvtpl initially recorded fair value plus million million related legal transaction costs remeasured subsequent reporting disputes million million related major dates fair value unrealised gains losses recognised restructuring programmes provision made legal income statement investment million nil disputes indemnified disposal liabilities employee represents shares held haleon demerger related liabilities costs restructuring programme extent balance sheet date legal investments constructive obligation existed could reliably estimated held investments carrying value december million million pensions postemployment benefits significant investments held december account pension postemployment vir biotechnology nimbus discovery investments arrangements accordance ias net deficits fair value december million million million pension arrangements million million million respectively million million unfunded post investments included equity stakes companies employment liabilities see note financial statements research collaborations provide pensions postemployment benefits access biotechnology developments potential interest interests companies arise business divestments noncurrent liabilities noncurrent liabilities amounted million derivative financial instruments assets december million held current derivative financial assets fair value million million noncurrent derivative financial contingent consideration liabilities assets held fair value nil million majority contingent consideration amounted million financial instruments related foreign exchange contracts december million million designated designated accounting hedges million represented estimated present value amounts payable shionogi relating viiv healthcare inventories million nil represented estimated present value inventories amounted million contingent consideration payable former shareholders december decrease mainly driven affinivax million million represented consumer healthcare demerger partially offset vaccines estimated present value contingent consideration payable stock build novartis related vaccines acquisition liability due shionogi million respect trade receivables preferential dividends explanation accounting trade receivables amounted million noncontrolling interests viiv healthcare set million december decrease mainly driven consumer healthcare demerger lower total contingent consideration payable posttax pandemic adjuvant sales compared last year basis december million million expected paid within one year consideration deferred tax assets payable expected paid number years deferred tax assets amounted million result total estimated liabilities discounted million december present values posttax basis using posttax discount rates derivative financial instruments liabilities shionogiviiv healthcare contingent consideration liability held current noncurrent derivative financial liabilities discounted novartis vaccines contingent fair value million million primarily consideration liability discounted partly partly related foreign exchange contracts designated designated accounting hedges strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial position resources continued maturity profile bond debt equivalent gbp bonds eur bonds usd bonds net debt december gsks cash liquid investments held follows liquid investments bank balances deposits cash cash equivalents us treasury treasury repo money short term borrowings market funds long term borrowings liquidity funds net debt end year cash cash equivalents liquid investments government securities december net debt billion compared billion december comprising gross debt billion cash liquid investments billion net cash liquid investments billion billion debt reduced billion primarily due billion free cash held centrally december flow continuing operations billion disposals equity analysis cash gross debt effects investments billion decrease discontinued hedging follows operations result demerger primarily reflecting billion preseparation dividends attributable gsk funded consumer healthcare debt partly offset purchases liquid investments businesses billion net cash acquired reflecting cash cash equivalents acquisitions sierra oncology affinivax dividends paid gross debt fixed shareholders billion net adverse exchange impacts floating billion translation nonsterling denominated debt net debt exchange financing items billion purchases equity investments movements net debt december gsk shortterm borrowings including overdrafts lease liabilities repayable within months billion billion repayable total net debt beginning year subsequent year decrease cash bank overdrafts decrease liquid investments net decrease longterm loans net decrease shortterm loans repayment lease liabilities debt subsidiary undertaking acquired exchange adjustments noncash movements decreaseincrease net debt continuing operations decreaseincrease net debt discontinued operations total net debt end year gsk annual report group financial review continued financial position resources continued total equity contractual obligations commitments december total equity decreased financial commitments summarised note million december million financial statements commitments summary movements equity set following table sets contractual obligations commitments december fall due payment total equity beginning year total comprehensive income year total yr yrs yrs yrs noncash distribution noncontrolling interests deconsolidation former subsidiaries loans dividends shareholders interest loans ordinary shares issued finance lease obligations changes noncontrolling interests future finance charges leases noncash dividends shareholders lease contracts hedging gainloss transferred nonfinancial yet commenced assets intangible assets transaction noncontrolling interest property plant sharebased incentive plans equipment tax sharebased incentive plans investments contributions noncontrolling interests purchase commitments distributions noncontrolling interests pensions post total equity end year retirement benefits total share purchases commitments respect loans future interest payable december gsk held million shares treasury loans disclosed taking account effect shares million shares cost million derivatives million deducted retained earnings entered number research collaborations develop new compounds pharmaceutical ordinary shares repurchased period january companies terms arrangements include march company expect upfront fees equity investments loans commitments make ordinary share repurchases remainder fund specified levels research addition often million treasury shares transferred agree make payments future milestones employee share ownership plan esop trusts achieved million shares transferred prior share consolidation agreements relate compounds early shares held trusts satisfy future exercises stages development potential obligation make options awards group share option award milestone payments continue number years schemes compounds move successfully development proportion shares held trusts respect process generally closer product marketing awards rules scheme require gsk satisfy approval greater probability success amounts exercises market purchases rather issue shown within intangible assets represent maximum new shares shares held trusts matched would paid milestones achieved options awards granted decrease commitments result reduction outstanding loan commitments december esop trusts held million million gsk shares future exercise share options share awards carrying value million million deducted reserves market value shares million million strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial position resources continued connection demerger consumer healthcare normal course business provided various december pension scheme valuations identified cash indemnification guarantees respect business disposals funding technical provisions deficits three gsk uk pension legal disputes subsequently arisen schemes scottish limited partnerships slps provision made outflow resources considered established provide funding mechanism gsks probable reliable estimate made likely uk defined benefit pension schemes slps together hold outcome dispute included note shares representing total issued share capital financial statements provisions haleon provide outcome tax legal disputes pension scheme slp interest entitled outflow resources considered probable receive distribution slp amount equal reliable estimate outflow may made december net proceeds sales haleon shares receive disputes provision dividend income haleon shares received made possible make reliable estimate aggregate amount equal agreed threshold proceeds potential outflow funds might required settle threshold proceeds thresholds total million disputes possibility outflow increased notional interest remaining balance remote time time payment amount would fully fund ultimate liability matters may vary significantly cash funding technical provisions deficits three amounts provided dependent upon schemes shown december valuations negotiations relevant tax authorities outcome proceeds threshold reached gskcontrolled litigation proceedings relevant discussed general partner slp entitled sell remaining principal risks uncertainties pages haleon shares held slp distribute proceeds note financial statements legal gsk december million remains proceedings outstanding uk pension trustees contingent liabilities contingent liabilities set note financial statements contingent liabilities following table sets contingent liabilities comprising performance guarantees letters credit items arising normal course business expected expire total yr yrs yrs yrs guarantees contingent liabilities total gsk annual report group financial review continued approach tax business makes major contribution public purse seek maintain open constructive relationships tax contribution includes direct taxes tax authorities worldwide meeting regularly discuss tax corporate income tax indirect taxes vat affairs real time business updates wherever possible customs duties well taxes employment also monitor government debate tax policy key taxes property taxes therefore important jurisdictions understand share informed companies explain approach tax helps inform point view regarding potential future changes tax law dialogue tax tax policy relevant provide pragmatic constructive supportive efforts ensure companies business input tax policy makers either directly appropriately transparent tax affairs industry trade bodies advocating reform support economic managed part tax strategy set detail growth job creation well needs patients within public policies section website key stakeholders support exchange countrybycountry reporting group corporate tax charge million cbcr data tax authorities validated million profits tax million existing information held taxpayers support million representing effective tax rate ability ensure multinational groups pay right amount made cash tax payments tax right places million year million addition taxes pay profits pay duties levies transactional global biopharmaceutical company employment taxes substantial business employment presence many countries around world pay significant amount adjusted tax rate tax includes corporate income tax business rate benefited closure open issues taxes tax associated employees also collect tax authorities various jurisdictions subject material significant amount tax behalf governments along changes product mix material changes tax supply chain including employees regulations laws countries operate groups average effective adjusted tax rate subject taxation throughout supply chain expected around worldwide nature operations means crossborder supply routes necessary ensure supplies groups total tax rate medicines numerous countries result conflicting lower adjusted tax rate reflecting different tax claims tax authorities profits taxed effects various adjusting items individual countries lead double taxation uk government confirmed spring finance bill profits taxed one country include legislation introducing global minimum profits recognised territories reference activities corporate income tax rate effect detail performed value generate ensure measures accounted still profits recognised jurisdictions aligned activity finalised possible accurately quantify undertaken line current oecd guidelines impact gsk stage base transfer pricing policy arms length principle details corporate tax charges year support transfer prices economic analysis set note reports comparative results restated consistent basis engage artificial tax arrangements previously published reflect demerger consumer without business commercial substance seek healthcare business see avoid tax use tax havens transactions would fully disclose tax authority zerotolerance approach tax evasion facilitation tax evasion tax risk countries operate managed robust internal policies processes training compliance programmes board directors audit risk committee responsible approving tax policies risk management arrangements part wider internal control framework strategic report governance remuneration financial statements investor information gsk annual report group financial review continued treasury policies report sterling pay dividends sterling cash interest rate risk management flows role treasury monitor manage gsks objective minimise effective net interest cost groups external internal funding requirements balance mix debt fixed floating interest financial risks support strategic objectives gsk rates time policy interest rate risk management operates global basis primarily subsidiary limits net amount floating rate debt specific cap companies manage capital ensure reviewed agreed less annually board subsidiaries able operate going concerns optimise returns shareholders appropriate foreign exchange risk management balance debt equity treasury activities governed objective minimise exposure overseas operating policies approved annually board directors subsidiaries transaction risk matching local currency recently october treasury management income local currency costs possible foreign group tmg meeting chaired chief financial officer currency transaction exposures arising external internal takes place regular basis review treasury activities trade flows selectively hedged gsks internal trading members receive management information relating transactions matched centrally manage activities intercompany payment terms reduce foreign currency risk possible manage cash surpluses borrowing treasury operations requirements subsidiary companies centrally using forward objective gsks treasury activities minimise contracts hedge future repayments back originating posttax net cost financial operations reduce currency volatility order benefit earnings cash flows gsk uses variety financial instruments finance operations order reduce foreign currency translation exposure derivative financial instruments manage market risks seek denominate borrowings currencies operations derivatives principally comprise foreign principal assets cash flows primarily exchange forward contracts swaps used denominated us dollars euros sterling swap borrowings liquid assets currencies required borrowings swapped currencies required group purposes well interest rate swaps used borrowings denominated swapped foreign manage exposure financial risks changes interest currencies match investments overseas group assets rates may treated hedge relevant assets derivatives used exclusively hedging purposes forward contracts major currencies also used reduce relation underlying business activities trading exposure groups investment overseas group assets speculative instruments tmg reviews ratio borrowings assets major currencies regularly capital management commodity risk management gsks financial strategy implemented groups financial architecture supports gsks strategic priorities objective minimise income statement volatility arising regularly reviewed board manage capital fluctuations commodity prices practical structure group appropriate mix debt cost effective tmg authorised approve equity continue manage financial policies execution certain financial derivatives hedge commodity credit profile particularly targets shortterm credit ratings price exposures p maintaining single longterm ratings counterparty risk management consistent targets set global counterparty limits banking gsks longterm credit rating standard poors investment counterparties based longterm credit ratings stable outlook moodys investor services moodys moodys standard poors usage limits stable outlook shortterm credit ratings actively monitored breach limits would p standard poors moodys respectively reported chief financial officer immediately liquidity risk management addition relationship banks credit ratings gsks policy borrow centrally order meet anticipated reviewed regularly changes ratings occur funding requirements cash flow forecasts funding changes made investment levels authority limits requirements monitored tmg regular basis appropriate banking counterparty limits reviewed strategy diversify liquidity sources using range least annually facilities maintain broad access financial markets day sweep cash number global subsidiaries central treasury accounts liquidity management purposesgsk annual report group financial review continued critical accounting policies group consolidated financial statements us medicaid programme stateadministered prepared accordance international accounting programme providing assistance certain poor standards conformity requirements vulnerable patients medicaid drug rebate companies act international financial program established reduce state federal reporting standards ifrs issued international expenditure prescription drugs patient accounting standard board iasb protection affordable care act became law participate providing rebates states accruals required make estimates assumptions medicaid rebates calculated based specific affect amounts assets liabilities revenue expenses terms relevant regulations patient protection reported financial statements actual amounts affordable care act results could differ estimates cash discounts offered customers encourage critical accounting policies relate following areas prompt payment accrued time turnover invoicing adjusted subsequently reflect actual taxation note experience legal disputes notes record accrual estimated sales returns applying historical experience customer returns contingent liabilities note amounts invoiced together marketrelated information pensions postemployment benefits note stock levels wholesalers anticipated price information judgements estimates made increases competitor activity areas given note financial statements critical reconciliation gross turnover net turnover us accounting judgements key sources estimation commercial operations follows uncertainty turnover margin margin margin respect turnover accounting policy largest gross turnover business us commercial operations us market complex arrangements rebates discounts marketdriven segments allowances following briefly describes nature government arrangements existence us commercial operations mandated arrangements certain indirect customers state programmes whereby customer able buy products cash discounts wholesalers reduced prices chargeback represents customer returns difference invoice price wholesaler prior year indirect customers contractual discounted price adjustments accruals estimating chargebacks calculated based items terms agreement historical experience total deductions product growth rates net turnover customer rebates offered key managed care group purchasing organisations direct indirect reconciliation revised include vaccines part customers arrangements require customer us commercial operations years achieve certain performance targets relating value marketdriven segments consist primarily managed care product purchased formulary status predetermined market medicare plans negotiate contract pricing shares relative competitors accrual customer rebates honoured via rebates chargebacks mandated estimated based specific terms agreement segments consist primarily medicaid federal historical experience product growth rates government programmes receive government mandated pricing via rebates chargebacks strategic report governance remuneration financial statements investor information gsk annual report group financial review continued critical accounting policies continued overall sales deduction percentage sales consistent may become involved significant legal proceedings year year sales growth coming primarily trelegy respect possible meaningfully assess specialty products including viiv deductions within whether outcome result probable outflow year split approximately follows general medicines quantify reliably estimate liability could result specialty medicines vaccines ultimate resolution proceedings cases appropriate disclosure cases would included december total accrual rebates discounts annual report provision would made allowances returns us commercial operations amounted million million position could change time therefore assurance losses result outcome monthly process operated monitor inventory levels legal proceedings exceed material amount wholesalers abnormal movements process uses amount provisions reported groups financial gross sales volumes prescription volumes based third party statements data sources information received key wholesalers aim maintain inventories consistent level like many pharmaceutical companies faced year year based pattern consumption various complex product liability antitrust patent litigation well investigations operations conducted basis us commercial operations inventory levels various governmental regulatory agencies throughout wholesalers distribution channels december year general counsel group head groups estimated amount approximately four weeks legal function senior vice president head turnover calculation uses third party information global litigation group responsible accuracy totally verified believed litigation government investigations routinely brief sufficiently reliable purpose chief executive officer chief financial officer board directors significant litigation pending legal disputes group governmental investigations group respect accounting policy legal disputes following briefly describes process meetings appropriate detail status significant determine level provision necessary litigation government investigations review matters number claims notified us information accordance requirements ias provisions potential claims yet notified assessment validity contingent liabilities contingent assets provide claims progress made settling claims recent settlement anticipated settlement costs outflow resources levels potential reimbursement insurers considered probable reliable estimate may made likely outcome dispute legal expenses meetings also include assessment whether arising claims group sufficient information available us able make reliable estimate potential outcomes disputes often external counsel assisting us various litigation matters investigations also assist briefing board senior management following discussions matters possible make reliable estimate amount provision may required level provision legal disputes reviewed adjusted appropriate matters discussed note financial statements legal proceedings strategic report strategic report approved board directors march iain mackay chief financial officer march gsk annual report corporate governance section board gsk leadership team chairs governance statement corporate governance architecture ahead together board oversight key decisions engagements board committee reports directors report strategic report governance remuneration financial statements investor information gsk annual report board sir jonathan symonds cbe skills experience nonexecutive chair jon extensive international financial life sciences governance experience jon served independent nonexecutive director hsbc holdings plc april age deputy group chairman august retirement board nationality british february previously chairman hsbc bank plc chief financial officer appointed september novartis ag partner managing director goldman sachs chief financial officer astrazeneca plc partner kpmg governance experience includes roles n nonexecutive director chair audit committees diageo plc qinetiq group plc nonexecutive chair proteus digital health inc nonexecutive director rubius therapeutics inc jon fellow institute chartered accountants england wales external appointments nonexecutive director genomics england limited previously served chairman nonexecutive chair energy aspects member european round table industry senior advisor chatham house dame emma walmsley skills experience chief executive officer prior appointment gsks ceo emma ceo gsk consumer healthcare joint venture gsk novartis creation march emma joined gsk age loreal worked years variety roles paris london new york nationality british shanghai emma previously nonexecutive director diageo plc appointed january emma holds classics modern languages oxford university chief executive officer external appointments april independent director microsoft inc iain mackay skills experience chief financial officer prior joining gsk iain group finance director hsbc holdings plc position held eight years chartered accountant iain lived worked asia us europe age hsbc general electric schlumberger dowell price waterhouse iain nationality british previously trustee british heart foundation chair audit risk committee appointed january iain holds business studies accounting holds honorary doctorate chief financial officer aberdeen university scotland april iain member institute chartered accountants scotland iain step cfo executive director may continue employee leave company december external appointments nonexecutive director chair audit risk committee member remuneration committee national grid plc member court university aberdeen chair remuneration committee member group chair stakeholder communications reporting committee elizabeth liz mckee anderson skills experience independent nonexecutive director liz brings significant experience commercial biopharmaceuticals seasoned biotech board member significant experience commercial biopharmaceuticals age operationally board level well deep understanding biotechnology sector nationality american invaluable gsk pure biopharma company appointed september prior current roles liz served worldwide vice president commercial leader r infectious diseases vaccines also immunology oncology janssen pharmaceuticals vice president general manager wyeth vaccines liz also previously board member bavarian nordic huntsworth plc external appointments board member biomarin pharmaceutical inc board member revolution medicines inc board member insmed inc trustee wistar institute director aro biotherapeutics company key committee chair c corporate responsibility science n nominations corporate governance audit risk r remunerationgsk annual report board continued charles bancroft skills experience senior independent nonexecutive charlie wealth financial management experience global biopharma director charlie retired successful career bristol myers squibb bms march held number leadership roles commercial strategy finance beginning career age bms held positions increasing responsibility within finance organisation nationality american commercial operational responsibility latin america middle east africa canada appointed may japan several pacific rim countries appointed chief financial officer senior independent nonexecutive director chief financial officer executive vice president global business operations july executive vice president head integration strategy business development charlie successfully steered bms period strategic transformation including n r billion acquisition celgene charlie also served member board colgate palmolive company march external appointments board member kodiak sciences inc board member biovector inc advisory board member drexel universitys lebow college business board determined charlie recent relevant financial experience agreed appropriate qualifications background audit committee financial expert dr hal barron skills experience nonexecutive director hal joined gsk chief scientific officer president rd august transitioned role nonexecutive director additional responsibilities support rd age prior joining gsk hal president rd calico llc california life company nationality american alphabetfunded company uses advanced technologies increase understanding appointed january lifespan biology prior hal executive vice president head global product chief scientific officer development chief medical officer roche responsible products president rd april combined portfolio roche genentech genentech senior vice president transitioned role nonexecutive development chief medical officer hal nonexecutive director chair director august science technology committee juno therapeutics inc march acquired celgene corporation hal previously served nonexecutive board director grail inc advisory board member verily life sciences llc external appointments ceo board cochair altos labs inc associate adjunct professor epidemiology biostatistics university california san francisco dr anne beal skills experience independent nonexecutive director anne brings extensive healthcare experience board physician entrepreneur combined passion patient advocacy recognised health policy expert age development global national programmes improving healthcare access nationality american patient groups ensuring voice patients reflected research programmes appointed may prior current roles anne spent six years harvard medical school massachusetts general hospital instructor paediatrics also held leadership roles c n r commonwealth fund aetna foundation anne previously deputy executive director chief engagement officer patientcentered outcomes research institute us chief patient officer global head patient solutions sanofi external appointments founder ceo absolutejoi skincare board member academyhealth board member prolacta bioscience key committee chair c corporate responsibility science n nominations corporate governance audit risk r remuneration strategic report governance remuneration financial statements investor information gsk annual report board continued dr harry hal c dietz skills experience independent nonexecutive director hal brings extensive experience field human genetics central gsks approach rd former president american society human genetics scientific medical expert recognised worlds leading authority genetic disorder known marfan syndrome age also brings experience development novel therapies particular relation nationality american diseasemodifying treatments fibrotic neurodegenerative diseases total hal authored original publications peerreviewed journals across career appointed january physician scientist dedicated entire career care study individuals heritable connective tissue disorders primary perturbations extracellular matrix homeostasis function lab identified genes many conditions uses model systems elucidate disease mechanisms hal received multiple prestigious awards including curt stern award american society human genetics colonel harland sanders lifetime achievement award medical genetics taubman prize excellence translational medical science harrington prize american society clinical investigation harrington discovery institute pasarow award cardiovascular research inbevbaillet latour health prize country belgium research achievement award american heart association inductee american society clinical investigation american association advancement science association american physicians national academy medicine national academy sciences external appointments victor mckusick professor paediatrics medicine molecular biology genetics department genetic medicine johns hopkins university school medicine investigator howard hughes medical institute consultant chair scientific advisory board aytu biopharma independent chair gsks human genetics scientific advisory board founded previously scientific adviser blade therapeutics dr jesse goodman skills experience independent nonexecutive director jesse brings scientific public health expertise boards deliberations wealth experience spanning science medicine vaccines regulation public health scientific medical expert proven record addressing pressing public health needs academic federal age sectors nationality american jesse previously served senior leadership positions us food drug administration appointed january fda including recently fdas chief scientist previously deputy commissioner science public health director center biologics c evaluation research cber jesse played leadership role developing fdas regulatory science medical countermeasures initiatives worked collaboratively industry academia government global public health regulatory partners prepare respond major public health threats including emerging infectious diseases disasters terrorism led fdas response west nile virus hn influenza pandemic served senior leadership team white house medical countermeasure review jesse previously member scientific advisory committee regulatory legal working group coalition epidemic preparedness innovations cepi external appointments professor medicine attending physician infectious diseases georgetown university directs georgetown university center medical product access safety stewardship compass board member formerly president united states pharmacopeia usp board member scientific counselors infectious diseases centers disease control prevention cdc board member intellia therapeutics inc member us national academy medicine board member adaptive phage therapeutics inc key committee chair c corporate responsibility science n nominations corporate governance audit risk r remunerationgsk annual report board continued urs rohner skills experience independent nonexecutive director urs broad business banking legal background extensive senior level experience multinational companies age urs served chairman number boards recently credit suisse group nationality swiss april prior joining credit suisse urs served chairman appointed january executive board ceo prosieben prosiebensat media ag followed number years private practice major law firms switzerland us r n admitted bars canton zurich switzerland state new york us external appointments member international advisory board investcorp chair vega cyber associates ag dr vishal sikka skills experience independent nonexecutive director vishal distinguished background technology particularly field artificial intelligence ai machine learning central gsks approach rd age founder ceo vianai systems inc silicon valleybased company provides nationality american advanced technological software services ai machine learning large appointed july enterprises around world prior founding vianai systems vishal served ceo infosys limited member c executive board sap se vishal phd artificial intelligence stanford university coauthored several research abstracts related ai technology database management external appointments founder ceo vianai systems inc board member oracle corporation member supervisory board bmw ag key committee chair c corporate responsibility science n nominations corporate governance audit risk r remuneration directors departing manvinder singh vindi banga sept july retired board appointment haleon plc board effective demerger dame vivienne cox july july lynn elsenhans july july retired board nine years service dr laurie glimcher sept oct retired board five years service strategic report governance remuneration financial statements investor information gsk annual report gsk leadership team glt skills experience emma walmsley emma joined gsk glt see board biographies pages chief executive officer iain mackay iain joined gsk glt see board biographies pages chief financial officer diana conrad diana appointed chief people officer member glt april chief people officer previously senior vice president hr pharmaceuticals rd played key strategic role leader rd people culture agenda support transformation diana joined gsk canadas hr team held several roles increasing responsibility becoming senior vice president hr consumer healthcare prior joining gsk held hr roles companies including ge capital gennum corporation zenon environmental laboratories diana honours bachelor arts mcmaster university canada james ford james joined glt appointed senior vice president group svp group general counsel general counsel later taking responsibility compliance corporate security investigations joined gsk served general counsel consumer legal compliance healthcare general counsel global pharmaceuticals vice president corporate legal acting head global ethics compliance prior gsk james solicitor clifford chance dla holds law degree university east anglia diploma competition law king 's college qualified solicitor england wales attorney new york state bar james based london practised law lived us singapore hong kong james cochair usbased civil justice reform group director european general counsel association association corporate counsel sally jackson sally joined glt march senior vice president global communications ceo svp global communications office leads communications government affairs function globally also ceos chief staff ceo office prior sally senior vice president office ceo cfo previously served head investor relations joined gsk sally holds degree natural sciences university cambridge luke miels luke joined gsk glt chief commercial officer responsible chief commercial officer commercial portfolio medicines vaccines luke also cochairs portfolio investment board tony wood member viiv healthcare board outside gsk luke member singapore economic development board previously worked astrazeneca executive vice president european business prior executive vice president global product portfolio strategy global medical affairs corporate affairs head asia roche based shanghai singapore prior held roles increasing seniority roche sanofiaventis us europe asia luke holds bachelor science degree biology flinders university adelaide mba macquarie university sydney shobie ramakrishnan shobie joined glt appointed chief digital technology officer chief digital technology officer joined gsk deep broad experience biotech hitech companies recently led digital technology gsks global commercial organisation transforming companys capabilities digital data analytics playing pivotal role establishing agile commercial operating model joining gsk shobie held senior technology leadership roles organisations including astrazeneca salesforce genentech roche former member board directors remediant member board directors sustainableitorg shobie holds bachelors degree electronics engineering vellore institute technology university madras india iain mackay step board glt succeeded cfo julie browngsk annual report gsk leadership team continued skills experience david redfern david joined glt chief strategy officer responsible corporate president corporate development development strategic planning previously senior vice president northern europe responsibility gsks pharmaceutical businesses region senior vice president central eastern europe joined gsk david appointed chairman board viiv healthcare limited nonexecutive director aspen pharmacare holdings limited board bachelor science degree bristol university chartered accountant regis simard regis joined glt became president pharmaceuticals supply chain president global supply chain responsible manufacturing supply gsks medicines vaccines addition leads quality environment health safety sustainability corporate level regis joined gsk site director france rising become senior vice president global pharmaceuticals manufacturing current role previously held senior positions sony konica minolta tyco healthcare member board viiv healthcare mechanical engineer holds mba phil thomson phil joined glt appointed president global affairs president global affairs responsibility groups strategic approach stakeholder engagement reputation policy development previously phil senior vice president communications government affairs joined glaxo wellcome commercial trainee phil also chair whitehall industry group holds degree english history russian studies durham university deborah waterhouse deborah appointed glt january became chief executive officer ceo viiv healthcare president viiv healthcare april addition viiv deborah also leads gsks global health organisation gsk global health deborah joined gsk prior viiv senior vice president primary care within gsks us business strong track record performance specialty primary care deborah led hiv business uk heading hiv centre excellence pharma europe held roles general manager australia new zealand senior vice president central eastern europe deborah nonexecutive director schroders plc holds degree economic history english literature liverpool university tony wood tony appointed chief scientific officer cso designate january became chief scientific officer cso head rd member glt august joined gsk pfizer senior vice president medicinal science technology responsible science technology platforms driving delivery new innovation tony led largescale global organisations drug discovery development multiple therapeutic areas including immunology oncology infectious diseases time pfizer tony responsible invention new antiretroviral medication used treat hiv infection fellow academy medical sciences honorary fellow royal society chemistry rsc highest honour given rsc fellow royal society biology tony bsc chemistry phd organic synthesis university newcastle postdoctoral fellow imperial college london also currently visiting professor imcm oxford glt members departing hal barron member glt chief scientific officer august transitioned nonexecutive director roger connor member glt president global vaccines december left company strategic report governance remuneration financial statements investor information gsk annual report chairs governance statement one important years gsks recent history saw delivery strong operational financial performance successful demerger consumer healthcare establishment new gsk fully focused global biopharma company intensity boards work supporting overseeing required number additional meetings scheduled illustrated board activity predemerger january july postdemerger july december routine additional routine additional board board nominations corporate governance nominations corporate governance science science corporate responsibility corporate responsibility audit risk audit risk remuneration remuneration chairs chairs additional activity additional activity development approval demerger cfo succession documentation forecast zantac litigation haleon plc haleon chair appointment board business development development gsk remuneration policy development investor approval gsk board development cso succession business development executing demerger creating new gsk included heart robust focus shareholder value creation embodied ambitions companies boards work first half year primarily communicated investor updates february occupied overseeing smooth execution demerger haleon previously june gsk consumer healthcare gsk resulting creation two strong businesses culminated approval gsk circular haleon prospectus overwhelmingly approved shareholders general meeting july votes cast favour work separation process disciplined board approach gsk investor haleon investor haleon deliver demerger update update demerger creation worldleading consumer healthcare business competitive longterm growth prospects compelling financial proposition q q q q q q q newly focused gsk strengthened balance sheet haleon chair haleon prospectus investment pipelinerd board circular appointments published companies clear targets upperquartile growth set investor updatesgsk annual report chair 's governance statement continued investor updates set believed consider deals respect contribution competitive financial aspirations new gsk namely ambitions periods beyond cumulative topline growth operating profit growth board review proposal knowing excluding covid solutions together important aspects established focus aspiration billion billion sales value associated transaction ambition board entered lightly contributes furthering strategy plan important demonstration confidence board process included appraisal approval business determination held accountable acquisitions stepchange improved performance strong operational financial performance good platform sierra oncology biopharmaceutical company focused progress targeted therapies rare forms cancer acquisition included momelotinib new medicine unique dual similarly haleon focus topline growth mechanism action intended address critical unmet aspiration signal business upper quartile medical needs myelofibrosis patients anaemia growth potential view robustly tested unsolicited conditional nonbinding proposal acquire affinivax clinical stage biopharmaceutical company consumer healthcare business received exercising providing gsk access next generation fiduciary duties proposals evaluated rejected pneumococcal vaccine candidate highly innovative board best interests shareholders multiple antigen presenting system known maps proposals fundamentally undervalued transactions reviewed board included haleon business future prospects board licensing agreement spero therapeutics confident haleon could deliver sustained organic sales tebipenem hbr latestage antibiotic targeted treat growth range cer medium term complicated urinary tract infections significant unmet pleasing see since separation haleon medical need subsequently announced strong performance collaboration wave life sciences bringing together key part aspiration gsk restructuring waves oligonucleotide platform gsks expertise gsk balance sheet appropriate level debt genetics genomics haleon sought ensure competitiveness companies separation gsks ability continue collaboration tempus provide gsk access invest external well internal science improved tempus aienabled platform including library refinancing approximately billion indebtedness deidentified patient data one worlds largest successfully completed first quarter timing sources clinical molecular data opportune given current environment gsk received billion preseparation dividends attributable gsk shareholder perspectives engagement funded consumer healthcare debt continue hold board believes importance maintaining high haleon shares divested due course continuous level engagement shareholders date publication report held rd business development individual meetings range investors make also previously described succession process approximately companys share register charles followed cso transition dr hal barron dr tony bancroft appointed new sid demerger wood pleased smooth process held introductory meetings shareholders making making good progress rd register also pleased able board receives regular reports rd dr wood hold annual governance meeting london december well science committee following reviews person meeting extended progress achieved organic inorganic business invitation shareholders representing holdings totalling development bd approximately share register event pleased representatives participated virtually efficient board cadence bd support person prime importance us maintain clear rd scientific screening target undertaken first understanding investors views companys science committee well advance boards performance meetings help achieve provide consideration ensure confident key input board planning scientific rationale underpinning deal progressing board proposal late later stage target asset also undertake commercial review forecasts commercial assumptions underpinning strategic report governance remuneration financial statements investor information gsk annual report chair 's governance statement continued board priorities externally facilitated board review agree priorities ways working focus value creation governance oversight ahead together strategy beyond delivery performance targets execution rd pipeline business development longterm rd strategy approach peopletalentculture esg leadership zantac litigation defence mitigation focus shareholder value creation new gsk board priorities also frame board discussions considering strategic decisions actions taken joined board september gsk entering period significant transition run separation connecting business people group board engaged structured externally facilitated appraisal governance architecture following covid restrictions board able board committees output board meet together person time set aside enable agenda focused linked directly business nonexecutive directors informal time together needs innovation pipeline performance culture glt members presenting meet separation refined committee architecture colleagues meeting location reinforced priorities board board committees following separation time set new board priorities ms hall business advisory company engaged boards agenda seeks focused duplicate facilitate work following success previous review work committee remit defines agenda support work comprised two key aspects priorities committee chairs continue responsible sharing board work committees undertake review current ways working main issues overseeing also highlight recommendations improvement establishing specific committee papers believe would benefit priorities board agenda next three five years boards wider understanding nonexecutive directors evaluation board committees may attend committee meeting full access agendas papers time time chairs committee board aligned management deliver new specific board committee may convened ahead together purpose strategy culture strong specific topic creates flexibility enables board emphasis value creation three time periods nearterm agile required given increased biopharma based around delivering public commitments expertise new board management also medium longterm beyond board sharing proposals opportunities earlier stage programme set accordingly facilitate efficient decisionmaking report formal independent external board following snapshot aspects board committee performance review set committees work board culture decisionmaking audit risk committee assisted establishment board fully supported new purpose strategy robust internal control risk management control performance culture new gsk wellpositioned framework haleon independent listed company deliver public commitments growth create also confirmed gsks framework remained fit new sustainable longterm value board discussions focus future committee took lead role completing powerful combination science technology talent scrutiny subsequently recommending board realising gsks desired culture support aim demerger listing documents shareholder approval general meeting july ambitious patients accountable impact right thinggsk annual report chair 's governance statement continued since demerger groups share price performance science committee good progress made rd second half year impacted uncertainties committee continues support ambitious agile associated zantac product liability litigation development pipeline organically us committee continues primary board smart business development overseeing reviewing accountability zantac litigation including accounting application science committee supported seamless disclosure communication assessments behalf transition leadership rd dr tony wood dr hal board committee clear remit recommends barron tonys role key architect rebuilding pipeline decisions navigation litigation board key appropriate would reiterate point company corporate responsibility committee new culture gsk remains confident position matters something powers purpose drives defend vigorously claims brought delivery strategy helps make gsk place nominations corporate governance committee people thrive committee continues focus supported demerger consumer healthcare business oversight evolving companys esg performance assisting haleon chair designate completing pleased able report track composition haleon board included transfer new esg rating reassured demerger two serving directors vindi banga enhancements esg reporting data oversight dame vivienne cox committee felt strongly remuneration committee focused new remuneration particular skills experience would valuable haleon policy fundamental part architecture new would also importantly provide continuity gsk postseparation critical build strong new haleon board performance culture generate sustained delivery committees focus continuing complete shareholder value new policy seeks achieve composition new gsk board changes key linkage executive remuneration rewarding glt key focus deepening boards scientific outperformance biopharma skills committee selected new directors engaged extensively shareholders shareholder strong emphasis life sciences technology help representative bodies developed new policy deepen biopharma expertise experience recognise importance new reward system support dr vishal sikka worldleading technologist field new gsks success final policy modified reflect advanced enterprise technologies extraordinary feedback received whilst recognising sizeable minority credentials ai machine learning shareholders voted continue engage shareholders demonstrate importance liz mckee anderson deep commercial expertise across place rewarding overperformance policy large specialty biopharma specific crucial next stage new gsks development strong experience global commercialisation market access operational financial performance company specialisms respiratory immunology vaccines encouraging start however gsk hiv underperformed terms tsr share price performance julie brown join gsk april incoming cfo many years new policy firmly focused addressing considerable listed pharmaceuticals commercial reversing trend outturns awards experience recognise significant improvement performance board scientific credentials ideally suited overall good progress made however board new purpose among strongest clear increase investor confidence industry moved away broader experience ability group sustain growth next board originally joined pleased decade debate discussion board committee meetings thank continued support look forward evolved new purpose deeper connecting year whether annual enriched result committee continue recruit general meeting may otherwise share continued diverse directors scientific biopharma expertise progress meet evolving needs board oversee companys strategy global biopharma business sir jonathan symonds chair march strategic report governance remuneration financial statements investor information gsk annual report corporate governance architecture board ceo chairs corporate science nominations audit risk remuneration committee responsibility committee corporate committee committee committee governance glt committee corporate governance architecture framework designed improve effectiveness board support oversight gsk leadership team glt delivery strategy continues evolve support infrastructure priorities pure biopharma business gsks internal control risk management arrangements integral part overall corporate governance framework described pages pages ensure framework 's optimal effectiveness requires clear division responsibilities individual collective board roles described next appropriate distribution workload board committee requisite focus skills highly committed board directors motivated discharge roles responsibilities success company c ommittee roles committee report committee role focus membership chairs acts behalf board scheduled meetings take decisions urgent sir jonathan symonds matters accordance matters authority delegated board time company chair time senior independent director chairs board 's committees corporate considers gsk 's trust priority oversight responsible business approach esg dr anne beal chair responsibility strategy performance reporting reflects important issues responsible dr jesse goodman sustainable business growth oversight views interests internal dr vishal sikka external stakeholders reviews issues potential serious impact upon gsks business reputation science supports board understanding key strategic themes upon companys dr hal dietz chair rd strategy based external transactions performing indepth reviews january underlying scientific assumptions give board technical assurance also undertakes dr jesse goodman indepth risk oversight rdrelated risks chair december dr hal barron nominations reviews structure size composition board appointment members sir jonathan symonds corporate board committees appointment corporate officers makes recommendations chair governance board appropriate also plans assesses orderly succession executive charles bancroft nonexecutive directors reviews management 's succession plan ensure adequacy dr anne beal urs rohner responsible reporting board overseeing monitoring corporate governance arrangements making recommendations board ensure companys standards arrangements consistent existing corporate governance standards emerging best practice also reviews board glt conflicts interest audit risk reviews financial reporting process integrity companys financial statements charles bancroft external internal audit process system internal control identification chair management risks companys process monitoring compliance laws elizabeth mckee regulations ethical codes practice also oversees esg data reporting assurance anderson urs rohner initiates audit tenders selection appointment external auditor setting remuneration exercising oversight work remuneration sets companys remuneration policy regard gsks workforce remuneration urs rohner chair gsk able recruit retain motivate executives charles bancroft dr anne beal remuneration policy regularly reviewed ensure consistent companys elizabeth mckee scale scope operations supports business strategy growth plans aligned anderson wider workforce helps drive creation shareholder value chair ceo responsible evaluating making recommendations board remuneration arrangements policy nonexecutive directors board committee written terms reference approved board reviewed least annually ensure comply latest legal regulatory requirements reflect best practice developments current full terms reference board committee available gskcom board committee meeting attendance oversight company 's policy external appointments set gsk annual report corporate governance architecture continued leadership independent oversight rigorous challenge chair nonexecutive directors jonathan symonds provide strong independent element board leads manages business board constructively support challenge management provides direction focus scrutinise performance achieving agreed ensures clear structure effective operation deliverables board committees shape proposals strategy offer specialist advice maintains dialogue shareholders management governance company letter appointment setting terms sets board agenda ensures sufficient time conditions directorship allocated promote effective debate support sound devote time necessary proper decisionmaking performance duties ensures board receives accurate timely clear expected attend meetings required information meets continuously nonexecutive director independence statement discuss individual contributions performance board considers nonexecutive directors together training development needs identified pages exception dr shares peer feedback provided part hal barron independent assessed board evaluation process provision financial reporting council 's frc uk meets regularly nonexecutive directors corporate governance code code independently executive directors independence commitment dr jesse goodman chairs role description available gskcom urs rohner served board six years subjected rigorous review chief executive officer gsk 's nonexecutive director role description available gskcom emma walmsley responsible management group senior independent director business charles bancroft develops groups strategic direction consideration acts sounding board chair trusted approval board intermediary directors implements agreed strategy together nonexecutive directors leads supported members glt annual review chairs performance taking maintains continual active dialogue account views executive directors shareholders respect companys performance discusses results chairs effectiveness review chair chief executive officers role description available gskcom leads search appointment process makes recommendation board new chair acts additional point contact shareholders maintains understanding issues concerns major shareholders meetings investors briefings company secretary investor relations g sk 's senior independent nonexecutive directors role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chairs annual agenda planning ensures information made available board members timely fashion supports chair designing delivering board inductions coordinates continuing business awareness training requirements nonexecutive directors undertakes internal board committee evaluations request chair advises directors board practice procedures corporate governance matters chairs groups disclosure committee operates boardapproved appointments policy reflects board external appointment requirements code point contact shareholders corporate governance matters strategic report governance remuneration financial statements investor information gsk annual report corporate governance architecture continued board committee attendance nominations corporate corporate board chairs responsibility science governance audit risk remuneration total number routine meetings current members attended attended attended attended attended attended sir jonathan symonds emma walmsley iain mackay elizabeth mckee anderson dr hal barron charles bancroft dr anne beal dr harry c dietz dr jesse goodman urs rohner dr vishal sikka retired members vindi banga dame vivienne cox lynn elsenhans dr laurie glimcher number additional meetings numbers brackets denote number meetings individuals eligible attend see board committee changes details committee members skills experience included biographies board pages frc uk corporate governance code provision requires alignment pension rates executive directors available local workforce since financial experience january current executive directors ' pension rates accordance frc 's code board aligned wider workforce local determined charles bancroft recent relevant replicates requirement pension arrangements financial experience also agreed new executive directors appointed gsk appropriate qualifications background audit committee financial expert defined sarbanes addition provision requires base salary oxley act determined pensionable us pension arrangements employees independent within meaning securities exchange allow basic salary bonus pensionable following act amended dr hal barron 's transition nonexecutive director effect august frc code requirement compliance also met board pleased report full compliance provisions frc 's code board also pleased report consistently exception code provision applied principles frc 's code set pages remuneration report copy code available frcs website wwwfrcorguk nonexecutive directors expected devote time necessary performance duties director required attend minimum scheduled board committees meetings however recognised may rare occasions possible special allowance given first year board membership calendars aligned high attendance record scheduled board committee meetings directors served set board directors external appointments governed board approved policy external appointments help board glt members widen expertise knowledge hence perform roles effectively proposing new nonexecutive director appointments board approval board takes account demands individuals time prior appointment board individual required disclose significant commitments may indication time involved additional prospective external appointments serving board directors considered approved board noting nature role type organisation time commitment potential conflicts envisaged company secretary maintains register commitments potential conflicts board satisfied given directors interests sufficient time carry role executive nonexecutive directors may undertake maximum one four listed company directorships respectivelygsk annual report ahead together board oversight board discharges responsibilities annual programme meetings papers presentations provided board committees focused strengthening fundamental elements business move ahead together pursuit company 's strategy deliver gsk 's growthbased performance ambitions oversee demerger listing haleon establishing gsk pure biopharma business drive esg leadership priorities papers presentations also highlighted relevant stakeholder impacts perspectives materials enable board 's effective decisionmaking input oversight business performance governance key items business considered critical gsks longterm success achievement gsk 's key priorities highlighted areas focus demerger boards preparation demerger valuebased process included listing haleon discussing strategy plans consumer healthcare period beyond separation haleon receiving regular performance reports scrutinising overseeing consumer healthcare capital markets day approach materials supporting appointments haleon board including transition vindi banga dame vivienne cox haleon scrutinising responding unsolicited proposal consumer healthcare business advance demerger approving gsk shareholder circular recommending demerger overseeing haleon prospectus approval demerger subsequent gsk share consolidation build gsk boards oversight creation gsk pure biopharma business delivery stepchange performance included pure biopharma regularly discussing scrutinising transformation plans gsk business scutinising updates rd strategy progress progression company 's pipeline requesting remuneration committee renew remuneration policy 's focus incentivise overdelivery reward new performance culture board management succession planning including approval appointment new chief scientific officer transition dr hal barron nonexecutive director appointment two new independent nonexecutive directors new chief financial officer approval charles bancroft successor vindi banga role senior independent director approval change approach workforce engagement ahead together boards oversight fundamentals commercial execution cost base management capital allocation pipeline culture included strengthening setting approving boards priorities fundamentals receiving regular progress updates providing input companys vaccines mrna strategy plan value creation receiving discussing commercial strategy performance reports pharmaceuticals vaccines viiv healthcare receiving updates rd strategy pipeline progress approving business development transactions acquisitions strategic partnerships third parties including sierra oncology affinivax mersana therapeutics spero therapeutics wave life sciences tempus receiving quarterly reports ceo cfo cso scrutinising groups financial performance setting companys new name purpose simplified culture new code conduct enhancing boards oversight new culture embedding esg core esg leadership approving supporting new gsk culture approving responsible business section annual report approving task force climaterelated financial disclosures section annual report final approval pricing access policy principles overseeing gsks overall response situation ukraine regular boards programme governance included corporate reviewing quarterly financial results dividend proposals earnings guidance investor materials results announcements governance receiving reports external auditor oversight approving final annual report form f setting annual budget forwardlooking threeyear plan conducting annual review boards enterprise risk responsibility framework enterprisewide risks undertaking annual board evaluation implementing agreed outcomes reviewing continuing evolve boards governance architecture evaluating ceos performance setting objectives reviewing talent succession plans annually receiving reports board committee work engaging gsk 's stakeholders wider workforce gather understand views companys activities operation reviewing employee pulse survey results receiving reports wider corporate governance regulatory developments company secretarys report approving company 's modern slavery statement gender pay gap positioning reviewing stakeholder perception research strategic report governance remuneration financial statements investor information gsk annual report ahead together board oversight continued action points board performance due consideration discussion following action board evaluates performance points improve performance agreed committees every year evaluation normally carried key area focus board continue externally every third year last one facilitated rd organic inorganic meeting pipeline goals jan hall business advisory company therefore delivering shareholder value seen connection gsk board felt top priority would helpful conduct evaluation following completion demerger haleon importance science committee working formation gsk new biopharma company cso help optimise pipeline supporting onboarding new cfo julie brown preparation board succession planning would progressed ensure met chair ceo advance evaluation broad range diverse candidates consideration update board operating understand successor remuneration committee chair gsks future priorities agree reviews objectives scope timetable company secretary also provided board committees access board committee materials review board committees focused progress information involved virtual interviews committee members conducted behalf respective committee interviews chairs committee considered operate effectively november december conducted following enhancements agreed confidential detailed interviews board selected glt members company secretary gsks external auditor importance optimising concise feedback committee chairs full board following incoming outgoing independent remuneration committee meeting adviser seek views boards effectiveness meetings reflected agreed discussion guideline following agreement overall board priorities sent participant beforehand included key topics board agenda committee chairs agreed review financial reporting councils guidance main areas responsibility committees line board effectiveness relevant requirements board priorities incorporate uk corporate governance code however limit committee programmes feedback participant could give particular importance science committee supporting organic inorganic rd evolving review ways committee works cso review sought determine board 's priorities team next three five years built board 's agenda evaluation results suggested next chair steps included summary report compiled discussed initially chair ceo senior sid sought feedback chair 's performance independent director sid review presented directors individually collectively concluded board january covered following main areas chair operating effectively leading board effectiveness review results review noted discussed chair sid overall review board board organisation agenda information board dynamics challenge input future strategy development performance deliverygsk annual report key decisions engagements particular board 's continuous engagement section statement investors people set section pages companys corporate governance architecture board members required law promote success processes summarised pages organisation benefit shareholders wider stakeholders including employees suppliers summary sets board considered relevant community statement meets requirement set matters making principal decisions contributed section section cza companies act formation two attractive viable businesses act states year directors compelling investment propositions addressed matters set section f delivering separation haleon gsk strong act performing duties focus shareholder value demerger board considers statement focuses risks building gsk pure biopharma company opportunities strategically important gsk ambitious patients accountable impact consistent groups size complexity allows right thing new gsk properly understand potential impacts decisions makes stakeholders demerger represented key step multiyear transformation gsk improve focus performance engagement main stakeholder groups including competitiveness maximise value shareholders patients shareholders consumers customers employees demerger also provided right opportunity implement levels across organisation summarised legal change name company glaxosmithkline throughout pages strategic report plc gsk plc designed mark new gsk brand culture protect build future change made may longterm results likely consequences decision long term newly independent global leader consumer health focused strategy drive penetration growth across end may board assessed companys portfolio capitalising new emerging growth readiness proceed demerger approved opportunities underpinned strong execution gsk circular agreed haleon prospectus sent financial discipline haleon independent company shareholders final stage demerger would able deliver sustainable abovemarket board exercised section duties reviewing growth moderate sustainable adjusted operating margin work management audit risk corporate expansion medium term attractive returns responsibility remuneration transformation shareholders separation committees progressing separation new gsk pure biopharmaceuticals company since mid included portfolio focused vaccines specialty medicines extensive consultations held key stakeholders general medicines clearly defined financial sharing longterm growth ambitions investor ambitions clear ambition deliver largescale events gsk june haleon february longterm positive human health impact strong considering rejecting unsolicited conditional balance sheet enabling growthoriented capital nonbinding proposals received acquire consumer allocation policy attractive shareholder returns healthcare business board believed demerger would unlock recommending proposals create two potential businesses strengthen balance sheet independent companies effectively serve new gsk ability invest growth maximise patients customers respectively board firmly longterm return shareholders believed decision would establish shareholders duly approved two resolutions proposed general meeting held july demerger effected july strategic report governance remuneration financial statements investor information gsk annual report key decisions engagements continued b workforce interests groups employees attended glt members nonexecutive board members including chair board continual regard interests people either remaining new gsk addition annual bonus longterm departing form haleon achieved using various incentive structure board also gave special thank employee voice mechanisms described pages people excluding glt allowing us recognise help explain future shape companies achieved together preparation understand assess impact changes demerger transformation company organisation experienced pure biopharma company result everyone received people oneoff payment equivalent weeks salary march separate bonus payout significant focus dedicated bringing life new gsks ahead together purpose strategy culture people also ensured treatment awards options across group strong emphasis given held gsk employees departing haleon individual ownership new culture formally employees delivered fair outcome accordance launched june events held around rules share schemes part demerger companys locations globally gsk share consolidation c business relationships importance developing groups business ethical behaviour promoted across business relationships suppliers customers others supporting people right thing working suppliers share standards operate key imperative board gsk responsible responsible way new code conduct seeks set business ensure company develops monitors expectations regard partnerships ultimately serve patients benefits relationships support third parties expected meet abac achievement ambitions described pages labour rights standards comply standards strategic report example quality health safety environment approximately total emissions footprint comes achieving ahead together ambition positively goods services buy september impact health billion people end support net zero carbon impact climate requires development vaccines medicines ambition launched sustainable procurement making available responsible pricing programme require suppliers among strategic access programmes partnerships things disclose emissions set carbon reduction targets switch renewable power heat community environment establishing six areas esg focus new gsk global biopharma company fundamental impact groups operations community dna success six areas detailed pages environment directly contribute longterm shareholder value approach making positive impact guided contributing health impact supporting thriving extensive stakeholder engagement key issues people reducing risk environment one relevant new gsk prior demerger haleons principal esg focus areas environmental respective industries nature companies scorecard measure introduced longterm board sought achieve incentive plans incentivise reward progress preparation demerger working haleons delivering net zero impact climate net management team developing distinctive positive impact nature public ambitions responsible business approach esg framework board also focused new gsks ahead bespoke needs customers together ambition impact lives billion patients communities serves also involved scrutinising next ten years human capital key gsk framework proposed targets including seeking strengthen early stem education environmental sustainability targets presented investments support longterm diverse talent haleon 's investor update february pool increase positive impact volunteering activities within communities servegsk annual report key decisions engagements continued e reputation desire maintain reputation high standards reaching agreement trustees gsk uk business conduct pension schemes package measures including funding protections relation demerger duty guided boards approach demerger gsk uk pension schemes triennial actuarial valuations creation new gsk achieved ensuring gsk remained one company transformation company initially launched operated point demerger overriding early included fundamentally reviewing emphasis driving topline growth improving margin structure cost base ways working effectiveness biopharma consumer healthcare implementing plans six areas esg focus new businesses implementing targeted enhancements gsk outlined investors june help retain advance demerger develop gsks reputation esg leadership responsible business conduct choosing optimal form separation demerger listing location structure developing distinctive holistic responsible business haleon gsk result haleon operate case esg framework haleon outlined premium listed legal corporate governance investors february supported haleons standards environment common business purpose strategy culture premium uk listed ethical values gsk company focus key responsible business issues extensive legal financial due diligence ensuring board people new gsk engagement key regulators investors key commit annually new code conduct introduced stakeholders undertaken preparing gsk june code sets board endorsed circular haleon prospectus haleon f ahead together purpose culture well performance commitments people make deliver companys ambitions right way f fairness shareholders aim act fairly members group shareholder receiving prorated shareholding haleon demerger receipt one haleon fundamental importance board able share gsk share held additionally haleon ensure shareholders treated fairly shares inception demerger equal demerger demonstrated rights participate capital dividend profit deciding appropriate capital structures distributions haleon required two companies competitive gsk share consolidation achieved consistency stock exchanges haleon list whether gsk share price pre postdemerger enable extent distribute shares haleon gsks comparability new gsk earnings per share shareholders retain stake haleon share price previous periods also preserved shareholder right vote one vote far reasonably possible value share options one share basis general meeting demerger awards granted people demerger new gsk share consolidation related party transactions resolutions ensure many shareholders possible could participate meeting shareholders able ask questions vote either electronically person voting majorities excess recorded resolution approach continuous engagement board placed two main stakeholders heart renewed culture people stakeholders rightly high expectations us ambitious patients accountable impact dynamic operating environment presents many challenges right thing culture described pages opportunities board aims make sure strategic report commercially successful balanced aligned meeting stakeholders expectations upholding reputation influence importance different stakeholder groups maintaining licence operate building trust vary depending matter considered certain board engages briefed views stakeholders interests conflict meaning board stakeholders ensure identifies responds needs make balanced judgements expectations effectively appropriately continuous stakeholder engagement feedback helps us engage main stakeholder groups including identify emerging issues also enables board make patients shareholders consumers customers employees decisions context relevant important across company covered pages strategic report strategic report governance remuneration financial statements investor information gsk annual report key decisions engagements continued principal board committees glt undertake workforce engagement dame vivienne concluded engagement boards behalf accordance workforce engagement activities first half year remit means build detailed understanding prior transfer haleon board july actions plans areor may impact stakeholders separation consumer healthcare business insights shared board programme visits conducted basis described previous annual reports particular board receives briefings stakeholders perspectives work corporate responsibility dame vivienne provided focus employee engagement committee discussed pages designated workforce engagement director december tenure coincided entirety board members regularly receive programme transform gsk focused biopharma ceos board report company demerger consumer healthcare form specific external stakeholders report provides haleon continued take questions gather feedback strategic insights based analysis key developments board employees future strategy shape achievements risks impacting reputation culture two new independent companies perceptions external stakeholders build separation held listening events crosssection regular investor relations report summarises investor perceptions consumer healthcare employees april prior transfer haleon regular corporate governance litigation regulatory updates digital tech employees june helping ensure strong secure technology platform board also learns stakeholder views companies engagement feedback events quarterly prior separation board reviewed formal workforce investor results calls annual general meeting employee engagement arrangements decided move survey reports boards workforce engagement specific workforce engagement director model apply activities experts presenting board committee alternative arrangement three methods set meetings addition chairs investor checkin meetings frcs code given new gsk board recently holds ongoing basis new sid charles refreshed terms tenure half independent bancroft joined meetings charles also met nonexecutive directors neds served less individually investors introduced gain three years gsk 's renewed purpose focus personal understanding issues views may global biopharma company considered important adopt collective board engagement model agreed opportunities board members also gain wider effective approach ensure newer board stakeholder views annual strategy meeting members meet people hear views glt part annual review strategy budget implemented planning process includes review specific aspects return direct inperson receptions local employees companys policies strategy addition board members following covid restrictions board site visits encouraged meet individually employees second half included stevenage shareholders key stakeholders induction uk one two global rd hubs boston us ongoing basis encouraged report global hq brentford board experiences relevant material chair undertaking range site visits including raleigh people durham us meet viiv employees kings cross london met artificial intelligence wellestablished strong engagement machine learning team well respiratory supply mechanisms colleagues described chain employees based ware uk aranda spain pages monitored regularly board three key governance channels help communicate chair corporate responsibility committee chair people thinking board meeting leaders employee resource groups ergs discuss experience gsk well regular board updates chief people officer hearing views progress diversity equity ceo culture talent inclusion dei agenda ambitions feedback range pulse surveys varying sizes utilising variety bespoke engagements employee groups help check sentiment culture enabled broad open dialogue facilitated first quickly frequently provide valuable insights hand engagement discussions neds impact major initiatives events communications people individually part small groups direct engagement board prior demerger encompassing perspectives strategy purpose designated workforce engagement director dame ahead together culture dei vivienne cox specific mandate connect peoplegsk annual report key decisions engagements continued shareholders annual governance meeting board seeks directly engage directly years event hybrid meeting central london accountable institutional investors private retail institutional shareholders key investment industry bodies shareholders seeks discharge direct continuous proxy advisory firms invited institutional accountability several ways include regular shareholders attended event representing approximately communications annual general meeting general company 's issued share capital chair meeting annual governance meeting joined new sid committee chairs gsks external work investor relations team chair sir jonathan audit partner successor symonds company secretary victoria whyte shared investors priorities focus board year ceo emma walmsley cfo iain committees progress made mackay gave quarterly results presentations institutional included investors analysts media webcast also execution clear plan separation haleon regularly joined cso chief commercial officer gsk strong focus shareholder value creation ceo viiv healthcare gsk global health able creation two attractive viable businesses provide investors detailed insights specific compelling investment propositions areas responsibility building two highlyqualified boards complement regular meetings emma iain ongoing world class management teams active dialogue institutional shareholders performance plans objectives ceo held rearchitecting gsk board total engagements major shareholders representing supporting haleon board build approximately company 's share register cfo held total engagements investors making approval new binding remuneration policy aligned nearly company 's share register delivery gsk 's public growth esg commitments announced investor update june chair always maintained constant dialogue shareholders including fund portfolio managers continuous engagement shareholders well engaging governance esg professionals stakeholders date publication report meeting wellreceived shareholder feedback chair held meetings range investors make shared subsequently full board approximately companys share register annual general meeting enables gain current understanding investor views pleased able hold hybrid meeting insights perspectives company discusses sofitel heathrow may first meeting many aspects board governance oversight succession able hold person attendance since onset charles bancroft appointed new sid july covid pandemic pleased see increase demerger consumer healthcare business attendance shareholders compared introducing shareholders seek views agm held virtually registered office gsk discuss key matters importance brentford shareholders joined meeting person appointment sid date publication report shareholders joined virtually watch listen updates meetings investors making chair ceo ask questions vote share register exception proposed remuneration policy resolution chair ceo rest board particular focus received shareholder approval proposed communicating final process demerging resolutions approved shareholders majorities haleon ambitions gsk global biopharma business ranging beyond demerger progression pipeline three agm year held hybrid format key focus periods beyond sofitel heathrow shareholders also also sought investors feedback new remuneration flexibility able watch listen vote ask questions policy meeting virtually via lumi platform ask questions via video connection see details general meeting addition board convened general meeting sofitel heathrow july seek shareholder approvals authorise demerger haleon related share consolidation gsk chair ceo cfo present person company secretary rest board joined meeting virtually shareholders joined meeting person shareholders joined virtually resolutions approved shareholders majorities excess strategic report governance remuneration financial statements investor information gsk annual report board committee reports esg performance deep dives corporate responsibility committee report throughout year committee discussed management following areas esg focus dr anne beal access pricing principles committee reviewed corporate responsibility committee recommended board adoption publication pleased present report first chair gsks pricing access principles principles corporate responsibility committee committee principles highlevel articulation managements joined committee may succeeded lynn current approach pricing access elsenhans chair july comprehensive prepared extensive internal external consultation transition handover time chair lynn made validated key audiences including patient outstanding contribution overseeing shaping advocacy groups drawn us uk embedding trust priority approach committee part detailed input principles responsible business recently establishing six made sure captured areas esg focus gsk pure biopharma company six areas detailed pages directly impact value gsks innovation terms economic contribute longterm shareholder value contributing benefit health impact supporting thriving people reducing health equity within countries risk importance supply network access drawing extensive healthcare experience principles sufficiently flexible evolve time physician public health expert including time subject regular review chief patient officer sanofi combined passion patient advocacy continue building committees diversity equity inclusion dei committee continues work framed work scrutiny committee regularly assess progress gsks dei approach following questions key metrics identified drive performance metrics support areas form part new esg performance company committee know rating explored performing across esg focus areas work includes efforts increase leadership challenge improve diversity build diverse talent pipeline foster inclusive performance culture committee pleased note strong overall best report key stakeholders progress made towards gender done level impact made ethnicity aspirations particular pleased us ethnic diversity aspiration least already driving boards oversight enhanced exceeded year work esg performance undertaken increase black vp representation uk central element committees work last firmly believe gsk outstanding work months devoted accelerating improvements area pleased committees esg performance understood managed feedback utilised management improve performance maximum impact committee agreed introduction disclosure new esg performance rating one company kpis committee also reviewed progress efforts broaden key management tool drive delivery esg across six diversity clinical trial participants grow supplier esg focus areas rating derived assessing diversity improve health equity within countries expand performance number stretching independently equitable access stem education assured metrics across focus areas arrive single environment committee recently reviewed progress composite measure committee regularly monitored companys ambition net zero impact climate companys progress metrics net positive impact nature committee satisfied course year recommended board good progress made date dual focus publication final track esg rating alongside maximising success inflight initiatives esg disclosures annual report esg developing targeted actions maintain momentum performance report details found stretching ambitions strategic report within esg performance report human rights committee reviewed managements available gskcom approach progress human rights including supply chain third party interactions also considered complex rapidly evolving legal regulatory landscape human rightsgsk annual report board committee reports continued esg disclosures reporting gsks capability respect science committee report esg reporting continually evolving challenge best report clearly concisely dr jesse goodman performance taking place greater scrutiny esg stakeholders esg reporting increasingly science committee moving voluntary mandatory pleased present report chair science committee considers gsk strong mature committee committee activities esg reporting approach opportunity bring first since demerger consumer healthcare haleon level control esg data level controls july financial data mind committee approved establishing esg data assurance hub key activities strengthen esg data oversight result demerger gsk pure biopharma business goal uniting science technology talent collaborating board committees better prevent treat disease rd combining careful division responsibilities power genetic genomic insights causes allocation workload committee disease speed scale artificial intelligence remuneration committee respect introduction machine learning make better predictions specific esg targets short longterm incentive treatment might work plans beginning monitoring renewed focus evident committees helping remuneration committee determine vesting discussions time excited future outcomes opportunities brings gsk patients audit risk committee arc supported committee committees key activities split following discussions introduction measurement key areas covered detail disclosure esg performance rating committee pipeline reviews monitoring gsks pipeline also work closely arc year onwards scientific deepdives discussion analysis key implementation operation enhanced esg data scientific themes drive companys rd strategy assurance oversight determinations arc chair sets report business development undertaking technical reviews assurance underlying science potential business dr anne beal development transactions corporate responsibility committee chair march pipeline progress fundamental gsks achievement growth ambitions delivery successful pipeline committee continued monitor throughout year committee participated chief scientific officer cso succession planning process led appointment dr tony wood august dr wood since continued build outstanding progress made dr hal barron prior appointment cso dr wood integrally involved delivering rd productivity improvement helped develop gsks current rd approach focused science immune system human genetics advanced technologies consequently wellplaced implement pipeline deliver gsks bold ambitions patients exceptional milestone year positive results latestage respiratory syncytial virus vaccine candidate vaccine demonstrated unprecedented efficacy older adults potential help reduce disease death major respiratory infection vaccine preventable regulatory submission vaccine accepted review japan accepted european medicines agency accelerated assessment submitted granted priority review status us food drug administration fda strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued committee also delighted positive phase iii spero therapeutics licensing agreement spero results gepotidacin novel oral antibiotic treatment therapeutics tebipenem hbr latestage antibiotic uncomplicated urinary tract infections important may treat complicated urinary tract infections step gsks continued scientific commitment investment significant unmet medical need novel oral antibiotic address antimicrobial resistance amr potentially provide alternative intravenous therapy particularly patients multidrug resistant organisms licensing agreement spero therapeutics see provides evidence continued leadership wave life sciences collaboration brings together focus tackling infectious diseases amr wave 's prismtm oligonucleotide platform gsk 's expertise genetics genomics drive discovery number key approvals also obtained year development oligonucleotide therapeutics focusing fda approval boostrix immunisation pregnancy novel genetic targets prevention whooping cough newborn infants tempus collaboration tempus provides gsk fda approval menveo new singlevial presentation access tempus aienabled platform including library help prevent disease caused meningococcal bacteria deidentified patient data one worlds largest sources serogroups c w clinical molecular data leading aiml fda approval priorix prevention measles mumps capability gsk work tempus identify new drug rubella individuals months age older targets improve clinical trial design speeding enrolment completion accelerating development well exciting latestage pipeline also personalised treatments patients robust earlystage portfolio number innovative programmes capable transforming lives patients gsks dedicated aiml team largest inhouse strategic function biopharma industry collaborations business development transactions rd technology within gsk become increasingly important drug discovery enabling gsk rapidly gsk viewing research development holistically effectively design new vaccines medicines placing great importance external well internal innovation source promising new medicines vaccines scientific deepdives year committee continued assess business development transactions scientific perspective committee also dedicated significant proportion acceleration business development key support time discussing exciting innovative gsks organic pipeline growth transactions reviewed areas science driving companys rd committee year include strategy deepdives undertaken year include sierra oncology acquisition sierra oncology phase pipeline review biopharmaceutical company focused targeted therapies rna based therapeutics vaccines rare forms cancer acquisition included momelotinib oncology new medicine unique dual mechanism action intended address critical unmet medical needs particular committees discussion rna including myelofibrosis patients anaemia new drug application oligonucleotide therapeutics provided important insights momelotinib treatment myelofibrosis emerging science potential transform lives accepted august fda december patients november company published positive ema results phase iib trial evaluating safety efficacy bepirovirsen potentially transformative treatment affinivax acquisition affinivax clinicalstage people living chronic hepatitis b biopharmaceutical company providing gsk access next generation pneumococcal vaccine candidate highly results offer early indication bepirovirsen might innovative multiple antigen presenting system maps potential treatment either monotherapy combination technology drugs could result functional cure gsks expertise human genetics functional genomics aiml mersana therapeutics collaboration mersana identify novel genetically validated targets well therapeutics codevelopment commercialisation recent collaboration wave life sciences referred xmt firstinclass sting antibody drug demonstrate wellpositioned become conjugate initially treatment advanced breast leader oligobased therapeutics cancergsk annual report board committee reports continued committee changes nominations corporate governance previously mentioned august dr tony wood committee report succeeded dr hal barron cso tony outstanding jonathan symonds highly respected scientist committee engaged nominations corporate governance committee regularly advance appointment dr barron transitioned nonexecutive director member pleased present fourth report chair committee committee gsk therefore continue nominations corporate governance committee benefit expert advice support scientific matters committee dr laurie glimcher retired board october key activities would like thank laurie valuable expertise scientific insights contributed committee year committee continued important role tenure process finally chaired committee since inception delivering demerger haleon group key six years ago rotation chair concluded effective board governance workstream january dr hal dietz joined committee creating two attractive viable businesses january succeeded committee chair compelling investment propositions directed overseen experience human genetics central gsks highly capable boards approach rd already proven invaluable achieved orderly targeted manner committees discussions excellent successor building two highlyqualified boards complement world role chair class leadership teams privilege work gsk 's outstanding supporting shaping creation haleon board scientists leaders well fellow committee members chair committee restructuring gsk board new focus expertise transformational period company pure biopharma business scientific fields operate remain member committee look forward continuing progress haleon board appointments outlined today report last year described work committee appointing ceo cfo chair designates haleon dr jesse goodman also disclosed two nonexecutive members gsk science committee chair board expected transfer haleon board march completion demerger committee subsequently supported haleon chair sir dave lewis finalising search appointment high calibre nonexecutive directors complete haleon board committees board subsequently endorsed committees recommendation transition vindi banga dame vivienne cox haleon board completion demerger committee considered haleon board would benefit knowledge experience would also provide important continuity haleon postdemerger separately companys consumer healthcare joint venture partner pfizer exercised right appoint two nonexecutive directors haleon board shaping new biopharma board previously described process transition gsk board pure focused global biopharma company work undertaken committee designing planning optimal structure composition new biopharma board new nonexecutive directors committee wanted ensure new nonexecutive director appointments would deepen biopharma skills expertise experience board global search process activated appoint directors deep life sciences commercial expertise artificial intelligence machine learning aiml expertise diverse list candidates identified shortlisted interviewed committee members ceo cso chief people officer strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued following careful review committee pleased committee proposed board approved recommend appointment two high calibre individuals appointment ms julie brown successor iain mackay dr vishal sikka elizabeth mckee anderson independent cfo julie currently chief operating financial officer nonexecutive directors effect july burberry group plc join gsk april work september respectively iain transition responsibilities take responsibilities cfo executive director may cfo vishal distinguished background worldleading succession process described detail technologist particularly field aiml central gsks approach rd also committees view ideal successor iain embraced across group meanwhile liz brings significant proven cfo global public company deep commercial understanding experience commercial biopharmaceutical experience would need biopharmaceuticals seasoned biotech board member effective business partner ceo successful delivery contributions already proving invaluable board gsks growth ambitions also important fully focused biopharma company committee successor good fit new culture high energy positive mindset details vishal lizs experience biographies found pages rationale thorough global search initiated agreed appointments included companys announcements profile shortlist viable candidates identified may august respectively available role ceo members committee chief gskcom people officer met julie unanimous support recommended iains successor dr hal dietz appointed board end joined board designated scientific medical expert board looking forward welcoming julie gsk january extensive experience field highly respected cfo extensive experience human genetics also central gsks approach biopharma medtech sectors details julies rd recruitment process appointment experience rationale appointment included committee described report last year companys announcement september year board dr dietz began rotation science available gskcom committee chair january succession dr jesse glt changes goodman addition new cso cfo committee also senior independent director sid succession reviewed following internal senior executive changes vindi banga performed role sid six years vindi 's glt help bring simplification alignment transition haleon board completion demerger glt areas created opportunity appoint successor luke miels chief commercial officer assumed full committee determined charles bancroft served accountability strategic commercial product two years board experience working development vaccines alongside current investors role cfo bristol myers squibb deep accountabilities strategic product development understanding pharma industry experience specialty general medicines commercial nonexecutive director listed companies performance gsk portfolio markets sufficient time dedicate role made ideal successor succeeded vindi effect july regis simard president global supply chain assumed board fully endorsed appointment accountability vaccines medicines supply deborah waterhouse chief executive officer viiv continuing shape gsk board healthcare assumed overall accountability gsk global future health management succession planning roger connor president vaccines global health left gsk progress new role healthcare outside biopharma previously described work committee appointment dr tony wood successor dr hal barron committee continues review talent succession cso member glt transition drs wood pipelines development plans key management roles barron roles cso nonindependent non successors executive director took effect planned august nonexecutive director succession planning cfo succession committee regularly reviews board 's composition cfo iain mackay advised board intention skills working science committee step board leave company potential add scientific medical expert committee activated cfo succession plan targeted board seeks contribute biopharma skills search highquality executives cfo succession expertise support growth ambitions committee already undertaken role profile next also looking identify successor urs rohner cfo gsk pure biotech remuneration committee chair due retire board look forward providing updates roles next yeargsk annual report board committee reports continued composition tenure nonexecutive tenure industry experience number board members years years years life sciences tech finance consumer predemerger postdemerger board seeks balance composition tenure pure biopharma company including life sciences committees refresh time pharmaceuticals industry rd tech vaccines enables board benefit experience longer healthcare medical research academia financial serving directors well fresh perspectives insights services collectively wealth experience newer appointees nonexecutive directors complex businesses global reach drawn industries backgrounds relevant diversity equity inclusion ethnicity gender female composition ethnically diverse white postcfo historic expected succession demerger refocus arget female representation board data gsk annual report published first quarter year current female representation date publication expected rise may postcfo succession committed diversity board gsk attributes including character intellect judgement honesty committed equal opportunities employees levels courage organisation board management seek committee responsible developing measurable encourage diverse inclusive culture throughout objectives monitoring progress towards achievement company assist implementation boards diversity policy effective board needs range balance skills policy including gender ethnic diversity minimum experience knowledge ethnicity gender socialeconomic seek align policy objectives financial backgrounds independence individuals conduct authority ftse women leaders review parker prepared challenge collaboratively mix review diversity targets ensure consistent needs complemented diversity personal board public diversity equity inclusion dei aspirations b oard glt gender diversity diversity objective status performance least board positions held women objective least one woman either chair sid role board andor one met objective one director ceo woman chief executive officer finance director role end least glt positions held women met objective least one board director ethnically diverse exceed objective two directors strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued may julie brown becomes new cfo female also continue oversee developing pipeline direct board representation stand gsk one reports glt gender ethnically diverse allfemale executive boards running ftse backgrounds company also expect fully restore board gender details gsks representation women ethnically diversity meet exceed diverse leaders covered part diversity board pleased many years gender global workforce progress dei representation objective excess target commitments including gender ethnicity illustrated board positions held women illustrated esg performance report gskcom good previous committee report composition progress also incentivised introduction diversity board currently transitional period esg dei measure annual bonus arrangements following demerger reshaping board executive directors glt members new biopharma company transfer board members haleon retirement two female board directors board committee glt membership role changes directorglt member membershiprole appointment date retirement date elizabeth mckee anderson audit risk remuneration committees september dr hal barron science committee following transition role august nonexecutive director charles bancroft science committee february stepped dr hal dietz joined committee senior independent director july remuneration committee july vindi banga audit risk nominations corporate governance july remuneration committees senior independent director dr anne beal corporate responsibility committee chair may nominations corporate governance july remuneration committees audit risk committee october dame vivienne cox corporate responsibility remuneration committees july dr hal dietz science committee january science committee chair january lynn elsenhans corporate responsibility committee chair may audit risk corporate responsibility nominations july corporate governance committees dr jesse goodman science committee chair december dr laurie glimcher audit risk science committees october urs rohner audit risk committee july dr vishal sikka corporate responsibility committee july roger connor president global vaccines december dr tony wood chief scientific officer glt member augustgsk annual report board committee reports continued audit risk committee report ways working committee seeks follow best practice charles bancroft appointments recommends agreeing criteria audit risk committee role appropriate interview panel pleased present report second considering comprehensive diverse long list chair audit risk committee committee candidates shortlisted candidates interviewed assessed chosen criteria due diligence report last year spoke initial favourable undertaken committee makes final impressions people processes systems culture recommendation executive search firms appointed gsk underpin successful management financial accordance companys procurement policy reporting audit litigation compliance risks pleased based expertise relative role report gsk continues exhibit strong compliance culture consistent tone engagement top committee agreed search firms runs throughout organisation financial signatories voluntary code conduct executive reporting controls framework remains robust search firms gender diversity best practice require fundamental changes year engaged committee worked number executive search key activities firms provided additional consultancy key decisions usual busy year services company outlined committee working regular programme korn ferry general recruitment executive search activities making important decisions support assessment services coaching hrrelated boards progression key priorities summary services recommended board approval planned egon zehnder executive search assessment separation consumer healthcare business july coaching services specific senior executives based committees awareness review transaction haleons operational readiness heidrick struggles executive search services approval final issuance public documents entry committee reviewed potential conflicts associated legal agreements interest judged appropriate exercised oversight zantac product liability litigation safeguards conflicts provided regular reports board progress conducted robust review process together cfo look forward reporting progress next year 's report select appoint replacement current lead audit partner fiveyear audit partner rotation sir jonathan symonds rules rotates publication annual report nominations corporate governance committee chair details set march completion demerger highlighted report last year details technical work committee key demerger governance workstream included overseeing evolution financial reporting matters risk controls public documents associated delivering demerger listing form haleon work continued intensified first half point committee able complete review processes recommend approval gsk circular haleon prospectus form f associated documents matters board separately committee reviewed processes establish financial reporting systems development robust internal control risk management framework haleon significant critical demerger workstream successfully delivered months prior demerger businessasusual basis strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued information cyber security audit quality indicators one principal risks regularly audit quality indicators aqis quantitative qualitative committees agenda committee oversaw measures external audit quality audit firmlevel merging programme deliverables updated cyber engagement level management company maturity plan cmp additional capabilities continue perspective together lead audit partner get ahead dynamic threat environment committee pleased participate project carried frc also reviewed benchmarking target cyber identify useful engagement level aqis relevant maturity industry bestpractice framework known audit help improve transparency drive audit quality national institute standards technology cyber improvements engagement frc focused security framework nistcsf learnings recent annual report considered interactions incorporated cmp committee continue auditor committee audit perform regular assessments delivery plan process constructive dialogue one hope enhance capabilities maturity cyber helpful frc progressing work promoting key security framework pleased committees drivers audit quality oversight area strengthened year expertise fellow board director colleague committee aims dr vishal sikka advises committee enterprise committees remit expanded onwards risk vishal distinguished career tech industry board requested exercise oversight review served ceo infosys limited provides committee gsks esg data assurance work committee management valuable insights currently overseeing build implementation new dedicated esg data assurance hub finance key risk indicators organisation support several years compliance function worked hub ensure minimum standards controls risk owners management develop report governance data quality assure accuracy esg committee key risk indicators kris enterprise level data support companys performance esg across markets core part process metrics compliance new esg reporting requirements using enhancements technology data meanwhile corporate responsibility committee behalf analytics capabilities employ datadriven approach board continues exercise oversight esg strategy risk management across constantly evolving risk performance assessment reporting landscape strengthen compliance oversight culture internal control framework earlier year committee examined review board recognises obligation present fair balanced principal risks resulting simplified process fewer kris understandable assessment gsks current position new kris revised definitions prioritisation prospects reflecting responsibility accountable meaningful indicators company committee evaluating approving effectiveness gsks internal pleased note simpler approach would result controls including financial operational compliance focus fewer kris reported risk oversight controls risk management processes compliance council rocc reports ensure reliability financial reporting committee greater focus brought bear compliance laws regulations internal escalation issues concerns material gsk control framework comprehensive enterprisewide risk meanwhile operational data monitoring findings management model supports boards continuous established risks would continue analysed risk owners identification evaluation management groups ensure appropriate risk mitigation continues escalation principal emerging risks required frcs code necessary framework designed manage risk gsk achieving business objectives zantac litigation oversight year primary oversight zantac litigation fitforpurpose framework complemented corporate related accounting disclosure communication culture speak processes ensures risks assessments continued undertaken associated business activities actively effectively committee report committees conclusions controlled line agreed risk appetite believe gsks matters board committee continues receive framework provides reasonable absolute assurance regular legally privileged updates december material misstatement loss welcomed ruling united states district court southern district florida dismissed federal cases alleging five remaining cancers multidistrict litigation continue defend claims brought state level vigorously based sciencegsk annual report board committee reports continued board mandates groups rocc senior leaders authority delegated committee assist committee overseeing risk management board conducted robust assessment groups principal internal control activities also provides business risks assessment line frcs code framework risk management upward escalation included consideration nature extent risk significant risks risk management compliance boards board willing take achieving gsks strategic objectives rmcbs across group promote tone top board via committee also oversaw effectiveness establish risk culture well ensuring effective oversight internal control environment risk management internal controls risk management processes processes across group whole year principal risk assigned risk owner drawn approval date annual report senior management accountable managing review groups risk management approach principal risk oversight glt member includes discussed risk management section strategic setting implementing risk mitigation plans risk owners report pages report quarterly respective risk management approach progress rocc appropriate board management principal risk explained committee compliance function assists rocc principal risks uncertainties pages rmcbs compliance responsible advancing enterprise groups viability discussed group risk management wide risk management developing riskbased section strategic report ethically sound working practices also actively promotes ethical behaviours enabling employees operate line significant issues relating financial culture comply applicable laws statements regulations considering gsks quarterly financial results announcements audit assurance aa function provides independent financial results annual report assurance senior management board committee reviewed significant issues management effectiveness risk management groupwide line judgements determining results reviewed management agreed assurance plan helps senior management papers setting key areas risk actions taken quantify board meet oversight advisory responsibilities effects relevant issues judgements made fulfilling gsks strategic objectives building trust management appropriate accounting required address patients stakeholders aa dual reporting line issues financial statements cfo committee significant issues considered relation financial committee receives regular reports principal risk statements year ended december set owners compliance aa areas significant risk following table summary financial outcomes group related internal controls reports assess appropriate committee external auditor internal control environment within principal risk area discussed significant issues addressed committee including enhancements strengthen controls following year areas particular audit focus consideration reports committee reports annually described independent auditors report pages board effectiveness gsks internal controls strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued significant issues considered committee relation financial statements issue addressed committee going concern basis preparation committee considered outcome managements halfyearly yearend financial statements reviews current forecast net debt positions various financing facilities options available group committee also considered managements review impacts current economic environment climate change impacts following consideration assessments included stress testing viability scenarios sources liquidity funding forecasts estimates committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including returns committee reviewed managements approach timing recognition rebates rar accruals revenue accruals customer returns rebates rar accrual us commercial operations billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us commercial operations determining level accrual necessary set critical accounting policies pages provisions legal matters including committee received detailed reports actual potential litigation investigations groups internal external legal counsel including zantac litigation together commercial practices number detailed updates investigations groups commercial practices management outlined levels provision corresponding disclosure considered necessary respect potential adverse litigation outcomes also areas yet possible determine provision necessary amount december provision legal matters billion see note financial statements provisions details provisions uncertain tax positions committee considered current tax disputes areas potential risk concurred managements judgement levels tax contingencies required december tax payable liability billion including provisions uncertain tax positions recognised groups balance sheet impairments intangible assets committee reviewed managements process reviewing testing goodwill intangible assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment charge million see note financial statements intangible assets details valuation contingent consideration committee considered managements judgement necessary relation viiv healthcare increase liability pay contingent consideration primarily result updated exchange rate assumptions well increases sales forecasts unwind discount cash payments nearly billion year december groups balance sheet included contingent consideration liability billion relation viiv healthcare see note financial statements contingent consideration liabilities details viiv healthcare put option committee reviewed agreed accounting pfizer put option concurred managements judgement valuation put option billion december consumer healthcare demerger committee reviewed managements process presenting consumer healthcare discontinued operation subsequent demerger accounting gain demerger billion included significant values relating fair value assets distributed ownership haleon retained net assets noncontrolling interest distributedderecognised cumulative foreign exchange recycled see note acquisitions disposals financial statements detailsgsk annual report board committee reports continued effectiveness quality external auditors independence qualifications objectivity expertise resources audit process committee committed ensuring gsk receives committee therefore agreed recommend highquality effective external audit evaluating reappointment deloitte board forthcoming deloittes performance prior making agm making recommendation committee free recommendation reappointment early influence third party committee reviewed effectiveness performance criteria agreed management auditors reappointment beginning detailed criteria used judging external auditor effectiveness deloitte external auditor available external auditor appointment gskcom based audit approach strategy last tender may december ensuring highquality independent audit effective partnership value money transition year committee monitors engagements external first shareholder approval current may auditor stakeholders relevant committees areas oversight including frc securities exchange commission first audited annual report f year ending december year frcs audit quality review aqr team new lead audit engagement partner reviewed deloittes audit groups financial next audit tender required regulations take effect statements part annual inspection audit firms committee received reviewed final report contractual similar obligations restricting aqr team identified key findings assessed groups choice external auditor audit requiring limited improvement noted several areas good practice audit partner rotation committee sought ensure deloitte would deliver external auditor required rotate audit smooth thorough efficientlyexecuted audit engagement partner gsk every five years undertaking review committee considered current audit partner due step overall quality audit position audit gsks financial statements independence deloitte concluded whether deloitte exhibited appropriate level challenge robust review process committee together scepticism work involvement cfo select replacement deloittes length tenure taken account committee approved appointment next audit assessing independence objectivity given engagement partner effect financial year commenced role auditor however commencing january committee consider effectively assumed role committee satisfied deloitte managing auditor committee also considered feedback orderly handover new audit engagement partner external audit survey committee members ensure seamless transition maintenance high financial management team corporate levels audit quality effectiveness business unit level survey covered effectiveness auditors challenge audit tender integrity deloitte committee considers company transparency reporting management complied mandatory audit processes audit committee committee responsibility provisions competition markets authority statutory audit services order clarity auditors communications ways working alignment audit groups investment deloitte continues maintain independence systems applications products sap objectivity committee remains satisfied performance gsk intend tender external quality audit teams leadership auditor contract end current required period skills experience audit team years identified considers best interests shareholders committee mindful committee chair regularly meets independently financial year see new cfo gsk audit audit partners committee also meets auditor partner deloitte help mitigate risks privately end meeting discuss progress overfamiliarity company auditor appropriate reviewed feedback noted areas improvement implemented audit team committee satisfied effectiveness auditor external audit process strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued nonaudit services fees paid company 's auditor associates set overleaf details given note management operates presumption financial statements operating profit accountancy firms provide nonaudit services gsk however external auditors skills experience year fees auditrelated assurance make suitable supplier nonaudit support services million included million related auditrelated matters tax services may continued work year associated deloitte 's reporting used best interests company line gsks accountant role preparing demerger consumer nonaudit services policy committee ensures auditor healthcare business including audit fees respect gsk objectivity independence safeguarded reviewing pension schemes million fees auditrelated preapproving external auditors provision assurance services represent annual audit services company policy complies frcs service fee excluding demerger work revised ethical standard sarbanesoxley act quarterly review work fees auditrelated observes following core policy features engaging assurance services would represented external auditor nonaudit services annual audit fee gsk nonaudit services policy key features committee 's rationale originally hiring deloitte undertake reporting accountant role set process nonaudit services put competitive gsk 's annual report tender financial services providers line groups procurement process unless skills committee considered level nonaudit services experience external auditor make suitable incurred part annual review deloittes independence supplier set previous satisfied auditor safeguards adequate safeguards established continued independent exercised objectivity objectivity independence group audit throughout threatened compromised fee cap total fee payable nonaudit services fair balanced understandable assessment exceed annual audit fee except special circumstances would clear advantage need annual report fair balanced auditor undertaking additional work understandable one key compliance requirements companys financial statements ensure gsks annual prohibitions gsks policy includes whitelist permitted nonaudit services line relevant regulations service report meets requirement wellestablished list prohibited documented process governing coordination review preapproval nonaudit services require preapproval set groupwide contributions publication runs table ensure services approved consistent parallel process followed external auditor gsks nonaudit policy permissible services committee received summary managements approach process ensures services fall within scope services gsks annual report ensure met requirements permitted preapproved committee frcs code enabled committee represent delegation authority preapproval board confirm gsks annual report whole value preapprover fair balanced understandable provides necessary committee chair cfo information shareholders assess companys position group financial controller performance business model strategy designate group code conduct reporting lines financial controller number wellestablished policies including new code conduct available gskcom audit services comparison together details confidential speak lines reporting investigating unlawful conduct charles bancroft audit risk committee chair march audit assurance services services including tax regulatory compliance treasuryrelated services services relating consumer healthcare demerger preparation note financial statements provides details fees payable company 's auditorgsk annual report directors report directors ' powers nominations corporate governance committee reviewed register potential conflict authorisations directors powers determined uk legislation register conflicts january committee articles association contain rules reported board conflicts appointment replacement directors provide appropriately authorised process directors may appointed ordinary resolution authorisation continued operate effectively committee members resolution board provided recommended approval register conflicts appointed board director retires next annual board subsequently approved except general meeting following appointment described note financial statements related articles also provide directors required seek party transactions end financial year reelection annually annual general meeting director person closely associated material interest accordance frc 's code contract significance group company director cease director articles prohibit director voting resolution becomes bankrupt concerning appointment terms termination appointment ceases director virtue companies act articles independent advice suffers mental physical ill health board resolves company agreed procedure directors take shall cease director independent legal andor financial advice companys missed directors meetings continuous period expense deem necessary six months without permission board resolves shall cease director indemnification directors prohibited director law qualifying third party indemnity provisions defined companies act force benefit directors resigns offers resign board accepts offer former directors held office required resign board approval signature annual report directors conflicts interest change control essential contracts directors duty companies act contracts arrangements avoid situation could direct individually fundamental ability business indirect conflict interest possible conflict operate effectively neither company party company articles provide general power board material agreements would take effect altered authorise conflicts terminate upon change control following takeover bid agreements director would board reviews new potential actual conflict provide compensation loss office employment recorded company secretary directors resulting takeover except provisions counted quorum authorisation actual companys share plans may cause options awards potential conflicts nominations corporate granted plans vest takeover governance committee reviews register conflicts annual basis board subsequently approves details termination provisions executive directors service contracts given full version companys continuing basis directors responsible remuneration policy available gskcom informing company secretary new actual investors section potential conflicts may arise changes circumstances may affect authorisation previously given even provided authorisation director absolved statutory duty promote success company actual conflict arises postauthorisation board may choose exclude director receipt relevant information participation debate suspend director board last resort require director resign strategic report governance remuneration financial statements investor information gsk annual report directors report continued following information also incorporated content directors report directors report purposes uk companies act location annual report directors report gsk plc year ended december interest capitalised financial statements comprises notes publication unaudited financial group financial review directors report information section pages details longterm incentive schemes remuneration report corporate governance report waiver emoluments director applicable employee engagement waiver future emoluments director applicable directors statements responsibilities non preemptive issues equity cash applicable investor information non preemptive issues equity cash applicable strategic report sets matters required unlisted major subsidiary undertaking disclosed directors report considered parent company participation placing applicable strategic importance listed subsidiary provision services controlling applicable strategic report shareholder shareholder waiver dividends financial statements section pages notes risk management objectives policies shareholder waiver future dividends financial statements notes likely future developments company agreements controlling shareholders applicable research development activities business relationships directors report diversity drawn presented accordance provision information consultations reliance upon english company law liabilities employees directors connection report shall subject carbon emissions limitations restrictions provided law section statement approved board directors march signed behalf throughout sir jonathan symonds chair march gsk annual report remuneration section committee chairs annual statement annual report remuneration remuneration policy summary strategic report governance remuneration financial statements investor information gsk annual report remuneration report committee chairs annual statement dear shareholder engaged extensively shareholders gain views feedback changes please see table behalf remuneration committee pleased sets full details process present remuneration report includes annual statement explaining committees work year result made adjustments quantum clarity annual report remuneration summary disclosure outcomes transparency relation remuneration policy approved shareholders targets set feature final policy agm details propose operate agm new policy approved policy year shareholders voting favour committee recognises significant minority shareholders voted gsks remuneration policy following agm committee ensured continued detailed last year introduced new remuneration consultation shareholders understand full range policy better link executive remuneration delivery views including voted proposals outperformance committee thanks shareholders feedback new arrangements designed reward delivery remains committed engaging remuneration continues bold new performance ambitions set investor believe incentivising outperformance stretching update deliver sales growth targets create longterm value shareholders noting cagr adjusted operating profit growth new issues raised committee comfortable cagr ambitions represent step change required annual bonus plan change performance group achievement committee review shareholders evolving deliver top quartile performance sector needs business advance renewal remuneration policy committee concluded design existing remuneration policy framework remained fit purpose two administrative amendments remuneration however given driving longterm performance policy proposed shareholder approval consistent yearonyear improvement main aim agm details set behind targets changing shortterm annual bonus plan determined key imperative remuneration outcomes strong operating performance gsk first year main change plan significantly reduce new remuneration arrangements highlighted annual bonus opportunity belowtarget performance importance incentivising exceptional performance increasing annual bonus opportunity exceptional performance salary increase overall annual set earlier annual report group bonus opportunity increase cash reward delivered strong sales growth vaccines specialty opportunity incremental reward delivered form medicines doubledigit growth operating profit shares deferred three years earnings per share committee aware sensitivity amongst stakeholders levels executive pay remuneration policy engagement details extensive consultation committee company chairs regarding remuneration policy prior agm vote continuing engagement shareholders afterwards set investor share capital engagement events dates participation represented initial individual consultation meetings october largest november shareholders invitations november investors annual governance meeting attendance december investors followup letter annual governance meeting nonattendees setting january february investors proposed remuneration policy asking input via meeting remuneration committee company chairs letter circulated advising feedback incorporated final remuneration march investors policy submitted annual general meeting binding approval meetings held shareholders prior agm january april investors invitations november investors annual governance meeting attendance december investors meetings held agm publication annual report may meetings february principal proxy advisory firms also consulted throughout remuneration policy process included invitations annual governance meeting receipt engagement letters meetings company remuneration committee chairsgsk annual report committee chairs annual statement continued remuneration awards year reflect excellent operating performance alongside successful delivery pay performance outcome demerger consumer healthcare form haleon largest demerger europe years lti vesting outcome performance period ended december annual bonus bonus outcomes ceo cfo relative adjusted determined reference performance stretching total sales adjusted operating profit diversity equity tsr free cash flow inclusion dei targets well committees assessment individual performance specific strategic overall vesting operational measures total sales growth rate target growth pipeline innovation rate adjusted operating profit growth rate progress sales target growth rate led overall payout financial elements salary vested targets set consideration given analyst lapsed consensus hence committee comfortable payout represents exceptional performance full target range set combined assessment nature strategic operational objectives nonfinancial elements overall payout salary executive director line agreed ceo salary delivered deferred shares annual bonus focus particularly individual areas salary cfo salary delivered accountability deliver companys strategy example deferred shares ceo clear pipeline delivery objectives executives objectives also require demonstration contribution committee believes bonus outcomes appropriately leading living culture performance integrity reflect overall performance achieved full details board believes critical lever longterm value provided creation gsk longterm incentive lti awards committee reflected length investor input performance share plan psp award vested regarding appropriate esg measures focus targets set pipeline progress innovation sales one theme arose consultation possibility adjusted free cash flow relative tsr introducing metric access medicines however disappointingly nilvesting relative tsr however gsk already industry leader area strong performance metrics evidenced full deeply engrained companys culture values vesting cash flow element partial vesting committee felt necessary include pipeline progress innovation sales reflects progress specific metric incentives instead committee rd including positive data companys potential new rsv selected measures aimed specific gsk challenges vaccine strong sales products launched last opportunities environmental sustainability dei five years including shingles vaccine shingrix generated performance targets calibrated consider sales billion year number internal external reference points particular following review contextual factors including previous analyst consensus considered financial metrics payouts committee believes formulaic outcomes available committee therefore satisfied appropriately reflect performance round targets set sufficiently stretching considered experience stakeholders including shareholders employees committee salary deem necessary exercise discretion incentive awards committee agreed ceo receive relation made accordance salary increase lower average remuneration policy increase wider workforce uk addition average salary increase company remuneration policy implementation implemented number monetary nonmonetary annual bonus lti performance measures initiatives colleagues reaction cost living following changes bonus crisis explained statement maintaining performance measures incentive plans continue align strategic goals workforce fairness annual bonus measures annual total sales growth setting executive pay important committee annual adjusted operating profit growth personal good understanding groups wider workforce performance strategic operational measures pay approach emphasis fairness equity esg diversity equity inclusion dei end annual basis meet senior human lti measures relative tsr total sales growth resources leaders across company understand three years adjusted operating profit growth three perspectives pay gsks remuneration arrangements years pipeline progress esg environment wider workforce year fourth annual composite scorecard meeting held strategic report governance remuneration financial statements investor information gsk annual report committee chairs annual statement continued performance measures align strategy performance measures alignment strategy weighting ab lti total sales growth ambition sales growth adjusted operating profit growth ambition profit growth pipeline emphasis innovation rewards acceleration strengthening pipeline relative total shareholder return alignment shareholders esg ambitions nature climate ambitions dei priorities strategic operational individual accountability delivery strategy public ambitions key ab annual bonus lti longterm incentives meeting discussed gsk continues support new cfo julie browns salary preliminarily diversity aspiration fair pay processes proactive set line predecessor september reviews enhancements employee benefits salary upon joining increased included line increase agreed ceo awarded uk wider workforce new global minimum standards parental leave care family member agm review medical insured benefits focus equity finally would like thank shareholders valued sex couples wherever legally possible input engagement welcome feedback new financial education support look forward receiving support report annual general meeting may given challenging economic environment cost living pressures many countries management taken action support current employees attract talent urs rohner competitive salary increases oneoff support remuneration committee chair payments staff lower grades enhancements march workforce wellbeing programmes start changes also made annual bonus plan glt level reflect greater focus consideration potential windfall gains performance new plan generally well received committee aware guidance investor first payments made q bodies around considering potential executive benefit arising share award grants around time director changes stock market fall onset covid pandemic august dr hal barron transitioned planned march role cso nonindependent nonexecutive director remuneration policy contains sufficient flexibility dr barron contractually entitled receive prorated reduce vesting awards required target bonus respect receive lti grant however committee determined reduction required respect awards granted march also announced appointment julie brown cfo making determination committee considered may iain mackay step share price following points board previously communicated mr mackay continue share price time february award receive base salary leaves gsk end year eligible receive annual bonus respect eligible receive lti awards share price final quarter receive salary increase full details share price time march award retirement arrangements including treatment inflight lti grant previous award awards found whilst upward downward movements gsks share price period taking points consideration committee satisfied risk windfall gainsgsk annual report annual report remuneration total remuneration audited fixed pay pay performance annual bonus vested lti awards ceo cfo overall bonus overall vesting salary salary delivered shares subject twoyear holding bonus period upon vesting benefits total cash remuneration deferred shares could b pension measures vested measures total sales growth relative tsr adjusted operating adjusted free cash flow profit growth innovation sales individual strategic pipeline progress operational objectives pivotal trial starts major esg dei regulatory approvals r ead pages pages pages total remuneration audited dr hal barron former cso emma walmsley ceo iain mackay cfo july fixed pay salary benefits pension total fixed pay pay performance annual bonus vesting psp lti awards total pay performance total remuneration notes mandatory deferred annual bonus plan dabp bonus deferrals set payment shown dr barron represents prorated ontarget payment respect january july lieu annual bonus opportunity dr barron transitioned role cso nonexecutive director august salary includes basic salary earned time cso january july plus payment lieu accrued holiday taken accordance gsks standard employee us holiday pay policy nonexecutive director fees earned august december please see details psp vesting figure ceo inclusive topup award salary made may following vote favour remuneration policy companys agm award vest may final actual value received psp restated annual report psp valued based vesting prices february ads price share ads prices february main date grant respect topup award ceo share price vested amounts executive directors nothing attributable share price appreciation performance period committee exercise discretion relation vesting awards share price changes value dr hal barron illustrative award vest august accordance terms executive senior management recoupment policy actual value received restated annual report committee may specific circumstances line stated principles apply malusclawback determines appropriate following due consideration committee recovery sums paid clawback reduction outstanding awards vesting levels malus applied respect ceo cfo former cso strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued total remuneration audited continued following sections provide details element total remuneration committee implemented companys shareholderapproved remuneration policy year terms fixed performance pay fixed pay audited salary table provides analysis total benefits grossed tax received executive directors table sets base salaries executive directors last two years compared increases benefits benefits uk us workforce salary emma walmsley effective date change benefits available employees businessrelated services uk us employees april total benefits emma walmsley iain mackay january iain mackay dr hal barron benefits available employees businessrelated services w ith effect august dr barron transitioned nonexecutive director role received salary since date receives total benefits nonexecutive director fees described dr barrons base salary increased effect dr hal barron august see annual report details benefits available employees businessrelated services details salary levels provided accommodation whilst business travel benefits total benefits uk remuneration reporting regulations require notes company add executive directors total benefits represents oneoff refund accommodation costs relating items deemed tax authorities taxable benefit comprise employee benefits line policy employees may vary location role businessrelated services provided employees assist enable carry role tax authority deemed taxable benefit individual business expenses company meets tax arises therefore items shown grossed tax include business travel related business costsgsk annual report annual report remuneration continued fixed pay audited continued pensions january pension arrangements executive directors aligned wider workforce details given executive director member since pension arrangements emma walmsley pension contributions base salary matching contributions first iain mackay salary cash payment base salary lieu pension salary excess line plan rates dr hal barron july member k plan open us employees executive supplemental savings plan essp savings scheme open us executives accrue benefits k plan limits received base salary less contribution k essp equivalent total base salary bonus net bonus deferred dabp addition line wider us workforce january combined contribution rate k essp plans core contribution plus match total base salary bonus net bonus deferred dabp following table shows breakdown pension values included total remuneration calculated accordance methodology set uk large mediumsized companies groups accounts reports regulations amended remuneration regulations emma walmsley iain mackay dr hal barron janjul pension remuneration values uk defined contribution us defined benefit employer cash contributions total pension remuneration value dr hal barron deferred member us style defined benefit plan details regarding pension values dr barron set table accrued benefit ie annual pension accrued date calculated increase accrued benefit adjusted inflation multiplied reflect fact benefit received number years normal retirement age cash balance pension plan age dr barron received additional benefit retiring early accrued pension pension remuneration july december value dr hal barron pension values us funded us unfunded total strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued pay performance audited annual bonus strategic total sales adjusted operating esg diversity operational growth profit growth equity inclusion annual bonus measures annual bonus performance measures following table shows annual bonuses earned compared bonus opportunity bonus opportunity bonus outcome adjusted strategic total sales operating operational total target maximum growth profit growth measures esg bonus total bonus salary salary salary salary salary salary salary salary bonus emma walmsley iain mackay details mandatory deferral executive directors dabp bonus set dr barron received prorated ontarget payment lieu bonus opportunity transitioned nonexecutive director role august contractual payment accordance companys remuneration policy included remuneration annual bonus table financial performance measures performance target target outcome positioning weighting growth rate growth rate achieved total sales growth adjusted operating profit growth targets set following consideration analyst consensus well internal budgets annual targets exceeded longterm sales profit targets stated investor update respectively committee therefore comfortable achievement represents exceptional performance threshold maximum performance targets set target growth respectively total sales adjusted operating profit targets outcomes purposes annual bonus calculation based cer exclude commercial benefit covid solutions overview performance financial performance measures saw stepchange commercial execution earnings guidance updated year momentum grew driven strong sales growth across specialty medicines vaccines exceeding guidance sales operating profit delivered fullyear reported group sales billion aer cer specialty growth aer cer doubledigit growth across specialty therapy areas vaccines growth aer record year shingrix outcome adjusted exclude benefit covid solutions adjusted group operating profit million target driven higher sales supported prioritised investment effective cost control outcome adjusted exclude commercial benefit covid solutions adjusted eps p aer cer ahead guidance excluding covid solutionsgsk annual report annual report remuneration continued pay performance audited continued strategic operational measures performance committee received considered performance assessment report executive director showing extent achievement individual personal strategic operational measures agreed committee support delivery strategic commitments committee also reviewed dr hal barrons performance july release contractual ontarget bonus payment financial elements annual bonus committee satisfied scale executive directors achievements year exceptional nature particular achievements relate pipeline commercial execution haleon demerger strategic operational measures performance achieved emma walmsley committee determined ceo clearly exceeded met individual objectives strengthen pipeline potential new medicines vaccine candidates development phase registration build gsks reputation twothirds pipeline focused infectious diseases innovation significant progress strengthen pipeline advance key assets including rsv oa vaccine bepirovirsen gepotidican daprodustat depemokimab offset termination decisions otilimab rsv maternal continued progress development longacting hiv treatments including launch apretude hiv prevention positive data new broadly neutralising antibody nls successful business development support future growth focus vaccines specialty medicines including affinivax sierra oncology spero therapeutics demonstrate continued stepchange commercial execution doubledigit sales growth across specialty medicines vaccines commercial execution products exceeding billion annual sales including trelegy nucala benlysta dovato excellence strong momentum shingrix sales billion reflecting post pandemic rebound new geographic launches excellent commercial execution complete separation haleon successfully demerged schedule gsk july largest demerger europe years unlocked value meaningful progress value recognition prior impact market uncertainty following zantac litigation demonstrate strong sustained leading esg performance delivery global health environment inclusion diversity environmental social commitments governance esg credentials maintained sectorleading rankings key esg indices ranked number access medicines index th build trust future delivery consecutive time nd sp corporate sustainability assessment pharmaceutical industry demonstrate strong culture drove rapid ownership new culture launch roll new internal gsk code talent management leadership performance choice programmes employee engagement versus continued development succession planning leadership team tony wood appointed cso new chief financial officer designate appointed iain mackay committee determined cfo successfully met individual objectives demonstrate financial group financial targets exceeded total sales billion aer cer excl covid adjusted leadership operating margin adjusted operating profit growth aer cer excl covid adjusted eps p cer cost discipline cash prioritised investment cost discipline supported strong growth operating profit eps flow management transformation programme delivering billion annual savings end track deliver billion end cash generated operations billion free cash flow billion complete separation haleon successfully demerged schedule gsk july largest demerger europe years unlocked value meaningful progress value recognition prior impact market uncertainty following zantac litigation demonstrate strong finance tech engagement confidence culture inclusivity employee survey scores increased culture leadership versus esg diversity equity inclusion dei performance first annual bonus esg measure reinforces achievement dei ambitions set dei important business imperative aspirational targets could set warrant additional reward stay track aspirational targets diversity senior leadership committee agreed interim annual aspirational targets including global gender representation us uk race ethnicity representation interim annual aspirations agreed committee ceo internal governance team comprising members reward legal audited performance interim aspirations consideration committee interim aspirations achieved year end gender representation us ethnicity uk ethnicity vp employee population track meet aspirations addition directorates also performed strongly respective contributions aspirations however directorates achieved expected contributions aspirational targets including finance strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued pay performance audited continued vesting psp lti awards following sets performance achieved companys psp includes update performance outstanding awards line committees agreed principles actual performance measure carefully reviewed adjustments made appropriate ensure vesting outcome reflects genuine underlying business performance delivered line culture responsible business priorities overall psp award vested targets set pipeline progress innovation sales adjusted free cash flow relative tsr disappointingly nilvesting relative tsr however strong performance metrics evidenced full vesting cash flow element partial vesting pipeline progress innovation sales period significant progress achieved accelerating delivery pipeline notably companys rsv vaccine depemokimab niraparib robust oversight resulted number assets discontinued resources reprioritised focus greatest potential major approvals period included niraparib ovarian cancer sotrovimab emergency use authorization covid cabenuva hiv treatment apretude hiv preexposure prevention innovation sales period reflected particularly strong performance hiv medicines shingles vaccine shingrix outcome vesting level performance measures relative weighting performance targets outcome maximum award pipeline progress pipeline progress measure targets rewarding strengthening pipeline progression high quality assets pivotal trials achievement regulatory approvals major markets points based achievement allocated two equally weighted elements lti award threshold maximum points measure points pivotal trial starts points points points points major regulatory points points points points approval milestones innovation sales innovation sales measure recognises importance launching new products billion successfully driving performance key commercial success measure aggregates threeyear sales new innovative products launched threeyear performance period preceding two years ie innovation sales billion vesting maximum threshold adjusted free line companys agreed principles afcf figures included billion cash flow afcf adjustments number material distorting items including legal settlements performance exchange rate movements special pension contributions original revised target billion target billion vesting maximum threshold revised target adjusted since annual report noted overleaf relative tsr tsr ranking within comparator group vesting ranked th performance maximum st nd rd th th threshold median th th tsr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holdings sanofi vesting schedule based delivering vesting median performance comparator group ten companies median falls two companies total vesting respect awards gsk annual report annual report remuneration continued pay performance audited continued adjusted free cash flow afcf target revised line disclosure annual report restated take account demerger removing share target cash flows related consumer healthcare following demerger revised phasing future ready programme restructuring cash payments based detailed programme planning undertaken revised timing divestments result target decreased billion billion committee exercise discretion relation vesting awards share price changes psp vesting value granted vested vested shares emma walmsley iain mackay dr hal barron prorated vested number shares value represented vesting includes dividend reinvestments performance period based vesting price closing ads price february shares granted emma walmsley include additional topup award made may vest may final actual value received amount attributable share price appreciation performance period restated annual report psp award dr hal barron vest august terms executive senior manager financial recoupment policy performance ongoing lti awards committee also reviewed performance psp awards granted executive directors following charts provide estimate vesting levels awards taking account performance december actual vesting levels determined based performance full threeyear performance periods indications therefore regarded predictions final vesting levels afcf measure target threshold associated vesting scales awards adjusted net overall impact decrease target billion billion award adjustments took account following items removal share target cash flows relating consumer healthcare following demerger revised phasing future ready programme restructuring cash payments revised timing divestments changes measures psp award psp award ranked rd ranked rd threshold bn target target maximum maximum median bn median threshold threshold p p relative tsr innovation adjusted free relative tsr total sales adjusted esg sales cash flow pipeline growth operating pipeline progress profit growth progress commercially sensitive target published vesting estimated vesting level p pivotal trial starts major regulatory approval milestones threshold performance award vest respect performance measure individual lti award levels appear annual report set lti awards strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued pay performance audited continued lti awards dabp awards respect deferral bonus psp awards shown table dabp awards psp awards total bonus number face value award level number face value deferred shares award base salary shares award emma walmsley shares shares iain mackay shares shares dr hal barron ads face values dabp awards calculated based share price ads price closing prices february day grant nilcost options uk executive directors restricted shares us executive director performance conditions attached dabp awards reflect mandatory threeyear deferrals respect annual bonus face values psp awards calculated based share price closing price february day grant conditional shares based performance measures outlined dr barron receive psp award given transition nonexecutive director role august performance period psp awards january december awards vest maximum threshold performance dr barrons dabp award vest normal three years date granted historical vesting lti plans following table summarises lti vesting performance measure gsk last ten years relative tsr adjusted free cash flow innovation sales previously rd new product pipeline progress business diversification total vested malus clawback policy details existing policy malus clawback please refer companys remuneration policy report annual report available gskcom committee reviews discloses whether recoupment committee exercised malus clawbackdisclosure made matter subject public reports misconduct fully resolved legally permissible disclose made without unduly prejudicing company therefore shareholders line disclosure guidelines neither committee recoupment committee exercised malus clawback administrative amendment proposed malus clawback section remuneration policy shareholder approval agm described policies details existing policies recruitment remuneration loss office termination payments please refer remuneration policy report pages annual report available gskcomgsk annual report annual report remuneration continued directors pay wider setting internal context remuneration structure employees compared executive directors glt element wider workforce pay comparison executive director glt pay salary market competitiveness base salaries across executive directors glt following company assessed local market level performance review increases base salaries competitiveness roles measured considered line market practice average external market internal peers kept increase wider employee population regular review comparotor tools increases may also made reflect change increases may also made reflect change scope scope individuals role responsibilities individuals role responsibilities experience experience agreeing increases executive directors glt committee mindful multiplier effect individuals total remuneration pensions company seeks provide appropriate executive directors glt eligible receive pension benefits package aligned benefits broadly line policy benefits competitive market practices countries employees may vary location company operates pension arrangements structured accordance employees based executive director glt member expected retire current future executive directors pension arrangements aligned wider workforce location since january annual exception sales force participate executive directors glt participate plan bonus separate arrangements wider workforce based assessment combination stretching participates plan based performance financialbusiness esg dei personal objectives four business financial measures executive directors bonus salary structured reflect priorities specific paid cash shares deferred three business area years bonus earned excess plan designed reward employees maximum salary would delivered fully collective contribution business achievement shares deferred three years separate mechanisms place recognise glt members bonus salary paid outstanding individual performance address cash shares deferred three years underperformance bonus earned excess maximum salary would delivered fully shares deferred three years clawback andor malus provisions apply lti plans employees senior vice president svp executive directors glt granted annual vice president vp level participate psp psp awards performance targets executive directors glt periods employees performance targets periods executive directors required hold vested awards clawback andor malus provisions apply additional twoyear period svp vp employees together directors clawback andor malus provisions apply managers glt receive annual share executive directors glt receive share value plan awards restricted shares value plan awards following appointment allemployee share plans dilution limits uk executive directors may participate majestys awards made plans incorporate dilution revenue customs approved allemployee share plans along limits consistent guidelines published wider uk workforce namely companys share save investment association ia limits rolling share reward plans tenyear period plans rolling tenyear period executive share plans granted senior executives participants companys share save plan may save estimated dilution existing awards made last ten month three years end period years december follows option buy gsk shares discount share price start savings contract gsk employee share plans participants share reward plan contribute month purchase gsk shares company matches one one basis details see executive share plans actual limit strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued directors pay wider setting continued ceo pay ratios option methodology lower quartile median upper quartile pay ratios calculated using actual earnings financial year p p p ceo uk employees ceos total single figure remuneration detailed total remuneration uk fulltime equivalent employees december calculated line single gsk continues use option methodology figure methodology reflects actual earnings received robust statistically accurate way calculate excluding business expenses used three ratios options available remuneration produce percentile calculation option regulations pay ratio broadly similar remuneration regulations business expenses reduction p influenced change workforce excluded reimbursed employees composition following consumer healthcare demerger sufficiently substantial value significantly impact ratios table shows salary total pay benefits percentiles p p p salary total pay benefits committee believes median pay ratio consistent companys pay reward progression policies base salaries employees including executive directors set reference range factors including market practice experience performance role supplemental additional ratios relative importance spend pay ceo pay ratio likely vary potentially significantly table shows total employee pay groups dividends time since driven largely ceo variable pay outcomes paid shareholders line reward principles ceo larger portion change pay based performance individuals p p total employee pay p means depending gsks performance dividends paid year ratio could increase decrease significantly figures table reflect payments made committee believes senior executives year impact movements exchange significant proportion pay linked directly performance rates set pages however cash light also provided supplemental ratios dividends declared respect million lti compensation excluded million decrease please see note believe provides additional view ltis formed financial statements details substantial percentage ceos total remuneration total employee pay based employees average highly variable dependent business performance number people employed please ceos total remuneration excluding lti compensation see note financial statements details share repurchases made company ceo pay ratios less lti awards option methodology financial year p p p gsk annual report aannnnuuaall rreeppoorrtt oonn rreemmuunneerraattiioonn ccoonnttiinnuueedd directors pay wider setting continued external context comparator groups tsr performance graph committee used two pay comparator groups following graph sets performance company considering executive pay european cross relative ftse index global pharmaceutical industry comparator group primary comparator group performance comparator group tenyear period used ceo cfo global pharmaceutical december indices selected comparison comparator group secondary group ceo purposes reflect primary index gsk also used measure relative tsr performance constituent industry operates european crossindustry comparator group roche holding ag linde deutsche telekom novartis sanofi kering lvmh astrazeneca heineken anheuserbusch inbev diageo basf unilever siemens vinci sap christian dior adidas loreal inditex bayer novo nordisk bat safran airbus volkswagen reckitt benckiser global pharmaceutical comparator group france us sanofi abbvie amgen switzerland novartis bristolmyers squibb roche holdings eli lilly johnson johnson uk merck co astrazeneca pfizer abbvie amgen included remuneration benchmarking included relative tsr comparator group target ceo total remuneration positioning reviewing ceos remuneration committees gsk total return gsk pharma peers ftse total return index total return index primary comparator group european crossindustry index comprises astrazeneca bristolmyers squibb eli lilly johnson comparator group also references pay global johnson merck co novartis pfizer roche holdings sanofi pharmaceutical comparator group historic ceo remuneration european emma walmsley crossindustry group total remuneration global maximum pharmaceutical group annual bonus award vesting lti awards lower quartile median upper emma walmsleys sir andrew witty median quartile current position remuneration includes salary expected value incentives based total remuneration committees agreed benchmarking methodology maximum annual bonus award vesting lti awards emma walmsleys total remuneration includes pay period january march became ceo sir andrew witty received prorata payment lieu variable bonus opportunity accordance remuneration policy psp dabp awards sir andrew witty granted vest april accordance terms executive financial recoupment policy strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued implementation remuneration policy fixed pay pay performance salary annual bonus committee aware sensitivity amongst changes operation annual bonus plan stakeholders levels executive pay reviewing full details policy please refer pages executive directors salary considered average increases annual report awarded employees level executive directors mindful multiplier effect increases bonus opportunity salary base pay due consideration wider economic target maximum context individual performance market positioning emma walmsley agreed appropriate award increases iain mackay wider workforce ceo equivalent first salary deferred portion year addition average salary increase excess deferred full company implemented number monetary weighting performance measures initiatives colleagues wider workforce reaction adjusted strategic esg diversity cost living crisis found pages total sales operating operational equity growth profit growth measures inclusion emma walmsley base salary change iain mackay wider workforce inevitably targets linked directly financial strategic emma walmsley plan commercially sensitive committee iain mackay consider appropriate disclose annual bonus targets based average increase budget employees level glt year may result competitive harm however details uk performance targets usual disclosed known leaver december mr mackay eligible receive salary increase retrospective basis annual report benefits deferred annual bonus plan dabp significant changes provision benefits awards proposed table provides details mandatory deferral full details policy relation benefits please refer dabp annual bonus payments remuneration policy report associated awards granted shares awarded annual report performance conditions must held three years regardless continued employment pension total bonus deferred dabp awards table provides overview pension shares shares arrangements executive director emma walmsley executive directors pensions reduced align iain mackay wider uk workforce effective january performance share plan psp awards new executive directors pension aligned table provides details awards granted appropriate wider workforce appointment psp pension contribution salary shares emma walmsley base salary contribution defined emma walmsley iain mackay contribution plan matched contributions first salary accordance terms plan lti performance measures base salary cash payment lieu measures weightings awards remain pension contribution salary excess unchanged used awards weightings five lti measures base salary cash payment lieu lti measure measure weighting pension contribution innovation pipeline progress performance relative tsr total sales growth adjusted operating profit growth trust esg environment gsk annual report annual report remuneration continued implementation remuneration policy continued innovation performance pipeline progress measure seeks reward acceleration relative tsr continue measured gsks strengthening pipeline based two global pharmaceutical comparator group see equally weighted elements key assets indications total sales growth adjusted operating profit growth measured threeyear performance period measures recognise importance commercial ambitions committee set targets align points allocated successful assets sub ambitions targets total sales growth measure based upon forecast commercial value peak adjusted operating profit growth commercially sensitive year sales end performance period time grant submeasures award vest follows esg environment pivotal trial starts esg environment measure based goal focuses mainly phase iii registrational trial starts nature net positive climate net zero impact may also include phase ii starts see pages targets esg performance level points payout environment measure grant based series nature goals relating water waste materials threshold nil reduction biodiversity impact climate goals threshold incorporate scope emission reduction targets carbon offsetting industrialisation green ventolin maximum esg environment measure includes six key performance measures major regulatory approvals x climate ambitions performance level points payout x nature ambitions threshold nil achieve threshold vesting six measures must met targets maximum vesting two six measures least one pipeline progress measure commercially sensitive climate one nature must exceeded time grant end performance period targets provide disclosure achieved shareholdings versus share ownership shares subject performance conditions excluded executive directors sor calculation end requirement sor audited performance period vested shares included align interests executive directors part directors sor extent performance shareholders required build maintain conditions met value holdings significant holdings shares gsk time executive calculated posttax basis directors required continue satisfy share ownership requirements sor holding sor emma walmsley iain mackay date publication first months leaving gsk less report exceed sor dr hal barron exceeded sor months leaving gsk sor prior transition nonexecutive director role august value holdings salary sor company processes place ensure salary march december executive director maintains sor leaving gsk emma walmsley executive director agrees terms sor part iain mackay service contract strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued implementation remuneration policy continued termination arrangements executive directors announced iain mackay step cfo executive director may continue employee leave company december remuneration element summary treatment annual bonus eligible receive bonuses determined committee based combination business individual performance service psp eligible receive psp awards outstanding psp dabp awards existing lti awards retained psp awards prorated time dabp deferred bonus awards awards respect bonuses deferred prior years vest normal vesting dates addition iain mackay required maintain sor accordance companys remuneration policy remuneration arrangements julie brown committee considered remuneration arrangements committee sought ensure ms brown compensated would appropriate enable company recruit likeforlike basis far possible concluding retain experienced cfo within criteria role buyout payments set companys remuneration policy sum bonus buyout equivalent ms browns given julie browns wealth experience cfo target burberry bonus period april industry agreed remuneration set march forego leaving burberry line iain mackays remuneration follows sum lti buyout equivalent aggregate value outstanding burberry ltis sip shares remuneration element notes lost leaving burberry price equivalent salary ms browns salary preliminarily set line average price shares onemonth period predecessor september ended september ii value salary upon dividend equivalents accruing shares joining higher date award departure burberry given figure line increase agreed ceo burberry ltis subject performance measure comparator group pay performance underpin discount cfo remains european applied value shares calculated crossindustry comparator group set committee agreed payments would made stages two year period follows cash amounts annual bonus ontarget bonus would equivalent maximum incremental exceptional bonus buyout onethird lti buyout performance mr mackay paid first payroll following award long term assumes expected value commencement employment gsk incentives ltis award performance shares psp onethird lti buyout paid x multiple base salary first payroll following first anniversary mr mackay commencement employment share ownership line requirement sor salary remuneration policy onethird lti buyout paid first payroll following second anniversary pension pension arrangements line wider uk commencement employment workforce accordance addition paid amount equivalent gsks commitment january lti buyout first payroll following commencement employment ms brown agreed invest benefits benefits line gsks net tax proceeds tranche gsk shares policy arrangements executives support first reasonably available opportunity subject dealing undertaking role clearance hold shares period least two years ms browns sor cfo three times base salary required build timegsk annual report annual report remuneration continued remuneration governance committee role membership statement consideration shareholder views details available incorporated committee engages regular dialogue shareholders reference report chair ceo chief people holds annual meetings gsks largest investors officer head reward group financial controller discuss take feedback remuneration policy company secretary assisted committee year practices governance matters adviser committee agm voting company undertook full commercial tender process details voting levels respect remuneration appointed willis towers watson llp wtw arrangements set independent adviser committee effect december wtw replaced pricewaterhousecoopers llp votes total votes total votes total votes withheld pwc served independent adviser december cast billion million four years total agm wtw pwc members remuneration remuneration report consultants group voluntarily operate remuneration policy code conduct relation executive remuneration consulting uk code conduct found service contracts letters appointment wwwremunerationconsultantsgroupcom table sets dates executive directors service contracts available review wtw provided additional market data committee companys registered office gskcom exception hr consulting services company prior julie brown whose contract available gskcom appointment independent committee advisers following appointment executive directors service year addition providing consultancy services contract contains month notice period committee pwc also provided consulting assurance services company prior wtws appointment date contract effective date expiry date emma walmsley line protocols agreed set committee iain mackay na chair wtw pwc provided advice julie brown na committee satisfied advice objective independent respective tenures nonexecutive directors letters appointment pwc wtw provided independent commentary available view companys registered office matters consideration committee updates nonexecutive director expected serve board market practice legislative requirements end agm following third anniversary appointment subject election subsequent committee also reviewed potential conflicts annual reelection subject mutual agreement interest judged appropriate safeguards expected serve three years nine conflicts wtws pwcs fees advice years appointment line provisions frcs period charged time uk corporate governance code subject annual reelection materials basis respectively committee satisfied fees compromise either firms independence strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued remuneration governance continued committee focus items discussed remuneration policy prepared agreed proposed remuneration policy committee sets remuneration policy remuneration impact consumer healthcare demerger shareholder approval determines shareholder advisory body engagement new remuneration remuneration executive directors chair policy see details corporate officers line policy review consideration shareholder proxy adviser feedback amendments proposed remuneration policy following careful consideration shareholder feedback continued engagement shareholders salary review executive director glt benchmarking competitiveness committee periodically reviews considers gsk comparator groups remuneration environment executive directors glt glt company secretary salary review recommendations approves appropriate annual adjustments necessary regard performance market executive director salary review recommendations positioning remuneration wider workforce setting remuneration julie brown new cfo review company chairs fee annual bonus ceo executive directors glt bonus recommendations committee responsible setting specific ceo executive directors bonus objectives performance measures annual bonus proposed new annual bonus performance measures aligned assessments performance measures june investor update commitments lti plans lti performance outcomes award vesting ceo committee responsible approving lti plan rule executive directors glt changes grants assessments performance confirmation lti grants ceo executive directors glt vesting lti awards executive directors glt including interim awards proposed new performance conditions aligned june investor update commitments governance areas focus remuneration considerations committee programme committee adheres robust remuneration review terms reference governance framework ensuring alignment committee evaluation annual review internal actions external reportingcompliance remuneration report requirements confirmation group budget remuneration purposes agm remuneration report feedback external remuneration environment performance target disclosure incentive plans remuneration report disclosures including ceo pay ratio annual governance meeting key committee messages committee chair consultation employee representatives setting pay wider workforce pay practices remuneration adviser tender processgsk annual report annual report remuneration continued nonexecutive directors fees chair nonexecutive directors company aims provide chair non executive directors fees competitive paid companies equivalent size complexity subject limits contained articles association chairs fees chairs fee set per annum nearly four years ago september first appointed board remained unchanged since time review independently sourced data committee january agreed appropriate increase fees january increase rate originally set chair invested approximately pretax fees notional shares gsk ned share allocation plan ned plan since september invests approximately net fees purchase gsk shares nonexecutive directors fees nonexecutive directors fees applied set table per annum standard annual fee supplemental fees chair audit risk committee senior independent director scientific medical experts chairs remuneration corporate responsibility science committees workforce engagement director science committee members undertaking significant additional responsibilities behalf gsk support rd nonexecutive director undertaking intercontinental travel meetings per meeting standard annual fee nonexecutive directors standard nonexecutive director annual fee last increased following review independently sourced data recognising everincreasing workload nonexecutive directors agreed appropriate increase standard annual fee per annum january view simplicity creating greater transparency overall standard nonexecutive director fee based review independent data going forward intercontinental travel allowance per meeting added standard fee ordinarily nonexecutive directors expected travel overseas attend two meetings per year expect receive two travel allowance payments totalling chair receive allowance amount added nonexecutive director standard fee january bringing total standard fee nonexecutive director share ownership requirement following approval new remuneration policy last agm july agreed implement minimum non executive director share ownership requirement sor least one times annual standard fee chairs fee maintained retirement board chair nonus based nonexecutive directors newly appointed nonexecutive directors commenced purchasing shares ads market towards new nonexecutive director sor september us nonexecutive directors began purchasing ads towards sor january shareholder approval sought agm administrative amendment nonexecutive director section remuneration policy allow notional shares ads previously allocated nonexecutive director plan delivered chair nonexecutive directors time committee board considers appropriate applicable tax withholding would subject chair nonexecutive directors undertaking hold shares ads retire board change give company greater operational flexibility also reduce administrative burden operating nonexecutive director plan ensure chair nonexecutive directors directly maintain meaningful prudent level investment closer aligns interests shareholders company expect make significant changes fee structure nonexecutive directors remainder remuneration policy period strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued total fees audited audited table sets value fees benefits received nonexecutive directors form cash shares ads details ned plan set nonexecutive directors fees paid currency sterling converted using average exchange rate reviewed time time average exchange rates updated nonexecutive directors fees converted us dollars using exchange rate benefits comprise grossed cash value travel subsistence costs incurred normal course business relation attendance board committee meetings fulfilling role nonexecutive directors nonexecutive directors fixed fees fixed fees emoluments audited cash sharesads benefits total pay cash sharesads benefits total pay sir jonathan symonds elizabeth mckee anderson charles bancroft dr hal barron dr anne beal dr hal dietz dr jesse goodman urs rohner dr vishal sikka retired directors vindi banga dame vivienne cox lynn elsenhans dr laurie glimcher r etired board july r etired board october gsk annual report annual report remuneration continued directors interests shares audited executive directors interests shares interests executive directors company office persons closely associated pca shown table december unvested share plan interests beneficial subject total directors interests interests subject performance performance march december sharesads sharesads options sharesads shares emma walmsley iain mackay ads dr hal barron total directors interests includes beneficial interests unvested share plan interests subject performance emma walmsley iain mackay balance march includes sharesads awarded psp dabp vested february less sold satisfy tax liabilities vested amounts relevant ads awarded psp dabp dr hal barron vest august accordance terms executive senior management recoupment policy executive directors shareholdings sor outlined b eneficial interests includes sharesads held executive directors pcas emma walmsley includes shares purchased gsk share reward plan iain mackay currently participate share reward plan us employee dr hal barron eligible participate share reward plan open uk employees dr barrons beneficial interests include ads notional ads held way investments gsk k plan executive supplemental savings plan essp details dr barrons membership plans found u nvested sharesads subject performance represent psp sharesads vested subject additional twoyear holding period unvested ads subject performance dr barron also represent bonus deferrals described note unvested options subject performance represent bonus deferrals dabp awarded nilcost options described note figure excludes options held emma walmsley gsk share save plan unvested sharesads subject performance represent unvested psp awards vested unexercised options none directors hold vested unexercised options abp table shows bonus deferrals subsequent reinvestment dividends dabp amounts represent gross sharesads balances prior sale sharesads satisfy tax liabilities vesting uk employees bonus deferrals dabp granted nilcost options emma walmsley iain mackay dabp bonus deferrals march december january shares emma walmsley iain mackay ads dr hal barron options exercised following table sets details options including nilcost options dabp exercised executive directors iain mackay exercise options year number shares date market price type award date grant option exercise grant price exercise gain exercise emma walmsley deferral award dabp share save respect nilcost options awarded dabp bonus deferred executive director recorded remuneration annual bonus total remuneration table respect number shares option includes initial award amount together reinvested dividends accrued date exercise respect options gsk share save plan remuneration receivable executive director calculated date options first vest remuneration difference amount executive director required pay buy shares total value shares vesting date executive director chooses exercise options vesting date subsequent increase decrease amount realised due movements share price vesting date date exercise increase decrease value result investment decision executive director recorded remuneration strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued directors interests shares audited continued nonexecutive directors interests shares interests nonexecutive directors company office persons closely associated pca shown table share allocation plan nonexecutive directors total directors interests number sharesads beneficial interests december december dividends december elected reinvested adjustments allocated march date date date share january retirement retirement year end retirementconsolidation year shares sir jonathan symonds vindi banga dame vivienne cox urs rohner ads elizabeth mckee anderson charles bancroft dr anne beal dr hal barron dr hal dietz lynn elsenhans dr laurie glimcher dr jesse goodman dr vishal sikka otal directors interests include beneficial interests notional sharesads received part fees ned plan dividends received notional sharesads ned plan year january converted notional sharesads january beneficial interests includes sharesads held nonexecutive directors pcas n otional sharesads allocated year ned plan includes dividends reinvested year ii reinvestment demerger amount equivalent value haleon plc sharesads attributable nonexecutive directors notional allocation gsk plc sharesads see note align closely possible treatment nonexecutive directors respect ned plan allocations shareholders demerger share consolidation ned plan allocations adjusted follows amount equivalent value haleon plc shares ads attributable nonexecutive directors notional holding gsk plc sharesadss reinvested increase notional allocations gsk plc sharesads july b notional gsk shareads allocations ned plan including allocations arising consolidated ratio four new notional gsk sharesads every five notional gsk sharesads held july vindi banga dame vivienne cox lynn elsenhans retired board july dr laurie glimcher retired board october gsk annual report annual report remuneration continued percentage change remuneration directors percentage change percentage change percentage change salaryfee benefits bonus salaryfee benefits bonus salaryfee benefits bonus uk employees executive directors emma walmsley iain mackay dr hal barron nonexecutive directors sir jonathan symonds elizabeth mckee anderson charles bancroft dr hal barron dr anne beal dr hal dietz dr jesse goodman urs rohner dr vishal sikka retired nonexecutive directors vindi banga dame vivienne cox lynn elsenhans dr laurie glimcher table provided accordance schedule companies directors remuneration policy directors remuneration report regulations uk employee population considered relevant comparison closely reflects economic environment encountered majority executive directors percentage changes calculated based total remuneration table executive directors total fees table nonexecutive directors increases benefits nonexecutive directors due increased travel costs following return inperson meetings postcovid information executive directors salary benefits found dr hal barron transitioned nonexecutive director role august fees nonexecutive directors include fees received cash form shares ads terms ned plan see details nonexecutive director changes year directors senior management information provided compensation interests directors senior management group group purpose group defined executive nonexecutive directors members glt company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate decrease accrued pension benefits net inflation aggregate payments defined contribution schemes members group awarded shares ads companys various lti plans set table align interests senior management shareholders executive directors glt members required build maintain significant holdings shares gsk time glt members required hold shares equivalent multiple two times base salary must continue satisfy share ownership requirements minimum months leaving gsk awards dividend reinvestment awards awarded shares ads shares ads performance share plan deferred investment awards share value plan n otional shares ads executive directors eligible receive deferred investment awards participate share value plan strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued directors senior management continued march group pcas following interests shares ads company interests awarded various lti plans described note financial statements employee share schemes pages interests march shares ads owned unexercised options deferred annual bonus plan performance share plan deferred investment awards share value plan n otional shares e xecutive directors eligible receive deferred investment awards participate share value plan fees respect executive directors external appointments ceo emma walmsley independent nonexecutive director microsoft corporation received delivered cash stock options microsoft corporations deferred compensation plan nonemployee directors cfo july iain mackay became independent nonexecutive director national grid plc received fees delivered cash payments past directors audited payments made past directors exception value deferred bonus accrued dividends made simon dingemans described annual report payments loss office audited loss office payments made remuneration policy continues reflect provision uk corporate governance code code clarity simplicity remuneration arrangements executive directors set clear simple way remuneration policy whilst compiling finalising remuneration policy committee consulted extensively shareholders representing issued share capital ensure full understanding views policy transparency clarity proposals would implemented fixed remuneration elements salary benefits pension closely aligned wider workforce arrangements pay performance plans annual bonus longterm incentive reward delivery financial strategic esg objectives short long term risk line code operate deferral postvesting holding arrangements addition operating malus clawback provisions committee retains discretion adjust award outcomes zero appropriate consider payout determined appropriately reflect overall position performance company predictability proportionality remuneration policy defines maximum limits total annual bonus longterm incentive opportunities payouts elements linked fulfilment performance conditions support companys publicly stated ambitions implementation maximum reward short longterm plans achievable material outperformance stated ambitions alignment culture gsks purpose strategy culture continue directly reflected performance conditions set annual bonus longterm incentive particular introduced esg measure short longterm plans currently reinforce diversity equity inclusion aspirations nature net positive climate net zero ambition share ownership requirements strengthen focus strategic aims ensure alignment interests experiences shareholders employment committee believes remuneration policy operated intended terms company performance quantum gsk annual report remuneration policy summary companys remuneration policy approved may gsks annual general meeting operated intended since approval full policy available gskcom investors section two administrative amendments companys remuneration policy proposed binding shareholder approval gsks annual general meeting described executive director remuneration policy salary provide core reward role set level appropriate secure retain high calibre individuals needed deliver groups strategic priorities operation opportunity individuals role experience performance independently formal maximum limit ordinarily salary sourced data relevant comparator groups considered increases broadly line average increases determining salary levels wider gsk workforce salary increases typically take effect first quarter however increases may higher reflect change year scope individuals role responsibilities experience salary adjustments may also reflect wider market conditions salaries normally paid currency executive geography individual operates directors home country details current salary levels set annual report remuneration performance measures overall performance individual key consideration determining salary increases benefits levels set recruit retain high calibre individuals execute business strategy operation executive director based outside uk required travel uk fulfil responsibilities executive directors eligible receive benefits line role attend board meetings may subject tax policy employees may vary location business travel expenses uk include limited car allowances provision accommodation uk although healthcare life assurancedeath service provided reality represents business expense tax treatment part individuals pension arrangements personal requires travel accommodation expenses financial advice contractual postretirement benefits included benefits business context line policy employees executive directors tax liabilities covered company grossedup may eligible receive overseas relocation allowances basis international transferrelated benefits required executive directors uk also eligible participate benefit provision tailored reflect market practice allemployee share schemes eg share save share geography executive director based reward plans subject terms different policies may apply current future executive employees directors based different country order recognise high business travel requirements opportunity role executive directors also entitled car travel formal maximum limit benefits costs exceptionally may accompanied spousepartner fluctuate depending changes provider cost individual business trips benefits include expenses incurred circumstances ordinary course business deemed taxable benefits individual details current benefits costs set annual report remuneration performance measure none strategic report governance remuneration financial statements investor information gsk annual report remuneration policy summary continued executive director remuneration policy continued pension pension arrangements provide competitive level retirement income pension arrangements provide competitive level retirement new executive directors uk receive date income appointment base salary contribution defined contribution plan operation matched contributions subject pension arrangements structured accordance relevant cap line implementation principles plans operated country individual likely members plan retire individual chooses become member base salary cash payment lieu pension pension plan cash lieu relevant pension contribution portion relevant cap contribution paid instead executive directors uk entitled either join defined contribution pension plan base salary cash payment lieu pension receive cash payment lieu pension contribution contribution individual member gsk legacy defined us benefit plan defined contribution plan alternative supplemental cash balance pension plan providing annual pension plan arrangement subsequently appointed contribution base salary less total base salary board may remain member plan bonus net bonus deferred dabp gsk k plan essp core contributions opportunity salary bonus matched contributions policy current executive directors salary bonus uk january current us executive directors base salary contribution defined contribution plan still role pension arrangements aligned matched contributions subject new executive directors arrangements follows relevant cap line implementation principles new executive directors us receive date members plan appointment base salary cash payment lieu pension gsk k plan essp core contributions contribution portion relevant cap salary bonus matched contributions salary bonus base salary cash payment lieu pension global contribution eligible appropriate equivalent arrangement excess january current uk directors still usuk arrangements role pension arrangements aligned new executive directors arrangements follows performance measures none n event change plans operated us similar treatment would provided successor arrangements introduced within market less bonus deferred dabp offset equal contribution k essp moved pension plans line wider us workforce january annual bonus incentivise recognise execution business strategy annual basis rewards achievement stretching annual financial strategic operational measures operation committee may adjust formulaic vesting outcome either ensure overall outcome reflects financial operational business targets set start underlying business performance vesting period year committee bonus levels determined clawback andor malus provisions apply described committee based performance annual report targets strategic operational measures set start opportunity year committee performance maximum bonus opportunity executive directors measures assessed committee salary target performance bonus payout financial measures nil target executive directors required defer part bonus earned performance bonus payout salary shares ads appropriate three years equivalent first salary deferred portion excess deferred full deferred bonus shares eligible dividend equivalents date vestinggsk annual report remuneration policy summary continued executive director remuneration policy continued performance measures based combination financial targets individual reason majority annual bonus opportunity strategic esg performance objectives majority based formal review performance stretching bonus assessed financial measures financial targets remainder bonus subject weighting different measures determined assessment individual performance key strategic year according business priorities details including operational measures aligned companys measures used financial year provided key objectives financial year andor assessment annual report remuneration performance esg targets annual bonus financial targets set reference selection annual bonus measures internal budget external consensus targets annual bonus designed drive achievement gsks annual financial strategic operational measures performance incentivise recognise delivery longer term business priorities financial growth share plan psp increases shareholder value compared pharmaceutical companies addition provide alignment shareholder interests retention element encourage longterm shareholding discourage excessive risk taking operation opportunity conditional awards made annually vesting dependent normal maximum award limits may granted achievement performance conditions three years psp individual one year set table subject additional twoyear holding period psp targets set reference internal budget external salary consensus targets ceo awards eligible dividend equivalents date cfo vesting release executive directors committee may adjust formulaic vesting outcome performance measures either ensure overall outcome reflects based combination financial share price related underlying business performance vesting period strategic esg performance conditions aligned companys strategic plan measures clawback andor malus provisions apply described awards vest threshold performance details annual report including performance targets attached psp respect year weightings targets psp awards provided annual report remuneration selection longterm incentive measures major adjustment calculation performance measures disclosed shareholders vesting committee selects performance measures focus executive directors longterm remuneration delivery audit risk committee chair members gsks key strategic priorities longer term addition also members remuneration committee provide input setting robust targets committee implemented number audit risk committees review groups safeguards ensure targets met sustainable way performance oversight risk factors relevant performance reflects genuine achievement targets remuneration decisions therefore represents delivery value shareholders details rationale behind performance measures performance measure impact acquisition selected calculated set divestment quantified adjusted annual report remuneration event strategic report governance remuneration financial statements investor information gsk annual report remuneration policy summary continued executive director remuneration policy continued share ownership requirements change align interests executive directors minimum executive directors required maintain shareholders required build maintain share ownership requirements end significant holdings shares gsk time first year following retirement company requirements executive director follows end second year salary ceo executive directors details policy clawback malus approach recruitment remuneration loss office termination payments please refer full remuneration policy report pages annual report available gskcom investors section differences remuneration policy executive directors employees setting remuneration executive directors employees directly consulted respect committee considers companys strategic priorities remuneration policy urs rohner committee chair prevailing market conditions global talent competitive meets senior hr representatives across business environment comparison remuneration review employee feedback dame vivienne cox executives companies similar size complexity independent nonexecutive director engages employees international reach positioning relativities pay various topics including remuneration role employment conditions across broader gsk workforce workforce engagement director board members engage employees around board meetings particular committee considers range base encouraged share views company management salary rises workforces parts gsk remuneration executive directors employed considered relevant comparison populations reflect since approval policy may board closely economic environments encountered evolved approach workforce engagement details individuals provided principles apply remuneration policy wider organisation aligned performance executive directors employees although reward systems innovation performance remuneration offered executive directors responsible business priorities culture anchored policy stronger emphasis performancerelated pay purpose performance performance system evaluates offered employees group employees need also senior people disincentivise unethical salary benefits including pension tailored working practices using clawback mechanism allows us local market recover performancerelated pay annual bonus plan applies wider employee population based business performance combination performancerelated restricted share plans apply wider employee population allemployee share plans available employees uk including hm revenue customs approved uk share save share reward plansgsk annual report remuneration policy summary continued nonexecutive director remuneration policy nonexecutive directors fees element purpose link strategy operation chairs fees provide inclusive flat formal maximum however fees reviewed annually set reference rate fee competitive review chairs performance independently sourced market data paid committee responsible evaluating making recommendations board companies equivalent size fees payable chair chair participate discussions respect complexity subject fees limits contained gsks articles association basic fees formal maximum chair fees reviewed annually set reference independently sourced data chair ceo responsible evaluating making recommendations board fees payable companys nonexecutive directors fee payment alignment shareholders fees paid cash nonexecutive directors including chair required invest least total net fees shares ads company company since replaced minimum investment requirement minimum share ads ownership requirement least one times nonexecutive directors chairs gross annual standard fees retained retirement board administrative amendment section remuneration policy proposed binding shareholder approval agm described supplemental compensate non additional fees senior independent director committee chairs scientific medical fees executive directors experts workforce engagement director role intercontinental travel chair taking company authority pay additional fee equivalent committee additional board chair supplement nonexecutive director company require significant additional responsibilities time commitment exceptional unforeseen circumstances undertaking intercontinental company authority pay additional fee nonexecutive travel directors excluding chair members science committee undertaking additional responsibilities behalf gsk support rd benefits facilitate execution travel subsistence costs nonexecutive directors incurred normal course responsibilities duties business relation meetings board committee matters gskhosted events required role overseasbased nonexecutive directors includes travel meetings uk event necessary business purposes whilst normal practice nonexecutive directors may accompanied spouse partner meetings events costs associated met company instances deemed taxable therefore treated benefits nonexecutive director approach recruitment remuneration following policy principles apply roles chair nonexecutive directors nonexecutive director seeks ensure alignment fee levels new nonexecutive directors set shareholders requirement invest company basis existing nonexecutive directors shares ads company subject local laws regulations chair event nonexecutive director different role fees set level competitive paid responsibilities appointed fee levels companies equivalent size complexity fees benchmarked set reference comparable roles paid partly shares companies equivalent size complexity loss office chair nonexecutive directors entitled receive payments respect fees loss office retire step board strategic report governance remuneration financial statements investor information gsk annual report administrative amendments remuneration policy proposed amendments clawback malus two administrative amendments companys shareholder approval sought amend clawback remuneration policy policy approved last years malus section policy expressly refer agm proposed ordinary resolutions binding companys ability update clawback policies make shareholder approval agm may policy disclosures relation clawback case required subject renewal respect remuneration given applicable regulatory requirements including recently changes purely administrative full consultation adopted securities exchange commission sec rules employees undertaken amendments new york stock exchange nyse listing standards implementing rules clawback event nonexecutive directors minimum share accounting restatement ownership requirement sec adopted new rules late require nonexecutive directors section policy nyse amongst others adopt new listing standards includes requirement nonexecutive directors including require listed company clawback erroneously awarded chair invest minimum net basic fees incentivebased compensation whenever required shares ads company policy also states prepare accounting restatement corrects error company replace requirement shares previously issued financial statement would result ads previously acquired accordance minimum material misstatement error corrected current investment requirement would continue held period left uncorrected current period new previous arrangements ii count towards expected listing standards expected become effective late minimum ownership requirement iii delivered gsk shares listed traded nyse released following nonexecutive directors chairs form ads gsk result subject new retirement board listing standards expected require clawback circumstances wider currently provided company since replaced minimum investment companys policies related sec rules also requirement set annual report require gsk make certain disclosures connection minimum share ads ownership requirement least one clawback policy annual report form f including times nonexecutive directors chairs gross annual filing copy clawback policy sec standard fees retained retirement board proposed changes clawback malus element policy intended ensure clarity expressly referring shareholder approval sought amend non companys ability update clawback policies executive directors section policy allow shares make disclosures relation clawback case ads acquired previous minimum investment required applicable regulatory requirements including requirement delivered released nonexecutive sec nyse requirements committee update director chair time board excluding current recoupment policies required meet new nyse nonexecutive director chair considers appropriate listing standards related sec disclosure requirements subject applicable tax withholding rather become effective continue held previous arrangements subject nonexecutive directors chair undertaking company hold shares ads company retire board give company greater operational flexibility reduce administrative burden implementation new minimum share ownership requirement whilst ensuring nonexecutive directors chair continue maintain meaningful prudent level investment aligns interests shareholdersgsk annual report operation scope remuneration policy remuneration policy policy set pages ii policy came effect provided terms annual report intended policy payment consistent shareholderapproved gsks executive nonexecutive directors operate remuneration policy force time agreed period three years date approval iii time relevant individual director companys annual general meeting may company opinion committee committee wrote policy principally relation payment consideration individual becoming remuneration arrangements executive directors whilst director company purposes payments taking account possible recruitment replacement includes committee satisfying awards variable additional executive director operation remuneration relation award shares ads policy committee intends policy operate terms payment agreed time award period set entirety however may due granted consideration seek change policy period performance share plan psp awards subject believes appropriate longterm terms psp plan rules award success company consultation shareholders granted committee may adjust amend awards sought shareholder approval general meeting accordance provisions plan rules includes committee reserves right make remuneration making adjustments reflect oneoff corporate events payments andor payments loss office including change companys capital structure exercising discretions available connection committee may also make minor amendments payments notwithstanding line policy regulatory exchange control tax administrative policy terms payment agreed purposes take account change legislation without agm may date companys obtaining shareholder approval amendments first shareholderapproved directors remuneration policy came effect basis preparation annual report remuneration prepared annual report remuneration approved accordance companies act large board directors signed behalf mediumsized companies groups accounts reports amendment regulations regulations accordance regulations following parts urs rohner annual report remuneration subject audit total remuneration committee chair remuneration figures executive directors including march details element remuneration salary benefits pension annual bonus longterm incentive awards nonexecutive directors fees emoluments received year directors interests shares including interests gsk share plans payments past directors payments loss office share ownership requirements holdings opinion thereon expressed remaining sections annual report remuneration subject audit pages referred within audited sections gsk annual report financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements gsk plc prepared uk gaap gsk annual report directors statement responsibilities directors responsible preparing annual report directors responsible keeping adequate remuneration report group parent company accounting records sufficient show explain financial statements accordance applicable law companys transactions disclose reasonable accuracy regulations time financial position group enable ensure group financial statements uk company law requires directors prepare financial remuneration report comply companies act statements financial year directors required also responsible safeguarding assets prepare group consolidated financial statements group hence taking reasonable steps accordance international accounting standards prevention detection fraud irregularities conformity requirements companies act international financial reporting standards ifrs group financial statements year ended issued international accounting standards board december comprising principal statements iasb directors elected prepare parent supporting notes set financial statements company financial statements accordance united pages report parent company kingdom accounting standards applicable law united financial statements year ended december kingdom generally accepted accounting practice financial comprising balance sheet statement changes reporting standard reduced disclosure framework equity year ended december supporting company law directors must approve notes set pages financial statements unless satisfied give responsibilities auditor relation financial true fair view state affairs group statements set independent auditors report profit loss period preparing financial pages statements directors required financial statements year ended december included annual report published printed select suitable accounting policies apply form made available website directors consistently responsible maintenance integrity corporate make judgements accounting estimates financial information included companys website reasonable prudent legislation united kingdom governing preparation dissemination financial statements may differ state group financial statements comply legislation jurisdictions ifrs issued iasb conformity requirements companies act current directors whose names functions listed corporate governance section annual state regard parent company financial report confirms best knowledge statements applicable uk accounting standards followed subject material departures disclosed group financial statements prepared explained parent company financial statements accordance ifrs issued iasb conformity requirements companies act give true fair view assets liabilities financial prepare financial statements going concern basis position profit group unless inappropriate presume group parent company continue business strategic report risk sections annual report represent management report include fair preparing group financial statements international review development performance business accounting standard requires directors properly select position company group taken apply accounting policies present information including whole together description principal risks accounting policies manner provides relevant uncertainties faces reliable comparable understandable information provide additional disclosures compliance specific annual report financial statement taken whole requirements ifrs standards insufficient enable users fair balanced understandable provide understand impact particular transactions information necessary shareholders assess event conditions entitys financial position companys position performance business model financial performance make assessment strategy companys ability continue going concern gsk annual report strategic report governance remuneration financial statements investor information directors statement responsibilities continued disclosure information auditor uk corporate governance code directors office date annual report board considers gsk plc applies principles confirmed complies provisions uk corporate governance code maintained financial reporting council far aware relevant audit described corporate governance section pages information companys auditor unaware board considers annual report taken taken steps ought whole fair balanced understandable provides taken director make aware information necessary shareholders assess relevant audit information establish groups position performance business model companys auditor aware information strategy confirmation given interpreted required financial conduct authoritys listing rules accordance provisions section auditor considered directors statement companies act compliance relation points uk corporate governance code specified review going concern basis pages pages contain information annual report performance group financial position cash flows annual report year ended december net debt position borrowing facilities climate related comprising report directors remuneration risks information including treasury risk management report financial statements additional information policies exposures market credit risk hedging investors approved board directors activities given note financial statements signed behalf financial instruments related disclosures assessed principal risks matters considered sir jonathan symonds connection viability statement directors chair considered appropriate adopt going concern basis march accounting preparing financial statements internal control board audit risk committee reviewed assessment risks internal control framework operates gsk considered effectiveness system internal control operation group year covered annual report date approval board directors detail review internal controls set governance report gsk annual report independent auditors report members gsk plc report audit financial statements opinion basis opinion opinion conducted audit accordance international standards auditing uk isas uk applicable law financial statements gsk plc parent company responsibilities standards subsidiaries group give true fair view described auditors responsibilities audit state groups parent companys affairs financial statements section report december groups profit year ended independent group parent company accordance ethical requirements relevant group financial statements properly audit financial statements uk including prepared accordance united kingdom adopted financial reporting councils frcs ethical standard international accounting standards international applied listed public interest entities fulfilled financial reporting standards ifrss issued ethical responsibilities accordance international accounting standards board iasb requirements confirm provided parent company financial statements nonaudit services prohibited frcs ethical standard properly prepared accordance united kingdom group parent company noted audit risk generally accepted accounting practice including frs committee report within corporate governance section reduced disclosure framework annual report disclosure provided financial statements prepared accordance note regarding fees payable groups auditor requirements companies act believe audit evidence obtained audited financial statements comprise sufficient appropriate provide basis opinion group audit scope execution consolidated balance sheet december structured approach audit reflect consolidated income statement year ended group organised well ensuring audit consolidated statement comprehensive income effective risk focused audit approach year ended summarised following areas enabled us obtain evidence required form opinion group consolidated statement changes equity year ended parent company financial statements consolidated cash flow statement year risk assessment audit planning group level ended central control common systems throughout group enabled us structure audit centrally use notes financial statements includes accounting principles policies data analytic tools allowed detailed understanding flow transactions enabling us parent company focus risk assessment design targeted audit testing procedures risk assessment procedures considered balance sheet december amongst factors impact global pandemic statement changes equity year ended climate change account balances disclosures company practices appointed partners notes financial statements includes group audit team lead global audit revised accounting principles policies operating segments commercial operations research development consumer healthcare addition financial reporting framework applied partners responsible component legal entity preparation group financial statements applicable audits country segment partners met law united kingdom adopted international accounting regularly senior segment management understand standards ifrss issued iasb financial strategy performance matters arose reporting framework applied preparation throughout year could impacted financial parent company financial statements applicable law reporting risk assessment audit planning included united kingdom accounting standards including frs consideration separation consumer healthcare reduced disclosure framework united kingdom generally business group july addition held accepted accounting practice regular meetings members internal audit internal legal counsel global ethics compliance teams understand work review reports enhance risk assessment gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued audit work performed global shared service centres controls deficiencies disclosed key audit matters section significant amount groups operational processes report mitigating controls existed allowed us cover financial reporting undertaken shared service continue take reliance controls planned centres group audit team included senior individuals audit scope addressed groups responsible global processes coordinated revenue groups profit tax audit work shared service centres inscope groups total assets group audit enable us develop good understanding endtoend processes supported material account impact climate change audit balances classes transactions disclosures within climate change potential impact group group financial statements evaluated number ways set strategic report pages effectiveness internal controls financial reporting annual report notes processes considered implications financial statements group set remainder audit work environmental goals paris climate accord audit work executed component level individual legal net zero impact climate net positive impact entities following components subject audit nature procedures well assessment effectiveness planning audit considered potential internal controls financial reporting include impact climate change groups business inscope entities consumer healthcare segment prior financial statements demerger australia belgium canada china france germany italy japan spain united kingdom united sought understand groups identification states group audit team active dialogue assessment potential impacts climate change throughout audit component audit teams risks influence groups strategy implications responsible audit work direction financial statements supervision group audit team included determining groups assessment focused impacts whether work planned performed accordance frequent extreme weather conditions water scarcity changes overall group audit strategy requirements political landscape media focus group audit instructions components propensity cause changes consumer market planned performed site visits components behaviour volatility costs availability materials overseas travel restrictions allowed satisfy resources could impact future financial performance oversight supervision appropriate performed asset valuations reviews audit working papers increased frequency length reviews depending significance risk consultation climate change specialists component continued attend planning conducted detailed risk assessment procedures across clearance meetings components inscope balances transactions determine risks audit procedures undertaken group level material misstatement financial statements parent company addition also performed applying expected impact climate change audit work group parent company financial understanding business statements including limited consolidation challenged appropriateness groups assessment groups results preparation financial statements potential impact climate change impact certain disclosures within directors remuneration report financial statements including area litigation provisions exposures addition entity level intangible assets described section report oversight controls relevant financial reporting used assessment impact climate change components legal entities annual revenue greater challenge groups assessment going concern total group revenue included including considering potential impact future audit scope components legal entities covered performance availability financing audit scope subject analytical procedures confirm conclusion significant risks part audit procedures required read material misstatement aggregated financial consider disclosures consider whether information materially inconsistent financial statements knowledge obtained audit identify internal controls testing approach tested material inconsistencies result procedures effectiveness internal controls financial reporting across inscope entities including consumer healthcare segment predemerger entity level controls application materiality group level common systems allowed relevant define materiality magnitude misstatement controls tested centrally across components financial statements makes probable economic consumer healthcare demerger impacted relevant systems decisions reasonably knowledgeable person would prior demerger reflected scope changed influenced use materiality planning testing able place reliance controls scope audit work evaluating results work planned efficient notwithstanding itgsk annual report independent auditors report continued report audit financial statements continued based professional judgement determined set performance materiality level lower materiality financial statements whole follows materiality reduce probability aggregate uncorrected undetected misstatements exceed parent company group financial statements financial statements materiality financial statements whole group parent company performance materiality set materiality million million million million group parent materiality respectively audit basis determining benchmark materiality determining performance materiality determining materiality considered determined using considered factors including materiality metrics used investors total assets risk assessment including assessment groups readers financial benchmark capped statements particular group overall control environment consider considered statutory profit materiality appropriate rely controls number business tax adjusted profit materiality represents processes tax revenue net cash flows total assets operations past experience audit indicated low using professional judgement number corrected uncorrected misstatements determined materiality identified prior periods million materiality reduced compared prior agreed audit risk committee would year predominantly due report committee audit differences excess lower benchmarks resulting million million well differences consumer healthcare threshold view warranted reporting qualitative demerger removed impact gilead settlement grounds also report audit risk committee million received q disclosure matters identified assessing determining profit overall presentation financial statements tax benchmark nonrecurring item reflective underlying trade conclusions relating going concern due size would distort auditing financial statements concluded materiality directors use going concern basis accounting benchmarks preparation financial statements appropriate continuing operations considered evaluation directors assessment groups relevant users parent companys ability continue adopt going financial statements concern basis accounting included metric enquiries group directors management regarding statutory profit tax assumptions used going concern models including adjusted profit potential impact climate change tax revenue evaluating groups existing access sources net cash inflow financing including undrawn committed bank facilities operating activities including impact changes interest rates reconciliation statutory profitability profit tax adjusted profit tax detailed adjusting reading analyst reports industry data external items section strategic report information determine provided corroborative rationale given importance parent company contradictory evidence relation assumptions used metrics used investors holds groups benchmark readers financial investments comparing forecasted sales recent historical financial applied statements concluded profit information statutory profit tax oriented strength primary benchmark balance sheet testing underlying data generated prepare adjusted profit tax key measure forecast scenarios determined whether revenue net cash inflow financial health adequate support assumptions underlying operating activities important forecast used supporting benchmarks shareholders since component materiality primary concern evaluating groups disclosures going concern allocated inscope parent company requirements ias components ranged payment million million dividends using based work performed identified range materiality allocated benchmark total material uncertainties relating events conditions assets therefore across components including individually collectively may cast significant doubt appropriate metric parent company audit groups parent companys ability continue going prior years group financial concern period least twelve months statements financial statements authorised issue million million gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued relation reporting group applied uk responsibilities responsibilities directors corporate governance code nothing material add respect going concern described relevant sections draw attention relation directors statement report accounting financial statements whether directors considered appropriate adopt going concern basis accounting key audit matters key audit matters matters professional judgement significance audit financial statements current period include significant assessed risks material misstatement whether due fraud identified matters included greatest effect overall audit strategy allocation resources audit directing efforts engagement team included two additional key audit matters consumer healthcare demerger valuation contingent liabilities significant legal proceedings reflects additional audit effort required year relation matters addressed context audit financial statements whole forming opinion financial statements whole provide separate opinion matters key audit matter description scope audit responded key audit matter valuation viiv healthcare shionogi contingent audit procedures performed consideration liability performed following audit procedures amongst others group completed number significant related sales forecasts transactions resulted recognition material obtained groups assessment key inputs contingent consideration liabilities key source assumptions used forecasts challenged estimation uncertainty significant reasonableness including enquiries key liabilities viiv healthcare shionogi contingent individuals senior leadership team commercial consideration liability viiv ccl strategy team key personnel involved budgeting group completed acquisition remaining forecasting process inspection supporting evidence interest shionogiviiv healthcare joint venture challenged us volume assumptions made group upon completion group recognised contingent estimate sales forecasts involved benchmarking forecast consideration liability fair value expected market share data external data total future payments made shionogi december prescription volumes new patient prescription volumes liability valued million order assess sources contradictory evidence identified viiv ccl key audit matter challenged reasonableness us pricing assumptions significant estimates assumptions relating group comparing forecasted returns sales forecasts used valuing viiv ccl rebates rate product current rate sensitivity valuation inputs assessing forecasted returns rebates significant relate sales forecasts united comparable products considering expected changes states us certain products treatment portfolio payer policy healthcare reform implications forecasts based assessment expected launch dates ability shift market practice considered results clinical studies undertaken year prescriber behaviour towards longacting injectable group key competitors order assess whether treatments drug regimens impact healthcare corroborative contradictory assumptions used reform subsequent sales volumes pricing product portfolio sales forecasts us incremental challenge forecasting sales associated benchmarked groups sales forecasts recently launched products due lack historical included reports nine analysts considered sales actual data forecasts also required significant audit forecasts total viiv basis individual product effort perform appropriate audit procedures challenge basis assessing identified contradictory data evaluate reasonableness forecasts tested controls key inputs assumptions used contingent consideration liabilities including viiv ccl valuation contingent consideration liability disclosed key source estimation uncertainty including review controls sales forecasts note group financial statements treatment product portfolio used value viiv ccl disclosures provided notes matter also discussed audit risk committee report within key observations communicated audit risk committee corporate governance section annual report sales forecasts used valuation reasonable line relevant supporting information satisfied sales forecasts appropriately reflect trends overall hiv treatment prevention markets including impacts competition healthcare reform predicted shifts towards longacting injectable products approach valuing viiv ccl consistent prior periods overall satisfied valuation liability reasonable consistent ifrsgsk annual report independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation us returns rebates rar accruals audit procedures performed us group sells customers various performed following audit procedures amongst others commercial government mandated contracts related estimates rar accruals reimbursement arrangements include rebates challenged assumptions selection utilisation rates chargebacks right return certain pharmaceutical focusing certain products concluded products revenue recognition reflects grosstonet accrual sensitive assumptions challenge sales adjustments adjustments known included comparison historical utilisation rates returns rebates rar accruals source consideration historical accuracy drivers market significant estimation uncertainty could changes impact competition material impact reported revenue macroeconomic trends us commercial operations million rar supplemented substantive analytical procedures deductions made gross revenue million developing independent expectation accrual resulting net revenue million balance sheet balance key segments based historical accrual december us commercial operations claims received adjusted reflect market changes amounted million period including assessment time lag four significant payer channels also referred initial point sale claim receipt compared buying groups rar accrual relates independent expectation recorded evaluate managed healthcare organisations medicaid ryan white appropriateness year ending accrual position medicare part considered historical accuracy estimates two main causes significant estimation uncertainty evaluated whether forecast assumptions appropriately updated selection cases utilisation rate portion total sales actual rebate claims differed amount accrued made payer channel estimated group recording accruals utilisation assumption evaluated appropriateness completeness challenging key assumptions used periodend adjustments liability made part derive accrual given influenced market ongoing review estimated accrual demand factors outside control group tested key controls estimation rar accruals including controls associated forecasting time lag point sale point utilisation rates process monthend accrual review exact rebate amounts known group upon controls receipt claim payer channels longest key observations communicated audit risk committee time lag result greater accrued period therefore greater level estimation uncertainty estimating satisfied estimated liability rar accruals period end accrual yearend appropriate observed level prudence estimate assessing level estimation uncertainty also impacted independent expectations accordance significant shifts channel mix driven changes requirements ifrs revenue contracts customers competitive landscape including competitor generic limit risk significant reversal revenue product launches macroeconomic factors focus utilisation assumptions products deem level estimation uncertainty significant furthermore auditing standards presume significant fraud risk exists revenue recognition line presumption also focus periodend adjustments made rar accruals adjustments reflected updates made initial assumptions included within forecasted rar rates view present greatest opportunity fraud revenue recognition notwithstanding existence internal controls us commercial operations returns rebates disclosed key source estimation uncertainty note group financial statements disclosures provided note matter also discussed audit risk committee report within corporate governance section annual report gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation intangible assets audit procedures performed december group held million performed following audit procedures amongst others intangible assets including licenses patents related future sales pricing volume growth rates trademarks trade names excluding goodwill probability technical regulatory success profit margin computer software includes million levels discount rates used assessment intangible assets acquired part business combinations valuation intangible assets sierra oncology inc affinivax inc year inquired key individuals corporate impairment charges million development team commercial forecasting leads key recorded personnel involved assets research development individual intangible asset intangible asset process discuss evaluate groups evidence forms part cashgenerating unit impaired support future pricing volume sales growth rates carrying amount exceeds recoverable amount probability regulatory technical success recoverable amount intangible assets relies evaluated key inputs assumptions applied estimating certain assumptions estimates future trading sales profit margin forecasts including benchmarking performance create estimation uncertainty forecasts external market data included future trading performance intangible assets includes independent market research therapeutic area price points key assumptions sales pricing volume growth rates price growth rates anticipated competitor market probability technical regulatory success landscape currently time forecast regulatory ongoing clinical trials includes assumptions timing approval plus assessment sources contradictory cash flows determined anticipated launch year peak evidence year sales subsequent sales erosion due generic product inspected independent research literature consider competition profit margin levels addition due corroborative contradictory evidence assess impact uncertainty driven ongoing global assumptions probability technical regulatory success macroeconomic volatility valuation intangible assets also affected discount rate assumptions made compared forecast sales profit margin levels group plan data asset asset internal forecasts approved gsk leadership team board directors identified valuation intangible assets indevelopment intangible asset forecast launch within key audit matter due inherent judgements involved next year period estimating future cash flows auditing assumptions estimates required extensive audit effort challenge assessed historical accuracy sales forecasts evaluate reasonableness forecasts judgements performing retrospective reviews across marketed assets within business disclosures relating intangible assets including acquired part business combinations considered whether events transactions occurred included note group financial balance sheet date reporting date affect statements matter also discussed audit risk conclusions reached carrying values assets committee report within corporate governance section associated disclosures annual report engaged internal fair valuation specialists ifvs assess reasonableness discount rates valuation methodology applied tested review controls key inputs assumptions used valuation intangible assets controls encompass review valuation models contain number assumptions probability technical regulatory success launch dates plus revenue cost assumptions number assumptions revenue growth rates profit margins key observations communicated audit risk committee intangible assets acquired period part sierra oncology inc affinivax inc business acquisition although identified control deficiencies concluded complex assumptions underpinning fair value intangible assets reflected purchase price allocations reasonable accordance ifrs intangible assets indevelopment subject impairment reviews concluded judgements made directors reasonable accordance ifrs satisfied controls intangible assets designed operating effectively control deficiencies identified mitigated compensating controlsgsk annual report independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation uncertain tax positions including transfer pricing audit procedures performed group operates numerous jurisdictions support tax specialists assessed open tax transfer pricing matters exposures appropriateness uncertain tax provisions performing uk us overseas tax authorities give rise following audit procedures amongst others uncertain tax positions wide range possible assessed challenged provisions uncertain tax outcomes provisions contingencies certain positions evaluation possible outcomes judgements respect estimates tax exposures procedures focused jurisdictions contingencies required order assess adequacy group greatest potential exposure tax provisions sometimes complex result highest level judgement required considerations required multiple tax laws regulations assessed assumptions judgements required determine range possible outcomes recognition december group recorded provisions measurement uncertain tax positions compliance million respect uncertain tax positions requirements ifric valuation uncertain tax positions disclosed key involved transfer pricing specialists evaluate source estimation uncertainty note group transfer pricing methodology group associated financial statements disclosures included approach provision recognition measurement note matter also discussed audit risk committee report within corporate governance section considered evidence actual results annual report recent tax authority audits enquiries thirdparty tax advice obtained group tax specialists knowledge market practice relevant jurisdictions tested key controls preparation review reporting judgmental tax balances transactions include provisions uncertain tax provisions key observations communicated audit risk committee satisfied estimates relation uncertain tax positions related disclosures accordance ifrs work concluded consistent approach applied estimating uncertain tax provisions whilst continuing prudent required ifric appropriate supportable gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter consumer healthcare demerger audit procedures performed set note july gsk plc separated performed following audit procedures amongst others consumer healthcare business gsk group form related consumer healthcare demerger haleon independent listed company separation consulted technical accounting specialists evaluate effected way demerger gsks entitys accounting conclusions respect relevant holding consumer healthcare business gsk accounting standards demerger steps including shareholders gsk retained haleon held scottish limited partnership structures slps presentation consumer healthcare results part recognised equity investment set note discontinued operations group derecognised net assets liabilities calculation gain demerger billion recognised gain demerger billion retained stake upon demerger consumer healthcare trading results demerger date presented part discontinued recalculated gain demerger fair value operations comparative results restated consumer healthcare business demerger date consistent basis demerger date assets tested accuracy completeness perimeters liabilities consumer business demerged business inspecting legal agreements derecognised balance sheet difference recalculating cumulative exchange differences arising value net assets fair value translation foreign currency net assets demerged business recognised consolidated engaged tax specialists assess impact income statement gain demerger cumulative demerger group tax balances exchange differences arising translation consumer healthcare foreign currency net assets engaged specialists assess impact relevant previously included comprehensive income systems prior demerger consumer healthcare also recognised consolidated income statement tested key controls reporting identified demerger consumer healthcare consumer healthcare demerger including review key audit matter significant estimates approval accounting considerations accuracy related calculating gain demerger completeness transactions demerger date remeasuring retained stake upon demerger assessing cumulative exchange reserve adjustments required perimeters demerged business validating relation classification continued cumulative exchange differences arising translation discontinued operations foreign currency net assets divested businesses key observations communicated audit risk committee evaluating groups tax treatment demerger assessing impact relevant systems prior satisfied groups accounting conclusions demerger required high degree auditor judgment calculation gain demerger presentation increased extent effort including need discontinued operations respect demerger involve technical accounting tax specialists consumer healthcare business appropriate performing audit procedures accordance ifrs matter also discussed audit risk committee report within corporate governance section annual reportgsk annual report independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter systems impact financial reporting audit procedures performed systems within group form critical component audit scope driven level reliance placed groups financial reporting activities impact technology obtain sufficient audit evidence within business account balances process technology deemed relevant audit based financial data system configured automated controls identified systems impact financial reporting andor key financial reports reside within used key audit matter specialists support evaluation risks associated pervasive reliance complex technology integral technology testing design operation key business processes financial operation controls reporting testing technology deemed relevant audit reliance technology continues increase included following areas line business strategy increase general controls including user access change use automation across group management controls importance controls maintaining effective key financial reports system configured automated control environment key interdependency exists controls ability rely controls ability rely financial data system configured automated controls provide assurance completeness controls system reports accuracy relevant data migrations including gsk consumer healthcare separation activities continued remediation controls supporting application systems relevant groups financial testing remediation previously identified deficiencies reporting activities risk assessment procedures included assessment separation activities undertaken across technology impact unremediated control deficiencies determine environment part gsk consumer healthcare impact audit plan relevant audit plan separation programme adjusted include testing additional manual business process controls mitigate unaddressed risk systems impact financial reporting discussed audit risk committee report within corporate key observations communicated audit risk committee governance section annual report satisfied controls impacting groups financial reporting activities designed operating effectively control deficiencies identified remediated year end mitigated compensating controls significant progress made remediating control deficiencies relating user access change management group many layers business process controls mitigate risk associated remaining control deficiencies gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation contingent liabilities significant legal audit procedures performed proceedings performed following audit procedures group operates environment subject tested groups controls completeness significant legal administrative proceedings including provisions robustness provision product liability intellectual property tax antitrust requirements ias appropriateness judgements consumer fraud governmental regulations used determine best estimate completeness group currently exposed number regulatory accuracy data used process litigation matters current year group evaluated assessment provisions associated classified zantac litigation significant legal matter probabilities potential outcomes accordance ias due increase cases groups provision matters million december matters disclosed contingent liabilities criteria evaluated methodology data significant recognising provision ias provisions contingent judgements assumptions used valuation liabilities contingent assets met provisions appropriate context applicable financial reporting framework identified contingent liabilities significant legal proceedings key audit matter inquired inspected correspondence significant judgement required group determining groups internal external counsel assess litigation whether ias particular relation zantac matter evaluate groups significant judgements matter assumptions whether outcome result probable outflow provision made critically evaluated particularly outcome litigation uncertain groups conclusion supportive contradictory evidence subject additional court proceedings requirements ias particularly respect zantac matter determination reliable estimate made amounts obligation respect zantac matter inspected evidence presented relevant scientific studies outcomes nature extent contingent liabilities product liability litigation jurisdictions underlying significant estimation uncertainties disclosed alongside entitys assessment possible outcomes contingent liabilities significant legal proceedings ongoing future trials disclosed notes respectively key audit evaluated whether disclosures made financial matter discussed within corporate governance statements appropriately reflect facts critical section annual report accounting judgements key observations communicated audit risk committee satisfied estimation provisions contingent liability disclosures consistent requirements ias gsk annual report independent auditors report continued report audit financial statements continued information information comprises information included annual report financial statements auditors report thereon directors responsible information contained within annual report opinion financial statements cover information except extent otherwise explicitly stated report express form assurance conclusion thereon responsibility read information consider whether information materially inconsistent financial statements knowledge obtained course audit otherwise appears materially misstated identify material inconsistencies apparent material misstatements required determine whether gives rise material misstatement financial statements based work performed conclude material misstatement information required report fact summarise work relation areas information including areas upon specifically required report matters specifically required report responsibility reporting principal risks viability statement review confirmation description light knowledge set corporate governance statement gathered audit considering directors section nothing material report add processes support statements made challenging key judgements draw attention respect matters estimates consideration historical forecasting accuracy evaluating macroeconomic assumptions consider statements aligned relevant provisions code directors remuneration report report whether part directors remuneration report audited set opinions matters prescribed properly prepared disclosures specified companies act companies act section opinion made part directors remuneration report audited prepared accordance companies act strategic report directors report report whether consistent audited financial statements set opinions matters prepared accordance applicable legal requirements prescribed companies act section opinion based work undertaken course report identified material misstatements either report audit information reports light knowledge understanding group consistent audited financial statements parent company environment obtained course prepared accordance applicable audit legal requirements referenced provided limited assurance accordance international standards assurance engagements isae assurance engagements greenhouse gas emissions isae issued international auditing assurance standards board iaasb selected metrics gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued reporting information responsibility reporting alternative performance measures apms apms measures defined generally accepted opinion accounting practice gaap therefore typically included use calculation disclosure apms financial statement part annual report group use apms consistent groups published definitions adjusted profit free cash flow constant currency growth policies rates reporting financial performance use apms groups reporting results reviewed assessed calculation reporting consistent guidelines produced esma metrics assess consistency groups published definitions frc policies items appropriate balance use also considered assessed whether use apms statutory metrics apms together clear groups reporting results consistent guidelines produced definitions reconciliation apms used regulators european securities markets authority financial reporting esma guidelines use apms frc alternative performance measures thematic review published october also considered whether appropriate balance use statutory metrics apms addition whether clear definitions reconciliation apms used financial reporting provided dividends distribution policy consider whether dividends policy transparent dividends opinion dividends policy appropriately paid consistent policy outlined strategic report disclosed dividends paid consistent policy responsibilities directors auditors responsibilities audit explained fully directors responsibilities financial statements statement directors responsible preparation objectives obtain reasonable assurance financial statements satisfied give whether financial statements whole free true fair view internal control directors material misstatement whether due fraud error determine necessary enable preparation financial issue auditors report includes opinion reasonable statements free material misstatement whether assurance high level assurance guarantee due fraud error audit conducted accordance isas uk preparing financial statements directors always detect material misstatement exists responsible assessing groups parent companys misstatements arise fraud error considered ability continue going concern disclosing applicable material individually aggregate could matters related going concern using going concern reasonably expected influence economic decisions basis accounting unless directors either intend users taken basis financial statements liquidate group parent company cease description responsibilities audit operations realistic alternative financial statements located frcs website www frcorgukauditorsresponsibilities description forms part auditors reportgsk annual report independent auditors report continued report audit financial statements continued extent audit considered audit response risks identified result performing identified valuation capable detecting irregularities including fraud us returns rebates accruals key audit matter irregularities including fraud instances noncompliance related potential risk fraud key audit matters laws regulations design procedures line section report explains matter detail responsibilities outlined detect material also describes specific procedures response key misstatements respect irregularities including fraud audit matter common audits isas uk extent procedures capable detecting also required perform specific procedures respond irregularities including fraud detailed risk management override identifying assessing potential risks related addition procedures respond risks irregularities identified included following identifying assessing risks material misstatement reviewing financial statement disclosures testing respect irregularities including fraud noncompliance supporting documentation assess compliance laws regulations considered following provisions relevant laws regulations described nature industry sector control environment direct effect financial statements business performance including design enquiring senior leadership team audit risk groups remuneration policies key drivers directors committee inhouse external legal counsel remuneration bonus levels performance targets concerning actual potential litigation claims results enquiries senior leadership team internal performing analytical procedures identify unusual audit audit risk committee including obtaining unexpected relationships may indicate risks material reviewing supporting documentation concerning misstatement due fraud groups policies procedures relating reading minutes meetings charged identifying evaluating complying laws governance reviewing internal audit reports regulations whether aware instances correspondence regulators noncompliance addressing risk fraud management override detecting responding risks fraud whether controls testing appropriateness journal entries knowledge actual suspected alleged adjustments assessing whether judgements made fraud making accounting estimates indicative potential internal controls established mitigate risks related bias evaluating business rationale significant fraud noncompliance laws regulations transactions unusual outside normal course business matters discussed among engagement team including significant component audit teams involving also communicated relevant identified laws relevant internal specialists including tax valuations regulations potential fraud risks engagement team pensions industry specialists regarding members significant component audit teams fraud might occur financial statements remained alert indications fraud noncompliance potential indicators fraud laws regulations throughout audit obtained understanding legal regulatory report legal regulatory requirements frameworks group operates focusing provisions laws regulations direct effect determination material amounts disclosures opinions matters prescribed financial statements key laws regulations companies act considered context included provisions uk opinion part directors remuneration report companies act pensions legislation tax legislation audited properly prepared accordance also considered key laws regulations companies act fundamental effect operations group including good clinical practice fda regulations general data opinion based work undertaken course protection requirements antibribery corruption policy audit foreign corrupt practices act information given strategic report directors report financial year financial statements prepared consistent financial statements strategic report directors report prepared accordance applicable legal requirements gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued light knowledge understanding group directors remuneration parent company environment obtained companies act also required report course audit identified material opinion certain disclosures directors remuneration misstatements strategic report directors report made part directors remuneration report audited agreement accounting corporate governance statement records returns listing rules require us review directors statement nothing report respect matters relation going concern longerterm viability part corporate governance statement relating groups matters required address compliance provisions uk corporate governance code specified review auditor tenure based work undertaken part audit following recommendation audit risk committee concluded following elements effect january appointed corporate governance statement materially consistent board directors audit financial statements financial statements knowledge obtained year ended december subsequent financial audit periods period total uninterrupted engagement firm five years directors statement regards appropriateness adopting going concern basis accounting consistency audit report additional report material uncertainties identified set audit risk committee directors explanation assessment groups audit opinion consistent additional report prospects period assessment covers audit risk committee required provide period appropriate set accordance isas uk directors statement fair balanced use report understandable annual report set report made solely parent companys members boards confirmation carried robust body accordance chapter part assessment emerging principal risks set companies act audit work undertaken pages might state parent companys members section annual report describes review matters required state auditors report effectiveness risk management internal control purpose fullest extent permitted law systems set pages accept assume responsibility anyone parent company parent companys members section describing work audit risk body audit work report opinions committee set formed matters required report due course required financial conduct authority fca disclosure guidance transparency rule dtr exception r financial statements form part adequacy explanations received accounting records european single electronic format esefprepared annual companies act required report financial report filed national storage mechanism opinion uk fca accordance esef regulatory technical standard esef rts auditors report provides received information explanations assurance whether annual financial report require audit prepared using single electronic format specified adequate accounting records kept esef rts parent company returns adequate audit parent company passed resolution accordance received branches visited us section companies act senior parent company financial statements statutory auditors name stated agreement accounting records returns nothing report respect matters deloitte llp statutory auditor london united kingdom march gsk annual report consolidated income statement year ended december notes turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit finance income finance expense loss disposal interest associates share tax lossprofits associates joint ventures profit taxation taxation profit taxation continuing operations profit taxation discontinued operations gainslosses demerger remeasurement discontinued operations distributed shareholders demerger profit taxation discontinued operations total profit taxation year profit attributable noncontrolling interests continuing operations profit attributable shareholders continuing operations profit attributable noncontrolling interests discontinued operations profit attributable shareholders discontinued operations total profit attributable noncontrolling interests total profit attributable shareholders basic earnings per share pence continuing operations p p p basic earnings per share pence discontinued operations p p p total basic earnings per share pence p p p diluted earnings per share pence continued operations p p p diluted earnings per share pence discontinued operations p p p total diluted earnings per share pence p p p consolidated statement comprehensive income year ended december notes total profit year comprehensive incomeexpense year items may subsequently reclassified continuing operations income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates fair value movements cash flow hedges reclassification cash flow hedges income statement deferred tax fair value movements cash flow hedges items reclassified continuing operations income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement lossesgains defined benefit plans tax remeasurement lossesgains defined benefit plans fair value movements cash flow hedges comprehensive expense year continuing operations comprehensive income year discontinued operations total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note andor impact share consolidation see note gsk annual report strategic report governance remuneration financial statements investor information consolidated balance sheet december notes noncurrent assets property plant equipment right use assets goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments current equity investments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings contingent consideration liabilities trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings corporation tax payable deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments contingent consideration liabilities noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity financial statements pages approved board march signed behalf sir jonathan symonds chairgsk annual report consolidated statement changes equity year ended december shareholders equity share share retained noncontrolling total capital premium earnings reserves total interests equity december profit year comprehensive expenseincome year total comprehensive income year distributions noncontrolling interests contributions noncontrolling interests changes noncontrolling interests dividends shareholders realised profits taxation disposal equity investments share associates joint ventures realised profits disposal equity investments shares issued shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive expenseincome year total comprehensive income year distributions noncontrolling interests contributions noncontrolling interests dividends shareholders shares issued realised tax profits disposal equity investments share associates joint ventures realised profits disposal equity investments writedown shares held esop trusts sharebased incentive plans transaction noncontrolling interests tax sharebased incentive plans december profit year comprehensive expenseincome year total comprehensive income year distributions noncontrolling interests noncash distribution noncontrolling interests contributions noncontrolling interests changes noncontrolling interests deconsolidation former subsidiaries dividends shareholders noncash dividend shareholders realised tax losses disposal liquidation equity investments share associates joint ventures realised profits disposal equity investments shares issued writedown shares held esop trusts shares acquired esop trusts sharebased incentive plans tax sharebased incentive plans hedging gain taxation transferred nonfinancial assets december analysis reserves presented part note movements equity gsk annual report strategic report governance remuneration financial statements investor information consolidated cash flow statement year ended december notes cash flow operating activities profit taxation continuing operations year adjustments reconciling profit tax operating cash flows cash generated operations attributable continuing operations taxation paid net cash inflow continuing operating activities cash generated operations attributable discontinued operations taxation paid discontinued operations net operating cash flows attributable discontinued operations total net cash inflows operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments purchase businesses net cash acquired proceeds sale equity investments contingent consideration paid disposal businesses investments associates joint ventures proceeds disposal associates joint ventures interest received decreaseincrease liquid investments dividends associates joint ventures net cash outflow continuing investing activities net cash investing cash flows attributable discontinued operations total net cash outflowinflow investing activities cash flow financing activities issue share capital repayment longterm loans issue longterm notes repayment shortterm loans increase inrepayment shortterm loans repayment lease liabilities interest paid dividends paid shareholders distributions noncontrolling interests contributions noncontrolling interests financing items net cash outflow continuing financing activities net financing cash flows attributable discontinued operations total net cash inflowoutflow financing activities increasedecrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments increasedecrease cash bank overdrafts year cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts comparative results restated consistent basis previously published reflect demerger consumer healthcare business see note gsk annual report notes financial statements presentation financial statements description business financial period gsk global biopharma group makes innovative financial statements cover financial year vaccines specialty medicines prevent treat disease january december comparative figures gsks rd focuses science immune system financial years january december human genetics advanced technologies primarily appropriate january december following four therapeutic areas infectious diseases hiv income statement cash flow comparatives oncology immunologyrespiratory restated consistent basis previously published reflect classification consumer healthcare compliance applicable law ifrs business discontinued operation see note financial statements prepared accordance international accounting standards conformity accounting principles policies requirements companies act international financial statements prepared using financial reporting standards issued iasb historical cost convention modified revaluation certain items stated accounting policies composition financial statements going concern basis consolidated financial statements drawn sterling financial statements prepared accordance functional currency gsk plc accordance groups accounting policies approved board ifrs accounting presentation financial statements described note accounting principles policies comprise information application accounting policies consolidated income statement including areas estimation judgement given note critical accounting judgements key sources estimation consolidated statement comprehensive income uncertainty consolidated balance sheet preparation financial statements conformity consolidated statement changes equity generally accepted accounting principles requires management consolidated cash flow statement make estimates assumptions affect reported amounts assets liabilities disclosure contingent notes financial statements assets liabilities date financial statements composition group reported amounts revenues expenses reporting period actual results could differ estimates list subsidiaries associates opinion directors principally affected amount profit net parent company financial statements assets group given note principal group financial statements parent company gsk plc companies prepared accordance uk gaap uk accounting presentation company balance sheet presented accounting policies given pages accounting principles policies consolidation group ability exercise joint control rights net assets entities entities consolidated financial statements include accounted joint ventures group assets liabilities results cash flows ability exercise joint control arrangement company subsidiaries including esop trusts rights specified assets obligations specified liabilities groups share results net assets associates arrangement arrangement accounted joint ventures joint operation group ability exercise significant influence entities accounted groups share assets liabilities revenue expenses associates results assets liabilities associates joint operations joint ventures incorporated consolidated financial statements entities consolidated made financial statements using equity method accounting december year assets liabilities revenue expenses joint operations entities group power direct included consolidated financial statements relevant activities affect returns group accordance groups rights obligations generally control financial operating interests acquired entities consolidated date policies accounted subsidiaries group acquires control interests sold de consolidated date control ceases gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information accounting principles policies continued transactions balances subsidiaries eliminated exchange adjustments arising opening net assets profit tax taken sales subsidiaries profits year retained overseas subsidiaries products sold customers outside group associates joint ventures translated sterling less relevant proportion profits transactions joint ventures exchange differences arising related foreign currency joint operations associates also deferred borrowings hedge groups net investment products sold third parties transactions non operations taken separate component equity within controlling interests recorded directly equity deferred tax retained earnings relief unrealised intragroup profit accounted translating sterling assets liabilities results extent considered recoverable cash flows overseas subsidiaries associates joint ventures reported currencies hyperinflationary business combinations economies adjustments made material reflect business combinations accounted using acquisition current price levels loss net monetary assets charged accounting method identifiable assets liabilities contingent consolidated income statement liabilities acquired measured fair value acquisition date consideration transferred measured fair value revenue includes fair value contingent consideration turnover fair value contingent consideration liabilities group receives revenue supply goods external reassessed balance sheet date changes customers orders received majority contracts recognised income statement payments contingent gsk enters relate sales orders containing single consideration reduce balance sheet liability result performance obligations delivery pharmaceutical recorded income statement vaccine prior demerger consumer healthcare part payment relating original estimate business consumer healthcare products average duration fair value contingent consideration acquisition reported sales order less months within investing activities cash flow statement part product revenue recognised control goods payment relating increase liability since passed customer point control passes acquisition date reported within operating cash flows determined customer arrangement generally occurs consideration transferred together non delivery customer controlling interest exceeds fair value net assets product revenue represents net invoice value including fixed liabilities contingent liabilities acquired excess variable consideration variable consideration arises sale recorded goodwill costs effecting acquisition goods result discounts allowances given accruals charged income statement period estimated future returns rebates revenue recognised incurred full highly probable significant reversal goodwill capitalised separate item case amount cumulative revenue recognised occur subsidiaries part cost investment case methodology assumptions used estimate rebates joint ventures associates goodwill denominated returns monitored adjusted regularly light currency operation acquired contractual legal obligations historical trends past experience projected market conditions estimates associated returns cost acquisition groups interest rebates revisited reporting date net assets acquired difference recognised directly resolved revenue adjusted accordingly please refer income statement note details rebates discounts allowances equity subsidiary acquired non group entered collaborative agreements typically controlling interest recognised either fair value pharmaceutical biotechnology companies develop noncontrolling interests share net assets subsidiary produce market drug candidates vaccines casebycase basis changes groups ownership qualify joint arrangements gsk control percentage subsidiaries accounted within equity commercialisation activities group recognises turnover cost foreign currency translation sales gross basis profit sharing amounts royalties due counterparty recorded within cost sales cost sales foreign currency transactions booked functional includes profit sharing costs royalties due counterparty currency group company exchange rate ruling million million million date transaction foreign currency monetary assets counterparty controls commercialisation activities records liabilities retranslated functional currency sale group deemed principal customer contract rates exchange ruling balance sheet date exchange instead records share gross profit copromotion differences included income statement income net basis within turnover nature copromotion consolidation assets liabilities including related activities group records costs sales goodwill overseas subsidiaries associates joint ventures commercial operations turnover includes copromotion revenue translated sterling rates exchange million million million reimbursements ruling balance sheet date results cash flows counterparty collaboration agreements overseas subsidiaries associates joint ventures selling general administration research development translated sterling using average rates exchange costs recorded net respective lines consolidated income statementgsk annual report notes financial statements continued accounting principles policies continued operating income royalty income liability includes groups portion total costs gsk enters development marketing collaborations also portion potentially responsible parties costs outlicences groups compounds products probable able satisfy parties contracts give rise fixed variable respective shares cleanup obligation recoveries consideration upfront payments development milestones reimbursements recorded assets virtually certain salesbased milestones royalties legal disputes income dependent achievement development provision made anticipated settlement costs legal milestone recognised highly probable significant disputes group outflow reversal amount cumulative revenue recognised resources considered probable reliable estimate occur usually related event occurs salesbased made likely outcome respect product liability milestone income recognised highly probable claims related certain products provision made sales threshold reached sufficient history claims made settlements salesbased royalties licence intellectual property enable management make reliable estimate recognised relevant product sale occurs provision required cover asserted unasserted claims revenue time recognition revenue certain cases incurred reported ibnr actuarial payment customer expected technique used determine estimate addition one year impact material amount provision made legal expenses arising consideration discounted using appropriate discount rates claims received disputes value added tax sales taxes excluded revenue group may become involved legal proceedings respect possible meaningfully assess expenditure whether outcome result probable outflow expenditure recognised respect goods services quantify reliably estimate liability cases received supplied accordance contractual terms appropriate disclosure cases included provision made obligation exists future liability provision made respect past event amount costs associated claims made group third obligation reliably estimated manufacturing startup parties charged income statement incurred costs validation achievement normal production expensed incurred pensions postemployment benefits advertising promotion expenditure charged costs providing pensions defined benefit schemes income statement incurred calculated using projected unit credit method spread shipment costs intercompany transfers charged cost period benefit expected derived sales distribution costs sales customers included employees services consistent advice qualified selling general administration expenditure actuaries restructuring costs recognised provided pension obligations measured present value estimated appropriate respect direct expenditure business future cash flows discounted rates reflecting yields reorganisation plans sufficiently detailed highquality corporate bonds pension scheme assets well advanced appropriate communication measured fair value balance sheet date affected undertaken costs postemployment liabilities calculated software service saas configuration costs expensed similar way defined benefit pension schemes spread incurred software configured period benefit expected derived controlled saas provider employees services accordance advice qualified actuaries research development service cost providing retirement benefits employees research development expenditure charged year together cost curtailment income statement period incurred charged operating profit year development expenditure capitalised criteria actuarial gains losses effect changes recognising asset met usually regulatory filing actuarial assumptions recognised statement made major market approval considered comprehensive income year arise highly probable property plant equipment used research development capitalised depreciated groups contributions defined contribution plans accordance groups policy charged income statement incurred environmental expenditure environmental expenditure related existing conditions resulting past current operations current future benefit discernible charged income statement group recognises liability sitebysite basis reliably estimated gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information accounting principles policies continued employee share plans finance costs charged income statement produce constant periodic rate charge remaining incentives form shares provided employees balance obligations accounting period share option share award schemes variable rents part lease liability right use fair values options awards calculated asset payments charged income statement grant dates using blackscholes option pricing model incurred lease rental costs shortterm lowvalue leases charged income statement relevant vesting periods capitalised also charged income statement group provides finance esop trusts purchase company incurred shares meet obligation provide shares employees nonlease components accounted separately exercise options awards costs running esop trusts lease components plant equipment leases charged income statement separately accounted land buildings vehicle shares held esop trusts deducted reserves leases transfer made reserves retained earnings modifications reassessments lease obligations occur vesting periods related share options awards lease liability right use asset remeasured reflect ultimate proceeds receivable employees exercise right use assets title expected pass gsk point future depreciated basis consistent property plant equipment similar owned assets cases right use assets property plant equipment ppe stated cost depreciated shorter useful life asset purchase construction less provisions depreciation lease term impairment financing costs capitalised within cost qualifying assets construction goodwill goodwill stated cost less impairments goodwill depreciation calculated write cost less residual deemed indefinite useful life tested value ppe excluding freehold land using straightline impairment least annually basis expected useful life residual values lives reviewed appropriate adjusted annually fair value interest acquired entitys normal expected useful lives major categories ppe assets liabilities contingent liabilities exceeds consideration paid excess recognised immediately gain income statement freehold buildings years leasehold land buildings lease term years intangible assets plant machinery years intangible assets stated cost less provisions equipment vehicles years amortisation impairments disposal ppe cost related accumulated licences patents knowhow marketing rights separately depreciation impairments removed financial acquired acquired part business combination statements net amount less proceeds taken amortised estimated useful lives generally income statement exceeding years using straightline basis time available use estimated useful lives leases determining amortisation charge take account patent group recognises right use assets lease lives exclusivity period applicable well value arrangements lessee except shortterm obtained periods nonexclusivity pharmaceutical leases defined leases lease term months less intangible assets depending characteristics leases low value assets rights use assets owned competitive environment estimated longterm profits third parties lease agreements capitalised asset book value amortised inception lease recognised consolidated exclusivity period straightline basis balance sheet remaining book value amortised nonexclusivity period years straightline basis vaccines corresponding liability lessor recognised intangible assets cost usually amortised exclusivity lease obligation within short longterm borrowings period plus years years exclusivity period carrying amount subsequently increased reflect interest granted straightline basis asset lives reviewed lease liability reduced lease payments made appropriate adjusted annually calculating discounted lease liability leases annual contingent milestone payments recognised point payments million implicit rate lease contingent event becomes probable used available incremental borrowing rate development costs incurred group associated lease specific adjustment used neither available acquired licences patents knowhow marketing rights leases annual payments less million written income statement incurred unless incremental borrowing rate used incremental borrowing criteria recognition internally generated intangible rate calculated rate interest gsk would asset met usually regulatory filing made able borrow similar term similar security major market approval considered highly probable funds necessary obtain similar asset similar marketgsk annual report notes financial statements continued accounting principles policies continued acquired process rd marketed products valued financial instruments independently part fair value businesses acquired third parties value substantial long financial assets term brands either contractual legal financial assets measured amortised cost fair value nature sold separately rest businesses comprehensive income fvtoci fair value acquired profit loss fvtpl measurement basis determined reference business model costs acquiring developing computer software managing financial asset contractual cash flow internal use internet sites external use capitalised characteristics financial asset financial assets intangible fixed assets software site supports trade receivables month expected credit loss significant business system expenditure leads ecl allowance recorded initial recognition creation durable asset controlled group erp subsequent evidence significant increase credit risk systems software amortised seven ten years asset allowance increased reflect full lifetime computer software three five years using ecl realistic prospect recovery asset straightline basis written impairment noncurrent assets expected credit losses recognised income statement carrying values noncurrent assets reviewed financial assets measured amortised cost fair impairment either standalone basis part larger value comprehensive income apart equity cash generating unit indication investments assets might impaired additionally goodwill intangible current equity investments assets yet available use tested current equity investments comprise equity investments impairment annually provision impairment charged group holds intention sell may sell income statement year concerned short term acquired intention impairments goodwill reversed impairment losses measured fvtpl initially recorded fair value noncurrent assets reversed remeasured subsequent reporting dates fair change estimates used determine recoverable amounts value unrealised gains losses recognised extent revised recoverable amounts income statement dividend income recognised exceed carrying values would existed net income statement groups right receive payment depreciation amortisation impairments established purchases sales current equity investments recognised accounted trade date investments associates joint ventures joint investments operations investments comprise equity investments investments associates joint ventures carried investments limited life funds group elected consolidated balance sheet groups share net designate majority equity investments measured assets date acquisition postacquisition fvtoci initially recorded fair value plus retained profits losses comprehensive income transaction costs remeasured subsequent together goodwill arising acquisition reporting dates fair value unrealised gains losses group recognises assets liabilities revenue expenses recognised comprehensive income disposal joint operations accordance rights equity investment gains losses deferred obligations comprehensive income transferred directly retained earnings inventories investments limited life funds measured fvtpl inventories included financial statements initially recorded fair value remeasured lower cost including raw materials direct labour subsequent reporting dates fair value unrealised gains direct costs related production overheads net losses recognised income statement realisable value cost generally determined first first dividends equity investments distributions funds basis prelaunch inventory held asset recognised income statement groups right high probability regulatory approval product receive payment established point provision made carrying value reduce recoverable amount provision purchases sales investments accounted reversed point high probability trade date regulatory approval determined gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information accounting principles policies continued trade receivables hedge accounting trade receivables measured accordance business derivatives designated hedging instruments classified model portfolio trade receivables held inception hedge relationship cash flow hedges net group portfolios three business models investment hedges fair value hedges ifrs collect contractual cash flows changes fair value derivatives designated cash factoring agreement place measured amortised cost flow hedges recognised comprehensive income sell contractual cash flows trade receivables extent hedges effective accumulated sold factoring agreement measured fvtpl cash flow hedge reserve ineffective portions collect sell contractual cash flows trade recognised profit loss immediately amounts deferred receivables may sold factoring arrangement cash flow hedge reserve reclassified income measured fvtoci trade receivables measured amortised statement hedged item affects profit loss cost carried original invoice amount less allowances hedged forecast transaction purchase nonfinancial expected credit losses asset amount deferred cash flow hedge reserve expected credit losses calculated accordance transferred directly equity included carrying simplified approach permitted ifrs using provision matrix value recognised nonfinancial asset applying lifetime historical credit loss experience trade net investment hedges accounted similar way receivables expected credit loss rate varies depending cash flow hedges reclassified income whether extent settlement trade statement hedged item affects profit loss receivables overdue also adjusted appropriate reflect current economic conditions estimates future changes fair value derivatives designated fair conditions purpose determining credit loss rates value hedges recorded income statement together customers classified groupings similar loss changes fair value hedged asset patterns key drivers loss rate nature liability business unit location type customer taxation trade receivable determined reasonable current tax provided amounts expected paid expectation recovery written firstly applying tax rates enacted substantively expected credit loss allowance available enacted balance sheet date tax charge income statement period recognised income statement statement subsequent recoveries amounts previously provided comprehensive income directly equity according written credited income statement longterm accounting treatment related transaction receivables discounted effect material deferred tax provided full temporary differences arising tax bases assets liabilities cash cash equivalents carrying amounts financial statements deferred tax cash held deposit accounts measured amortised cost assets recognised extent probable investments money market funds held fair value future taxable profits available profit loss funds fail solely temporary differences utilised deferred tax provided payments principal interest sppi test temporary differences arising investments subsidiaries borrowings associates joint ventures except timing borrowings initially recorded amount proceeds reversal temporary difference controlled received net transaction costs borrowings subsequently probable temporary difference reverse carried amortised cost difference foreseeable future deferred tax provided using rates tax proceeds net transaction costs amount due enacted substantively enacted redemption recognised charge income balance sheet date deferred tax assets liabilities statement period relevant borrowing offset legally enforceable right offset current tax assets current tax liabilities relate derivative financial instruments income taxes levied tax authority derivative financial instruments used manage exposure company subsidiaries intend settle current tax market risks principal derivative instruments used assets liabilities net basis gsk foreign currency swaps interest rate swaps foreign deferred tax assets liabilities recognised exchange forward contracts options group temporary differences arise initial recognition hold issue derivative financial instruments trading goodwill initial recognition assets speculative purposes liabilities transaction business combination derivative financial assets liabilities including derivatives affects neither accounting taxable profit embedded host contracts separated loss unrecognised deferred tax assets reassessed host contract classified heldfortrading reporting date recognised extent measured fair value changes fair value become probable future taxable profits allow derivative instruments qualify hedge deferred tax asset recovered accounting recognised immediately income statementgsk annual report notes financial statements continued accounting principles policies continued uncertain tax position identified management assets liabilities held sale distribution make judgement probable outcome discontinued operations assuming relevant tax authority full knowledge disposal groups classified held sale distribution situation assessed economic outflow carrying amount recovered principally sale probable arise provision made best estimate distribution shareholders rather continuing liability estimating liability gsk applies use available sale distribution present riskbased approach takes account appropriate condition sale distribution considered highly probability group would able obtain probable assets held assets held sale distribution compensatory adjustments international tax treaties measured lower carrying amount fair value estimates take account specific circumstances less costs sell distribute noncurrent assets included dispute relevant external advice assets held sale distribution depreciated discounting amortised assets liabilities classified held sale distribution presented current assets current time value money material balances liabilities separately assets liabilities discounted current values using appropriate discount rates balance sheet unwinding discounts recorded finance income finance expense discontinued operation component group disposed distributed classified held sale distribution represents separate major line business results discontinued operations presented separately consolidated income statement consolidated statement comprehensive income consolidated statement cash flows comparatives restated consistent basis critical accounting judgements key sources estimation uncertainty preparing financial statements management required sales pharmaceutical vaccine products us make judgements items complex arrangements rebates discounts allowances recognised financial statements estimates turnover commercial operations products us assumptions affect amounts assets liabilities million million revenue expenses reported financial statements recording deductions million million actual amounts results could differ estimates rebates allowances returns discounts following considered critical accounting december total accrual amounted million judgements key sources estimation uncertainty million due nature accruals practicable give meaningful sensitivity estimates due turnover large volume variables contribute overall reported group turnover million rebates chargebacks returns revenue accruals million significant variability final outcomes group applies constraint measuring variable estimates element within revenue revenue recognised gross turnover reduced rebates discounts allowances suitably cautious amount objective constraint product returns given expected given ensure highly probable significant reversal vary product arrangements buying groups revenue occur uncertainties resolved arrangements purchasing organisations dependent constraint applied making suitably cautious upon submission claims time initial estimates inputs assumptions used estimating recognition sale accruals made time sale variable consideration amounts estimated rebates discounts allowances payable estimated may fully reflect final outcome returns made based available market information amounts subject change dependent upon amongst historical experience things types buying group product sales mix constraints applied recognising revenue mean risk material downward adjustment revenue next comparative results restated consistent basis financial year low previously published reflect demerger consumer healthcare business see gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information critical accounting judgements key sources estimation uncertainty continued level accrual rebates returns reviewed legal disputes adjusted regularly light contractual legal legal costs year million million obligations historical trends past experience projected december provisions legal disputes market conditions market conditions evaluated using amounted million million wholesaler thirdparty analyses market research data internally generated information reasonably estimates possible could significant adjustment within management makes judgement whether sufficient next months recognise additional revenue actual information able make reliable estimate likely outcomes better cautious constrained estimates outcome dispute legal expenses revenue recognised full highly probable arising claims group insufficient information significant reversal amount cumulative revenue available provision made disclosure claim recognised occur amount turnover recognised given year performance obligations satisfied previous estimated provisions take account specific periods set note turnover segment information circumstances dispute relevant external advice indication level sensitivity estimate inherently judgemental could change substantially future events could cause assumptions time dispute progresses new facts emerge accruals based change could materially affect details status various uncertainties involved future results group significant unresolved disputes set note legal proceedings taxation companys directors taken legal advice tax charge year million established provisions taking account relevant million december current tax payable facts circumstances matter accordance million million noncurrent corporation tax accounting requirements respect product liability claims payable million million current tax related certain products sufficient history claims recoverable million million made settlements enable management make reliable estimate provision required cover unasserted claims estimates group open tax issues number revenue group may become involved legal proceedings respect authorities management makes judgement whether possible meaningfully assess whether sufficient information able make reliable estimate outcome result probable outflow quantify reliably outcome dispute insufficient information estimate liability cases appropriate disclosure available provision made cases would provided provision would made contingent liability quantified sufficient information available estimating potential tax liability gsk applies riskbased approach takes ultimate liability legal claims may vary amounts account appropriate probability group would provided dependent upon outcome litigation able obtain compensatory adjustments proceedings investigations possible settlement negotiations international tax treaties estimates take account position could change time therefore specific circumstances dispute relevant assurance losses result outcome external advice inherently judgemental could change legal proceedings exceed amount provisions substantially time dispute progresses new reported groups financial statements material amount facts emerge contingent consideration december group recognised provisions income statement charge contingent million respect uncertain tax positions consideration million million million due number uncertain tax positions held number jurisdictions relate december liability contingent consideration practicable give meaningful sensitivity estimates amounted million million uncertain tax position individually significant group amount million million related acquisition former shionogiviiv healthcare joint venture factors affecting tax charge future years set note taxation gsk continues believe made adequate provision liabilities likely arise open estimates assessments open issues exist ultimate liability contingent consideration included consideration matters may vary amounts provided payable business combination recorded fair value dependent upon outcome negotiations relevant date acquisition fair values generally based tax authorities necessary litigation proceedings riskadjusted future cash flows discounted using appropriate posttax discount rates fair values reviewed regular basis least annually changes comparative results restated consistent basis reflected income statement see note contingent previously published reflect demerger consumer consideration liabilities healthcare business see gsk annual report notes financial statements continued critical accounting judgements key sources estimation uncertainty continued pensions postemployment benefits discount rates derived aa rated corporate bond yields except countries deep market corporate judgement bonds government bond yields used sensitivity surplus defined benefit scheme arises analysis provided note pensions post potential surplus arise committed future employment benefits reduction discount rate contributions rights trustees prevent group would lead increase net pension deficit obtaining refund surplus future considered approximately million increase annual pension determining whether necessary restrict amount cost approximately million similarly increase surplus recognised two uk schemes surplus discount rate would lead decrease net pension deficit three uk schemes combined surplus million approximately million decrease annual december million recognised pension cost approximately million reduction pension surpluses totalling million spread across five countries discount rate would lead increase net pension deficit million across six countries gsk made approximately million increase annual judgement amounts meet requirements pension cost approximately million similarly recoverability increase discount rate would lead decrease net pension deficit approximately million decrease estimates annual pension cost approximately million costs providing pensions postemployment selection different assumptions could affect future results benefits assessed basis assumptions selected group management assumptions include future earnings pension increases discount rates expected longterm rates return assets mortality rates disclosed note pensions postemployment benefits new accounting requirements amendments accounting standards issued iasb certain new accounting standards amendments adopted year ended december accounting standards interpretations material impact results financial position group published mandatory december reporting periods adopted early group standards amendments interpretations expected material impact results financial position group future reporting periods exchange rates group uses average exchange rates prevailing period translate results cash flows overseas subsidiaries joint ventures associates sterling period end rates translate net assets entities currencies influence translations relevant exchange rates average rates period end rates us us euro euro yen yen gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information turnover segment information operating segments reported based financial information provided chief executive officer responsibilities gsk leadership team glt gsk revised operating segments q q previously gsk reported results four segments pharmaceuticals pharmaceuticals rd vaccines consumer healthcare first quarter gsk reported results three segments commercial operations total rd consumer healthcare q gsk reports two segments continuing operations demerger consumer healthcare segment completed july members glt responsible segment comparative information retrospectively revised consistent basis rd investment essential sustainability business however segment reporting commercial operating profits exclude allocations globally funded rd total rd segment responsibility chief scientific officer reported separate segment operating costs segment includes rd activities across specialty medicines including hiv vaccines includes rd sga costs relating regulatory functions groups management reporting process allocates intragroup profit product sale segment sale recorded profit analyses presented basis revised revised turnover segment commercial operations consumer healthcare april gsk completed divestment horlicks consumer healthcare nutrition products india number countries excluding bangladesh unilever merger gsks indian listed consumer healthcare entity hindustan unilever indian listed company gsk completed divestment bangladesh june business excluded consumer healthcare joint venture included consumer healthcare segment performance product sales reported within three product groups specialty medicines vaccines general medicines revised revised commercial operations hiv oncology immunoinflammation respiratory pandemic specialty medicines meningitis influenza shingles established vaccines pandemic vaccines vaccines respiratory general medicines general medicines total commercial operations total consumer healthcare comparatives revised reflect commercial operations segmentgsk annual report notes financial statements continued turnover segment information continued sales made three us wholesalers million million million million million million million million million respectively allocating finalcustomer discounts wholesalers revenue recognised year performance obligations satisfied previous periods totalled million million including million million impacting turnover arising changes prior year estimates rar returns rebates accruals million million milestone income million million royalty income recognised current year revised revised segment profit commercial operations research development consumer healthcare segment profit corporate unallocated costs reconciling items segment profit operating profit total operating profit finance income finance costs loss disposal interest associates share aftertax profitslosses associates joint ventures profit taxation continuing operations taxation profit taxation year continuing operations april gsk completed divestment horlicks consumer healthcare nutrition products india number countries excluding bangladesh unilever merger gsks indian listed consumer healthcare entity hindustan unilever indian listed company gsk completed divestment bangladesh june reconciling items segment profit operating profit comprise items specifically allocated segment profit include impairment amortisation intangible assets major restructuring costs include impairments tangible assets computer software transactionrelated adjustments related significant acquisitions proceeds costs disposals products businesses significant legal charges expenses settlement litigation government investigations operating income royalty income items please refer detail reconciling items segment profit operating profit analysis adjusting items group financial review revised revised depreciation amortisation segment commercial operations research development segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information turnover segment information continued revised revised ppe intangible asset goodwill impairment segment commercial operations research development segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment ppe intangible asset impairment reversals segment commercial operations research development segment impairment reversals corporate unallocated impairment reversals reconciling items segment impairment reversals total impairment reversals total impairment reversals revised net operating assets segment commercial operations research development segment net operating assets corporate unallocated net operating assets discontinued operations net operating assets net debt investments associates joint ventures current equity investment derivative financial instruments current deferred taxation assets held sale excluding cash cash equivalents net assets commercial operations segment includes shionogiviiv healthcare contingent consideration liability million million pfizer put option million million geographical information uk regarded groups country domicile revised revised turnover location customer uk us rest world external turnover noncurrent assets location subsidiary uk us belgium switzerland rest world noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables countries individually material external revenue noncurrent assets comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note comparatives revised reflect new segmentsgsk annual report notes financial statements continued operating incomeexpense upfront settlement income fair value remeasurements equity investments disposal businesses assets fair value remeasurements contingent consideration recognised business combinations remeasurement viiv healthcare put option liabilities preferential dividends fair value adjustments derivative financial instruments income comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note february viiv healthcare reached agreement gilead sciences inc gilead settle global patent infringement litigation relating commercialisation gileads biktarvy concerning viiv healthcares patents relating dolutegravir antiretroviral medication used together medicines treat human immunodeficiency virus hiv terms global settlement licensing agreement gilead made upfront payment billion million viiv healthcare february addition gilead also pay royalty future us sales biktarvy respect bictegravir component future bictegravircontaining products sold us royalties payable gilead viiv healthcare february expiry viiv healthcares us patent october recorded royalty income income statement fair value remeasurement equity investments included gainloss million remeasurement groups retained investment haleon plc fair value december initial recognition fair value fiveday average share price demerger see details note disposal businesses assets includes milestone income reversal provisions longer required disposal businesses assets included net gain disposal rights royalty stream cabozantinib net gain disposal cephalosporin antibiotic brands sandoz disposal businesses assets included net profit disposal horlicks consumer healthcare nutritional brands two subsidiaries india bangladesh million reflected reversal million embedded derivative gains value shares taken prior years partly offset related million loss shares hindustan unilever limited including fair value remeasurement losses acquisition consideration divestment gsk consumer healthcare limited india subsequent disposal operating income also included increase profit milestone income number asset disposals fair value remeasurements contingent consideration recognised business combinations included million related acquisition former shionogiviiv healthcare joint venture million payable novartis related vaccines acquisition together fair value movements related hedging contracts gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals depreciation right use assets impairment right use assets amortisation intangible assets impairment intangible assets net reversals impairment intangible assets held sale net reversals impairment goodwill allocated disposal group net reversals net foreign exchange gainslosses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories shortterm lease charge lowvalue lease charge variable lease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration net foreign exchange gainslosses include net loss million million gain million loss arising recycling exchange liquidation disposal overseas subsidiaries recycling exchange disposal overseas associates loss nil million reported loss disposal interest associates recycling exchange disposal overseas subsidiaries include recycling exchange disposal consumer healthcare subsidiaries reported profit taxation demerger discontinued operations included within operating profit major restructuring charges million million million see note major restructuring costs fees payable companys auditor associates audit parent company consolidated financial statements including attestation sarbanesoxley act audit companys subsidiaries total audit services auditrelated assurance services total audit services auditrelated assurance services assurance services provided auditor related agreed upon procedures assurance services outside statutory audit requirements addition fees paid auditor respect gsk pension schemes audit immaterial fees million paid versus nil million auditors respect audits certain companys subsidiaries audit related assurance services include million million due reporting accountant work performed preparation consumer healthcare demerger comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note gsk annual report notes financial statements continued employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance cost sharebased incentive plans analysed follows share value plan performance share plan share option plans cash settled plans average number persons employed group including directors year number number number manufacturing selling general administration research development total continuing operations discontinued operations total note consumer healthcare divested july shown discontinued operations table average monthly number group employees excludes temporary contract staff numbers group employees end financial year given financial record compensation directors senior management members glt aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans information remuneration directors given sections annual report remuneration labelled audited within pages comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information major restructuring costs within pharmaceuticals sector highly regulated manufacturing operations supply chains long lifecycle business mean restructuring programmes particularly involve rationalisation closure manufacturing rd sites likely take several years complete major restructuring costs related specific boardapproved major restructuring programmes including integration costs following material acquisitions structural significant scale costs individual related projects exceed million january board approved separation preparation programme prepare separation gsk two companies materially separation preparation restructuring programme included part continuing operations legacy consumer healthcare joint venture integration programme included part discontinued operations acquisition sierra oncology july affinivax august board approved major restructuring programme integration significant acquisitions designed integrate achieve synergies total restructuring costs million incurred following areas restructuring costs prepare separation gsk two companies continued transformation central functions including gsk technology platforms interfaces deliver greater digital synergies simplification applications staff reductions integration acquisitions analysis costs charged operating profit continuing operations programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash chargescredit cash costs provision reversals million million million reflected provision releases mainly related separation preparation programme asset impairments million noncash credit million principally comprised fixed asset writedowns manufacturing facilities accelerated depreciation asset lives shortened supply chain manufacturing network result major restructuring programmes offset profit disposals charges settled cash include site closure costs consultancy project management costs analysis major restructuring charges continuing operations programme follows cash noncash total separation preparation programme significant acquisitions legacy programmes cash noncash total separation preparation programme legacy programmes comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note gsk annual report notes financial statements continued major restructuring costs continued analysis major restructuring charges continuing operations income statement line follows cost sales selling general administration research development finance income finance income arising financial assets measured amortised cost financial assets measured fair value profit loss net gains arising forward element forward contracts net investment hedge relationships finance income finance expense finance expense arising financial liabilities amortised cost net losses arising financial instruments mandatorily measured fair value profit loss retranslation loans reclassification hedges comprehensive income unwinding discounts provisions finance expense arising lease liabilities finance expense comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information associates joint ventures groups share aftertax profits losses associates joint ventures set share aftertax profits associates share aftertax losses joint ventures comparatives restated demerged consumer healthcare business contained associates joint ventures following disposal innoviva inc may see details note december december group held significant individual associates december group held one significant associate innoviva inc summarised income statement information respect innoviva may set groups share aftertax profits associates comprehensive income included profit million comprehensive income nil respect innoviva results innoviva included summarised income statement information represent estimated earnings innoviva relevant periods based publicly available information balance sheet date figures include share innovivas turnover profit total comprehensive income date disposal turnover profit taxation total comprehensive income aggregated financial information respect gsks share associated undertakings joint ventures set share aftertax losses share comprehensive incomeexpense share total comprehensive incomeexpense groups sales associates joint ventures nil nil nil please refer balance sheet information associates joint ventures note gsk annual report notes financial statements continued taxation groups tax charge sum total current deferred tax expense taxation charge based profits year uk current year charge rest world current year charge chargecredit respect prior periods current taxation deferred taxation gsk made corporate income tax payments globally billion continuing discontinued operations million uk corporation tax paid hmrc amounts corporate income tax include various business taxes borne gsk year deferred tax credits period reflect current year losses offset taxable profits future periods probable release deferred tax liabilities latter relates primarily unwind deferred tax liabilities intangible assets deferred tax credit also reflected impact remeasurement deferred tax assets liabilities following enactment increase headline rate uk corporation tax following table reconciles tax charge calculated uk statutory rate group profit tax actual tax charge year reconciliation taxation group profits profit tax uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits permanent differences disposals acquisitions transfers permanent differences reassessments prior year current tax estimates reassessments prior year deferred tax estimates changes tax rates tax chargetax rate global biopharmaceutical company substantial business employment presence many countries around world impact differences overseas taxation rates arose profits earned countries tax rates higher uk statutory rate significant us belgium germany japan adverse impact offset benefit intellectual property incentives uk patent box belgian innovation income deduction regimes provide reduced rate corporation tax profits earned qualifying patents claim incentives manner intended relevant statutory regulatory framework changes tax rates included credits relation enactment increase headline rate uk corporate income tax effective changes tax rates included credits relation uk reduction corporate income tax rate cancelled india tax treatment dividends changed effect april permanent differences disposals acquisitions transfers includes tax internal restructuring simplify group structure tax credit reflected tax impact disposal horlicks consumer healthcare brands subsequent disposal shares received hindustan unilever groups tax rate also influenced updates estimates prior period tax liabilities following closure open issues tax authorities various jurisdictions comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information taxation continued future tax charges therefore effective tax rate may affected factors acquisitions disposals restructurings location research development activity tax regime reforms resolution open matters continue bring tax affairs date around world uk government confirmed spring finance bill include legislation introducing global minimum corporate income tax rate effect line oecds pillar two model framework detail measures accounted still finalised possible accurately quantify impact gsk stage tax items charged equity statement comprehensive income current taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements equity investments deferred taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements equity investments total credit equity statement comprehensive income comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note items charged statement comprehensive income except tax sharebased payments issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets line current oecd guidelines base transfer pricing policy arms length principle support transfer prices economic analysis reports however different tax authorities may seek attribute profit activities undertaken jurisdiction potentially resulting double taxation group also open items several jurisdictions concerning matters deductibility particular expenses tax treatment certain business transactions gsk applies risk based approach determine transactions likely subject challenge probability group would able obtain compensatory adjustments international tax treaties calculation groups total tax charge therefore necessarily involves degree estimation judgement respect certain items whose tax treatment finally determined resolution reached relevant tax authority appropriate formal legal process december group recognised provisions million respect uncertain tax positions million net decrease recognised provisions driven reassessment estimates agreement number open issues tax authorities various jurisdictions amounts related discontinued operations whilst ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate group continues consider made appropriate provision periods open yet agreed tax authorities provision deferred tax liabilities million december million made respect taxation would payable remittance profits certain overseas subsidiaries whilst aggregate amount unremitted profits balance sheet date approximately billion billion majority unremitted profits would subject tax including withholding tax repatriation uk legislation relating company distributions provides exemption tax overseas profits subject certain exceptions deferred tax provided temporary differences million million arising unremitted profits management ability control future reversal consider reversal probablegsk annual report notes financial statements continued taxation continued movement deferred tax assets liabilities pensions share accelerated post option net capital intangible contingent intragroup employment tax award temporary allowances assets consideration profit benefits losses schemes differences total january exchange adjustments creditcharge income statement creditcharge statement comprehensive income acquisitionsdisposals rd credits utilisation december exchange adjustments creditcharge income statement creditcharge statement comprehensive income acquisitionsdisposals rd credits utilisation transfer assets held sale distribution december deferred tax liabilities relation intangible assets predominately relate temporary differences arising result historic business combinations group continues recognise deferred tax assets future obligations respect contingent consideration amounts payable minority shareholders payments tax deductible point time payment made deferred tax asset recognised intragroup profits arising intercompany inventory eliminated within consolidated accounts intragroup profits eliminated individual entities tax returns temporary difference arises reverse point time inventory sold externally deferred tax asset recognised tax losses million million relates trading losses deferred tax assets recognised probable future taxable profit available utilise losses supported longrange product level forecasts current forecasts indicate assets utilised around net temporary differences included accrued expenses tax deduction available paid basis deferred tax assets liabilities recognised balance sheet follows deferred tax assets deferred tax liabilities unrecognised unrecognised deferred tax deferred tax tax losses asset tax losses asset unrecognised tax losses trading losses expiring within years years available indefinitely december capital losses expiring available indefinitely december deferred tax assets recognised probable future taxable profit available utilise losses gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information earnings per share pence pence pence basic earnings per share continuing operations basic earnings per share discontinued operations total basic earnings per share diluted earnings per share continuing operations diluted earnings per share discontinued operations total diluted earnings per share comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note andor impact share consolidation see note basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights cash dividends gsk shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted restated reflect impact share consolidation see note dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paid pence paid pence first interim july july july second interim october october october third interim january january january fourth interim april april april total estimate fourth interim dividend disclosed annual report million million less dividend ultimately paid dividends per share retrospectively adjusted reflect share consolidation periods presented see details note ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends demerger consumer healthcare business effected gsk declaring interim dividend specie haleon plc shares fair value distribution million amounts recognised year follows cash dividends shareholders dividends specie shareholders haleon plc shares note gsk annual report notes financial statements continued property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held saledistribution cost december exchange adjustments additions business combinations additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held saledistribution cost december depreciation january exchange adjustments charge year disposals writeoffs transfer assets held saledistribution depreciation december exchange adjustments charge year disposals writeoffs transfer assets held saledistribution depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held saledistribution impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information property plant equipment continued weighted average interest rate capitalised borrowing costs year disposals writeoffs year included number assets nil net book value longer use business impairment losses principally arose decisions rationalise facilities calculated based fair value less costs disposal fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate specific segment country currency risk assets continue used group generally assessed part associated cash generating unit value use basis value use calculations posttax cash flows include impact future uncommitted restructuring plans improvements impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately net impairment losses charged cost sales million million rd million million sga million million included million million arising major restructuring programmes reversals impairment arose subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales million million computer software reclassified assets construction intangible assets becoming ready use gsk assessed qualitative quantitative impact climate related risks asset recoverable amounts concluded material impairments right use assets land plant buildings equipment vehicles total net book value january exchange adjustments additions depreciation disposals impairments net book value december exchange adjustments additions business combinations additions depreciation transfer assets held saledistribution disposals impairments net book value december group entered commitments lease contracts yet commenced see note analysis lease liabilities set note net debtgsk annual report notes financial statements continued goodwill cost january exchange adjustments additions business combinations note movements transfer assets held saledistribution cost december net book value january net book value december goodwill allocated groups segments follows commercial operations total rd net book value december prior changes groups segment reporting note goodwill allocated follows pharmaceuticals vaccines consumer healthcare net book value december goodwill million allocated consumer healthcare transferred assets held saledistribution prior consumer healthcare demerger note recoverable amounts cash generating units assessed using fair value less costs disposal model fair value less costs disposal calculated using discounted cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific segment country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy rd segment evaluated arms length pricing model see assumptions details relating discounted cash flow models used impairment tests follows valuation basis fair value less costs disposal key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates jurisdiction period specific projected cash flows five years terminal growth rate discount rate terminal growth rate discount rate commercial operations pa pa rd pa pa pharmaceuticals pa pa vaccines pa pa consumer healthcare pa pa terminal growth rate exceed longterm projected growth rates relevant markets reflects impact future generic competition take account new product launches goodwill monitored impairment segmental level valuations indicated sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill gsk assessed qualitative quantitative impact climate related risks asset recoverable amounts concluded material impairments gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information intangible assets licences patents computer amortised indefinite life software brands etc brands total cost january exchange adjustments capitalised development costs additions disposals asset writeoffs transfer assets held saledistribution reclassifications cost december exchange adjustments capitalised development costs additions business combinations additions disposals asset writeoffs transfer assets held saledistribution reclassifications cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held saledistribution amortisation december impairment january exchange adjustments impairment losses reversal impairments disposals asset writeoffs impairment december exchange adjustments impairment losses transfer assets held saledistribution reversal impairments disposals asset writeoffs impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year net book value computer software included million million internally generated costs carrying value december intangible assets impairments charged year following impairments million million carrying value december intangible assets impairment reversals charged year following impairment reversals million million individual intangible asset accounted material impairment patent expiry dates groups significant assets relevant set pages please refer note groups accounting policy estimate useful life intangible assets exclusivity nonexclusivity periodsgsk annual report notes financial statements continued intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note licences patents amortised brands etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development note acquisitions disposals gives details additions business combinations year book values largest individual items follows tesaro assets meningitis portfolio momelotinib affinivax assets dolutegravir benlysta alector assets iteos assets shingrix okairos bms assets spero vir assets fluarixflulaval stiefel trade name curevac assets lamisila others disposed part consumer healthcare demerger note july gsk completed acquisition sierra oncology inc main asset momelotinib august gsk completed acquisition affinivax inc indefinite life brands related healthcare brands used within consumer healthcare business indefinite life brands disposed part consumer healthcare demerger note group consider reasonably possible changes key assumptions would cause recoverable amount intangible assets disclosed fall carrying values gsk assessed qualitative quantitative impact climate related risks asset recoverable amounts concluded material impairments gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals distributions received net fair value movements comprehensive income impairment interest associates profitloss tax recognised consolidated income statement december may group agreed innoviva inc sell shares innoviva back innoviva million following settlement transaction gsk longer held innoviva stock loss million including million recycling exchange differences innoviva presented loss disposal interest associates consolidated income statement transaction include changes innovivas commercial interest royalties paid gsk loss disposal interest associates also includes million gain disposal another immaterial associate please refer income statement information associates joint ventures note current equity investments investments measured fvtpl current january exchange adjustments additions net fair value movements profit loss december current equity investments represent haleon plc shares held demerger consumer healthcare shares held trading measured fair value profit loss fvtpl based haleon plc share price changes fair value demerger presented operating incomeexpense continuing operations groups investment haleon plc end december held glaxo group limited scottish limited partnerships slps set collateralise agreed additional funding gsks uk defined benefit pension schemes note esop trusts net fair value movement profit loss million includes fair value gain million million adjustmentsgsk annual report notes financial statements continued investments investments investments designated investments designated investments measured measured measured measured fvtoci fvtpl fvtoci fvtpl noncurrent january exchange adjustments additions net fair value movements comprehensive income net fair value movements profit loss disposals december noncurrent investments comprise noncurrent equity investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments recent financing rounds discounted cash flows underlying net assets movements arising translation overseas net assets consolidation group accounts recorded exchange adjustments net fair value movements include impact exchange gains million comprehensive income nil profit loss gains million comprehensive income million profit loss investments include listed investments million million gsk elected designate majority equity investments measured fair value comprehensive income fvtoci significant investments held december vir biotechnology inc fair value december million million nimbus therapeutics llc fair value december million million fair value investment curevac nv disclosed significant investment december million december million investments include equity stakes companies gsk research collaborations companies provide access biotechnology developments potential interest disposal equity investments measured fvtoci accumulated fair value movements reclassified fair value reserve retained earnings investments measured fvtoci fair value million million disposed year cumulative gain investments tax million million certain investments investments funds limited lives investments acquired intention sell measured fair value profit loss fvtpl gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables amounts receivable insurance contracts held cash surrender value movements profit loss within receivables million million million million classified financial assets million million classified fair value profit loss remaining balance million million expected credit loss allowance immaterial december inventories raw materials consumables work progress finished goods trade receivables trade receivables net loss allowance accrued income prepayments interest receivable employee loans advances receivables trade receivable balances nil due associates joint ventures significant component receivables comprises receivables taxes corporate income tax significant balances within receivables royalties receivable amounts receivable collaboration partners loss allowance trade receivables january exchange adjustments charge year transfer assets held sale subsequent recoveries amounts provided utilised december total trade receivables balance million million considered credit impaired million million expected credit loss allowance applied amount purchased originated credit impaired within receivables million million million million classified financial assets nil nil classified held fair value profit loss december expected credit loss allowance million million recognised respect financial assets charge reported profit loss year discussion credit risk practices please refer note gsk annual report notes financial statements continued cash cash equivalents cash bank hand shortterm deposits million transferred assets held sale relating consumer healthcare business demerged year see note cash cash equivalents included billion billion available general use due restrictions applying subsidiaries held restrictions include exchange controls taxes repatriation assets held sale property plant equipment noncurrent assets disposal groups transferred assets held sale expected carrying amounts recovered principally disposal sale considered highly probable held lower carrying amount fair value less costs sell q consumer healthcare business classified held sale following completion demerger consumer healthcare business q total billion net assets liabilities distributedderecognised part gain demerger gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information trade payables trade payables wages salaries social security viiv healthcare put option payables deferred income customer return rebate accruals accruals trade payables included nil nil due associates joint ventures group provides limited supplier financing arrangements certain customers amounts involved december material revenue recognised year included deferred income january million million customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers fully described group financial review december customer return rebate accruals included million million respect us commercial operations accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual amounts paid changes arrangements future events could cause assumptions accruals based change could affect future results group pfizers put option shareholding viiv healthcare currently exercisable pfizer may request ipo viiv healthcare time either gsk consent ipo offering completed within nine months pfizer could require gsk acquire shareholding amount liability put option held gross redemption basis derived internal valuation viiv healthcare business utilising discounted forecast future cash flow multiplesbased methodologies table shows indicative basis income statement balance sheet sensitivity pfizer put option reasonably possible changes key assumptions increasedecrease financial liability lossgain income statement increase sales forecasts increase sales forecasts decrease sales forecasts decrease sales forecast basis points increase discount rate basis points increase discount rate basis points decrease discount rate basis points decrease discount rate cent appreciation us dollar cent appreciation us dollar cent depreciation us dollar cent depreciation us dollar cent appreciation euro cent appreciation euro cent depreciation euro cent depreciation euro sales forecast viiv healthcare sales respect viiv healthcare put option accruals includes interest accrued financial liabilities amortised cost million million explanation accounting viiv healthcare set gsk annual report notes financial statements continued net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings commercial paper bank loans overdrafts us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us medium term note new york stock exchange lease liabilities longterm borrowings us us medium term note new york stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange longterm borrowings lease liabilities net debt partially purchased cancelled february gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information net debt continued current assets liquid investments classified financial assets amortised cost december included us treasury notes government bonds effective interest rate liquid investments december approximately approximately liquid investment balances december earning interest floating rates amount million million liquid investment balances december earning interest fixed rates amount nil million balances reported within cash cash equivalents original maturity three months less effective interest rate cash cash equivalents december approximately approximately cash cash equivalents december earning interest floating fixed rates amounted million million respectively million million noninterest bearing holdings amounted million million gsks policy regarding credit quality cash cash equivalents set note financial instruments related disclosures shortterm borrowings gsk billion billion us commercial paper programme million million issue december nil gsk billion euro commercial paper programme million million issue december million million february gsk cancelled billion three year billion billion day committed facilities replaced new revolving credit facilities equivalent size maturities september september respectively post separation consumer healthcare business facilities reduced billion billion billion respectively weighted average interest rate commercial paper borrowings december weighted average interest rate current bank loans overdrafts december average effective preswap interest rate notes classified shortterm december longterm borrowings yearend gsk longterm borrowings billion billion billion billion fell due five years three bonds repaid earlier original maturity us us medium term note us us medium term note us us medium term note also gsk undertook tender outstanding sterling notes repaying face values million euro medium term note million euro medium term note million euro medium term note million euro medium term note average effective preswap interest rate notes issue december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates ranging effective rates exclude impact oneoff premiums associated early repayment sterling notes pledged assets group held pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions lease liabilities maturity analysis discounted lease liabilities recognised group balance sheet follows rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total lease liabilities gsk annual report notes financial statements continued pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service pension costs defined benefit schemes accounting purposes calculated using projected unit credit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years remeasurement movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rates pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females us mortality rates calculated using pri white collar table adjusted reflect recent experience rates projected using mp allow future improvements life expectancy gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information pensions postemployment benefits continued average life expectancy assumed individual age projected apply individual age follows uk us male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment physical asset allocation strategy three four uk plans returnseeking assets liabilitymatching assets buyin insurance contract purchased cover substantially obligations uk plan december value insurance contract million million asset allocation us plans currently set returnseeking assets liabilitymatching assets pension plans exposed risk arises estimated market value plans assets might decline investment returns might reduce estimated value plans liabilities might increase line agreed mix returnseeking assets generate future returns liabilitymatching assets better match future pension obligations group defined overall longterm investment strategy plans investments across broad range assets main market risks within asset hedging portfolio credit risk interest rates long term inflation equities property currency bank counterparty risk plan liabilities series future cash flows relatively long duration ias basis cash flows sensitive changes expected longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation corresponds increase liabilities increase discount rate corresponds decrease liabilities interest rate risk credit rate risk us partially hedged targets based accounting measure plan liabilities uk plans interest rate inflation hedging strategy place targets based economic measure plan liabilities uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme addition group operates number postretirement healthcare schemes principal one us following period consultation impacted employees announced december uk defined benefit plans would closed future accrual effective march result post closure accrued benefits active participants revalued line inflation rpi legacy glaxo wellcome plans cpi legacy smithkline beecham plans subject relevant caps arrangement rather capped pay increases addition defined benefit plan participants still active april received defined pension contribution effect closure defined contribution enhancement together resulted oneoff cost million announced plan closed new entrants march april former defined benefits plans employees transferred defined contribution plans announced september us cash balance pension plans would closed future accrual january change resulted credit million june september two amendments made retiree healthcare plans us resulting credit million group applied following financial assumptions assessing defined benefit liabilities uk us rest world pa pa pa pa pa pa pa pa pa rate increase future earnings na na na na discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate sensitivity analysis detailing effect changes assumptions provided analysis provided reflects assumption changes material impact results groupgsk annual report notes financial statements continued pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service cost net interest cost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement losses recorded statement comprehensive income amounts included within past service costs uk included million million million augmentation costs arose major restructuring programmes together charge nil nil million relation impact closure defined benefit schemes future accrual past service credit million us reflected closure cash balance pension plans january amendments retiree healthcare plan us resulted credit million past service costs post retirement benefits hese numbers include remeasurement gainslosses related demerged consumer healthcare business comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised pensions postemployment benefits pension schemes deficit postretirement benefits event plan windup gsk believes uk pension scheme rules provide company right refund surplus assets following full settlement plan liabilities result net surplus uk defined benefit pension schemes recognised full fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets multiasset funds comprise investments pooled investment vehicles invested across range asset classes increasing diversification within growth portfolio value funds asset class quoted market price million million liabilitiesassets category comprises cash mark market values derivative positions indexlinked gilts held part uk repo programme included government bonds related loan million december million million deducted within assetsgsk annual report notes financial statements continued pensions postemployment benefits continued uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets asset ceiling restrictions present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements fair values assets assets january exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions transfer assets held saledistribution benefits paid assets december connection demerger consumer healthcare december pension scheme valuations identified cash funding technical provisions deficits three gsk uk pension schemes march gsk transferred gsk consumer healthcare holdings limited gskchh c ordinary shares representing aggregate gsks interest gskchh three scottish limited partnerships slps providing funding mechanism separate gsk uk defined benefit pension scheme part steps relating demerger separation slps transferred applicable portion gskchh c ordinary shares haleon plc haleon consideration shares haleon slps together hold shares representing total issued share capital haleon pension scheme slp interest entitled receive distribution slp amount equal net proceeds sales haleon shares receive dividend income haleon shares received aggregate amount equal agreed threshold proceeds threshold proceeds thresholds total million increased notional interest remaining balance time time payment amount would fully fund cash funding technical provisions deficits three pension schemes shown december valuations applicable proceeds threshold reached gskcontrolled general partner slp entitled sell remaining haleon shares held slp distribute proceeds gsk pension scheme receive aggregate cash equal applicable proceeds threshold within months separation trustee pension scheme ability require slp instruct broker liquidate remaining haleon shares behalf slp accordance agreed mandate group made additional funding contributions uk pension schemes million million million additional funding nil nil us schemes december total cash contributions totalling million made towards proceeds thresholds leaving principal amount million outstanding uk pension schemes cash contributions million include voluntary cash contributions made gsk q two uk defined benefit pension schemes totalling million response market volatility uk gilt marketsgsk annual report notes financial statements continued pensions postemployment benefits continued outstanding accelerated contributions collateralised creation three scottish limited partnerships slps gsk inserted total haleon ordinary shares across three slps three principal uk defined benefit pension schemes two benefiting current former glaxo welcome employees third benefiting current former smithkline beecham employees interest one slps shown scottish limited partnership general partner limited partners gsk scottish limited partnership gsk gp ltd gsk lp ltd berkeley square pension trustee company ltd acting behalf gsk pension scheme gsk scottish limited partnership gsk gp ltd gsk lp ltd berkeley square pension trustee company ltd acting behalf gsk pension fund gsk scottish limited partnership gsk gp ltd gsk lp ltd smithkline beecham pension plan trustee ltd acting behalf smithkline beecham pension plan slp partnership agreements limited partners involvement management business shall take part control slp general partner cases controlled gsk plc responsible management control slp slp consolidated results group slp therefore takes advantage exemption regulation partnership accounts regulations act prepare deliver audited accounts uk registrar slp partnership agreement distributions made partnership income defined benefit pension schemes equivalent payments already made three defined benefit pension schemes another gsk entity date million paid defined benefit pension schemes gsk structure contributions structure reach million defined benefit pension schemes interests slps ends remaining economic interest slps held gsk lp ltd owned subsidiary gsk plc december million additional contributions remains paid employer contributions excluding special funding contributions stated estimated approximately million respect defined benefit pension schemes million respect postretirement benefits postretirement pensions benefits uk us rest world group group movements defined benefit obligations obligations january exchange adjustments disposals service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions transfer assets held saledistribution benefits paid obligations december gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information pensions postemployment benefits continued defined benefit pension obligation analysed follows funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter december us postretirement healthcare scheme obligation million million million postretirement benefits unfunded movement net defined benefit liability follows january exchange adjustments service cost past service cost interest cost settlements curtailments remeasurements return plan assets excluding amounts included interest lossgain change demographic assumptions gainloss change financial assumptions experience lossgain employer contributions transfer assets held saledistribution expenses december remeasurements included within postretirement benefits detailed gain change demographic assumptions gainloss change financial assumptions experience gains defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits membership numbers restated disclosure relates postretirement benefit obligationsgsk annual report notes financial statements continued pensions postemployment benefits continued sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension postretirement costs detailed information determined taking account duration liabilities overall profile plan memberships increase decrease discount rate decreaseincrease annual pension cost increasedecrease annual postretirement benefits cost decreaseincrease pension obligation decreaseincrease postretirement benefits obligation increase decrease decreaseincrease annual pension cost increasedecrease annual postretirement benefits cost decreaseincrease pension obligation decreaseincrease postretirement benefits obligation increase decrease inflation rate increasedecrease annual pension cost increasedecrease pension obligation increase decrease increasedecrease annual pension cost increasedecrease pension obligation year increase life expectancy increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation increase annual postretirement benefits cost increase postretirement benefits obligation gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information provisions legal major employee restructuring related disputes programmes provisions provisions total january exchange adjustments charge year reversed unused unwinding discount utilised transfer assets held saledistribution additions business combinations reclassifications movements transfer pension obligations december settled within one year settled one year december legal disputes nature groups business number matters may subject negotiation litigation group involved substantial number legal many years litigation proceedings including various disputes including notification possible claims set appeal procedures often take many years reach resolution note legal proceedings provisions legal outofcourt settlement discussions also often disputes include amounts relating product liability protracted indemnified disputes result provision antitrust government investigations contract terminations charge corresponding receivable self insurance group potential settlement discussions number group may become involved significant legal disputes amounts provided proceedings respect possible based current assessment progress meaningfully assess whether outcome result disputes estimates million amount provided probable outflow quantify reliably estimate liability december settled within one year could result ultimate resolution december expected nil million proceedings cases group would provide provision made legal disputes appropriate disclosures cases provision reimbursed third parties discussion legal issues would made see note legal proceedings net charge year million including reversals major restructuring programmes estimated insurance recoveries primarily related provisions product liability cases commercial disputes group two major restructuring various government investigations programmes progress separation preparation programme focused preparing separation discount provision million nil gsk two new companies significant acquisitions discount calculated using riskadjusted projected programme focused integration recent cash flows riskfree rates return acquisitions respect product liability claims related certain restructuring provisions primarily include severance costs products provision made sufficient history management made formal decision eliminate claims made settlements enable management make certain positions communicated reliable estimate provision required cover groups employees affected appropriate consultation unasserted claims ultimate liability matters may procedures completed appropriate provision vary amounts provided dependent upon made staff severance payments paid immediately outcome litigation proceedings investigations possible settlement negotiations discount provisions increased million increased million groups position could change time therefore assurance losses result pension augmentation includes million relating outcome legal proceedings exceed defined benefit plan arising staff redundancies shown material amount amount provisions reported note pensions postemployment benefits groups financial accountsgsk annual report notes financial statements continued employee related provisions given nature provisions amounts likely settled many years employee related provisions include obligations certain medical benefits disabled employees spouses provisions us included provisions provisions onerous december provision benefits contracts insurance provisions number amounted million million employee provisions including vehicle insurance regulatory matters benefits reflect variety provisions severance costs jubilee awards longservice benefits gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information contingent consideration liabilities consideration certain acquisitions includes amounts contingent future events development milestones sales performance group provided fair value contingent consideration follows shionogi viiv novartis healthcare affinivax vaccines total january remeasurement income statement cash payments operating cash flows cash payments investing activities december remeasurement income statement cash payments operating cash flows cash payments investing activities december remeasurement income statement exchange movement reserves initial recognition business combinations cash payments operating cash flows cash payments investing activities december contingent consideration payable december million million expected paid within one year consideration payable acquisition shionogiviiv healthcare joint venture affinivax novartis vaccines business expected paid number years result total estimated liabilities discounted present values shown shionogiviiv healthcare contingent consideration liability discounted affinivax contingent consideration liability discounted novartis vaccines contingent consideration liability discounted commercialised products pipeline assets shionogiviiv healthcare novartis vaccines contingent consideration liabilities calculated principally based forecast sales performance specified products lives products affinivax contingent consideration based upon two potential milestone payments billion billion paid certain pediatric clinical development milestones achieved table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuations contingent consideration liabilities shionogi shionogi viiv novartis viiv novartis increasedecrease financial liability healthcare affinivax vaccines healthcare vaccines lossgain income statement increase sales forecasts na increase sales forecasts na decrease sales forecasts na decrease sales forecasts na increase discount rate increase discount rate decrease discount rate decrease discount rate cent appreciation us dollar cent appreciation us dollar cent depreciation us dollar cent depreciation us dollar cent appreciation euro na cent appreciation euro na cent depreciation euro na cent depreciation euro na increase probability milestone success na na decrease probability milestone success na na sales forecast viiv healthcare sales respect shionogiviiv healthcare contingent consideration explanation accounting viiv healthcare set gsk annual report notes financial statements continued noncurrent liabilities accruals deferred income payables payables includes number employeerelated liabilities including employee savings plans contingent liabilities december contingent liabilities gsk present obligation result past event comprising guarantees items arising normal course business amounted million million december million million financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow possible meaningfully assess whether outcomes result probable outflow quantify reliably estimate liability provision recorded descriptions significant legal disputes group party set note legal proceedings commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions postretirement benefits interest loans future finance charges leases lease contracts yet commenced commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted net decrease intangible asset commitments mainly attributable termination certain agreements offset number new rd collaborations including collaborations spero therapeutics inc wuxi biologics ireland limited springworks therapeutics inc arrowhead pharmaceuticals inc gsk reached agreement trustees uk pension schemes make additional contributions million eliminate pension deficit identified december actuarial funding valuation prior consumer healthcare demerger gsk agreed collateralise commitment accelerate funding additional contributions see note december million additional contributions remained unpaid group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information share capital share premium account share consolidation following completion consumer healthcare business demerger july gsk plc ordinary shares consolidated maintain share price comparability demerger consolidation approved gsk shareholders general meeting held july shareholders received new ordinary shares nominal value pence every existing ordinary share nominal value pence earnings per share diluted earnings per share adjusted earnings per share dividends per share retrospectively adjusted reflect share consolidation periods presented ordinary shares p preshare consolidation share ordinary shares p postshare consolidation premium number share capital issued fully paid january issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes ordinary shares acquired esop trusts december impact share consolidation issued employee share schemes ordinary shares acquired esop trusts december december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid shares authorised issue nominal carrying market values shares held esop trusts disclosed note employee share schemes movements equity retained earnings reserves amounted million december million million million million million related associates joint ventures cumulative translation exchange equity follows net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates december exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates december exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates movement attributable continuing operations movement attributable discontinued operationsa december includes million reclassification consolidated income statement exchange movements related demerger consumer healthcare businessgsk annual report notes financial statements continued movements equity continued analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal subsidiaries associates fair value movements cash flow hedges tax fair value movements cash flow hedges reclassification cash flow hedges income items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement defined benefit plans tax remeasurement defined benefit plans fair value movements cash flow hedges comprehensive expenseincome year continuing operations comprehensive expenseincome year discontinued operations total comprehensive expenseincome year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal subsidiaries associates fair value movements cash flow hedges tax fair value movements cash flow hedges reclassification cash flow hedges income statement items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement losses defined benefit plans tax remeasurement defined benefit plans comprehensive expenseincome year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal subsidiaries associates fair value movements cash flow hedges tax fair value movements cash flow hedges reclassification cash flow hedges income statement items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement gains defined benefit plans tax remeasurement defined benefit plans comprehensive expenseincome year information net investment hedges provided part note financial instruments related disclosures gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information movements equity continued analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january exchange adjustments transferred retained earnings year disposal equity investments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december exchange adjustments transferred income expenses year impairments equity investments transferred retained earnings year disposal equity investments net fair value movement year december exchange adjustments transferred retained earnings year disposal equity investments balances derecognised demerger net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million noncontrolling interests total noncontrolling interests includes following individually material noncontrolling interests noncontrolling interests individually material viiv healthcare gsk holds viiv healthcare subgroup giving rise material noncontrolling interest summarised financial information available latest practicable date respect viiv healthcare subgroup follows turnover profit taxation comprehensive incomeexpense total comprehensive income noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net liabilities net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities increasedecrease cash bank overdrafts year gsk annual report notes financial statements continued noncontrolling interests continued financial information relates viiv healthcare group standalone basis impact grouprelated adjustments primarily related recognition preferential dividends profit taxation million million million stated charging preferential dividends payable gsk pfizer charge million million million remeasurement contingent consideration payable consideration expected paid number years following amounts attributable viiv healthcare group included gsks financial statements share profit year attributable noncontrolling interest dividends paid noncontrolling interest noncontrolling interest consolidated balance sheet consumer healthcare joint venture gsk held consumer healthcare subgroup demerger july see details note giving rise material noncontrolling interest summarised financial information respect consumer healthcare subgroup december follows noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets financial information relates former consumer healthcare joint venture standalone basis impact grouprelated adjustments classification cash pooling accounts group companies outside consumer healthcare joint venture major restructuring charges following amounts attributable consumer healthcare joint venture included gsks financial statements prior years noncontrolling interest consolidated balance sheet related party transactions december loans due gsk related parties million due medicxi ventures lp cash distributions received investment medicxi ventures lp million medicxi ventures lp million longwood founders fund lp million apollo therapeutics llp million part joint venture agreement qura therapeutics llc group obligation fund joint venture april gsk joint venture partner committing financial support amount million december outstanding liability due qura million million group significant related party transactions might reasonably expected influence decisions made users financial statements aggregate compensation directors glt given note employee costs gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given business acquisitions july gsk completed acquisition sierra oncology inc californiabased latestage biopharmaceutical company focused targeted therapies treatment rare forms cancer billion billion main asset momelotinib targets medical needs myelofibrosis patients anaemia total transaction costs million august gsk completed acquisition affinivax inc clinicalstage biopharmaceutical company based cambridge boston massachusetts focused pneumococcal vaccine candidates consideration acquisition comprised upfront payment billion billion adjusted working capital acquired paid upon closing two potential milestone payments billion billion paid upon achievement certain paediatric clinical development milestones estimated fair value contingent consideration payable million values provisional subject change total transaction costs million since acquisition sales arising sierra oncology affinivax businesses included group turnover revenue expected regulatory approval received acquired assets gsk continues support ongoing development acquired assets consequently assets loss making regulatory approval assets received development assets integrated groups existing rd activities impracticable quantify development costs impact total profit taxation period goodwill million million sierra oncology million affinivax expected deductible tax purposes recognised goodwill represents workforce place specific synergies available gsk business combinations goodwill allocated groups commercial operations rd segments refer note goodwill allocation methodology sierra oncology affinivax total net assets acquired intangible assets property plant equipment right use assets inventory trade receivables cash cash equivalents lease liabilities trade payables taxation goodwill total total cash fair value contingent consideration november gsk signed agreement buy noncontrolling interest glaxo saudi arabia ltd sar million million paid gsk annual report notes financial statements continued acquisitions disposals continued demerger consumer healthcare business july gsk plc separated consumer healthcare business gsk group form haleon independent listed company separation effected way demerger gsks holding consumer healthcare business gsk shareholders following demerger haleon held aggregate gsk shareholders remains held gsk including shares received gsks consolidated esop trusts remains held certain scottish limited partnerships slps set provide collateral funding mechanism pursuant gsk provide additional funding gsks uk defined benefit pension schemes note aggregate ownership gsk including ownership esop trusts slps demerger measured fair value changes profit loss pfizer continued hold haleon demerger ifric distributions noncash assets owners liability equity distribution measured fair value assets distributed dividend appropriately authorised longer entitys discretion liability equity movement associated gain distribution recognised q demerger distribution authorised occurred asset distributed ownership consumer healthcare business net carrying value consumer healthcare business consolidated financial statements including retained net amount attributable noncontrolling interest approximately billion end june gsks billion share shareholder loans made q advance preseparation dividends eliminated consolidated financial statements assets distributed reduced consumer healthcare transactions july principally included preseparation dividends declared settled end q july dividends included billion billion attributable gsk dividends funded consumer healthcare debt partially onlent q dividends billion billion attributable gsk available cash balances fair value ownership consumer healthcare business distributed billion measured reference quoted average haleon share price first five days trading fair value measured observable inputs considered representative fair value distribution date gain distribution fair value less book value attributable net assets consumer healthcare business billion recorded income statement additional gain billion remeasure retained book value fair value billion using fair value methodology used distributed shares gain distribution remeasurement retained stake upon demerger presented part discontinued operations future gains losses retained stake haleon recognised continuing operations addition reclassification groups share cumulative exchange differences arising translation foreign currency net assets divested subsidiaries offsetting net investment hedges reserves income statement billion total gain demerger consumer healthcare billion transactions presented profit discontinued operations fair value consumer healthcare business distributed fair value retained ownership haleon plc total fair value carrying amount net assets liabilities distributedderecognised carrying amount noncontrolling interest derecognised gain demerger exchange movements transaction costs reclassification exchange movements net investment hedge movements disposal overseas subsidiaries total gain demerger consumer healthcare gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information acquisitions disposals continued consumer healthcare presented discontinued operation june disclosed interim financial statements consolidated income statement consolidated cash flow statement distinguish discontinued operations continuing operations comparative figures restated consistent basis financial information relating operations consumer healthcare period set includes financial information july financial information differs purpose basis preparation historical financial information interim financial information included haleon prospectus published haleon march result whilst two sets financial information similar certain differences accounting disclosure ifrs total results turnover expense profit tax taxation tax rate lossprofit taxation discontinued operations consumer healthcare gainslosses demerger remeasurement discontinued operations distributed shareholders demerger profit taxation demerger discontinued operations noncontrolling interest discontinued operations earnings attributable shareholders discontinued operations earnings per share discontinued operations p p p business disposals material business disposals business business business disposals disposals cash flows acquisitions demerger cash consideration net deferred consideration paid cash cash equivalents divestedacquired transaction costs paid cash outflowinflow cash consideration business acquisitions included million related business acquisition activity business acquisitions gsk completed material business acquisitions business disposals gsk made number business disposals net cash consideration received year million profit disposal businesses year million calculated follows total consideration cash consideration including currency forwards purchase adjustments deferred consideration total net assets sold property plant equipment cash cash equivalents net assets total costs deal costs reclassification exchange comprehensive income gain disposals gsk annual report notes financial statements continued acquisitions disposals continued associates joint ventures may gsk agreed innoviva inc innoviva sell approximately million shares common stock innoviva back innoviva price per share raising gross proceeds approximately million following settlement transaction gsk longer hold innoviva stock see details note investment associates joint ventures cash flows associates joint business ventures disposals disposals cash consideration received net deferred consideration paid transaction costs cash cash equivalents divestedacquired cash outflowinflow business acquisitions gsk completed one smaller business acquisition acquired pfizer biotech corporation taiwan part pfizers consumer healthcare business previously recognised part consumer healthcare joint venture september non cash consideration million represented goodwill million cash million assets acquired million less noncontrolling interest million net liabilities million total net assets acquired intangible assets property plant equipment inventory trade receivables cash cash equivalents trade payables noncontrolling interest goodwill noncash consideration settlement promissory note total consideration business disposals april gsk completed divestment horlicks consumer healthcare nutrition products india number countries excluding bangladesh unilever merger gsks indian listed consumer healthcare entity hindustan unilever indian listed public company gsk received equity stake hindustan unilever million cash gsk disposed equity stake hindustan unilever may divestment bangladesh closed june total cash consideration received million cash divested part disposal india bangladesh consumer healthcare entities million gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information acquisitions disposals continued profit disposal businesses year million calculated follows horlicks divestment total consideration cash consideration receivable including currency forwards purchase adjustments equity investment hindustan unilever limited total net assets disposed goodwill intangible assets property plant equipment inventory cash cash equivalents net liabilitiesassets total costs transaction costs derivative reclassification exchange comprehensive income total gain disposals exposure share price movements embedded agreement merge gsks indian listed consumer healthcare entity hindustan unilever limited part divestment horlicks nutrition products india number countries recognised derivative signing agreement completion transaction million recorded cost table derecognition derivative asset largely reflects fair value gains recognised income statement prior periods associates joint ventures year gsk made investments associates million million paid cash associates joint cash flows business business ventures acquisitions disposals investments cash consideration receivedpaid net deferred consideration transaction costs cash cash equivalents acquireddivested cash outflowinflow includes consumer healthcare disposals income statement impact restatedgsk annual report notes financial statements continued djustments reconciling total profit tax operating cash flows total profit tax continuing operations tax profits share aftertax profits associates joint ventures finance expense net finance income depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets loss sale investments associates profit sale equity investments changes working capital decreaseincreasein inventories increase trade receivables increase trade payables increase receivables contingent consideration paid see note noncash increase contingent consideration liabilities increase payables increasedecrease pension provisions sharebased incentive plans fair value adjustments operating cash flow continuing operations operating cash flow discontinued operations total cash generated operations comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information reconciliation net cash flow movement net debt net debt beginning year adjusted increase cash bank overdrafts increasedecrease liquid investments increase longterm loans repayment shortterm notes repayment ofincrease shortterm loans repayment medium term notes mtns repayment lease liabilities debt subsidiary undertakings acquired exchange adjustments noncash movements decreaseincrease net debt continuing operations decreaseincrease net debt discontinued operations total net debt end year january interest change reclass december exchange expense fair value ifications demerger cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts liquid investments attributed continuing operations liquid investments attributed discontinued operations debt due within one year commercial paper europeanus mtn bank facilities lease liabilities debt due within one year attributed continuing operations debt due within one year attributed discontinued operations debt due one year europeanus mtn bank facilities lease liabilities debt due one year attributed continuing operations debt due one year attributed discontinued operations net debt interest payable derivative financial instruments total liabilities financing activities excluding cash cash equivalents overdrafts liquid investmentsgsk annual report notes financial statements continued reconciliation net cash flow movement net debt continued january interest change reclass december exchange expense fair value ifications cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts debt due within one year commercial paper europeanus mtn bank facilities lease liabilities debt due one year europeanus mtn bank facilities lease liabilities net debt interest payable derivative financial instruments total liabilities financing activities excluding cash cash equivalents overdrafts liquid investments information significant changes net debt see note net debt gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information financial instruments related disclosures objective gsks treasury activities minimise gsk access shortterm finance billion posttax net cost financial operations reduce billion us commercial paper programme million volatility benefit earnings cash flows gsk uses variety million issue december nil financial instruments finance operations derivative gsk access shortterm finance billion euro financial instruments manage market risks commercial paper programme million million operations derivatives principally comprise foreign exchange issue december million forward contracts swaps used swap million february gsk cancelled billion three borrowings liquid assets currencies required group year billion billion day committed facilities purposes well interest rate swaps used replaced new revolving credit facilities manage exposure financial risks changes interest equivalent size maturities september rates financial instruments reduce uncertainty september respectively post separation consumer foreign currency transactions interest payments healthcare business facilities reduced billion billion billion respectively derivatives used exclusively hedging purposes relation underlying business activities trading committed facilities undrawn december speculative instruments gsk considers level committed facilities adequate given current liquidity requirements capital management gsk billion euro medium term note programme gsks financial strategy supports groups strategic priorities december billion notes issue regularly reviewed board gsk manages programme group also billion capital structure group appropriate mix billion notes issue december us debt equity shelf registration gsk currently process renewing capital structure group consists net debt us shelf registration statement order maintain access billion see note net debt total equity including us debt markets gsks borrowings mature dates items related noncontrolling interests billion see consolidated statement changes equity put option owned pfizer viiv healthcare total capital including provided noncontrolling exercisable reviewing liquidity requirements gsk considers interests billion sufficient financing options available put group continues manage financial policies credit option exercised profile particularly targets shortterm credit ratings p maintaining single longterm ratings consistent market risk targets groups longterm credit rating interest rate risk management standard poors stable outlook moodys gsks objective minimise effective net interest cost investor services moodys stable outlook balance mix debt fixed floating rates time groups shortterm credit ratings p standard groups main interest rate risk arises borrowings poors moodys respectively investments floating rates refinancing maturing fixed rate debt changes interest rates affect liquidity risk management future cash flows fair values financial instruments gsks policy borrow centrally order meet anticipated policy interest rate risk management limits net amount funding requirements strategy diversify liquidity floating rate debt specific cap reviewed agreed sources using range facilities maintain broad less annually board access financial markets day sweep cash number global subsidiaries central treasury majority debt issued fixed interest rates accounts liquidity management purposes gsk utilises changes floating rates interest significantly physical notional cash pool arrangements appropriate affect groups net interest charge shortterm borrowings location currency notional cash pools liquidity including bank facilities exposed risk future drawn foreign currency balances provide local changes market interest rates majority cash funding central liquidity required balances liquid investments actively managed maintained appropriate levels balances notional pooling arrangements settled across currencies gross cash overdraft balances reported december gsk billion borrowings repayable within one year held billion cash cash equivalents liquid investments billion held centrallygsk annual report notes financial statements continued financial instruments related disclosures continued foreign exchange risk management treasuryrelated credit risk groups objective minimise exposure overseas gsk sets global counterparty limits gsks banking operating subsidiaries transaction risk matching local investment counterparties based longterm credit currency income local currency costs possible ratings moodys standard poors usage foreign currency transaction exposures arising external limits actively monitored internal trade flows selectively hedged gsks internal gsk actively manages exposure credit risk reducing trading transactions matched centrally intercompany surplus cash balances wherever possible part gsks payment terms managed reduce foreign currency risk strategy regionalise cash management concentrate possible gsk manages cash surpluses borrowing cash centrally much possible table sets requirements subsidiary companies centrally using forward credit exposure counterparties rating liquid contracts hedge future repayments back originating investments cash cash equivalents derivatives currency gross asset position derivative contract order reduce foreign currency translation exposure considered purpose table although isda group seeks denominate borrowings currencies agreements amount risk net position principal assets cash flows primarily counterparty table e sets groups denominated us dollars euros sterling borrowings financial assets liabilities offset basis swapped currencies required borrowings denominated swapped foreign currencies match investments overseas group assets may treated hedge relevant assets forward contracts major currencies also used reduce exposure groups investment overseas assets see net investment hedges section note details credit risk credit risk risk counterparty default contractual obligations resulting financial loss group arises cash cash equivalents favourable derivative financial instruments held banks financial institutions well credit exposures wholesale retail customers including outstanding receivables group considers maximum credit risk december million december million total groups financial assets exception investments comprising equity investments bear equity risk rather credit risk see details groups total financial assets december gsks greatest concentration credit risk billion wholesaler us billion wholesaler us see information groups credit risk exposure respect three largest us wholesaler customers change estimation techniques significant assumptions made current reporting period assessing loss allowance financial assets amortised cost fvtoci since adoption ifrs start reporting period gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information financial instruments related disclosures continued december million million cash categorised held unrated subinvestment grade rated counterparties lower bbbbaa nil million cash transit remaining exposure concentrated overseas banks used local cash management investment purposes including million nigeria held united bank africa zenith bank access bank stanbic ibtc bank million halk bank uk million produbanco ecuador million j trust royal bank cambodia million banco brasil brazil million banco de honduras honduras million bac san jos costa rica million bank balances deposits held bbbbaa rated counterparties million held bbbbaa rated counterparties including balances deposits million state bank india india banks used local investment purposes gsk measures expected credit losses cash cash equivalents function individual counterparty credit ratings associated month default rates expected credit losses cash cash equivalents thirdparty financial derivatives deemed immaterial loss experienced credit ratings assigned standard poors moodys respectively opinions two rating agencies differ gsk assigns lower rating two counterparty local rating agency fitch data source available ratings converted global ratings equivalent standard poors moodys using published conversion tables credit ratings form basis assessment expected credit loss treasuryrelated balances held amortised cost bank balances deposits government securities bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities third party financial derivatives total bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities third party financial derivatives total gsks centrally managed cash reserves amounted billion concentration trade receivables reflective standard december available within three months market practice us pharmaceuticals sector includes billion cash managed group viiv significant portion sales made three wholesalers healthcare owned subsidiary group invested disclosed note gsks assessment limited centrally managed liquid assets bank deposits aaaaaa rated credit risk associated customers us treasury treasury repo money market funds groups credit risk monitoring activities relating aaaaaa rated liquidity funds wholesalers include review quarterly financial wholesale retail credit risk information standard poors credit ratings development outside us customer accounts gsk internal risk ratings establishment periodic review groups trade receivables balance credit limits us line pharmaceutical companies group new customers subject credit vetting process sells products small number wholesalers existing customers subject review least annually addition hospitals pharmacies physicians groups vetting process subsequent reviews involve obtaining sales three largest wholesalers amounted approximately information including customers status government sales us commercial operations private sector entity audited financial statements credit bureau business reports debt rating agency eg moodys standard poors reports payment performance history trade references december group trade receivables due industry credit groups bank references three wholesalers totalling million total trade receivables million group exposed concentration credit risk respect wholesalers one encounters financial difficulty could materially adversely affect groups financial resultsgsk annual report notes financial statements continued financial instruments related disclosures continued trade receivables consist amounts due large number fair value financial assets liabilities customers spread across diverse industries excluding lease liabilities geographical areas ongoing credit evaluation performed table presents carrying amounts financial condition accounts receivable fair values groups financial assets liabilities appropriate credit insurance purchased factoring excluding lease liabilities december arrangements put place december amount information obtained proportional level fair values financial assets liabilities exposure considered information evaluated included price would received sell asset quantitatively ie credit score qualitatively ie judgement paid transfer liability orderly transaction conjunction customers credit requirements determine market participants measurement date credit limit following methods assumptions used measure trade receivables grouped customer segments fair values significant financial instruments carried fair similar loss patterns assess credit risk receivables value balance sheet financial assets assessed individually historical forwardlooking information considered determine investments equity investments traded active appropriate expected credit loss allowance market determined reference relevant stock exchange quoted bid price equity investments group believes credit risk provision required determined reference current market value excess allowance expected credit losses see note similar instruments recent financing rounds trade receivables discounted cash flows underlying net assets credit enhancements trade receivables carried fair value based invoiced group uses credit enhancements including factoring amount credit insurance minimise credit risk trade receivables group december million interest rate swaps foreign exchange forward contracts million trade receivables insured order swaps options based present value protect receivables loss due credit risks contractual cash flows option valuation models using default insolvency bankruptcy market sourced data exchange rates interest rates balance sheet date group entity assesses credit risk private customers determine credit insurance required cash cash equivalents carried fair value based net asset value funds factoring arrangements managed locally entities used mitigate risk arising large credit risk contingent consideration business acquisitions concentrations factoring arrangements nonrecourse divestments based present values expected future cash flows following methods assumptions used estimate fair values significant financial instruments measured fair value balance sheet receivables payables including put options carried amortised cost approximates carrying amount liquid investments approximates carrying amount cash cash equivalents carried amortised cost approximates carrying amount longterm loans based quoted market prices level fair value measurement case european us medium term notes approximates carrying amount case fixed rate borrowings floating rate bank loans shortterm loans overdrafts commercial paper approximates carrying amount short maturity instruments gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information financial instruments related disclosures continued carrying fair carrying fair value value value value notes financial assets measured amortised cost noncurrent assets b trade receivables b liquid investments cash cash equivalents financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables ab financial assets mandatorily measured fair value profit loss fvtpl current equity investments investments noncurrent assets ab trade receivables ab held trading derivatives designated effective hedging relationship ade cash cash equivalents derivatives designated effective hedging instruments fair value movements comprehensive income ade total financial assets financial liabilities measured amortised cost borrowings excluding obligations lease liabilities bonds designated hedging relationship bonds bank loans overdrafts commercial paper designated hedging relationship commercial paper borrowings total borrowings excluding lease liabilities f trade payables c provisions noncurrent liabilities c financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities ac held trading derivatives designated effective hedging relationship ade derivatives designated effective hedging instruments fair value movements comprehensive income ade total financial liabilities excluding lease liabilities net financial assets financial liabilities excluding lease liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets trade payables provisions contingent consideration liabilities noncurrent liabilities reconciled relevant notes pages gsk annual report notes financial statements continued financial instruments related disclosures continued fair value investments gsk shares december employee share ownership plan esop trusts held gsk shares carrying value million million market value million million based quoted market price shares held esop trusts satisfy future exercises options awards employee incentive schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earnings financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations investments provide access biotechnology developments potential interest level level level total december financial assets fair value financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl current equity investments investments noncurrent assets trade receivables held trading derivatives designated effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value movements oci financial liabilities fair value financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities held trading derivatives designated effective hedging relationship derivatives designated effective hedging instruments fair value movements oci level level level total december financial assets fair value financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets trade receivables held trading derivatives designated effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value movements oci financial liabilities fair value financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities held trading derivatives designated effective hedging relationship derivatives designated effective hedging instruments fair value movements oci gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information financial instruments related disclosures continued movements year financial instruments measured using level valuation methods presented january exchange adjustments net losses recognised income statement net gains recognised comprehensive income contingent consideration related business acquisitions period settlement contingent consideration liabilities additions disposals settlements transfers level december total net losses million million attributable level financial instruments recognised income statement million million respect financial instruments held end year reported operating incomeexpense charges million million arose remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture million million arose remeasurement contingent consideration payable acquisition novartis vaccines business acquisition affinivax resulted additon million contingent consideration level financial liabilities million remeasurement charge arising period acquisition december transfers level financial instruments year transfers related equity instruments transferred level valuation methodology result listing recognised stock exchange year movements arising translation overseas net assets consolidation group accounts recorded exchange adjustments net gains losses include impact exchange movements financial liabilities measured using level valuation methods december included million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years vary line future performance specified products movements certain foreign currencies million million respect contingent consideration acquisition novartis vaccines business consideration expected paid number years vary line future performance specified products achievement certain milestone targets movements certain foreign currencies result groups acquisition affinivax contingent consideration payable million recognised december consideration expected paid number years vary line achievement certain development milestones movements usdgbp exchange rate sensitivity analysis balances provided note contingent consideration liabilities b trade receivables noncurrent assets scope ifrs following table reconciles financial instruments within trade receivables noncurrent assets fall within scope ifrs relevant balance sheet amounts financial assets predominantly noninterest earning nonfinancial instruments include tax receivables pension surplus balances prepayments outside scope ifrs non non amortised financial financial amortised financial financial fvtpl fvtoci cost instruments instruments total fvtpl fvtoci cost instruments instruments total trade receivables note noncurrent assets note trade receivables include trade receivables million million group portfolios three business models ifrs million million measured fvtpl held sell contractual cash flows receivables sold factoring arrangement million million measured fvtoci held either collect sell contractual cash flows receivables may sold factoring agreement million million measured amortised cost held collect contractual cash flows factoring agreement placegsk annual report notes financial statements continued financial instruments related disclosures continued c trade payables provisions contingent consideration liabilities non current liabilities scope ifrs following table reconciles financial instruments within trade payables provisions contingent consideration liabilities noncurrent liabilities fall within scope ifrs relevant balance sheet amounts financial liabilities predominantly noninterest bearing nonfinancial instruments include payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ifrs non non amortised financial financial amortised financial financial fvtpl cost instruments instruments total fvtpl cost instruments instruments total trade payables note provisions note contingent consideration liabilities note noncurrent liabilities note derivative financial instruments hedging programmes derivatives used economic hedging purposes speculative investments classified held trading designated effective hedging instruments presented current assets liabilities expected settled within months end reporting period otherwise classified noncurrent group following derivative financial instruments fair value fair value assets liabilities assets liabilities noncurrent cash flow hedges interest rate swap contracts principal amount nil million current cash flow hedges foreign exchange contracts principal amount million million net investment hedges foreign exchange contracts principal amount million million derivatives designated effective hedging instruments noncurrent embedded derivatives current foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading total derivative instruments gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information financial instruments related disclosures continued fair value hedges december december group designated fair value hedges net investment hedges december certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro singaporean sgd canadian cad japanese jpy foreign operations shown table carrying value bonds included million million designated hedging instruments net investment hedges cash flow hedges group entered forward foreign exchange contracts designated cash flow hedges entered hedge foreign exchange exposure arising cash flows euro denominated coupon payments relating notes issued groups european medium term note programme hedge foreign currency payments due collaboration licensing arrangements group manages cash flow interest rate risk using floatingtofixed interest rate swaps addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued prior years current year balance reclassified finance costs life bonds foreign exchange risk current year group designated certain foreign exchange forward contracts swaps cash flow net investment hedges foreign exchange derivative financial assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet following tables detail foreign exchange forward contracts swaps outstanding end reporting period well information related hedged items hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessments ensure economic relationship exists hedged item hedging instrument group enters hedge relationships critical terms hedging instrument match exactly terms hedged item qualitative assessment effectiveness performed changes circumstances affect terms hedged item critical terms longer match exactly critical terms hedging instrument group uses hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationships effect counterparty groups credit risk fair value foreign exchange forward contracts swaps reflected fair value hedged item attributable changes foreign exchange rates ineffectiveness rolling cash flow hedges divestments mentioned sources ineffectiveness emerged hedging relationships ineffectiveness recorded cash flow hedges nil ineffectiveness recorded net investment hedges nil periodic change value calculating average foreign notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments cash flow hedges foreign exchange contracts buy foreign currency less months usd months eur months eur sell foreign currency less months eur gsk annual report notes financial statements continued financial instruments related disclosures continued periodic change value calculating average foreign notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments net investment hedges foreign exchange contracts sell foreign currency less months eur jpy months cad sgd borrowings less months eur months eur months eur balance cash flow hedge cumulative balance cash reserve arising hedging periodic change value flow hedge reserveforeign relationships hedge calculating hedge currency translation reserve accounting longer ineffectiveness continuing hedges applied hedged items cash flow hedges variability cash flows highly probable forecast transaction variability cash flows foreign exchange exposure arising euro denominated coupon payments relating debt issued net investment hedges net investment foreign operations periodic change value calculating average foreign notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments cash flow hedges foreign exchange contracts buy foreign currency less months usd months eur months eur periodic change value calculating average foreign notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments net investment hedges foreign exchange contracts sell foreign currency less months eur sgd jpy borrowings less months eur months eur gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information financial instruments related disclosures continued cumulative balance cash periodic change value flow hedge reserveforeign calculating hedge currency translation reserve ineffectiveness continuing hedges hedged items cash flow hedges variability cash flows foreign exchange exposure arising euro denominated coupon payments relating debt issued net investment hedges net investment foreign operations million million balances cash flow hedge reserve arise hedging relationships hedge accounting longer applied following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss amount reclassified balance sheet line item hedged amount profit future cash line item line item hedging hedge loss flows due profit loss balance gainslosses ineffectiveness hedge longer hedged item due hedged sheet recognised recognised ineffectiveness expected affecting reclassification item affecting reclassification reserves profit loss included occur profit loss adjustment balance sheet adjustment included included cash flow hedges variability cash flows finance intangible highly probable forecast income assets transaction expense variability cash flows finance finance foreign exchange exposure income income arising euro denominated expense expense coupon payments relating debt issued net investment hedges net investment foreign finance discontinued operations income operations expense amount reclassified profit loss amount reclassified balance sheet line item hedged amount profit future cash line item line item hedging hedge loss flows due profit loss balance gainslosses ineffectiveness hedge longer hedged item due hedged sheet recognised recognised ineffectiveness expected affecting reclassification item affecting reclassification reserves profit loss included occur profit loss adjustment balance sheet adjustment included included cash flow hedges variability cash flows highly probable forecast operating operating transaction income income expense expense variability cash flows finance finance foreign exchange exposure income income arising euro denominated expense expense coupon payments relating debt issued net investment hedges net investment foreign finance finance operations income income expense expense reclassified consolidated income statement demerger consumer healthcare businessgsk annual report notes financial statements continued financial instruments related disclosures continued interest rate risk group manages cash flow interest rate risk using floatingtofixed interest rate swaps quarterly intervals difference fixed contract rates floating rate interest amounts calculated reference agreed notional principal amounts exchanged none swaps outstanding december december interest rate risk element future debt issuance managed entering forward starting interest rate swaps effectively lock interest rates debt advance closed time issuing debt resulting gain loss held cash flow hedge reserve reclassified income statement interest payments debt impacted income statement debt derecognised demerger consumer healthcare business july forward starting interest rate swaps forward starting interest rate contracts exchanging floating interest fixed interest designated cash flow hedges hedge interest variability interest cash flows associated future fixed rate debt interest rate swaps following tables provide information regarding interest rate swap forward starting interest rate swap contracts outstanding related hedged items december swaps december interest rate swap contract assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet million million balances cash flow hedge reserve arise hedge relationships hedge accounting longer applied change fair value average notional recognising fair value contracted principal hedge assets fixed rate value ineffectiveness liabilities hedging instruments years years years balance change cash flow value used hedge reserve calculating continuing hedge hedges ineffectiveness tax hedged items prehedging longterm interest rate gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information financial instruments related disclosures continued following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss line item due line item amount profit hedged future profit loss hedging hedge loss cash flows due gainslosses ineffectiveness hedge longer hedged item reclassification recognised recognised ineffectiveness expected affecting adjustment reserves profit loss included occur profit loss included cash flow hedges prehedging longterm interest rates finance finance income income matured past expense expense amount reclassified profit loss line item due line item amount profit hedged future profit loss hedging hedge loss cash flows due gainslosses ineffectiveness hedge longer hedged item reclassification recognised recognised ineffectiveness expected affecting adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows finance finance income income expense expense prehedging longterm interest rates matured past finance finance years income income expense expense years years e offsetting financial assets liabilities financial assets liabilities offset net amount reported balance sheet legally enforceable right offset recognised amounts intention settle net basis realise asset settle liability simultaneously also arrangements meet criteria offsetting still allow related amounts offset certain circumstances bankruptcy termination contract following tables set financial assets liabilities offset subject enforceable master netting arrangements similar agreements offset december december column net amount shows impact groups balance sheet offset rights exercised gross gross net financial related financial financial assets amounts assets liabilities liabilities per set liabilities assets set balance sheet balance sheet net december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments gsk annual report notes financial statements continued financial instruments related disclosures continued gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset balance december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party presently legally enforceable right offset amounts offset balance sheet presented separately table f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings lease liabilities total debt total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information financial instruments related disclosures continued g sensitivity analysis tables illustrate estimated impact income statement equity result hypothetical market movements foreign exchange interest rates relation groups financial instruments range variables chosen sensitivity analysis reflects managements view changes reasonably possible oneyear period foreign exchange sensitivity group operates internationally primarily exposed foreign exchange risk relation sterling movements us dollar euro japanese yen foreign exchange risk arises translation financial assets liabilities functional currency entity holds based groups net financial assets liabilities december weakening strengthening sterling currencies variables held constant illustrated tables tables exclude financial instruments expose group foreign exchange risk risk fully hedged another financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation us dollar cent appreciation euro cent appreciation euro yen appreciation yen yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent depreciation us dollar cent depreciation us dollar cent depreciation euro cent depreciation euro yen depreciation yen yen depreciation yen equity impact shown foreign exchange sensitivity relates derivative nonderivative financial instruments hedging groups net investments european euro foreign operations cash flow hedges foreign exchange exposure arising euro denominated coupon payments relating notes issued groups european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation euro cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent depreciation euro cent depreciation euro gsk annual report notes financial statements continued financial instruments related disclosures continued tables present groups sensitivity weakening strengthening sterling relevant currency based composition net debt shown note adjusted effects foreign exchange derivatives part net debt affect future foreign currency cash flows increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent appreciation us dollar cent appreciation euro cent appreciation euro yen appreciation yen yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent depreciation us dollar cent depreciation us dollar cent depreciation euro cent depreciation euro yen depreciation yen yen depreciation yen interest rate sensitivity group exposed interest rate risk outstanding borrowings investments changes interest rates affect future cash flows fair values financial instruments majority debt issued fixed interest rates changes floating rates interest significantly affect groups net interest charge although majority cash liquid investments earn floating rates interest table hypothetically shows groups sensitivity changes interest rates relation sterling us dollar euro floating rate financial assets liabilities basis points movement usd interest rates would cause increase nil equity million basis points movement usd interest rates would cause increase nil equity million basis points basis points movement eur sterling interest rates deemed material effect equity increasedecrease increasedecrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase us dollar interest rates basis points increase euro interest rates basis points increase euro interest rates gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information financial instruments related disclosures continued h contractual cash flows nonderivative financial liabilities derivative instruments following tables provide analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis purpose table debt defined classes borrowings except lease liabilities interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december finance trade payables charge interest lease lease liabilities debt debt liabilities liabilities net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance trade payables charge interest lease lease liabilities debt debt liabilities liabilities net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows table provides analysis anticipated contractual cash flows groups derivative instruments excluding equity options give rise cash flows embedded derivatives material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purpose table although practice group uses standard settlement arrangements reduce liquidity requirements instruments gross cash inflows gross cash outflows gross cash inflows gross cash outflows foreign foreign foreign foreign forward exchange forward exchange forward exchange forward exchange starting forward starting forward starting forward starting forward interest rate contracts interest rate contracts interest rate contracts interest rate contracts swaps swaps swaps swaps swaps swaps swaps swaps less one year one two years two three years three four years four five years greater five years gross contractual cash flows gsk annual report notes financial statements continued employee share schemes gsk operates several employee share schemes including share value plan whereby awards granted employees acquire shares ads gsk plc cost threeyear vesting period performance share plan whereby awards granted employees acquire shares ads gsk plc cost subject achievement group specified performance targets granting restricted share awards replaced granting options employees cost schemes readily equates potential gain made employee group also operates savings related share option schemes whereby options granted employees acquire shares gsk plc discounted price grants restricted share awards normally exercisable end threeyear vesting performance period awards normally granted employees acquire shares ads gsk plc circumstances may settled cash grants savingsrelated share option schemes normally exercisable three years saving accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant options historical share option schemes granted market price ruling date grant value plans participating employees maintained demerger consumer healthcare business effect share consolidation see note total charge sharebased incentive plans million million million amount million million million arose share value plan see note employee costs details comparatives restated reflect consistent basis previously published reflect demerger consumer healthcare business see note gsk share award schemes share value plan share value plan share awards granted certain employees cost awards vest two half three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december comparatives restated reflect demerger consumer healthcare business aid year year volume comparability awards granted gsk employees performance share plan performance share plan share awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted performance conditions based three equally weighted measures threeyear performance period adjusted free cash flow tsr rd new product performance awards granted performance conditions based four measures threeyear performance period adjusted free cash flow tsr rd new product performance pipeline progress awards granted performance conditions based five measures threeyear performance period tsr pipeline progress profit measure sale measure esg environment fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant awards continuing business made million shares weighted fair value million ads weighted fair value december outstanding awards million shares million ads gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information employee share schemes continued share options savingsrelated options purposes valuing savingsrelated options arrive sharebased payment charge blackscholes option pricing model used assumptions used model follows grant grant grant riskfree interest rate dividend yield volatility expected life years years years savingsrelated options grant price including discount savingsrelated options outstanding share save plan share option schemes weighted number exercise price december range exercise prices options outstanding year end weighted average market price exercise year weighted average remaining contractual life years options million shares granted year savingsrelated share option scheme weighted average fair value december million savingsrelated share options exercisable change effective exercise price outstanding options year employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares gsk plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves amortised value proceeds receivable employees exercise transfer retained earnings trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report notes financial statements continued p rincipal group companies following represent principal subsidiaries countries incorporation group december equity share capital entities shown percentage columns companies incorporated principal country operation except stated england scotland glaxo group limited gsk scottish limited partnershipc glaxo operations uk limited gsk scottish limited partnershipc glaxo wellcome uk limited gsk scottish limited partnershipd glaxosmithkline capital plc glaxosmithkline export limited us glaxosmithkline finance plc affinivax inc glaxosmithkline holdings limiteda corixa corporation glaxosmithkline ihc limited glaxosmithkline capital inc glaxosmithkline intellectual property limited glaxosmithkline holdings americas inc glaxosmithkline intellectual property limited glaxosmithkline llc glaxosmithkline intellectual property limited gsk equity investments limited glaxosmithkline intellectual property development limited human genome sciences inc glaxosmithkline intellectual property limited stiefel laboratories inc glaxosmithkline research development limited tesaro inc glaxosmithkline services unlimiteda viiv healthcare company glaxosmithkline uk limited glaxosmithkline us trading limited setfirst limited smithkline beecham limited viiv healthcare finance limited viiv healthcare uk limited viiv healthcare uk limited europe others glaxosmithkline ag switzerland glaxo saudi arabia limited saudi arabia glaxosmithkline bv netherlands glaxo wellcome manufacturing pte ltd singapore glaxosmithkline biologicals sa belgium glaxosmithkline thailand limited thailand glaxosmithkline gmbh co kg germany glaxosmithkline australia pty ltd australia glaxosmithkline pharma gmbh austria glaxosmithkline brasil limitada brazil glaxosmithkline pharmaceuticals sa belgium glaxosmithkline far east bv taiwan glaxosmithkline sa spain glaxosmithkline ilaclari sanayi ticaret turkey glaxosmithkline spa italy glaxosmithkline inc canada glaxosmithkline single member aebe greece glaxosmithkline kk japan glaxosmithkline trading services limited republic irelandb glaxosmithkline korea limited republic korea gsk capital bv netherlandsb glaxosmithkline limited hong kong gsk services sp z oo poland glaxosmithkline mexico sa de cv mexico gsk vaccines gmbh germany glaxosmithkline pakistan limited pakistan gsk vaccines srl italy glaxosmithkline pharmaceuticals limited india jsc glaxosmithkline trading russia gsk enterprise management co ltd china laboratoire glaxosmithkline france gsk pharma vietnam company limited vietnam laboratorios viiv healthcare sl spain id biomedical corporation quebec canada viiv healthcare gmbh germany viiv healthcare kk japan viiv healthcare srl italy viiv healthcare ulc canada viiv healthcare sas france irectly held whollyowned subsidiary gsk plc b ax resident uk c g sk gp limited subsidiary undertaking gsk plc berkeley square pension trustee company limited general partner gsk scottish limited partnership gsk scottish limited partnership gsk gp limiteds share capital indirectly owned gsk plc owned berkeley square pension trustee company limited g sk gp limited subsidiary undertaking gsk plc general partner gsk scottish limited partnership gsk gp limiteds share capital indirectly owned gsk plc subsidiaries associates listed principally affect figures groups financial statements glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline finance plc gsk captial bv glaxosmithkline llc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline finance plc gsk capital bv glaxosmithkline llc see pages complete list subsidiary undertakings associates joint ventures form part financial statements gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information legal proceedings group involved significant legal administrative december teva filed petition rehearing en proceedings principally product liability intellectual property banc court granted tevas petition tax antitrust consumer fraud governmental rehearing threemember panel issued original investigations significant matters decision august original panel issued tax matters described group makes rehearing opinion majority reinstated provision proceedings regular basis jurys damages award million gsks favour summarised note accounting principles policies teva filed petition rehearing en banc note provisions note also describes rejected court appeals federal circuit disclosure made proceedings february july teva filed petition writ provision legal expenses incurred provisions related certiorari supreme court united states seeking legal claims charged selling general administration overturn federal court decision october costs group believe information supreme court invited united states solicitor general amount sought plaintiffs known would file briefs expressing views united states meaningful respect legal proceedings due number factors including limited stage dolutegravir proceedings proceedings entitlement parties appeal decision tivicaytriumeq clarity theories liability damages governing september viiv healthcare received paragraph iv law letter lupin relating tivicay mg dosage oral december groups aggregate provision suspension challenging crystal form patent legal disputes including tax matters described november viiv healthcare filed suit lupin note taxation million us district court district delaware trial date assurance losses result outcome yet set legal proceedings exceed material amount dovato amount provisions reported groups financial september viiv healthcare received paragraph iv statements happen could material letter cipla relating dovato challenging adverse impact results operations group crystal form patent november viiv healthcare filed reporting period judgements incurred suit cipla us district court district settlements entered delaware settlement reached case juluca intellectual property january viiv healthcare received paragraph iv intellectual property claims include challenges validity letter lupin relating juluca challenging crystal enforceability groups patents various products form patent well patent relating combination processes well assertions noninfringement dolutegravir rilpivirine expires january patents loss cases could result loss february viiv healthcare filed suit lupin patent protection product issue consequences patents settlement reached lupin loss could significant decrease sales additionally june cipla sent viiv healthcare product could materially affect future results operations paragraph iv letter related juluca july viiv group healthcare filed suit cipla federal court delaware coreg court set trial date gsk initiated suit teva inducing infringement patent relating use carvedilol product liability coreg decreasing mortality caused congestive heart group currently defendant number product failure june case proceeded jury trial us liability lawsuits district court district delaware jury returned avandia verdict gsks favour awarding gsk lost profits two pending us class actions brought thirdparty reasonable royalties total award million payers assert claims racketeer influenced march trial judge ruled posttrial motions filed corrupt organizations act rico state consumer teva found substantial evidence trial protection laws december third circuit court support jurys finding induced infringement overturning appeals reversed summary judgements granted favour jury award gsk appealed october group remanded thirdparty payer cases back divided panel court appeals federal circuit district court discovery underway district court reversed district courts ruling reinstated jury award trial dates yet set possible class gsks favour certification hearing held gsk annual report notes financial statements continued legal proceedings continued zantac california zantac litigation cases jccp jccp group contacted several regulatory court held sargon hearing regarding admissibility authorities regarding detection nnitroso expert witness testimony including testimony general dimethylamine ndma zantac ranitidine products based specific causation expert witnesses first bellwether information available time correspondence trial hearing occurred fourday period february regulators group made decision suspend march first bellwether trial bladder release distribution supply dose forms zantac cancer case expected start february markets pending outcome ongoing tests california jccp however court moved trial date investigations also precautionary action group july three california bellwether trials made decision initiate voluntary pharmacyretail level scheduled may august october although recall zantac products globally dates likely extended well april european medicines agency ema illinois supreme court recently consolidated illinois recommended suspension ranitidine medicines ranitidine cases cook county pretrial proceedings following publication emas recommendation trial dates set later date including previously company communicated decision reenter scheduled madison county trial market us fda requested manufacturers beyond personal injury actions class actions alleging withdraw ranitidine products market economic injury thirdparty payer class action also group named defendant approximately filed federal court plaintiffs moved personal injury cases us state courts federal stay class actions pending appeal daubert ruling zantac multidistrict litigation mdl court proceeding defendants oppose request stay asking southern district florida approximately court dismiss class actions outside us plaintiffs named cases significant majority seven class actions pending group canada plaintiffs named series multiplaintiff complaints along class action israel filed delaware state court plaintiffs given complex ownership marketing zantac previously mdl census registry removed prescription overthecounter otc medicine many allege cancer cancers years numerous claims involve several defendants result pursued mdl plaintiffs mdl plaintiffs originally defendants served one another including identified different types cancers wished pursue group notice potential indemnification claims plaintiffs subsequently dropped cancers possible liabilities connected particularly zantac otc proceeded bladder esophageal gastric liver given early stage proceedings group pancreatic cancers although plaintiffs state courts continue meaningfully assess liability may pursue claims beyond designated cancers meaningfully assess liability parties relevant unfiled claims relating group co indemnification provisions defendants mapped group concerning designated cancers mdl census registry addition march department justice also california state court cases subject doj sent group notice civil investigation agreement group plaintiffs opened allegations false claims act violations suspends statute limitations allow plaintiffs group related zantac june doj served bring claims later date filed unfiled counts civil investigative demand group formalizing subject change request documents day new mexico attorney general filed lawsuit multiple defendants december court presiding federal including group alleging violations state consumer mdl proceeding granted defendants daubert motions protection false advertising statutes among claims finding plaintiffs experts causation opinions regarding whether zantac cause five cancers issue mdl zofran liver bladder pancreatic esophageal stomach group defendant product liability cases unreliable thus inadmissible without expert causation involving zofran pending multidistrict litigation mdl opinions mdl court granted summary judgment gsk proceeding district massachusetts cases alleged brand defendants mdl court found children suffered birth defects due mothers scientist outside litigation concluded ingestion zofran andor generic ondansetron ranitidine causes cancer plaintiffs scientists within pregnancy related nausea vomiting plaintiffs asserted litigation systemically utilized unreliable methodologies group sold zofran knowing unsafe pregnant failed use consistent objective sciencebased standards women failed warn risks illegally marketed evenhanded evaluation data ruling effectively zofran offlabel use pregnant women dismissed approximately filed cases mdl binding claims census registry plaintiffs indicated appeal mdl decision gsk annual report notes financial statements continued strategic report governance remuneration financial statements investor information legal proceedings continued june mdl court granted groups motion lamictal summary judgment federal preemption grounds purported classes direct purchasers filed suit us court found fda fully informed relevant district court district new jersey alleging safety information regarding zofran repeatedly group teva pharmaceuticals unlawfully conspired rejected attempt add birth defect warning delay generic competition lamictal resulting label time court granted judgment group overcharges purchasers entering allegedly cases pending mdl approximately cases anticompetitive reverse payment settlement resolve patent closed mdl proceeding plaintiffs appealed decision infringement litigation separate count accuses group january united states court appeals monopolising market first circuit affirmed district courts decision december trial judge granted plaintiffs class favour group certification motion certifying class direct purchasers remains one state court case four proposed class group filed rule f motion court appeals actions canada third circuit challenging class certification decision april court appeals vacated lower courts sales marketing regulation grant class certification remanded issue back groups marketing promotion pharmaceutical lower court analysis vaccine products subject certain governmental october district court heard argument investigations private lawsuits brought litigants plaintiffs renewed motion class certification remand various theories law april district court denied plaintiffs motion gsk korea proceedings fair trade laws class certification putative direct purchaser class august gsk korea indicted koreas leaving potential class brandonly purchasers plaintiffs monopoly regulation fair trade laws relation moved supplement expert report seek additional government tenders hpv cervarix pcv synflorix discovery support addition certain generic vaccines prosecutor alleged gsk purchasers january district court denied korea actions least one employees plaintiffs motion supplement expert report seek interfered tender process national additional discovery held issue generic immunisation programme using straw bidders purchasers already decided denied courts ruling decertification parties conducted former gsk korea employee also charged briefing class certification remaining brandonly individual capacity prosecutor relation purchasers plaintiffs also seeking add smaller matter number wholesalers codefendants category purchasers proceedings february court rendered guilty verdict respect defendants gsk korea fined february district court denied plaintiffs krw million approximately appeal renewed class certification motion followon complaint proceedings ongoing filed us district court eastern district pennsylvania february group alleged korea fair trade commission also commenced purchasers proceedings regarding matter gsk korea cooperating authorities matters commercial corporate group involved certain contractual andor antitrustcompetition commercial disputes certain governmental actions private lawsuits brought group alleging violation competition zejula royalty dispute antitrust laws october tesaro inc wholly owned subsidiary gsk entered two worldwide patent license agreements astrazeneca uk limited related niraparib later approved zejula may astrazeneca filed lawsuit tesaro high court england wales alleging tesaro failed pay royalties due license agreements tesaro counterclaimed based calculated overpayment trial scheduled march post balance sheet events material post balance sheet event requires adjustment disclosure within financial statementsgsk annual report company balance sheet uk gaap including frs reduced disclosure framework december notes fixed assets investments e current assets trade receivables f cash bank total current assets trade payables g total current liabilities net current assets total assets less current liabilities provisions liabilities h noncurrent liabilities net assets capital reserves share capital j share premium account j reserves k retained earnings january profitloss year treasury shares transferred esop trust dividends specie dividends paid shareholders k equity shareholders funds financial statements pages approved board march signed behalf sir jonathan symonds chair gsk plc registered number company statement changes equity year ended december share share premium retained total capital account reserves earnings equity january profit total comprehensive income attributable shareholders dividends shareholders shares issued employee share schemes december profit total comprehensive income attributable shareholders treasury shares transferred esop trust dividends shareholders note dividends specie note shares issued employee share schemes december gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap including frs reduced disclosure framework presentation financial statements balance sheet prepared accordance companys accounting policies approved board description business described note b policies consistently gsk plc parent company gsk major global applied unless otherwise stated biopharma group makes innovative vaccines specialty medicines prevent treat disease gsks rd key accounting judgements estimates focuses science immune system human genetics key accounting judgements estimates required advanced technologies primarily following four current year therapeutic areas infectious diseases hiv oncology immunologyrespiratory b accounting policies preparation financial statements foreign currency transactions financial statements prepared using foreign currency transactions recorded exchange historical cost convention modified include rate ruling date transaction foreign currency assets revaluation certain financial instruments going liabilities translated rates exchange ruling concern basis prepared accordance financial balance sheet date reporting standard reduced disclosure framework dividends paid received uk accounting presentation companies act dividends paid received included financial december comparative figures statements period related dividends december actually paid received permitted section companies act expenditure income statement company presented expenditure recognised respect goods services annual report received supplied accordance contractual terms company included group financial statements provision made obligation exists future liability gsk plc publicly available respect past event amount obligation reliably estimated following exemptions requirements ifrs applied preparation financial statements investments subsidiary companies accordance frs investments subsidiary companies held cost less provision impairment also includes capital paragraphs b ifrs sharebased contribution relation movements contingent payment consideration ifrs financial instruments disclosures impairment investments paragraphs ifrs fair value measurement carrying value investments reviewed impairment paragraph ias presentation financial statements indication investment might comparative information requirements respect impaired one assessment methods used compare paragraph iv ias carrying value investment share net assets value investment share paragraphs f b valuation subsidiary based expected discounted ias presentation financial cash flows total amount investments also evaluated statements groups valuation basis overall market ias statement cash flows capitalisation impairment charge recognised income statement year concerned paragraph ias accounting policies changes accounting estimates errors assets held saledistribution noncurrent assets held disposaldemerger paragraph ias related party disclosures available immediate disposaldemerger present requirement ias disclose related party condition disposaldemerger highly probable transactions entered two members expected completed within one year date group classification assets measured lower accounting convention standards carrying value fair value less cost disposal balance sheet prepared using historical sharebased payments cost convention complies applicable uk accounting issuance company subsidiaries grant standards companys shares represents additional capital accounting principles policies contributions company subsidiaries additional preparation balance sheet conformity investment subsidiaries results corresponding increase generally accepted accounting principles requires shareholders equity additional capital contribution management make estimates assumptions affect based fair value grant issued allocated reported amounts assets liabilities disclosure underlying grants vesting period contingent assets liabilities date balance sheet actual amounts could differ estimatesgsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework continued taxation financial guarantees current tax provided amounts expected paid liabilities relating guarantees issued company applying tax rates enacted substantively behalf subsidiaries initially recognised fair value enacted balance sheet date amortised life guarantee deferred tax provided full using liability method c perating profit temporary differences arising tax bases assets liabilities carrying amounts financial fee relating audit statements deferred tax assets recognised company charged operating profit extent considered recoverable future taxable profits deferred tax measured average tax rates expected apply periods temporary differences expected realised settled deferred tax liabilities assets discounted dividends directors declared four interim dividends resulting dividend year pence adjusted share consolidation details see note group financial statements dividends addition demerger consumer healthcare business implemented gsk declaring interim dividend follows dividend specie haleon plc shares distributed external shareholders dividend specie haleon plc shares distributed esop trusts e fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline consumer healthcare holdings limited shares glaxosmithkline mercury limited shares gsk lp limited capital contribution relating sharebased payments contribution relating contingent consideration investments glaxosmithkline consumer healthcare holdings limited derecognised part demerger consumer healthcare business executed specie shares see note group financial statements f trade receivables amounts due within one year uk corporation tax recoverable debtors amounts owed group undertakings amounts due one year amounts owed group undertakings movement amounts owed group undertakings period reflected within notes f g primarily reflects receipt dividend income subsidiaries including predemerger dividend glaxosmithkline consumer healthcare holdings limited utilisation companys current account fund payment interim dividends gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap including frs reduced disclosure framework continued g trade payables amounts due within one year creditors contingent consideration payable corporation tax amounts owed group undertakings company guaranteed debt issued subsidiary companies one receives fees aggregate company outstanding guarantees billion debt instruments billion amounts due subsidiary company relation guarantee fees recovered life bonds disclosed within trade receivables see note h provisions liabilities january charge year utilised december provisions relate number legal disputes company currently involved noncurrent liabilities contingent consideration payable contingent consideration relates amount payable acquisition novartis vaccines portfolio current year liability included within trade payables details see note group financial statements contingent consideration liabilities j share capital share premium account share premium ordinary shares account number share capital issued fully paid january issued employee share schemes december impact share consolidation issued employee share schemes ordinary shares acquired esop trust december december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid shares authorised issue nominal carrying market values shares held esop trusts disclosed note employee share schemesgsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework continued k retained earnings reserves profit gsk plc year million million profit dividends paid distributed specie million including consumer healthcare business demerger dividend million million effect million treasury shares transferred subsidiary company nil retained earnings december stood million million million unrealised million dividends shareholders paid realised profits company december amounted million million reserves includes capital redemption reserve reserve reflecting historical contributions shares company issued satisfy share option awards granted employees subsidiary companies l divestment july gsk plc separated consumer healthcare business gsk group form haleon plc independent listed company separation effected way demerger gsks holding consumer healthcare business gsk shareholders following demerger haleon plc held aggregate gsk shareholders held gsk including shares received gsks consolidated esot trusts held three scottish limited partnerships slps set provide collateral funding mechanism pursuant gsk provide additional funding gsks uk pension schemes aggregate ownership gsk including ownership esot trust slps demerger following completion consumer healthcare business demerger july gsk plc ordinary shares consolidated order maintain share price comparability demerger consolidation approved gsk plc shareholders general meeting held july shareholders gsk plc received new ordinary shares nominal value pence existing ordinary share nominal value pence group companies see pages complete list subsidiaries associates joint ventures significant shareholdings forms part financial statements gsk annual report investor information section commercial operations turnover three year record product development pipeline products competition intellectual property principal risks uncertainties share capital control dividends financial calendar annual general meeting tax information shareholders shareholder services contacts us law regulation group companies glossary terms gsk annual report financial record commercial operations turnover therapeutic area total us europe international growth growth growth growth cer cer cer cer hiv dolutegravir products tivicay triumeq juluca dovato rukobia cabenuva apretude others oncology zejula blenrep jemperli immunoinflamm respiratory benlysta nucala specialty medicines excl pandemic pandemic xevudy specialty medicines meningitis bexsero menveo influenza fluarixflulaval shingles shringrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix others vaccines excluding pandemic pandemic vaccines pandemic adjuvant vaccines respiratory arnuity ellipta anoro ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair trelegy ellipta ventolin respiratory general medicines dermatology augmentin avodart lamictal general medicines total commercial operations gsk annual report financial record continued strategic report governance remuneration financial statements investor information commercial operations turnover therapeutic area total us europe international growth growth growth growth cer cer cer cer hiv dolutegravir products tivicay triumeq juluca dovato rukobia cabenuva apretude others oncology zejula blenrep jemperli immunoinflamm respiratory benlysta nucala specialty medicines excl pandemic pandemic xevudy specialty medicines meningitis bexsero menveo influenza fluarixflulaval shingles shringrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix others vaccines excluding pandemic pandemic vaccines pandemic adjuvant others vaccines respiratory arnuity ellipta anoro ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair trelegy ellipta ventolin respiratory general medicines dermatology augmentin avodart lamictal general medicines total commercial operations gsk annual report financial record continued threeyear selected financial data record financial performance provided analysed accordance current reporting practice information included selected financial data except number employees adjusted results prepared accordance international accounting standards conformity requirements companies act also ifrs issued international accounting standards board three year financial data presented reflecting restated results following demerger consumer healthcare business financial results restated presented revised revised group turnover geographic region us europe international revised revised group turnover product group specialty medicines vaccines general medicines consumer healthcare revised revised specialty medicines turnover hiv oncology immunoinflammation pandemic vaccines turnover meningitis influenza shingles established vaccines pandemic vaccines general medicines respiratory general medicines financial results total turnover profit taxation continuing operations profit taxation discontinued operations gainslosses demerger remeasurement discontinued operations distributed shareholders demerger profit taxation discontinued operations profit taxation year pence pence pence basic earnings per share continuing operations p p p basic earnings per share discontinued operations p p p total basic earnings per share p p p diluted earnings per share continuing operations p p p diluted earnings per share discontinued operations p p p total diluted earnings per share p p p g sk revised operating segments year see note consolidated financial statements details april gsk completed divestment horlicks consumer healthcare nutrition products india number countries excluding bangladesh unilever merger gsks indian listed consumer healthcare entity hindustan unilever indian listed public company gsk completed divestment bangladesh june comparatives restated consistent basis previously published reflect demerger consumer healthcare business see note impact share consolidation see note consolidated financial statements gsk annual report financial record continued strategic report governance remuneration financial statements investor information three year selected financial data continued financial results adjusted turnover continuing operating profit continuing profit taxation continuing profit taxation reconciliations total adjusted operating profit last three years summarised follows total continuing operating profit intangible asset amortisation intangible asset impairment major restructuring transactionrelated items divestments significant legal items adjusted continuing operating profit reconciliation total adjusted earnings per share last three years summarised follows pence pence pence total continuing earnings per share p p p intangible asset amortisation p p p intangible asset impairment p p p major restructuring p p p transactionrelated items p p p divestments significant legal items p p p adjusted continuing earnings per share p p p return capital employed nm return capital employed calculated total profit taxation percentage average net assets year restated return capital employed calculated meaningful nm average net assets year include consumer healthcare balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees us europe international manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis employee numbers restated purposes consumer healthcare demergergsk annual report pipeline products competition pharmaceuticals vaccines product development pipeline key nlicense alliance relationship third party eua emergency use authorisation v iiv healthcare global specialist hiv company phase e valuation clinical pharmacology usually conducted gsk pfizer inc shionogi limited shareholders volunteers responsible developing delivering hiv medicines phase ii etermination dose initial evaluation efficacy bla biological licence application conducted small number patients maa marketing authorisation application europe phase iii l arge comparative study compound versus placebo nda new drug application us andor established treatment patients establish approved clinical benefit safety submitted maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla oncology momelotinib jak jak acvr inhibitor myelofibrosis registration snov sjun jemperli antiprogrammed cell death protein receptor l endometrial cancer iii dostarlimab pd antibody l endometrial cancer combination iii zejula niraparib nonsmall cell lung cancer ii zejula poly adpribose polymerase parp inhibitor l maintenance ovarian cancer combination iii niraparib jemperli dostarlimab l maintenance non small cell lung cancer iii nsclc combination pembrolizumab premetastatic select biomarker population iii breast cancer blenrep adc targeting bcell maturation antigen l multiple myeloma combination iii belantamab pomalyst dexamethasone mafodotin l multiple myeloma combination iii velcade dexamethasone multiple myeloma combination ii anticancer treatments platform study l multiple myeloma combination velcade revlimid dexamethasone cobolimab antitcell immunoglobulin mucin domain nonsmall cell lung cancer combination iii tim antibody jemperli dostarlimab docetaxel antitigit nonsmall cell lung cancer combination ii eos jemperli platform study antilymphocyte activation gene lag cancer antibody antipvrig cancer sting cytosolic dna pathway agonist advanced solid tumors myeloid malignancies anticd cancer xmt sting agonist adc cancer wholly owned mersana therapeutics hiv apretude hiv integrase strand transfer inhibitor longacting hiv preexposure prophylaxis approved sjun dec cabotegravir hiv infection mgml formulation hiv maturation inhibitor hiv infection ii hiv broadly neutralising antibody hiv infection ii hiv maturation inhibitor hiv infection hiv capsid protein inhibitor hiv infection hiv capsid protein inhibitor hiv infection hiv integrase inhibitor hiv infection brand names appearing italics trade marks owned licensed gsk group companies footnotes nonregistrational gsk exclusive global license option codevelop commercialize candidate progress phase gsk annual report strategic report governance remuneration financial statements investor information pipelines products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla infectious diseases xevudy sotrovimab antispike protein antibody covid approved adec eua may priorix mmr vaccine live attenuated measles mumps rubella prophylaxis us approved jun menveo vaccine conjugatedliquid formulation meningococcal c w disease prophylaxis approved oct adolescents rotarix vaccine live attenuated pcv porcine circovirus rotavirus prophylaxis us approved nov free vidprevtyn beta recombinant proteinadjuvanted covid approved nov covid vaccine vaccine sanofi recombinant protein adjuvanted respiratory syncytial virus prophylaxis older adult registration soct soct rsv vaccine vaccine population years age older respiratory syncytial virus prophylaxis older adult iii population years age skycovione recombinant protein nanoparticle covid registrationsjul sk bioscience adjuvanted vaccine gepotidacin triazaacenaphthylene bacterial type ii uncomplicated urinary tract infection uuti iii topoisomerase inhibitor urogenital gonorrhea gc iii bepirovirsen hbv antisense hepatitis b iii hepatitis b sequential therapy pegylated ii interferon bexsero vaccine recombinant protein vaccine meningococcal b disease prophylaxis months iii age older us recombinant protein conjugated meningococcal b c w disease prophylaxis iii men abcwy vaccine vaccine adolescents tebipenem pivoxil antibacterial carbapenem complicated urinary tract infection uti iii leucyl trna synthetase inhibitor tuberculosis ii bvlgsk ethionamide booster tuberculosis ii vir neutralizing monoclonal antibody influenza ii recombinant protein adjuvanted malaria prophylaxis plasmodium falciparum ii malaria fractional vaccine dose generalized modules membrane shigella diarrhea prophylaxis ii antigens gmma vaccine primeboost viral vector co treatment chronic hepatitis b infections aims ii therapeutic hbv sequentially administrated functional cure controlling resolving adjuvanted recombinant proteins clinical sequelae infection reducing need treatment recombinant protein conjugated meningococcal b c w disease prophylaxis ii men abcwy nd genvaccine adolescents children weeks older live attenuated vaccine active immunization prevention varicella ii varicella new strain individuals months age older sanfetrinem cilexetil serine beta lactamase inhibitor tuberculosis ii recombinant proteinadjuvanted active immunization girls women boys ii vaccine men years prevention cancer genital warts precancerous dysplastic lesions girls boys caused human papillomavirus hpv brand names appearing italics trade marks owned licensed gsk group companies footnotes apr sotrovimab longer authorized treat covid us due increases proportion covid cases caused omicron ba subvariant gsk contributing pandemic adjuvant covid vaccines collaborations approved south korea jun phase study start expected gsk exclusive option codevelop post phase gsk annual report pipelines products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla infectious diseases continued targeted immunotherapy viral vector treatment chronic hepatitis b virus infection ii chbv aso combo adjuvanted recombinant proteins individuals years without decompensated direct acting antiviral gsk 's cirrhosis bepirovirsen vaccine using multiple antigen prevention pneumonia invasive ii presenting system maps platform pneumococcal disease caused streptococcus pneumoniae serotypes included vaccine children aged weeks years vaccine using multiple antigen prevention pneumonia invasive ii presenting system maps platform pneumococcal disease caused streptococcus pneumoniae serotypes included vaccine adults aged years older live attenuated vaccine active immunization prevention measles ii mmrv new strain mumps rubella varicella children months years age fimh antagonist uncomplicated urinary tract infection uuti crk inhibitor visceral leishmaniasis proteasome inhibitor visceral leishmaniasis mtb cholesterol dependent inhibitor tuberculosis vir antispike protein antibody covid pik beta inhibitor viral copd exacerbations recombinant protein adjuvanted active immunization prevention primary vaccine c difficile diseases prevention recurrences recombinant protein bioconjugated klebsiella pneumoniae prophylaxis adjuvanted vaccine recombinant subunit adjuvanted cytomegalovirus cmv infection prophylaxis vaccine females years age mrna vaccine active immunization prevention disease caused influenza viruses adults years older mrna vaccine active immunization prevent covid disease caused sarscov virus individuals years older recombinant proteinadjuvanted active immunization suppress recurrence therapeutic hsv genital herpes adults aged years older bivalent generalized modules invasive nontyphoidal salmonella membrane antigens gmma vaccine bivalent generalized modules invasive nontyphoidal salmonella typhoid membrane antigens gmma vaccine fever typhoid conjugate vaccine tcv bivalent typhoid paratyphoid salmonella typhoid paratyphoid enteric feveri conjugate papdpapd inhibitor hepatitis b tlr agonist hepatitis b p falciparum whole cell inhibitor malaria pyrrolidine amides generalized modules membrane active immunization prevent gonorrhea antigens gmma vaccine individuals age years older regardless previous gonorrhea infection history brand names appearing italics trade marks owned licensed gsk group companies footnotes transition activities underway enable progression partner gsk annual report strategic report governance remuneration financial statements investor information pipelines products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla immunology respiratory nucala mepolizumab antiil copd iii depemokimab antiil longacting asthma iii chronic rhinosinusitis nasal polyps crswnp iii eosinophilic granulomatosis polyangiitis egpa iii hypereosinophilic syndrome hes iii latozinemab antisortilin monoclonal antibody frontotemporal dementia ftd due iii heterozygous mutations progranulin gene amyotrophic lateral sclerosis als ii frontotemporal dementia ftd due mutations ii corf gene benlysta b lymphocyte stimulator monoclonal systemic sclerosis associated interstitial lung ii belimumab antibody disease anticcl osteoarthritis pain al antisortilin monoclonal antibody neurodegenerative disease antiil atopic dermatitis antiil multiple sclerosis ms opportunity driven jesduvroq prolyl hydroxylase inhibitor anaemia chronic kidney disease approved sfeb afeb daprodustat linerixibat ileal bile acid transporter ibat cholestatic pruritus pbc primary biliary iii inhibitor cholangitis hsdb silencer nonalcoholic steatohepatitis nash ii dnmt inhibitor sickle cell disease brand names appearing italics trade marks owned licensed gsk group companies footnotes phase study start expected imminent study startgsk annual report pipelines products competition continued pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu respiratory anoro ellipta umeclidinium bromide copd spioltostiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi aerosphere brimica genuair avamysveramyst fluticasone furoate allergic rhinitis dymista xhance expired expired nasonex fluticasone gx relvarbreo ellipta fluticasone furoate asthma copd symbicort foster vilanterol trifenatate budesonideformoterol nce nce gx sirdupla dulera device device seretideadvair salmeterol xinafoate asthma copd symbicort foster expired expired fluticasone propionate budesonide diskus device diskus device formoterol gx expired sirdupla dulera hfadevice hfadevice trelegy ellipta fluticasone furoate copd asthma trimbow pmdi vilanterol trifenatate nexthaler breztri nce nce umeclidinium bromide aerosphere trixeo aerosphere enerzair device device breezhaler ventolin hfa salbutamol sulphate asthma copd generic companies expired hfadevice hfadevice xevudy sotrovimab early treatment regencov na covid bamlanivimab nbe etesevimab evusheld central nervous system lamictal lamotrigine epilepsy bipolar disorder vimpat trokendi xr expired expired inovelon keppra keppra levetiracetam epilepsy briviact vimpat na na lamictal depakene depacon cardiovascular urogenital avodart duodart dutasteride benign prostatic generic products expired expired dutasteride tamsulosin hyperplasia bph finasteride alpha blockers antibacterials augmentin amoxicillin trihydratepotassium common bacterial generic products na expired clavulanate infections clavam moxikindcv enhancin curam calamox oral cephalosporins cefuroxime axetil cefixime cefpodoxime cefdinir cephalexin oral macrolides azithromycin clarithromycin includes supplementary protection certificates granted multiple countries eu including uk patent term extensions granted us gsk annual report strategic report governance remuneration financial statements investor information pipelines products competition continued pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands us eu dermatology dermovate clobetasol propionate inflammatory skin generic products marketed expired betnovate betamethasone valerate conditions topical us cutivate fluticasone propionate corticosteroids like eumovate clobetasone butyrate mometasone furoate methylprednisolone aceponate hydrocortisone oncology zejula niraparib ovarian cancer lynparza rubraca nce nce blenrep belantamab mafodotin relapsedrefractory sarclisa xpovio multiple myeloma jemperli dostarlimab dmmr recurrent keytruda advanced endometrial nbe nbe cancer solid tumours immunoinflammation benlysta benlysta belimumab systemic lupus erythematosus lupkynis saphnelo sc iv lupus nephritis jesduvroq duvroq daprodustat anaemia chronic kidney evrenzo roxadustat disease vadadustat nce nce hiv apretude cabotegravir hiv prevention descovy truvada nce nce cabenuvavocabria cabotegravir rilpivirine hivaids descovy genvoya rekambys odefsey biktarvy nce nce rukobia fostemsavir hivaids trogarzo nce nce dovato dolutegravir lamivudine hivaids descovy genvoya odefsey biktarvy nce nce juluca dolutegravir rilpivirine hivaids descovy genvoya odefsey biktarvy nce nce triumeq dolutegravir lamivudine hivaids descovy genvoya abacavir odefsey biktarvy nce nce tivicay dolutegravir hivaids isentress prezista symtuza reyataz nce nce biktarvy see note financial statements legal proceedings includes supplementary protection certificates granted multiple countries eu including uk patent term extensions granted us related compoundsindications measles mumps rubella vaccineprophylaxisb b related compound varicella vaccinegsk annual report pipelines products competition continued vaccine products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu bexsero meningococcal groupb vaccine meningitis group b prevention trumenba boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expired expired pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expired expired polio hepatitis b haemophilus tetanus pertussis polio pentaxim pentavac influenzae type b eu hepatitis b haemophilus hexaxim hexyon influenzae type b eu vaxelis cervarix hpv virus like human papilloma virus gardasil silgard expired particles vlps type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv expired expired antigens virus subtypes vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip expired expired antigens virus subtypes fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w nimenrix menactra conjugate vaccine prophylaxis priorix priorix tetraab live attenuated measles mumps measles mumps rubella mmr ii mmrvaxpro expired expired varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugated pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis media shingrix zoster vaccine herpes zoster zostavax recombinant adjuvanted shingles see note financial statements legal proceedings includes supplementary protection certificates granted multiple countries eu including uk patent term extensions granted us related compoundsindications measles mumps rubella vaccineprophylaxisb b related compound varicella vaccine gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties outline principal risks uncertainties relevant detail status various uncertainties gsks business financial condition operations may significant unresolved disputes potential litigation set affect performance ability achieve objectives note legal proceedings risks believe could cause actual details regarding risk management framework results differ materially expected historical results identify principal risks found pages operating biopharmaceutical sector carries various incorporated herein risks level inherent risks uncertainties may affect business principal risk opportunities related environmental social governance esg including environmental must comply broad range laws regulations sustainability climate change managed apply research development manufacturing six focus areas described esg performance report testing approval distribution sales marketing additional information climate related risk management pharmaceutical vaccine products affect cost climate related financial disclosure see pages product development time required reach market likelihood successfully uninterrupted basis uk regulations require description principal risks uncertainties explanation rules regulations change government interpretation managed mitigated description evolves business activities develop nature principal risks together summary manage particular risk may also alter changes regulatory regimes risk across businesses listed order may substantial alteration failure comply significance consistent principal risks detailed applicable laws regulations could materially pages july board agreed adversely affect financial results separation longer principal risk following similarly global business exposes us litigation successful demerger analysis residual risk government investigations including product liability litigation patent antitrust litigation sales marketing litigation litigation government investigations related provisions may make unfavourable outcomes increases related costs insurance premiums could also materially adversely affect financial results patient safety risk definition context risk gsk including third parties potentially fails fully accountable safeguarding patients failure appropriately collect review follow report human safety effectively could result importantly harm information including adverse events potential patients well reputational damage andor product sources gsk potentially fails act relevant liability litigation conduct internal safety surveillance findings timely manner rely access safety information external sources information safety efficacy products risk impact humans collected clinical development gsk tolerate unfavourable benefittorisk profile comprehensive information incorporated realworld use patients use products important products marketed examples consequence ineffective pharmacovigilance potential regulatory agencies using realworld evidence sources harm patients maintain robust processes may accessible industry supplement managing human safety information conducting timely safety validate evidence use support safety efficacy signal detection ensuring appropriate measures products potential emerging risk place manage risks patients gsk also intends fully technology companies data custodians may similarly comply pharmacovigilance relevant regulations draw communicate conclusions safety worldwide noncompliance could result inspection findings products based digital health data collected regulatory scrutiny civil criminal sanctions either platforms inaccessible either industry temporary permanent loss product marketing regulatory agencies authorisation regularly review respond patient safety risks limit potential reputational damage loss trust patients healthcare providers productrelated litigation loss shareholder confidence gsk annual report principal risks uncertainties continued patient safety continued licence operate depends compliance third party oversight framework ensures third parties regulatory requirements worldwide directly may encounter human safety information identified related patient safety extending privacy trained appropriately manage safety information information security regulations well regulatory products sources compliance global compliance depends appropriate identification regulations information allows us detect safety signals management human safety information employees products take timely action information third parties acting behalf pursuing changes products riskbenefit profile innovative solutions enhance ability perform actions discussed beforehand regulatory pharmacovigilance including artificial intelligence authorities include updating prescribing machine learning technology augment capacity information communicating healthcare providers manage increasing volumes adverse event reports restricting product prescribingavailability help assure safe varied sources advancing technical solutions use carrying clinical trials certain cases delivering safety information risk minimisation measures may appropriate stop clinical trials withdraw patients health care providers product specific batch market covid pandemic impact completed simplification optimisation pharmacovigilance activities increasing public focus core patient safety processes expect improve safety efficacy medicines vaccines highlighting crossfunctional stakeholder engagement safety activities importance robust business continuity planning across gsk began automated endtoend processing uninterrupted safety oversight regulatory compliance individual case safety reports deliver better case quality including ability accommodate remote regulatory consistency well enhanced efficiency inspections accelerating automation manage pharmacovigilance operations model expanded ensure increasing volumes adverse events connectivity central local safety teams created resources rd leaders enable mitigating activities advocate need industry access safety data chief medical officer accountable patient safety sources best way safeguard patients enterprise risk human safety matters collaboration transition twovendor singlevendor model key head global safety crossenterprise safety governance operational activities improve efficiency reduce board oversees implementation control framework risk regulatory noncompliance also expand including risk management global safety board ensures global safety team include additional expertise optimise address human safety proactively throughout strategy approach productrelated risk mitigation products lifecycle global policy management human minimisation safety information requires employees immediately report issues relating safety products product quality risk definition context risk gsk third parties potentially fail ensure external environment product quality remains appropriate controls governance quality challenging increased cyberattacks data breaches development commercial products compliance across industry cyberattacks remain key risk industry practices regulations manufacturing integrity product quality data audit trail met distribution activities terms gsk product licenses commitments european medicines agency ema supporting regulatory activities requirements licensing medical devices continue plan deployment new annex guidance risk impact manufacture sterile medicinal products published failure ensure product quality could farreaching september sets expectation compliance implications patient safety cause product launch delays august actively managing implementation drug shortages product recalls regulatory legal context global equipment component supply chain financial consequences could materially constraints effecting industry increasingly applying adversely affect gsks reputation financial results advanced digital technologies insights drive scientific excellence enhance development manufacture testing products example use new electronic documentation systems advanced laboratory information management tools quality organisations aligned make sure quality procedures governance facilitate new company strategy prepandemic levels onsite inspections resumed continue take steps ensure inspection readiness gsk annual report principal risks uncertainties continued strategic report governance remuneration financial statements investor information product quality continued mitigating activities implemented riskbased approach assessing managing third party suppliers provide materials align extensive global network quality used finished products expect contract compliance professionals sitelevel senior manufacturers make products comply gsk management within business unit provide oversight standards regularly conduct audits provide us assist delivery quality performance assurance product incident committee operational compliance deliver management processes place investigate product issues make oversight hierarchy quality councils recommendations remediation activities including independent chief product quality officer global product necessary recall medicines vaccines protect quality office oversees product quality risk across patients public company developed implemented single quality management system defines quality standards established complaint process ensures respond systems businesses associated appropriately product quality issues raised patients development commercialisation vaccines specialty independent functions review triage allegations general medicines consolidation regulatory noncompliance misconduct received formal requirements markets across world augments informal speak channels global disciplinary system means meets external expectations enforcement procedures apply breaches product quality markets supply system based standards initiated appropriate following internationally recognised principles ich q investigations use key risk indicators support risk pharmaceutical quality system framework management activities provide gsks leadership team risk oversight compliance council integrated routinely update quality management system qms assessment product quality performance keeps pace evolving external regulatory completed product assessments presence environment new scientific understanding products nitrosamines reported necessary health processes also made policies authorities also developed mitigation plans procedures simpler understand implement executed throughout per regulatory adopted innovative tools make userfriendly requirements actively working industry bodies regularly train staff regulatory expectations learnings european regulatory authorities complete inspections existing procedures maintain safety evaluation titanium dioxide medicines well current good manufacturing practice standards identifying potential substitutes financial controls reporting risk definition context risk gsk fails comply current tax laws fails required laws various jurisdictions publicly report accurate financial information compliance disclose financial results events could materially accounting standards applicable legislation incurs affect groups financial results regulators routinely review significant losses due treasury activities financial statements listed companies compliance new revised existing accounting regulatory risk impact requirements believe comply appropriate noncompliance existing new financial new esg regulatory requirements concerning financial statements reporting disclosure requirements changes disclosure material information including recognition income expenses could expose gsk transactions relating business restructuring litigation regulatory action could materially acquisitions divestitures however subject adversely affect financial results failure comply investigation potential noncompliance changes substance application laws governing accounting disclosure requirements could lead transfer pricing dividends tax credits intellectual property restatements previously reported results significant could also materially adversely affect financial results penalties failure comply applicable sanctions laws treasury group deals daily high value transactions regulations could result gsk investigated relevant mostly foreign exchange cash management transactions government agencies authorities andor legal transactions involve market volatility counterparty proceedings us government investigations risk groups effective tax rate reflects locations litigation unpredictable regardless activities value generate determine outcome may costly require significant management jurisdictions profits arise applicable tax rates attention damage reputation inconsistent application treasury policies transactional settlement errors counterparty defaults could lead significant losses gsk annual report principal risks uncertainties continued financial controls reporting continued may higher lower uk statutory rate disclosure committee reporting board reviews may reflect regimes encourage innovation investment gsks quarterly results annual report throughout year rd providing tax incentives changed could consultation legal advisors disclosure affect gsks tax rate addition worldwide nature committee also determines whether necessary disclose operations means crossborder supply routes publicly information group stock exchange necessary ensure supplies medicines vaccines announcements treasury management group meets result conflicting claims tax authorities profits regularly ensure liquidity interest rate counterparty taxed individual countries lead double foreign currency transaction foreign currency translation taxation profits taxed one country risks managed line prudent approach complexity tax regulations also means may detailed risk strategies policies adopted occasionally disagree tax authorities technical board interpretation particular area tax law tax charge counterparty exposure subject defined limits approved included financial statements best estimate tax board credit rating individual counterparties liability pending audits tax authorities expect middle office within treasury monitor management continued focus tax reform driven initiatives counterparty risk line agreed policy oversight oecd ec address tax challenges arising corporate compliance officer operating independently digitalisation economy together domestic treasury details mitigation treasury risks initiatives around world may result significant found pages manage tax risk changes established tax principles increase tax robust internal policies processes training compliance authority disputes regardless merit outcomes programmes may costly divert management attention adversely impact reputation relationship key stakeholders maintain open constructive relationships tax laws regulations orders measures restrict dealings authorities worldwide monitor government debate tax certain countries governments government officials policy key jurisdictions understand entities individuals use financial institutions movement potential future changes tax law share informed funds circumvention sanctions export controls point view relevant provide pragmatic criminal offence gsk seeks comply constructive business input tax policy makers either directly sanctions obligations believe group complies industry trade bodies includes advocating applicable sanctions material respects laws reform support economic growth job creation well complex continue evolve rapidly needs patients key stakeholders tax affairs managed global basis team tax mitigating activities professionals led global head tax work closely keep date latest developments financial business daytoday basis global tax team reporting requirements reviewing updates regulators suitably qualified roles perform support working external auditor legal advisors training needs provide date technical performing responding emerging risks financial results advice line responsibilities submit tax returns reviewed approved regional management according statutory time limits engage proactively reviewed gsks group financial controller chief tax authorities ensure tax affairs current entering financial officer cfo allows financial controller continuous audit programmes advance pricing cfo assess evolution business time agreements appropriate arrangements provide evaluate performance plan significant judgements longterm certainty tax authorities gsk reviewed confirmed senior management tax treatment business based full disclosure integrate technical organisational transformation newly relevant facts seek resolve differences acquired activities external risks risk assessments interpretation tax legislation tax authorities apply appropriate controls reviews maintain cooperative manner exceptional cases may control environment designed identify material errors resolve disputes formal proceedings gsk financial reporting disclosure standardised committed complying applicable sanctions laws global financial reporting operating model regulations deployed programme enable management sanctions risk programme jointly led design operating effectiveness key financial gsk finance legal compliance made various reporting controls regularly reviewed management systems controls including limited policies tested external third parties locations procedures training awareness screening monitoring standard model apply minimum standard set risk reporting controls reviewed management monitored independently gives us assurance controls key financial reporting disclosure processes operating effectively global finance risk management controls frmc group provides extra support significant transformations system deployment management structural reorganisations add operational resources adapt programme timelines ensure processes controls maintained significant changes gsk annual report principal risks uncertainties continued strategic report governance remuneration financial statements investor information antibribery corruption abac risk definition continue assess understand money laundering risk exposure mitigate existing risk risk gsk third parties potentially fail comply applicable laws regulations internal requirements code conduct culture commitment zero ensure appropriate controls governance bribery tolerance towards bribery corruption integral corruption business activities mitigate risk light complexity geographic breadth risk constantly evolve oversight risk impact activities data reinforce workforce gsks clear failure mitigate risk could expose gsk associated expectations regarding acceptable behaviours maintain persons governmental investigation regulatory action regular communications local markets civil criminal liability may compromise gsks ability built abac programme based bestinclass supply products certain government contracts principles help us manage risk top addition failure prevent bribery corruption could bottom example programme includes seniorlevel substantial implications gsks reputation credibility commitment board leadership data senior leaders might erode investor confidence analytics programme create embed local key risk governance risk management future performance indicators enable targeted intervention risk consequential negative impact share performance management activities continue actively consider could also lead imposition significant financial improvements programme penalties imposition additional reporting obligations abac programme underpinned global abac policy written standards controls address context business activities give rise bribery corruption continues strong enforcement appetite risks establish due diligence requirements foreign bribery investigations prosecutions engagement third parties programme also mandates particular focus conduct multinational companies enhanced controls interactions government officials wherever operate financial penalties handed business development transactions proven corruption cases often significant dedicated team responsible programmes implementation evolution abac team works disruption global supply chains commercial groups across organisation address improve pressures caused higher usual inflation rates likely controls monitoring requirements audit assurance increase risks bribery corruption certain independent business monitoring teams complement contexts abac teams work provide added assurance however greater transparency collaboration among use issues found oversight assurance exercises enforcement authorities advances technology use investigations identify areas specific intervention data analytics providing better platforms streamline markets drive continuous improvement processes detect potential issues programme mitigating activities provide mandatory abac training least annually enterprisewide abac programme designed employees relevant third parties differentiated according ensure compliance applicable laws regulations seniority roles responsibilities geographic location prohibiting bribery corruption related offences formal informal speak channels available builds business standards culture form report misconduct noncompliance central comprehensive practical approach compliance investigations team reviews triages allegations non responds evolving nature business gsks abac compliance triggers investigation appropriate governance board oversees provides programme governance enterprise risk management includes representation key functional areas continue enhance controls around thirdparty engagements ensure sufficient meet evolving emerging risks plan continue pre posttransaction abac due diligence increase capabilities organisation around onboarding continual monitoring management third parties gsk annual report principal risks uncertainties continued commercial practices risk definition mitigating activities risk gsk third parties potentially engage achieve strategic objectives must meet price commercial activities fail comply laws regulations expectations payers hcps consumers community industry codes internal controls requirements culture provides guide lead make decisions constantly strive right thing deliver risk impact quality medicines vaccines sustain reliable supply failure engage activities consistent letter meet customer needs seek ensure actions spirit law industry regulations groups reflect gsks values behaviours purpose understand requirements relating sales promotion medicines impact data industry strive become vaccines appropriate interactions healthcare organisation makes datadriven decisions approach professionals hcps organisations patients aligned efforts become agile work pace legitimate transparent transfers value pricing gsk acted enhance improve policies competition antitrust regulations commercial standards application data analytics channel practices including trade channel activities business activities evolved policies standards incrementally tendering could materially adversely affect ability ensure commercial activities undertake deliver strategy longterm priorities additionally conducted behalf executed within established may result incomplete awareness riskbenefit profile governance train employees relevant information products possibly suboptimal treatment patients focus interactive learning elements behavioural consumers governmental investigation regulatory action science commercial activities worldwide must conform legal proceedings brought group high ethical regulatory industry standards local governmental private plaintiffs could result standards differ global ones apply government sanctions criminal andor financial penalties stringent standards acquired company joint practices found misaligned values venture partner differ global standards remediate expectations could also result reputational harm legacy policies implement revisions align dilute trust established external stakeholders businesses continue use internal control framework support assessment management risks business context unit risk management compliance boards manage operate highly regulated extremely competitive risks across global incountry business activities oversee biopharma industry amongst peers make significant commercial activities monitoring programmes product innovations technical advances intensify promotional materials activities must reviewed price competition additional external factors impacting approved according policies standards business operations include ongoing effects conducted accordance local laws regulations covid global pandemic access limitations requirements seek ensure materials customers macroeconomic inflationary dynamics pricing activities fairly represent groups products services pressure across markets achieve strategic objectives necessary event misconduct must continue develop commercially viable new disciplined employees including termination products deliver additional uses existing products contract clawed back remuneration senior address needs patients consumers hcps payers management continued evolve incentive financially new productsindications carry programme sales representatives better recognise uncertainty regards future success product reward individual effort nearly markets capped development costly lengthy uncertain carries variable pay element representatives compensation potential failure stage even successful evaluated basis individual sales targets product development face challenges launch competitors products pricing strategies could allow fairmarket value payments made gsk render assets less competitive support product expert practitioners speak innovative medicines innovation continued focus inperson vaccines restricted period products lifecycle virtual engagement constant focus patient new competitive data published support rolled global endtoend process across gsk approved medicine vaccine drive consistent ways working efficiencies obligation provide important information healthcare strengthen controls automation use data community various ways always responsible legal permitted report payments individual hcps part ethical manner appropriate product promotion ensures hcps commitment transparency responsible disclosure access information need patients consumers facts medicines vaccines require products prescribed recommended used manner provides healthcare benefit committed ethical responsible commercialisation products support purpose improve quality human life get ahead disease together gsk annual report principal risks uncertainties continued strategic report governance remuneration financial statements investor information scientific patient engagement risk definition expect activities scientifically sound accurate conducted ethically transparently risk gsk third parties potentially fail engage compliant applicable codes laws regulations externally gain insights educate communicate many industry local codes laws science medicines associated disease areas regulations apply privacy data integrity provide grants donations legitimate transparent means measured risktaking rooted sound ethical manner compliant laws regulations industry codes considerations principlesbased decisionmaking internal controls requirements training communication monitoring activities risk impact key managing risk enabling full appropriate engagement without controls place risk could result real perceived disguised promotion including offlabel prior mitigating activities authorisation promotion real perceived provision chief medical officer cmo oversees nonpromotional medical advice turn could lead criminal scientific patient engagement enterprise risk owner investigations penalties civil litigation competitor gsk code practice key internal policy non complaints time engage fully promotional engagement activities activities include appropriately could result patient harm failure scientific interactions support medical education advice advance science innovation reputational damage seeking gathering insights unmet needs patients financial loss consequences may reduce trust scientific communication research disease public patients healthcare professionals payers regulators awareness governments since covid pandemic seen continued context increase virtual engagements eg external experts scientific patient engagements diverse non advisory boards patient advocacy patient engagements promotional activities directed healthcare professionals scientific congresses developed modernised patients payers external stakeholders digital approach hcps patient engagement engagements aim improve patient care framework insightgathering applied internal exchange provision knowledge use products principles policies rapidly changing growing related diseases scientific patient engagement environment external stakeholder groups vital gsk research continuously improve internal controls networks based biopharma company ambitious patients identify emerging risks early support staff conduct necessary advance science medicine activities compliance gsks culture policies local laws regulations building effective risk management management monitoring systems data ethics privacy risk definition context risk gsk third parties potentially fail ethically data protection privacy legislation diverse limited collect use reuse artificial intelligence data analytics global harmonisation simplification challenging automation secure share destroy personal information multinationals standardise approach compliance accordance laws regulations internal controls data privacy laws governments enforcing compliance requirements data protection privacy laws rigorously approach focus data protection privacy regulators risk impact also differs regions countries noncompliance data privacy laws globally could lead creates challenges global organisations seeking harm individuals gsk could also damage trust implement single harmonised global privacy programme gsk individuals communities business partners increases volume data processed advances government authorities many countries increased technology resulted greater focus data enforcement powers data protection authorities governance ethical use personal information allowing impose significant fines impact crossborder compliance data privacy laws companies data flows temporarily ban data processing many new seeking foster innovation artificial intelligence national laws also enable individuals bring collective legal new technologies faced evolving decisions actions companies gsk failure follow global policymakers best promote trust data privacy laws systems avoid unintended outcomes harmful impacts gsk annual report principal risks uncertainties continued data ethics privacy continued additionally number emerging laws concerning head dpc leads global crossfunctional core team localisation data restrictions international transfers digital privacyqualified attorneys privacy data security changing existing frameworks compliance professionals supported network privacy gsk previously relied upon increasing trend leaders within business unitsfunctions privacy contracts data sovereignty affects ability drive medical innovation locally wider legal compliance team gsk effectively operate internationally global privacy framework based eu general data protection regulation deployed every market mitigating activities based factors including robustness local privacy general counsel gsks enterprise risk owner ero legislation established data protection authorities gsks chairs privacy governance board oversees gsks footprint beyond countries deploying overall data privacy operating model gsk business area proportionate control framework set minimum privacy appointed risk owner accountable overseeing standards irrespective applicable legislation privacy risks supported privacy leaders within core team responsible business countries local data privacy laws require appointment data protection officer dpo gsk operating improving centralised global privacy made appointments including eu dpo control framework result gsks focus technology datadriven science continuously assessing providing relevant use artificial intelligencemachine learning evolving proportionate controls aid nondeployed markets global data strategy sought address key risks monitoring new changing laws adapting privacy creating new team group legal compliance framework accordingly responsible advising global digital privacy deploying comprehensive training programme drive cybersecurity strategy ero appointed head greater awareness accountability managing digital privacy cybersecurity head dpc personal information across entire organisation daytoday accountability designing implementing control framework certify key gsk privacy network roles sufficient training experience carry roles effectively continuously improve processes issue identification reporting handling monitoring core team works business ensure build privacy controls existing new business initiatives well ensuring meet accountability obligations accordance global data protection privacy laws research practices risk definition context risk gsk third parties potentially fail research involving animals raise ethical concerns many adequately conduct ethical credible preclinical cases however research involving animals way clinical research collaborate research activities compliant investigate effects potential new medicine living laws regulations internal controls requirements body humans animal research provides critical information causes mechanisms diseases risk impact therefore remains vital part research potential impacts risk include harm human continually seek ways minimise use subjects reputational damage failure obtain necessary animals research development testing regulatory approvals products governmental complying regulatory requirements reducing investigation legal proceedings brought gsk impact animals used human subject research critical governmental private plaintiffs product liability suits assessing demonstrating safety efficacy claims damages loss revenue due inadequate patent investigational products evaluating products protection inability supply products regulatory approved research includes clinical action fines penalties loss product authorisation trials healthy volunteers patients adheres poor data integrity governance could compromise gsks regulations high ethical medical scientific standards rd efforts negatively impact reputation disclose results research externally regardless could materially adversely affect financial results whether reflect positively negatively products damage trust patients customers scientific community learn outcomes research also work human biological samples fundamental discovery development safety monitoring products gsk annual report principal risks uncertainties continued strategic report governance remuneration financial statements investor information research practices continued committed managing human biological samples established office animal welfare ethics accordance relevant laws regulations ethical strategy risk oawesr led chief veterinary officer principles manner respects interests supports humane responsible care animals sample donors data pivotal rd strategy carries ethical reviews independent scientific reviews maximising use data serve patients governing animal studies shares knowledge advocates data accordance relevant laws regulations contractual application nonanimal alternatives oawesr provides obligations expectations culture across privacy framework animal welfare governance defines provides information security data integrity essential oversight training animal care promotes replacement refinement reduction animal research conducts quality use wide variety biological materials discovery assessments manages programme external animal research development assets diligence develops deploys strategies reproducing convention biological diversity cbd nagoya experiments translating human clinical end points protocol international community established global ensuring implement maintain proper data governance framework regulating access use genetic resources controls remains important priority especially scientific nonhuman origin research development support strategy evolving take advantage breadth principles access benefitsharing genetic data example genomics artificial intelligence resources outlined cbd nagoya protocol machine learning focus building data integrity privacy also recognise importance appropriate effective usage controls internal control framework quality proportionate implementation measures national assurance teams conduct audits provide independent regional levels business monitoring internal controls rd mitigating activities organisation maintains controls prepublication procedures guard public disclosure patent applications research practices risk overseen enterprise filed addition lack data integrity framework seeks strengthen governance across rd preparing patent application data information lead leadership research practices enterprise risk loss patent protection legal experts collaborate rd owner management risk takes pragmatic approach support review process new patent applications information sharing streamlining risk identification rd organisation also collaborates legal experts escalation ensuring ownership risk mitigation stays throughout development assets take account business relevant thirdparty patent rights environment health safety ehs risk definition mitigating activities risk gsk third parties potentially fail ensure gsk leadership team responsible ehs governance appropriate controls governance organizations risk oversight ensure effective control assets facilities infrastructure business activities framework inplace inuse manage ehs risks including execution hazardous activities handling impacts legal compliance issues businesses hazardous materials release substances harmful includes assigning responsibility senior managers environment disrupts supply harms employees third providing maintaining controls ensuring parties environment tiered monitoring governance processes place within business units function leaders ensure ehs control risk impact framework implemented effectively respective business failure manage ehs risks could lead significant harm area compliant applicable laws regulations people environment communities adequately resourced maintained communicated operate fines inability meet stakeholder expectations monitored every employee qualified contractor acting regulatory requirements litigation regulatory action behalf gsk personally responsible ensuring damage companys reputation could materially follow applicable local standard operating procedures adversely affect financial results riskbased proactive approach articulated global ehs policy detailed global ehs standards context audit operations ensure compliance ensure gsk subject health safety environmental laws hazards appropriately controlled design various jurisdictions laws impose duties protect facilities equipment systems rigorous procedures people environment communities applied correctly put effective barriers place protect operate employees health safety created safety improvement plan focusing life saving rules safety leadership warehouse safety significant milestones programmes delivered according plan safety leadership experience warehouse improvements continue implementation gsk annual report principal risks uncertainties continued information security risk definition mitigating activities risk gsk third parties potentially fail ensure cyber security office cyber maturity programme appropriate controls governance unauthorised gsk cyber security office chief information access disclosure theft unavailability corruption gsks security officer responsible identifying putting information key systems technology infrastructure place measures help gsk mitigate manage cyber risk impact security risks includes active monitoring initiating remediation actions response cyber security failure adequately protect information systems may intelligence threats also enhancing capabilities cause harm patients workforce customers ongoing programme investment people disruption business andor loss commercial process technology improve ability prevent strategic advantage regulatory sanction damage detect respond recover cyber security incidents reputation risk based thirdparty security risk management program context also place aid assessing cyber security risk selection third parties also provide ongoing monitoring external environment continues extremely external partner supplier ecosystem challenging making hard keep pace increasingly sophisticated cyber threats due many factors information security governance including increased geopolitical conflict digital cyber security office periodically provides updates key nationalism rising frequency severity data breaches information security risks issues well progress reports growing capability sophistication bad actors cyber maturity programme risk oversight cyber criminals gsks business relies operating highly compliance council audit risk committee connected information network internal external information security enterprise risk plan cyber maturity systems hold confidential research development programme overseen chief digital technology manufacturing commercial workforce financial data officer well chief financial officer means systems information cyber security awareness training readiness continue target cyberattacks acceleration use digital data analytics cloud computing cyber security awareness training programs including capabilities drive gsks pipeline performance requires phishing simulation programs place increase us continuously adapt strengthen controls awareness cyber related risks reinforce message defensive capabilities gsk also relies thirdparty security everyones responsibility gsk periodic crisis contractors partners suppliers face similar cyber simulation tabletop exercises planned various levels threats continues vector risk manage organisation test ability respond cyber well incidents compliance various governmental cyber security regulations cyber security office general counsels guidance works stay abreast various emergent governmental regulations emergent trends compliance expectations regarding cyber security information security new regulatory guidance becomes available remedial compliance related actions put place appropriate gsk annual report principal risks uncertainties continued strategic report governance remuneration financial statements investor information supply continuity risk definition new technology modality platforms within supply chains changing requirements skillsets people risk gsk third parties potentially fail deliver working field implemented new chemistry continuous supply compliant finished product respond manufacturing controls operating model effectively crisis incident timely manner recover brings crossfertilisation talent focus skills needed sustain critical supply operations future innovative manufacturing risk impact industrial relations also current risk supply continuity recognise important continuity supply threat industrial action averted uk products patients rely supply disruption manufacturing sites successful dialogue unions lead continued business monitoring place assess risk product shortages product recalls spread industrial relations challenges resulting global cost living pressures regulatory intervention mitigating activities reputational harm lost sales revenue risk management medicines vaccine supply chains set ensure consequently need sophisticated endtoend supply chain sustainable global supply gsk internal control framework management robust crisis management business drives approach risk management continuity plans place respond designed identify emerging new risks support clear decision making risk oversight managed context hierarchy risk management compliance boards run supply chains continually evolving highly assure risk mitigation including identifying new emerging regulated environment single set global threats regulations governs manufacture distribution medicines must adhere requirements inventory management markets licence sell manufacture products supply chain governance committees medicines rely upon internal quality management system vaccines closely monitor inventory status delivery internal control framework ensure continue products core commercial cycle links supply chain preserve licence operate forecasting commercial ambition designed reduce risk demand fluctuations manage temporary complex endtoend supply chains often involve third shortages supply periodically review node party suppliers active pharmaceutical ingredient api supply chains ensure hold adequate safety stocks whilst manufacturers raw material suppliers third balancing working capital put particular emphasis party logistics providers contract engineering firms mitigating supply risks associated medicallycritical embed integrated risk management sourcing day highrevenue products new product launches example day business processes alongside thirdparty oversight using dual sourcing key products apis use programme monthly performance management process across supply external factors continued challenge supply continuity chains monitor business activity highlight adverse early part year covid continued trends supply operations budget workforce capability disrupt sourcing biosciences materials across medicines vaccines supply chains eg vials syringes business continuity singleuse systems components ukraine conflict crisis management business continuity plans place resulted supply disruption region manage across supply chains include authorised response disruptions deployed bespoke derisking plans using crisis recovery strategies key areas responsibility clear continuity plans manage detail mitigate risk communication routes regularly use business continuity supply continuity problems eg dual sourcing plans manage potential supply disruptions materials rerouting shipments avoid conflict zones manufacturing sites crisis management plans keeping patients supplied medicines place plans tested least annually ensure priority maintenance core skills crisis management gsk annual report shareholder information demerger share consolidation monday july company completed circular relation demerger share demerger consumer healthcare business consolidation circular prospectus regarding group form haleon group demerger terms admission haleons ordinary shares premium listing demerger shareholders received one haleon plc share segment official list financial conduct authority gsk plc share held record time pm uk fca trading main market london stock friday july exchange lse published company haleon plc respectively wednesday june following demerger company consolidated share capital share consolidation share consolidation took effect tuesday july resulted shareholders receiving four new gsk plc shares nominal value pence every five gsk plc shares nominal value pence held record time pm uk monday july share capital control details issued share capital number shares similarly certain economic sanctions may held treasury december found force time time limitations relating note financial statements share capital share nonresidents uk english law companys premium account articles association right holder vote respect companys shares ordinary shares listed lse also quoted new york stock exchange nyse form interests voting rights american depositary shares ads ads represents two stated far aware ordinary shares details listed debt listed persons significant direct indirect holdings company refer note financial statements net debt information provided company pursuant fca 's holders ordinary shares ads entitled receive disclosure guidance transparency rules dtr dividends declared companys annual report published regulatory information service also entitled attend speak appoint proxies companys website gskcom exercise voting rights general meetings company company received notifications accordance restrictions transfer limitations dtr following notifiable interests voting rights holding ordinary shares ads requirements companys issued share capital obtain approval prior transfers ordinary shares december march ads carry special rights regard control percentage percentage company restrictions voting rights major total total shareholders voting rights per share voting voting voting voting rights rights rights rights shareholders known arrangements blackrock inc financial rights held person holder shares known agreements restrictions share dodge cox transfers voting rights p ercentage total voting rights date notification shares acquired groups employee share plans company rank equally shares issue special c omprising indirect interest ordinary shares holding qualifying financial instruments contracts rights trustees employee share ownership plan difference trusts waived rights dividends shares held c omprising indirect interest ordinary shares trusts ads exchange controls limitations company acquired disposed interests affecting holders shares period review certain economic sanctions may force time time currently applicable laws decrees regulations force uk restricting import export capital restricting remittance dividends payments holders companys shares nonresidents uk strategic report governance remuneration financial statements investor information gsk annual report shareholder information continued share capital control continued share buyback programme share price board authorised issue allot ordinary january shares article companys articles association december power article authority company increasedecrease make purchases shares subject shareholder high year authorities sought annual basis annual low year general meeting agm shares purchased company may cancelled held treasury shares table sets middle market closing prices used satisfying share options grants group 's companys share price decreased employee share plans compares increase ftse index year middle market closing share price march programme covers purchases shares cancellation held treasury shares accordance authority renewed shareholders agm may share price trend three years ended company authorised purchase maximum december million shares details shares purchased cancelled held treasury shares subsequently uk us transferred treasury satisfy awards groups employee share plans disclosed note financial statements share capital share premium account determining specific share repurchase levels company considers development free cash flow year treasury shares purchased since company confirms currently intend make market purchases company review potential future share buybacks line usual annual cycle subject return ratings criteria market capitalisation market capitalisation based shares issue excluding treasury shares gsk december billion date gsk th largest company market capitalisation ftse index uk share price uk us ads price us nature trading market following table sets periods indicated high low middle market closing prices companys ordinary shares lse ads nyse ordinary shares ads uk per share us per share high low high low march february january december november october september quarter ended december quarter ended september quarter ended june quarter ended march quarter ended december quarter ended september quarter ended june quarter ended march year ended december year ended december year ended december year ended december march gsk annual report shareholder information continued analysis shareholdings december number total total number accounts accounts shares shares holding shares held institutional corporate holders individuals corporate bodies guaranty nominees limited adr programme held treasury shares gsk jp morgan chase bank na depositary companys american depository receipt adr programme companys ads listed nyse ordinary shares representing companys adr programme managed depositary registered name guaranty nominees limited march guaranty nominees limited held ordinary shares representing issued share capital excluding treasury shares march number holders ordinary shares us holdings ordinary shares number registered holders ads holdings ads certain ordinary shares ads held brokers nominees result number holders record registered holders us representative number beneficial holders residence beneficial holders dividends company pays dividends quarterly continues return gsk previously stated expected declare p cash shareholders dividend policy dividends per share dividend first half p per share remain essential component total shareholder return dividend second half p per share gsk recognises importance dividends shareholders dividend share consolidation targeted dividends per share would increase step june new gsk investor update gsk share consolidation maintain aggregate set progressive dividend policy dividend payout absolute pound sterling terms accordingly implemented guided percent payout ratio using consolidation ratio gsks expected dividend investment cycle dividend policy total fourth quarter converts p per new ordinary expected cash distribution respective dividend share results expected total dividend second payout ratios gsk remain unchanged half p per new ordinary share expected dividend p per new ordinary share line dividends per share original expectation converted share table sets dividend per share per ads consolidation rounded last five years dividend per ads translated details dividends declared amounts us dollars applicable exchange rates payment dates given note financial statements year pence us dividends dividend calendar quarter exdividend date record date payment date q february february april q may may july annual fee per ads per ads per quarter charged q august august october depository amounts shown dividends paid per ads q november november january annual fee charged q february february april adjusted share consolidation prior years adjusted dividends declared paid respect p per share q p per share q p per share q dividend p per share declared q q ordinary dividend receivable ads holders calculated based exchange rate april cumulative dividend receivable ads holders q q q strategic report governance remuneration financial statements investor information gsk annual report shareholder information continued financial calendar event date results announcements quarter results announcement april results announcements issued lse available annual general meeting may news service also sent us securities quarter results announcement july exchange commission sec nyse issued quarter results announcement november media made available website preliminaryquarter results announcement january financial reports annual report publication februarymarch annual report distribution march company publishes annual report made available website date publication information company including share ads shareholders may elect receive notification email price available website gskcom information made publication annual reports registering available website constitute part annual wwwshareviewcouk may also elect receive report printed copy annual report contacting registrar equiniti limited copies previous annual reports available website printed copies also obtained registrar see contact details annual general meeting annual general meeting agm held pm ads holders wishing attend meeting electronically uk time wednesday may sofitel london refer agm notice details request heathrow terminal london heathrow airport tw gd proxy appointment depositary jp morgan chase also broadcast live join electronically bank na enable attend ask questions vote electronically business transacted agm companys principal forum communication meeting ads holders reminded instruct private shareholders addition formal agm depositary way shares represented business presentation ceo ads voted completing returning performance group future development voting card provided depositary shares opportunity questions asked board voted chairs boards committees available take questions relating roles documents display details access agm electronically articles association company directors attend person ask questions vote found service contracts applicable letters appointment notice annual general meeting agm notice directors company subsidiaries available website gskcom side letters relating severance terms pension investors holding shares nominee service arrangements available inspection companys arrange service appointed proxy registered office made available inspection respect shareholding attend vote agm meeting electronically tax information shareholders summary certain uk tax us federal income tax us holders ads generally treated owners consequences holders shares ads citizens underlying shares purposes current ukus uk us set complete double taxation conventions relating income gains analysis possible tax consequences purchase income tax convention estate gift taxes estate gift ownership sale securities intended tax convention purposes internal revenue general guide holders advised consult advisers code amended respect tax consequences purchase ownership sale shares ads consequences state local tax laws us implications current ukus tax conventionsgsk annual report shareholder information continued tax information shareholders continued uk shareholders overall exposure dependent specific circumstances situation also important note summary applies uk resident shareholder tax charges may arise jurisdictions bespoke advice holds shares capital assets tailored individuals personal circumstances taxation dividends therefore obtained tax professional uk tax year uk resident individuals stamp duty stamp duty reserve tax entitled dividend tax allowance uk stamp duty andor stamp duty reserve tax sdrt first dividends received tax year free subject certain exemptions payable transfer tax dividends excess allowance taxed shares rate rounded nearest case basic rate taxpayers higher rate stamp duty consideration transfer taxpayers additional rate taxpayers note notwithstanding provided instrument executed april dividend allowance reduced pursuance agreement gave rise charge sdrt april dividend allowance instrument stamped within six years agreement reduced including stamped exempt sdrt charge uk resident shareholders corporation taxpayers cancelled sdrt already paid note dividends payable ordinary shares repaid listed shares transferred company generally entitled exemption corporation tax connected transferor chargeable consideration deemed less market value shares taxation capital gains transferred market value override also applies uk resident shareholders may liable uk tax gains nonlisted shares transferred company connected disposal shares ads transferor consideration includes issue shares disposals individuals uk tax year us shareholders taxable capital gain accruing disposal shares ads taxed basic rate taxpayers summary applies shareholder citizen allowable deductions individuals taxable income resident us domestic corporation person year exceeds basic rate income tax banding note otherwise subject us federal income tax net income following use exemptions available basis respect shares ads holds shares ads individual taxpayer annual exempt amount capital assets resident uk uk tax purposes hold shares purposes trade profession corporation taxpayers may entitled indexation vocation carried uk branch agency allowance applies reduce capital gains extent gains arise due inflation indexation allowance summary also address tax treatment holders may reduce chargeable gain create allowable subject special tax rules banks taxexempt loss assets acquired january entities insurance companies dealers securities currencies legislation finance act freezes level persons hold shares ads part integrated indexation allowance given calculating companys investment including straddle comprised share ads chargeable gains value would apply disposal one positions persons directly asset december assets acquired indirectly constructively companys stock january onwards legislation finance act vote value address tax treatment may removes indexation allowance disposal applicable result international income tax treaties inheritance tax taxation dividends individual ukdomiciled otherwise shareholders may gross amount dividends received treated foreign liable uk inheritance tax transfer shares ads source dividend income us tax purposes eligible exposure uk inheritance tax charge typically occurs dividend received deduction allowed us corporations death asset owner however transfers shares dividends ads payable us dollars dividends commercial sales within years death remain relevant ordinary shares payable sterling dividends paid inheritance tax exposure death transfers sterling included income us dollar amount trust arrangement lifetime give rise immediate calculated reference exchange rate day inheritance tax charge dividends received holder subject certain exceptions shortterm hedged positions individual tax may charged amount value eligible us holder subject us taxation maximum shareholders estate reduced result transfer way federal rate plus applicable state local tax lifetime gift disposal less full market value respect qualified dividends qualified dividend defined case bequest death tax may charged us internal revenue service irs dividend value shares date shareholders death meets following criteria exposure uk inheritance tax us estate gift tax exists careful planning must undertaken understand ust issued us corporation corporation opportunity utilise usuk estate gift double tax incorporated us possession corporation convention manage tax credits avoid double taxation eligible benefits comprehensive income tax treaty deemed satisfactory published irs strategic report governance remuneration financial statements investor information gsk annual report shareholder information continued tax information shareholders continued dividends type listed irs estate gift taxes dividends qualify estate gift tax convention us shareholder required dividend holding period met generally subject uk inheritance tax however us shares must owned holder may subject us federal estate gift tax days holding period defined stamp duty day period begins days exdividend date day stock trades without uk stamp duty andor sdrt subject certain dividend priced example stocks exdividend exemptions payable transfer shares ads date october shares must held custodian depository rate amount days period august november consideration provided transferred sale value year order count qualified dividend transferred consideration dividends qualified subject taxation however stamp duty sdrt payable us federal graduated tax rates maximum rate transfer agreement transfer ads transfers types dividends automatically excluded within clearance service notwithstanding qualified dividends even meet clearance service operator made election requirements include limited sa finance act broadly stamp duty sdrt charge arise transfer capital gains distributions clearance service transfers within system dividends bank deposits change beneficial ownership would ividends held corporation employee stock attract charge ownership plan esop demerger share consolidation dividends paid taxexempt corporations summary certain uk us tax consequences respect us state local tax rates qualified nonqualified demerger share consolidation relevant dividends may vary would assessed addition companys shareholders resident case federal tax rates communicated individuals resident domiciled uk uk tax purposes citizens resident us us tax taxation capital gains purposes set part circular pages generally us holders subject uk capital gains circular along information regarding tax subject us tax capital gains realised demerger share consolidation found gskcom sale disposal shares ads gains demerger section longterm capital gains subject reduced rates taxation information tax base cost allocation assist uk individual holders shares ads held shareholders apportion base cost gsk plc one year date shares vestedreleased shares haleon plc shares uk capital gains tax shortterm capital gains subject taxation rates purposes following demerger including worked example whereas longterm capital gains may subject found tax section gskcom demerger rates state local tax rates capital section gains may also apply information reporting backup withholding dividends payments proceeds sale shares ads paid within us certain usrelated financial intermediaries subject information reporting may subject backup withholding unless us holder corporation exempt recipient provides taxpayer identification number certifies loss exemption occurred nonus holders generally subject information reporting backup withholding may required provide certification nonus status connection payments received amounts withheld allowed refund credit holders us federal income tax liability provided required information furnished irsgsk annual report statutory disclosures shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel equiniti provides range services shareholders service offers participate dividend reinvestment plan alternative receiving cash dividends may choose drip election form terms conditions drip reinvest dividends buy gsk shares information fees downloaded wwwshareviewcouk requested contacting equiniti dividend payment direct dividends paid directly bank building society dividend bank mandate form bank account bank mandate account receive cash dividends must provide equiniti downloaded wwwshareviewcouk bank building society account details quick requested contacting equiniti secure method payment dividend payment direct bank equiniti convert dividend local currency send information overseas payment account overseas shareholders direct local bank account overseas payment service service including information fees overseas payment service available approximately countries worldwide found wwwshareviewcouk contacting equiniti electronic communications shareholders may elect receive electronic notifications please register wwwshareviewcouk company communications including annual report dividend payments dividend confirmations availability online voting general meetings time gsk publishes shareholder documents receive email containing link document relevant website shareview portfolio service enables create free online portfolio view please register wwwshareviewcouk share balance movements update address dividend payment instructions register votes general meetings deduplication publications receive duplicate copies mailings may please contact equiniti mailings one account please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificated information share dealing please note market trading form corporate sponsored nominee online telephone service including information fees hours pm via postal dealing service provided equiniti financial services found wwwshareviewcoukdealing uk time monday friday limited online transactions please log excluding public holidays wwwshareviewcoukdealing england wales telephone transactions please call uk outside uk lines open pm uk time monday friday excluding uk public holidays postal transactions please call request dealing form corporate sponsored nominee convenient way manage shares without requiring application form requested account share certificate service provides facility hold wwwshareviewcouk shares nominee account sponsored company contacting equiniti continue receive dividend payments attend vote companys general meetings shareholders names appear publicly available share register service free join individual savings accounts isas equiniti financial services limited provide eqi flexible isa details including information fees hold gsk shares available wwweqicouk requested calling equiniti customer experience team lines open pm uk time monday friday excluding uk public holidays lines open pm uk time monday friday excluding public holidays england wales please use country code dialling outside uk provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser strategic report governance remuneration financial statements investor information gsk annual report shareholder information continued shareholders services contacts continued ads depositary contacts adr programme administered jp morgan investor relations chase bank na investor relations may contacted follows regular correspondence uk eq shareowner services great west road po box brentford middlesex tw gs st paul mn tel delivery stock certificates overnight mail us eq shareowner services walnut street centre pointe curve suite philadelphia pa mendota heights mn tel us toll free shareowneronlinecominformationalcontactus tel outside us us gsk response center outside us tel us toll free depository also provides global invest direct direct tel outside us ads purchasesale dividend reinvestment plan ads holders details enrol please visit wwwadrcom share scam alert receive unsolicited telephone call offering sell call helpline number obtain enrolment buy shares please take extra care caller may part pack highly organised financial scam donating shares save children uk shareholder please contact financial gsk embarked ambitious global partnership conduct authority wwwfcaorgukconsumers save children share expertise resources consumer helpline aim finding innovative ways reduce number children dying preventable diseases tel uk shareholders small number shares value tel outside uk makes uneconomical sell may wish consider donating lines open pm uk time monday friday except uk save children donated shares aggregated public holidays pm saturdays sold behalf save children use funds raised help reach goal obtain share donation form please contact registrar equiniti managing donation sale uk shares save children free charge provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser stock exchange announcement notifications provide shareholders service receive automatic email notifications publish stock exchange announcement receive email notifications please sign announcements gskcom investors sectiongsk annual report statutory disclosures continued us law regulation number provisions us law regulation apply section corporate responsibility company shares quoted nyse financial reports form ads sarbanesoxley requires ceo cfo complete nyse rules formal certifications confirming general nyse rules permit company follow uk reviewed annual report form f corporate governance practices instead applied based knowledge annual report form f us provided explain significant variations contains material misstatements omissions explanation contained form f accessed sec 's edgar database via website based knowledge financial statements nyse rules require us file annual interim written financial information fairly present material affirmations concerning audit risk committee arc respects financial condition results operations statement significant differences corporate cash flows dates periods presented governance annual report form f responsible establishing maintaining sarbanesoxley act disclosure controls procedures ensure material following number corporate accounting scandals information made known evaluated us congress passed sarbanesoxley act effectiveness controls procedures year sarbanesoxley wideranging piece legislation end results evaluation contained concerned largely financial reporting corporate annual report form f governance responsible establishing maintaining recommended sec company established internal control financial reporting provides disclosure committee committee reports ceo reasonable assurance regarding reliability financial cfo arc chaired company secretary reporting preparation financial statements members consist senior managers finance external purposes accordance generally accepted legal corporate communications investor relations accounting principles appropriate external legal counsel external disclosed annual report form f auditors sponsor bank internal experts invited changes internal controls financial reporting attend disclosure committees meetings periodically period covered annual report form f committee responsibility considering materiality materially affected reasonably likely affect information timely basis determining disclosure materially companys internal control financial information responsibility timely filing reporting disclosed based reports sec formal review annual recent evaluation internal control financial reporting report form f committee met times external auditor arc significant including purpose receiving relevant appropriate deficiencies material weaknesses design training operation internal controls financial reporting sarbanesoxley requires annual report form f reasonably likely affect adversely companys contains statement whether member arc ability record process summarise report financial audit committee financial expert defined rules information fraud regardless materiality sarbanesoxley statement relevant members involving persons significant role arc charles bancroft included board companys internal control financial reporting committee information area corporate governance group carried evaluation supervision report biography participation management including additional disclosure requirements arise section ceo cfo effectiveness design operation section sarbanesoxley respect disclosure controls groups disclosure controls procedures procedures internal control financial reporting december inherent limitations effectiveness system disclosure controls procedures including possibility human error circumvention overriding controls procedures accordingly even effective disclosure controls procedures provide reasonable assurance achieving control objectives strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued us law regulation continued ceo cfo expect complete certifications group exports certain pharmaceutical vaccine report conclusions effectiveness disclosure consumer products iran via sales nonus entities controls procedures march following subsidiaries us entity two privately held iranian certifications filed sec part groups distributors form f group regularly receive information regarding identity distributors ' downstream customers section managements annual report intermediaries iran possible parties internal control financial reporting include entities governmentowned hospitals accordance requirements section pharmacies owned directly indirectly iranian sarbanesoxley following report provided government persons entities sanctioned connection management respect companys internal control terrorism proliferation activities financial reporting defined rules af df group regularly receive information us securities exchange act amended regarding identity distributors ' downstream customers exchange act establish proportion gross revenue sales management responsible establishing maintaining potentially attributable entities affiliated iranian adequate internal control financial reporting government parties sanctioned disclosable activities group internal control financial reporting designed result group reporting entire gross revenues provide reasonable assurance regarding reliability million net profits million group 's financial reporting preparation financial sales iran statements external purposes accordance ifrs group also aware hospitals medical management conducted evaluation effectiveness facilities lebanon may affiliated controlled internal control financial reporting based hezbollah groups designated united framework internal control integrated framework states pursuant executive order group issued committee sponsoring organisations deal directly hospitals facilities treadway commission coso instead sells distributors group unable changes groups internal control establish proportion gross revenue sales potentially financial reporting materially attributable reportable activities result group affected reasonably likely materially affect reporting entire gross revenues million net losses groups internal control financial reporting million group 's sales lebanon management assessed effectiveness internal unless noted group intends continue activities control financial reporting december described conclusion filed part groups form addition section r exchange act us law f generally restricts dealings us persons dealings deloitte llp audited consolidated financial otherwise subject us jurisdiction certain countries statements group year ended december territories subject comprehensive sanctions also assessed effectiveness groups currently crimea cuba socalled donetsk people 's internal control financial reporting auditing republic iran socalled luhansk people 's republic north standard public company accounting oversight korea syria well government venezuela board united states audit report filed though country venezuela whole groups form f group business via nonus entities owned controlled us entities certain jurisdictions section r exchange act believe group complies applicable us sanctions section r exchange act requires issuers make material respects laws complex continue specific disclosure annual reports certain types evolve rapidly dealings iran including transactions dealings governmentowned orcontrolled entities well dealings entities sanctioned activities related terrorism proliferation weapons mass destruction even activities prohibited us law involve us personsgsk annual report statutory disclosures continued donations political organisations political expenditure ensure consistent approach political contributions result definitions may cover legitimate business across group global policy introduced activities ordinary sense considered political voluntarily stop corporate political contributions donations political expenditure designed support political party independent election candidate period january december group make political donations eu therefore notwithstanding policy noneu organisations intend make donations eu political parties organisations incur eu political expenditure notwithstanding introduction policy accordance annually seek shareholder authorisation inadvertent federal election campaign act us continue expenditure support employeeoperated political action committee pac facilitates voluntary political donations eligible authority precautionary measure ensure gsk employees company subsidiaries inadvertently breach legislation pac controlled gsk decisions amounts recipients contributions governed pac board authorisation process expenditure directors contributions pac made year dates back agm held may following participating eligible employees exercising legal right introduction political parties elections pool resources make political contributions referendums act authority since subject strict limitations us law total renewed annually us us donated political organisations gsk employee pac english law requires prior shareholder approval political contributions eu political parties independent election candidates well eu political expenditure definitions political donations political expenditure political organisations used legislation however quite broad particular definition eu political organisations may extend bodies concerned policy review law reform representation business community special interest groups concerned environment company subsidiaries might wish support strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies accordance section companies act full list subsidiaries associates joint ventures joint arrangements address registered office effective percentage equity owned december disclosed unless otherwise stated share capital disclosed comprises ordinary shares indirectly held gsk plc percentage held class share stated less unless otherwise stated subsidiary companies registered office tax resident country incorporation name security registered address wholly owned subsidiaries alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limited ordinary great west road brentford middlesex tw gs england adechsa gmbh ii ordinary co prv provides treuhandgesellschaft ag dorfstrasse baar switzerland affinivax securities corporation common co affinivax inc binney street cambridge united states affinivax inc common corporation service company little falls drive wilmington de united states allen hanburys limited ii ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary town planning way ilupeju lagos nigeria allen pharmazeutika gesellschaft mbh ordinary wienerbergstrae wien austria austria beecham group plc p ordinary b great west road brentford middlesex tw gs england p ordinary beecham pharmaceuticals pte limited ordinary quality road jurong industrial estate jurong singapore beecham portuguesaprodutos farmaceuticos e quimicos lda quota rua dr antonio loureiro borges arquiparque miraflores alges portugal beecham sa ordinary avenue fleming wavre belgium biovesta ilalari ltd sti ii nominative bykdere caddesi levent plaza b blok levent istanbul turkey cascan gmbh co kg partnership capital prinzregentenplatz munich germany cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome limited liquidation ordinary co bdo llp temple square temple street liverpool l rh united kingdom charles midgley limited liquidation ordinary co bdo llp temple square temple street liverpool l rh united kingdom clarges pharmaceuticals limited liquidation ordinary co bdo llp temple square temple street liverpool l rh united preference kingdom clarges pharmaceutical trustees limited ii iv ordinary great west road brentford middlesex tw gs england colleen corporation common corporation service company little falls drive wilmington de united states corixa corporation common corporation service company little falls drive wilmington de united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energia solar alternativa sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain duncan pharmaceuticals philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines etex farmaceutica ltda social capital av andrs bello costanera center torre piso providencia santiago chile genelabs technologies inc common corporation service company gateway oaks drive suite n sacramento ca united states glaxo group limited ordinary great west road brentford middlesex tw gs england glaxo kabushiki kaisha ii ordinary akasaka minatoku tokyo japan glaxo laboratories nigeria limited ii ordinary marine road apapa lagos nigeria glaxo laboratories limited liquidation ordinary baker street london wu eu united kingdom glaxo new zealand pension plan trustee limited ordinary level e generator gridakl madden street wynyard quarter auckland new zealand glaxo operations uk limited ordinary great west road brentford middlesex tw gs england glaxo properties bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxo trustees limited liquidation ordinary baker street london wu eu united kingdom glaxo verwaltungs gmbh ordinary prinzregentenplatz munich germany glaxo wellcome farmaceutica limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production ordinary rue franois jacob rueilmalmaison france glaxo wellcome vidhyasom limited ii ordinary th floor wave place wireless road lumpini pathumwan bangkok thailandgsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgos spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxoallenburys nigeria limited ii ordinary creek road apapa lagos pmb nigeria glaxochem pte ltd iii ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxosmithkline cambodia co ltd ordinary th floor dksh building preah monivong boulevard co sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room unit floor mid th east ring road chaoyang district beijing china glaxosmithkline china rd company limited equity f building huanke road pilot free trade zone shanghai china glaxosmithkline gsk srl ordinary costache negri street opera center one th th floors zone district bucharest romania glaxosmithkline ireland limited ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline malta limited ordinary first floor de la cruz avenue qormi qrm malta glaxosmithkline private limited ii ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quota luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aires caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline australia pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands glaxosmithkline beteiligungs gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biologicals kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biologicals sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biologicals sa ordinary rue de l'institut b rixensart belgium preference glaxosmithkline brasil limitada quotas estrada dos banderiantes rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc n market street th floor wilmington de united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital av andrs bello torre piso providencia santiago regin metropolitana chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer holding bv ii ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline doo sarajevo u likvidaciji liquidation quotas zmja od bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beogradnovi beograd u likvidaciji ordinary milutin milankovic j novi beograd belgrade serbia liquidation glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline el salvador sa de cv ordinary municipio de san salvador departamento de san salvador el salvador glaxosmithkline eood ordinary nedelcho bonchev str sofia bulgaria glaxosmithkline export limited ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary ra av zona torre citibank nivel guatemala city guatemala glaxosmithkline holding ordinary drammensveien oslo norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street th floor wilmington delaware glaxosmithkline holdings one limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings limited ordinary great west road brentford middlesex tw gs england strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline holdings pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limited ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline inc class common milverton drive suite mississauga lr h canada class c preference glaxosmithkline insurance ltd ordinary co trinity corporate services ltd trinity hall cedar avenue hamilton hamilton hm bermuda glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property holdings limited ordinary great west road brentford middlesex tw gs england b ordinary glaxosmithkline intellectual property limited deferred great west road brentford middlesex tw gs england ordinary glaxosmithkline intellectual property management limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline investments pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline kk ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline lietuva uab ordinary ukmerges st vilnius lt lithuania glaxosmithkline limited ordinary f tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline limited ii ordinary great west road brentford middlesex tw gs england glaxosmithkline llc llc interests corporation service company little falls drive wilmington de united states glaxosmithkline manufacturing spa ordinary viale dellagricoltura verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou hamed el glaza casablanca morocco glaxosmithkline medical healthcare products limited ordinary h csorsz utca budapest hungary glaxosmithkline mercury limited ordinary great west road brentford middlesex tw gs england glaxosmithkline mexico sa de cv ordinary av real mayorazgo piso colonia xoco alcaldia benito jurez ordinary b ciudad de mexico mexico glaxosmithkline nz limited ordinary level e generator gridakl madden street wynyard quarter auckland new zealand glaxosmithkline oy ordinary piispansilta po box espoo fin finland glaxosmithkline peru sa ordinary av vctor andrs belande n va principal n piso distrito de san isidro lima lima per glaxosmithkline pharma ordinary vallensbk company house iii delta park dk valle denmark glaxosmithkline pharma gmbh ordinary wienerbergstrae wien austria austria glaxosmithkline pharmaceutical kenya limited ordinary likoni road nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary hz horizon penthouse powerhouse persiaran bandar utama bandar utama petaling jaya selangor malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals costa rica sa ordinary autopista florencia del castillo kilmetro siete oficentro terracampus edificio uno cuarto piso san diego cartago costa rica glaxosmithkline pharmaceuticals sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceuticals ukraine llc chartered capital pavla tychyny avenue v kiev ukraine glaxosmithkline philippines inc ordinary rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common corporation service company puerto rico inc co rvm professional services llc reparto mendoza humacao puerto rico glaxosmithkline republica dominicana sa ordinary blue mall tower floor ave winston churchill santo domingo dominican republic glaxosmithkline research development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline spa ordinary viale dellagricoltura verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg partnership capital prinzregentenplatz munchen germanygsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline services unlimited ordinary great west road brentford middlesex tw gs england glaxosmithkline single member aebe ordinary kifissias avenue halandri athens greece glaxosmithkline sl llc llc interests corporation service company little falls drive wilmington de united states glaxosmithkline sl lp ii viii partnership great west road brentford middlesex tw gs england glaxosmithkline slovakia sro v likvidcii liquidation ordinary kpmg slovensko advisory ks dvokovo nbreie bratislava slovakia glaxosmithkline south africa pty limited ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline trading services limited iii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline tunisia sarl ordinary immeuble regus lot b centre urbain nord tunis tunisia glaxosmithkline uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa registered provisory stock salto cp montevideo uruguay glaxosmithkline us trading limited ordinary great west road brentford middlesex tw gs england glaxosmithkline venezuela ca ordinary calle altagracia edificio pg piso mezzanina torre torre sur urbanizacion sorokaima la trinidad caracas venezuela bolivarian republic glaxosmithkline vietnam limited liability company ii equity capital metropolitan dong khoi street district th floor unit ho chi minh city vietnam glycovaxyn ag common grabenstrasse schlieren switzerland preferred preferred b preferred c groupe glaxosmithkline ordinary rue franois jacob rueilmalmaison france gsk scottish limited partnership x partnership lothian road festival square edinburgh scotland eh wj united kingdom gsk biopharma argentina sa nominative non endorseable ordinary tucumn piso buenos aires caaa argentina gsk business service centre sdn bhd ordinary level quill jalan prof khoo kay kim petaling jaya selangor malaysia gsk capital kk ordinary akasaka minatoku tokyo japan gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk enterprise management co ltd ordinary floor lane huanke road zhongke road shanghai china gsk equity investments limited units corporation service company interstate drive suite harrisburg pa united states gsk finance limited ordinary great west road brentford middlesex tw gs england gsk finance plc ordinary great west road brentford middlesex tw gs england gsk india global services private limited equity level luxor north tower bagmane capital business park outer ring road bangalore karnataka india gsk international holding finance bv ordinary van asch van wijckstraat h lp amersfoort netherlands gsk kazakhstan llp participation interest furmanov street almaty medeu district kazakhstan gsk pharma india private limited equity battery house bhulabhai desai raod mumbai maharashtra india gsk pharma vietnam company limited chartered capital unit th floor metropolitan tower dong khoi street ben nghe ward district ho chi minh vietnam gsk pharmaceutical trading sa ii ordinary bucharest costache negri street opera center one th floor discussions room district romania gsk psc poland sp z oo equal indivisible shares ul grunwaldzka pozna pol gsk services sp z oo ordinary ul grunwaldzka poznan poland gsk vaccines bv ordinary hullenbergweg cl amsterdam netherlands gsk vaccines gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quotas via fiorentina siena italy gsk vaccines srl quotas via fiorentina siena italy gsk vaccines vertriebs gmbh ordinary rudolfdieselring holzkirchen germany human genome sciences inc common corporation service company little falls drive wilmington de united states id biomedical corporation quebec common boul du parc technologique qubec qubec gp r canada instituto luso farmaco limitada ii quotas rua dr antonio loureiro borges arquiparque miraflores alges portugal interpharma dienstleistungen gmbh ii quotas wienerbergstrae wien austria austria jj technologies lc ii llc interests corporation service company shockoe slip nd floor richmond va united states jsc glaxosmithkline trading ordinary leningradskiy prospect building floor premises xv room moscow russian federation strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoires paucourt ii ordinary rue franois jacob rueilmalmaison france laboratoires saintgermain ii ordinary rue franois jacob rueilmalmaison france laboratorios dermatologicos darier sa de cv ordinary av real mayorazgo piso colonia xoco alcaldia benito jurez ordinary b ciudad de mexico mexico laboratorios farmaceuticos stiefel portugal ltda ii ordinary rua dr antonio loureiro borges arquiparque miraflores alges portugal laboratorios stiefel de venezuela sa ordinary calle altagracia edificio pg nivel mezzanina piso mezzanina local torre sur urbanizacion sorokaima la trinidad caracas venezuela bolivarian republic laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem bairro de bonsucesso municipality guarulhos sao paulo cep brazil laboratorios wellcome de portugal limitada ii quotas rua dr antonio loureiro borges arquiparque miraflores alges portugal montrose pharma company limited ii ordinary quota h csorsz utca budapest hungary pt glaxo wellcome indonesia class jl pulobuaran raya kaviiidd kws industri pulogadung class b jatinegara cakung jakarta timur indonesia setfirst limited ordinary great west road brentford middlesex tw gs england sierra oncology australia pty ltd ordinary co maddocks lawyers angel place level pitt street sydney australia sierra oncology canada ulc common burrard street suite vancouver british columbia vc g canada sierra oncology canada llc llc interests corporation service company little falls drive wilmington de united states sierra oncology llc common stock corporation service company little falls drive wilmington de united states sitari pharma inc common stock corporation service company little falls drive wilmington de united states smith kline french portuguesaprodutos farmaceuticos ordinary rua dr antonio loureiro borges arquiparque miraflores lda ii alges portugal smithkline beecham bangladesh private limited ii ordinary housea roadgulshan dhaka bangladesh smithkline beecham cork limited ordinary riverwalk citywest business campus dublin ireland smithkline beecham manufacturing limited liquidation ordinary riverwalk citywest business campus dublin ireland smithkline beecham egypt llc quotas amoun street el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham limited ordinary great west road brentford middlesex tw gs england smithkline beecham legacy h limited ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited ii ordinary great west road brentford middlesex tw gs england smithkline beecham pension trustees limited liquidation ordinary baker street london wu eu united kingdom smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltungs gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited ii ordinary flushing meadows building campus sloane street bryanston south africa smithkline beecham pharmaceuticals co common corporation service company little falls drive wilmington de united states smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex tw gs england limited ii stiefel gmbh co kg partnership capital prinzregentenplatz munchen germany stiefel laboratories legacy ireland limited ordinary unit building avenue cork airport business park cork ireland stiefel laboratories limited liquidation ordinary co bdo llp temple square temple street liverpool l rh united kingdom stiefel laboratories pte limited ordinary pioneer sector singapore stiefel laboratories inc common corporation service company little falls drive wilmington de united states stiefel maroc sarl ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary mountain highway boronia victoria vic australia stiefel research australia pty ltd ordinary mountain highway boronia victoria vic australia stiefel west coast llc llc interests corporation service company little falls drive wilmington de united states strebor inc common corporation service company little falls drive wilmington de united statesgsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued tesaro bio gmbh liquidation ordinary poststrasse zug switzerland tesaro bio netherlands bv ordinary joop geesinkweg ab amsterdamduivendrecht netherlands tesaro development ltd ordinary clarendon house church street hamilton hm bermuda tesaro inc common corporation service company little falls drive wilmington de united states sydney ross co ii ordinary corporation service company princeton south corporate center suite charles ewing blvd ewing nj united states ucb pharma asia pacific sdn bhd ii ordinary th floor menara symphony jalan prof khoo kay kim seksyen petaling jaya malaysia wellcome consumer healthcare limited ii ordinary great west road brentford middlesex tw gs england wellcome consumer products limited liquidation ordinary co bdo llp temple square temple street liverpool l rh united kingdom wellcome limited ordinary great west road brentford middlesex tw gs england effective name security ownership registered address subsidiaries effective interest less amoun pharmaceutical industries co sae new monetary shares el salam city po box cairo egypt biddle sawyer limited equity dr annie besant road mumbai india british pharma group limited capital great west road brentford middlesex tw gs england galvani bioelectronics inc common corporation service company little falls drive wilmington de united states galvani bioelectronics limited ordinary great west road brentford middlesex tw gs england b ordinary glaxo saudi arabia limited ordinary po box area warehouse city first stage al khomrah jeddah saudi arabia glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline consumer nigeria plc ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt gsk scottish limited partnership ix partnership lothian road festival square edinburgh scotland eh wj united kingdom gsk scottish limited partnership ix partnership lothian road festival square edinburgh scotland eh wj united kingdom laboratorios viiv healthcare sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street po box el salam city cairo egypt phivco llc llc interests corporation service company little falls drive wilmington de united states phivco llc llc interests corporation service company little falls drive wilmington de united states shionogiviiv healthcare llc ii common interests corporation service company little falls drive wilmington de united states smithkline beechambiomed ooo participation interest leningradskiy prospect building floor premises xiv room moscow russian federation stiefel egypt llc ii quotas amoun street po box el salam city cairo egypt viiv healthcare south africa proprietary limited ordinary flushing meadows building campus sloane street bryanston south africa viiv healthcare bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands viiv healthcare company common corporation service company little falls drive wilmington de united states viiv healthcare finance limited liquidation ordinary co bdo llp temple square temple street liverpool l rh united kingdom viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england redeemable preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued viiv healthcare hong kong limited ordinary f tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare kk ordinary akasaka minatoku tokyo japan viiv healthcare limited ordinary great west road brentford middlesex tw gs england b ordinary c ordinary preference ordinary deferred e cumulative preference viiv healthcare pty ltd ordinary mountain highway boronia victoria vic australia viiv healthcare puerto rico llc llc interests corporation service company puerto rico inc co rvm professional services llc reparto mendoza humacao puerto rico viiv healthcare srl quotas viale dellagricoltura verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc ii participation interest leningradskiy prospect building floor premises xiv room moscow russian federation viiv healthcare trading services uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada viiv healthcare venture llc llc interest corporation service company little falls drive wilmington de united states viivhiv healthcare unipessoal lda quota rua dr antonio loureiro borges arquiparque miraflores alges portugal winster pharmaceuticals limited ordinary association avenue ilupeju industrial estate lagos po box nigeria effective name security ownership registered address associates glaxosmithkline landholding company inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines index ventures life vi jersey lp partnership interest esplanade st helier jersey je wg channel islands kurma biofund ii fcpr partnership interest rue royale th floor paris france longwood fund lp partnership interest prudential tower suite boylston street boston medicxi ventures lp partnership interest esplanade st helier jersey je wg channel islands joint ventures chiron panacea vaccines private limited equity shares th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india qualivax pte limited ordinary robinson road singapore qura therapeutics llc units corporation service company little falls drive wilmington de united states significant holdings axon therapies inc common west th street new york usa series preference alpheus medical inc series preference hopkins place north oakdale minnesota usa series preference global farm sa shares mendoza ciudad autnoma de buenos aires argentina b shares c shares longwood fund ii lp partnership interest prudential tower suite boylston street boston sanderling ventures vii lp partnership interest el camino real suite san mateo ca sr one capital fund ib lp partnership interest corporation service company little falls drive city wilmington county new castle delaware gsk annual report statutory disclosures continued group companies continued following uk subsidiaries take advantage audit exemption set within section companies act period ended december unless otherwise stated undertakings listed owned either directly indirectly gsk plc effective company name security ownership registered address number uk registered subsidiaries exempted audit burroughs wellcome international limited ordinary great west road brentford middlesex tw gs england domantis limited ordinary great west road brentford middlesex tw gs england edinburgh pharmaceutical industries limited ii ordinary shewalton road irvine ayrshire ka ap united kingdom sc preference eskaylab limited ordinary great west road brentford middlesex tw gs england glaxo wellcome uk limited ordinary great west road brentford middlesex tw gs england glaxo wellcome international bv iii ordinary huis ter heideweg lz zeist netherlands glaxochem uk unlimited ordinary great west road brentford middlesex tw gs england ordinary b ordinary c glaxosmithkline intellectual property ordinary great west road brentford middlesex tw gs england limited glaxosmithkline intellectual property ordinary great west road brentford middlesex tw gs england limited glaxosmithkline intellectual property ordinary great west road brentford middlesex tw gs england limited glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england gsk capital bv iii v ordinary great west road brentford middlesex tw gs england gsk gp limited iv shares lothian road festival square edinburgh scotland eh wj sc b shares united kingdom gsk gp limited iv ordinary lothian road festival square edinburgh scotland eh wj sc united kingdom gsk lp limited iv ordinary great west road brentford middlesex tw gs england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap united kingdom sc phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limited ordinary great west road brentford middlesex tw gs england smith kline french laboratories limited ordinary great west road brentford middlesex tw gs england smithkline beecham export limited ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative great west road brentford middlesex tw gs england nonredeemable ordinary smithkline beecham investments limited ordinary great west road brentford middlesex tw gs england smithkline beecham marketing technical ordinary great west road brentford middlesex tw gs england services limited smithkline beecham nominees limited ordinary great west road brentford middlesex tw gs england smithkline beecham overseas limited ordinary great west road brentford middlesex tw gs england stiefel laboratories uk ltd ordinary great west road brentford middlesex tw gs england tesaro uk limited ordinary great west road brentford middlesex tw gs england wellcome foundation limited ordinary great west road brentford middlesex tw gs england viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england accordance section c companies act company guarantee debts liabilities uk subsidiary undertakings december total sum debts liabilities million million key directly owned gsk plc ii ormant entity iii ax resident uk iv e xempt regulation partnership accounts regulations requirement deliver registrar financial statements qualifying partnerships entity member accordance companies act v incorporated netherlands vi consolidated subsidiary accordance section companies act grounds dominant influence vii principal business address puerto rico viii exempt provisions regulations partnership accounts regulation accordance exemptions noted regulation regulation ix gsk gp limited subsidiary undertaking gsk plc berkeley square pension trustee company limited general partner gsk scottish limited partnership gsk scottish limited partnership gsk gp limiteds share capital indirectly owned gsk plc owned berkeley square pension trustee company limited x gsk gp limited subsidiary undertaking gsk plc general partner gsk scottish limited partnership gsk gp limiteds share capital indirectly owned gsk plc strategic report governance remuneration financial statements investor information gsk annual report glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ads gsk adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company gsk plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity group gsk plc subsidiary undertakings gsk gsk plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties ordinary share fully paid ordinary share capital company profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity gsk exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance codegsk annual report shareholder information continued index remuneration policy summary key performance indicators access legal proceedings accounting principles policies major restructuring costs acquisitions disposals movements equity adjustments reconciling total profit tax operating net debt cash flows new accounting requirements annual general meeting nominations committee report approach tax noncontrolling interests assets held sale noncontrolling interests viiv healthcare associates joint ventures nonexecutive directors fees audit risk committee report nonfinancial information statement business model notes financial statements cash cash equivalents operating profit cash generation conversion intangible assets ceos statement investments chairs statement noncurrent assets chairs governance statement noncurrent liabilities chairs remuneration annual statement operating incomeexpense climaterelated financial disclosure provisions commitments culture consolidated balance sheet external environment consolidated cash flow statement longterm priorities consolidated income statement pensions postemployment benefits consolidated statement changes equity performance consolidated statement comprehensive income pharmaceutical products competition contingent consideration liabilities intellectual property contingent liabilities pipeline corporate governance post balance sheet events corporate responsibility committee report presentation financial statements critical accounting judgements key sources principal group companies estimation uncertainty principal risks uncertainties critical accounting policies property plant equipment data engagement reconciliation net cash flow movement net debt demerger consumer healthcare business registrar directors senior management related party transactions directors interests shares reliable supply directors report remuneration governance directors statement responsibilities remuneration report dividends reporting framework donations political organisations responsible business political expenditure right use assets earnings per share risk management employee costs science technology employee share schemes science committee report environment section statement ethical standards share capital control exchange rates share capital share premium account finance expense share consolidation finance income shareholder information financial calendar shareholder services contacts financial instruments related disclosures specialty medicines financial performance stakeholder engagement financial position resources task force climaterelated financial disclosures financial statements gsk plc prepared taxation uk gaap tax information shareholders general medicines threeyear selected financial data glossary terms board goodwill trade payables group companies trade receivables group financial review treasury policies gsk leadership team trust independent auditors report turnover segment information innovation us law regulation inventories vaccines investments associates joint ventures vaccine products competition intellectual property investor relations viability statement gsk glaxosmithkline plc incorporated english brand names appearing italics throughout report trade marks either owned public limited company december andor licensed gsk associated companies trade marks property formed merger glaxo wellcome plc respective owners smithkline beecham plc gsk acquired printed sustainably uk pureprint two english companies december part carbonneutral company fsc chain custody iso certified merger arrangements effective may environmental management system recycling dry waste glaxosmithkline plc changed name gsk plc printed arena eco ew smooth wood july gsk plc separated consumer free uncoated paper ecf fsc certification made recycled fibre healthcare business gsk group form haleon independent listed company shares listed london stock exchange new york stock exchange download pdfs wwwgskcom annual report form f esg performance report cautionary statement regarding impacts covid pandemic forward changes healthcare environment unexpected forwardlooking statements looking statements made behalf group significant changes pricing result government groups reports filed furnished us speak date made based competitor action guidance factors securities exchange commission sec including upon knowledge information available divestments product exits announced date document written information directors date annual report groups guidance assumes successful delivery released oral statements made public number nonifrs measures used report groups integration restructuring plans future behalf group may contain performance business measures material costs investment new product launches forwardlooking statements forwardlooking defined pages reconciliation rd factored expectations statements give groups current expectations adjusted results total results set pages given given potential development options forecasts future events investor identify groups pipeline outlook may affected statements fact relate information document constitute additional datadriven rd investment decisions strictly historical current facts use words offer sell invitation buy shares gsk plc guidance given constant currency basis anticipate estimate expect intend invitation inducement engage outlooks ambitions expectations project plan believe target words investment activities past performance read together pages stock exchange terms similar meaning connection relied upon guide future performance nothing announcement relating update investors discussion future operating financial performance annual report construed profit dated june paragraph part particular include statements relating forecast circular shareholders relating demerger future actions prospective products product haleon dated june guidance approvals future performance results current assumptions related guidance assumptions cautionary statements groups anticipated products sales efforts expenses outlining guidance group made q earnings release outcome contingencies legal proceedings certain assumptions healthcare sector dividend payments financial results different markets group operates notice regarding limitations director liability accordance legal regulatory obligations delivery revenues financial benefits english law including market abuse regulations uk current portfolio pipeline restructuring uk companies act safe harbour listing rules disclosure transparency programmes due phasing quarterly results limits liability directors respect statements rules financial conduct authority group resulting comparators gsk expects omissions directors report see undertakes obligation update forward turnover adjusted operating profit growth strategic report remuneration looking statements whether result new slightly lower first half including report english law directors would liable information future events otherwise reader challenging comparator q somewhat company third party one however consult additional disclosures higher second half relative fullyear reports contained errors result group may make documents expectations despite recovery healthcare recklessness knowing misstatement dishonest publishes andor files sec readers systems uncertain economic conditions prevail across concealment material fact would otherwise wherever located take note disclosures many markets gsk operates continue liable pages accordingly assurance given expect see variability performance inclusive comprise directors report pages particular expectation met investors quarters inclusive comprise strategic report pages cautioned place undue reliance expect sales specialty medicines increase mid inclusive comprise remuneration report forwardlooking statements high singledigit per cent sales vaccines drawn presented forwardlooking statements subject increase midteens per cent sales general accordance reliance upon english company assumptions inherent risks uncertainties many medicines decrease slightly law liabilities directors connection reports shall subject limitations relate factors beyond groups planning assumptions well operating profit restrictions provided law control precise estimate group cautions guidance dividend expectations assume investors number important factors including material interruptions supply groups website document could cause actual results products material mergers acquisitions gsks website wwwgskcom gives additional differ materially expressed implied disposals material litigation investigation costs information group notwithstanding forwardlooking statement company save already references make annual report gsks factors include limited recognised provisions made website none information made available discussed principal risks uncertainties change groups shareholdings viiv website constitutes part annual report shall pages annual report healthcare assumptions also assume material deemed incorporated reference herein unite science technology talent get ahead disease together head office registered office gsk plc great west road brentford middlesex tw gs united kingdom tel registered number